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Chapter 1 } General Introduction
Introduction
What drives you to read this thesis (right now)? Are 
your drives different from other people reading this? 
And do you think that your drive to read it will have 
any influence on your behaviour in the future? 
 These questions all pertain to motivation, the 
concept that is central to this thesis. Specifically, the 
main objective of the thesis is to come to a better 
understanding of the motivation of patients with 
severe mental illness to engage with psychiatric 
treatment services and the influence of their 
motivation on subsequent treatment engagement 
behaviour and health outcomes. To let us understand 
and more fully bring the subject of this thesis into 
being, I would like to introduce you to Anna and Otto 
(please see the frames on the next pages)*. 
 After reading the stories of Anna and Otto, 
try to imagine their motives for engaging with 
psychiatric treatment services or vice versa, their 
motives for rejecting it. Why did Anna accept and 
reject treatment after treatment, taking her at least 
7 psychologists to arrive at where she is right now? 
What has defined her motivation and that of her 
therapists to (dis)engage from treatment? What 
are the crucial factors that have helped Anna to 
engage with the treatment that is now offered? Is 
assertive outreach a better treatment model for her 
than ‘regular’ outpatient treatment for personality 
disorders (and if so, why)? Regarding Otto, why 
did he let Remco and his colleagues come in? Does 
Remco understand the motivation of Otto to accept 
treatment services? And will Otto keep refusing to 
accept medication for his psychotic symptoms or 
will Remco be able to motivate him to give it a try 
once again? What will happen if Otto never accepts 
medication for his psychotic symptoms? How does 
Otto perceive his current and future (psychosocial) 
functioning and how do mental health care 
professionals perceive it? 
 All of these motivational questions are relevant in 
daily clinical practice for patients with severe mental 
illness and for mental health professionals working 
with them. In this thesis, the above questions are 
considered in light of three motivation theories, 
as applied to the outpatient care for patients with 
severe mental illness in the Netherlands. Anna and 
Otto will return in the General Discussion of this 
thesis, where their stories will be reviewed in light 
of the three motivation theories. 
*  The characters and case descriptions of Anna 
and Otto as well as their therapists are fictional 
but based on real-life stories.
Ch. 1
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Anna
Anna is 32 years old and has already had a turbulent life. Her parents got divorced when she was 9 years 
old, after many years of physically abusing each other and neglecting Anna. From then, Anna lived with 
her mother. Around age 11, she started experiencing heavy mood swings and anger. She frequently 
clashed with her mother and felt alone. She started experimenting with alcohol and drugs at age 14 and 
got expelled from school at age 16. At this time, she tried to commit suicide for the first time, using all 
the pills that her mother kept in the house and a glass of whisky. In the years after this, Anna had many 
therapists who came and went. In the end, they all turned out to be “no good”, according to Anna. She 
got admitted to psychiatric hospitals several times due to repeated suicide attempts, and was diagnosed 
with complex posttraumatic stress disorder and borderline personality disorder. Over the last 5 years, 
she has been treated by an assertive outreach team, who offer psychological treatment at home and 
keep in contact with her, including in periods of high distress, anger, and during hospitalizations.
Anna: 
“I feel like I have finally entered a different phase in my life right now. I always felt that everything was 
doomed to fail for me. Now, when I am stressed, I can still become angry and suspicious, but I am learning 
how to reach out for help in these moments. At times, my emotions were so overwhelming that I gave up 
on treatment, and myself. For me, alcohol was a way to deal with those emotions. It has cost me a lot of 
time and energy to build some trust with the team, and to build confidence in myself. Now, I am trying to 
get a job as a waitress. The team helps me with this through individual placement and support. It’s been 
7 months since my last drink, but occasionally I still smoke weed.”
Wilma (former psychologist of Anna):
“Anna was referred to me when she was 25 years old. I was her 7th psychologist. When I first expressed 
my compassion for Anna and told her that it must have been really hard for her as a child to have had 
parents who did not attend to her, she reacted offended. She didn’t want me to be so critical of her 
parents and wondered if I meant to say that she should have known better and should have left home 
sooner. In the following weeks, I noticed that Anna became easily irritated by things that I said, and 
despite my attempts to try to understand and help her, I started doubting myself a little and became 
hesitant to provide feedback to Anna. I knew she had difficulties with attachment and with trust, but 
also felt that I could not get through to her. When I – cautiously – tried to discuss this with Anna, she 
took this as a personal attack and left the room angrily. Although such behavior is not uncommon in 
patients with borderline personality disorder, Anna’s anger did not seem to pass. In the following months, 
she frequently did not show up for appointments, sometimes showed up drunk, and I felt unable to 
effectively work with Anna. This affected my own motivation in a negative way, and I also doubted 
whether she was motivated and ready for psychotherapy. When I asked her about this, she thought that 
I was going to end the treatment: “See, nobody cares for me, everybody drops me!”. It turned out to be 
a self-fulfilling prophecy; she did not show up for appointments, I explained the necessary conditions for 
effective psychotherapy to her, she could not be reached for several weeks and I had to conclude that 
psychotherapy was currently not feasible. Just before her 27th birthday, she was re-admitted to the clinic 
and then referred to an assertive outreach team.”
12
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Otto
Otto is 43 years old and lives by himself in a rental apartment. He has been in and out of contact with mental health 
care services from age 22, when he was diagnosed with schizophrenia. Otto is convinced that a secret Chinese 
organization wants him dead and that they have spies who try to read his mind. They want to find out where he is 
and then poison him. His family is also involved, according to Otto, which is why he broke contact with them. Otto 
has been admitted to psychiatric hospitals four times, all of which were involuntary. These experiences were very 
distressing for Otto. When Otto was 26, he accused an Asian man of being a spy, which resulted in a fight and Otto 
being imprisoned. After his release, Otto was not able to keep a day job, but he managed to get a job as a night 
porter at a small hotel for many years. Although it was rare for Otto to talk extensively to others, as he feared 
they could be involved with the organization, he did enjoy the small talk with some of the guests. Three years ago 
however, there was a reorganization and he lost his job. Over the last years, problems started to accumulate. Otto 
got into financial problems, the housing association started complaining about stench and threatened with eviction. 
Otto was also becoming increasingly lonely but was afraid to leave his house, as the Chinese might spot him.
Remco (current case manager of Otto, specialized psychiatric nurse):
“We received word of Otto’s situation through our network with other social services and we decided to reach out to 
him. We started visiting his house about a year ago. At first, the curtains were closed and Otto did not open the door. 
We left notes through his mailbox to inform him about who we were and what we could do for him. After several 
weeks of failed attempts, Otto came to the door once and agreed to let us in. We could see that he was skinny and 
it smelled like garbage in his apartment. He told us in an incoherent and rushed way about how he was certain that 
his food was poisoned, and that he was victim of Chinese voodoo (showing his right arm which had a rash). All the 
while, he looked at us in a suspicious way. We acknowledged that the rash was worrisome and that we were there 
to see if we could assist in his problems with the housing association and other stressors. Over the next days, he 
accepted our visits and gradually, he also accepted our help in cleaning his house and allowed us to assist him with 
financial problems. Otto talked more about his experiences and lifestyle. On the condition that he could wear a hat 
and sunglasses (such that he was less easily detected by the Chinese), we took him to see his house doctor for a 
physical examination. Otto’s view on his problems is different from ours, which is why he still refuses medication, but 
he started taking better care of himself and he is gradually going outside more often.”
Otto: 
“This guy, Remco, he visits me every week. He asks me how I am doing and we go through my mail together. He is 
one of the few people that I like to talk to. Even if I don’t open my door sometimes, because I’m not sure if it’s safe, 
he keeps coming back. He listens and I feel like he respects me, even though he sometimes has a different view on 
things. He has explained how medication might help me, but from experience I know that this changes me… and I 
don’t want that. Besides, my problem is not something psychological, the problem is the Chinese secret organization. 
They should be exposed and imprisoned. Remco knows I do not want to be admitted to a psychiatric hospital again 
and that I want to keep living here. Recently, he has offered to visit a daytime activities center with me, to see which 
activities I might like and to meet some people. He has done so much for me already, I might give it a shot.”
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In the following, it will be explained who is referred 
to when talking about ‘patients with severe mental 
illness’, why motivation for treatment is a relevant 
topic in this population and how ‘motivation for 
treatment’ may be defined. The chapter ends with 
an overview of the contents of this thesis. 
Severe mental illness (SMI) 
The term ‘severe mental illness’ is difficult to define 
and even controversial, as one may (successfully) 
argue that all mental illnesses are severe1,2. After all, 
“ask anyone who’s been living with a mental illness 
for any length of time and they’ll tell you it can be 
severe, debilitating, and even life-threatening”2. 
Nevertheless, the term ‘severe mental illness’ was 
introduced in the eighties of the previous century 
in an attempt to identify people who were most 
in need of mental health care, such that resources 
could be adequately targeted to such people3,4. In a 
comprehensive review where 17 definitions of SMI 
were compared, Schinnar et al. 5 found that between 
4% and 88% of psychiatric patients qualified as 
having SMI, depending upon the definition selected. 
They concluded that the 1987 definition of the 
National Institute of Mental Health (NIMH) reached 
most consensus and was most representative of the 
middle range of prevalence estimates of 45% to 55%. 
This definition described severe mental illness as 1) 
a diagnosis of non-organic psychosis or personality 
disorder, 2) a duration characterised as involving 
“prolonged illness and long-term treatment” 
operationalised as a two-year or longer history of 
mental illness or treatment, and 3) disability, which 
is defined as role impairment in at three of eight 
domains: employment, self-care, self-direction, 
interpersonal relationships, learning, recreation, 
independent living and economic self-sufficiency4,6. 
 Although most definitions of SMI have in 
common that they include criteria for diagnosis, 
duration and disability, there is still little consensus 
in the literature regarding the exact definition of 
SMI3,6-8. For example, some definitions include 
simplifications of the NIMH definition, such as 
including only people with a diagnosis of any 
non-organic psychotic disorder and a treatment 
duration of at least two years6, while others reflect 
extensions of this definition to broader populations 
such as to those with any psychiatric disorder that is 
accompanied by severe impairments in social and/
or societal functioning that requires professional 
coordinated treatment9. It appears that most 
definitions of SMI include diagnoses of psychotic 
disorders, personality disorders, bipolar disorders, 
major depressive disorders and/or substance abuse 
disorders3-7. Duration is commonly defined as 
duration of illness or as the type and/or duration of 
treatment3,6,7, while disability is commonly defined 
as having several disabilities in the domains of 
housing, employment, finances, social support and 
relationships, organizing daily activities and/or 
problematic behaviour which results in intervention 
by the mental and/or judicial system3,4,9. 
 In the current thesis, the definition of SMI 
is limited to people who receive outreaching, 
community based mental health care or were at 
least in contact with such mental health services 
(such that we may refer to them as patients) for 
treatment of a primary diagnosis of a psychotic 
disorder or personality disorder. This definition 
closely resembles the 1987 NIMH definition and was 
also chosen for pragmatic reasons. That is, people 
with these diagnoses could be easily identified based 
on the psychiatric diagnoses obtained from medical 
records of the participating community mental 
health teams, with a high likelihood that all three 
criteria for SMI would be met. For ease of reading, 
we will refer to our patient research population as 
patients with SMI in the remainder of this thesis. 
The following paragraph describes the outreaching 
community mental health services from which SMI 
patients were recruited in the current research 
project. 
Patients with SMI in the context of 
Dutch psychiatric treatment
In the Netherlands, the group of adult people with 
severe mental illness is estimated to be between 
120.000 to 160.000 people 9,10. Of the general 
population, around 3% have a psychotic disorder, 
while around 8% has psychotic experiences that do 
not necessarily have a clinical psychotic disorder11. 
The prevalence of any personality disorder is 
estimated to be around 10%12,13, but the prevalence 
of specific types of personality disorders differ. For 
example, it is estimated that around 0.4% to 4% of 
the population has a paranoid personality disorder, 
around 1% to 6% has borderline personality disorder 
and around 0.4% to 4% has an antisocial personality 
disorder12,13. 
	 The	 care	 for	 patients	 with	 SMI	 is	 increasingly	
being	 provided	 by	 so-called	 Flexible	 Assertive	
Community Treatment Teams (FACT) teams10,14. 
FACT is a team treatment model that aims to 
provide	 community-based,	 assertive,	 outreaching	
and	 supportive	 psychiatric	 services	 to	 individuals	
with SMI14,15.	The	 formation	of	 this	 type	of	care	was	
driven	by	a	movement	towards	more	outpatient	and	
less	 inpatient	psychiatric	 treatment,	more	 individual	
housing and less hospital beds and towards more 
patient	autonomy	and	less	patient	dependence16. 
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On average, a FACT team monitors about 250 patients, 
of which around 20% is in need of intensive high-
frequent care at any time, while the other 80% need 
less intensive treatment and support14. To combine 
care for these two groups, the FACT team employs 
a flexible switching system. The group requiring the 
most intensive care is discussed daily and for this 
group the team adopts a shared caseload approach. 
Besides assertive outreach, there is an emphasis 
on out-of-office interventions and home visits. Van 
Veldhuizen14 has described Dutch FACT as follows: 
“FACT is a rehabilitation-oriented clinical case 
management model, which is based on the Assertive 
Community Treatment (ACT) model but is more 
ﬂexible and able to serve a broader range of clients 
with severe mental illness. FACT offers the original 
ACT as one of several treatment or care models. The 
FACT team is a case management team with partly an 
individual approach and partly a team approach; the 
approach varies from patient to patient, depending 
on the patient’s needs. For more stable long-term 
patients FACT provides coordinated multidisciplinary 
treatment and care by individual case management. 
Unstable patients at risk of relapse, neglect and 
readmission are provided with intensive assertive 
outreach care by the same team, working with a 
shared caseload for this subgroup” (p.422). When 
patients constitute a danger to themselves or others 
and are not motivated for treatment, health care 
professionals can start a procedure such that these 
patients are committed to a psychiatric hospital14. 
During hospitalisations, the FACT team keeps into 
contact with the patient to secure continuity of care. 
 Patients with psychotic disorders constitute 
the majority of patients treated in (flexible) 
assertive community mental health teams in the 
Netherlands and patients with severe personality 
disorders constitute another significant part of the 
caseload14,17. Previous Dutch research suggests that 
patients with psychotic disorders and personality 
disorders constitute a higher chance of being 
perceived as ‘difficult’ by their clinicians18 which 
puts them at higher risk of ineffective treatment 
strategies18. Also, patients with these diagnoses are 
more often considered non-adherent to treatment 
and tend to have problematically high rates of 
disengagement, as will be explained in the following 
paragraph. 
Problem: disengagement from 
psychiatric treatment
Assuming that psychosocial and psychiatric 
treatments for patients with SMI are effective 
in reducing the burden of the mental illness and 
achieving better functioning and quality of life, 
engaging patients with such services is important 19,20. 
Once patients are in contact with services, keeping 
up the engagement and adherence is of importance 
to maximize the treatment efficacy, especially for 
severe and persistent disorders where treatments 
are designed to prevent symptom recurrence20. 
Alternatively, treatment disengagement and non-
adherence can compromise the (cost)-effectiveness 
of the treatment. Estimates of treatment 
disengagement vary across different psychiatric 
patient populations and depend on the definitions 
of disengagement and non-completion. For example, 
non-adherence to antipsychotic medication among 
patients with psychotic disorders was observed 
in over 50% of patients21,22, while non-completion 
of personality disorder treatment is estimated at 
37%23. Lehner et al.24 found that among individuals in 
treatment for SMI, appointment failures ranged from 
50% to 73%, drop-out estimates ranged from 14% to 
92% and medication failure estimates ranged from 
5% to 71%. Disengagement and non-completion of 
treatment pose a major problem for the successful 
treatment of patients with SMI, since they are 
associated with several clinical and socio-economic 
problems such as recurrent psychiatric problems, 
rehospitalisation, and increased risk of suicide and 
episodes of violence 24-26. Thus, the consequences 
of nonadherence and disengagement can be 
devastating, both for patients and their families in 
terms of personal suffering, reduced quality of life 
as well as for society in general due to loss of income 
and direct costs of healthcare27. It is therefore not 
surprising that studies have focussed on determining 
which factors are related to (non-)adherence and 
treatment engagement, and that many trials have 
focused on adherence and engagement as primary 
intervention targets. 
Factors related to treatment (dis)
engagement and treatment outcomes
Research into the determinants of treatment 
engagement and completion of treatment in severe 
mental illness has revealed numerous important 
factors, including patient-related factors (e.g. age, 
ethnicity, beliefs about treatment efficacy, income 
level, psychiatric history), illness-related factors (e.g. 
the type of disorder, symptom severity, comorbidity) 
and treatment-related factors (e.g. treatment 
setting, type of treatment, treatment efficacy, 
adverse treatment effects, therapeutic alliance) 
20,26,28,29. Although some of these factors are static 
and cannot be influenced, others are more dynamic 
and may therefore be targeted in interventions to 
enhance treatment engagement. 
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The evaluation of the effectiveness of specific 
types of treatment is one of the most common 
approaches to empirical tests of therapeutic 
factors, as evidenced by the wealth of randomized 
controlled trials and meta-analyses in this area of 
research30. Other treatment-related factors are 
generally considered as non-specific factors or 
“common factors” that are at play in all types of 
treatment, and may also be subject to interventions. 
Among the common factors are the therapeutic 
relationship, goal consensus/collaboration, 
expressed empathy, positive regard, expectations 
of the patient and therapist characteristics31. It 
has been noted that the scientific exploration 
of common factors has gained considerable less 
attention in rigorous empirical (clinical) research31 
as compared to treatment methods, whereas these 
factors may prove to be of equal or even superior 
importance to treatment outcomes31. Although the 
therapeutic alliance and the expression of empathy 
are studied commonly, most of these studies are 
correlational studies (as opposed to experimental 
studies)31. The relative scarcity of rigorous empirical 
studies into common factors may be related to the 
notion that, of all aspects of treatment that can 
influence outcome, the treatment method is often 
considered the only aspect that can be manipulated 
in a clinical experiment to test its efficacy, and, if 
proven valuable, can be trained and disseminated 
to other mental health care professionals31. This 
approach can be argued to put the patient in the 
position of a “dependent variable” who is operated 
on by supposedly effective therapeutic techniques32. 
Alternatively, the common factor approach assumes 
that different kinds of treatment do not achieve 
their effects through their specific techniques and 
principles, but that their effectiveness is due to, 
often unacknowledged, factors that they share31,33. 
The common factors approach leaves more room 
for both patient and clinician characteristics as the 
mediators and moderators of change, next to the 
treatment methods. Supporters of the common 
factors approach hold that research into patient 
progress through treatment, including the use 
of feedback systems that provide therapists and 
patients with information about various common 
factors, have great potential to address the central 
matter of how change happens in treatment by 
considering a wider range of potential moderators 
of change than is typically attended to in trials 34.
 One dynamic common factor that has long 
been recognized as an important determinant of 
treatment engagement is the patient’s motivation to 
make the efforts required by the treatment 29,35-38. At 
its most general level, the term motivation is used to 
explain reasons why people think and behave as they 
do 39. Motivation has been ascribed to both internal 
mechanisms such as needs, desires and physiological 
processes, to functional processes such as goal-
directed behaviours and attraction by incentives, and 
to short-term processes as well as the cause of all 
behaviour 40. Distinctions have been made between 
implicit motives that function at an unconscious 
level and explicit goals that function at a conscious 
level, and between approach motivation (towards 
pleasurable experiences) and avoidance motivation 
(away from harmful experiences)41. In relation to 
psychiatric treatment, motivation may relate to why 
a patient (does not) engage in treatment, how hard 
the patient actually works at certain challenges that 
are presented during treatment (i.e. the intensity), 
how long the patient is willing to remain working at 
the activity (i.e. the persistence) and what the patient 
might be feeling and thinking while engaged in the 
treatment-related behaviour (i.e. the emotions and 
cognitions accompanying the behaviour)42. 
 However, despite a large amount of literature 
regarding treatment motivation and probably due to 
an abundance of conceptualizations of ‘motivation for 
treatment’, it has proven difficult for both academics 
and clinicians to effectively work with the concept. 
Because of this, the choice of which definition of 
motivation is most appropriate for clinical practice 
for patients with SMI is not a straightforward one. 
Although the literature provides some guidance in 
which variables are important regarding motivation 
and treatment engagement, there is no consensus as 
to which theory is most precise and applicable in the 
explanation and prediction of treatment engagement 
in outpatients with SMI. There appears to be a lack of 
empirical comparisons between motivation theories, 
whereas such comparisons can advance what is 
currently known about intrapersonal changes and 
interpersonal differences in motivation, treatment 
engagement and outcomes in severely mentally 
ill patients. Therefore, the research in the current 
thesis aimed to empirically test and compare current 
influential definitions of motivation for treatment 
made by three different motivation theories. 
Definitions and theories of motivation 
Numerous	 theories	 of	 motivation	 and	 behaviour	
change exist today. In a recent paper by Davis et 
al. 43	 who	 aimed	 to	 identify	 theories	 of	 potential	
relevance	to	public	health	interventions,	82	different	
theories emerged. The authors found that the most 
commonly used theories in the current literature are 
the	Transtheoretical	model44, the Theory of Planned 
Behaviour45,	 Social	 Cognitive	 theory46, the Health 
Belief Model 47	 and	 Self-Determination	 Theory	 48. In 
16
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search	for	a	useful	motivation	theory	for	application	
in	 the	 context	 of	 outpatient	 community	 mental	
health	for	patients	with	SMI,	we	decided	to	examine	
three	 motivation	 theories	 for	 empirical	 testing	 in	
the context of treatment engagement in community 
mental health care in the Netherlands. These three 
theories were selected based on their dominance in 
the	field	49-51,	 including	the	recognition	that	they	are	
currently	used	in	mental	health	care	interventions	or	
have been suggested by previous researchers to be 
potentially	 useful	 in	 this	 domain,	 they	 have	 gained	
considerable interest and popularity in the literature 
over	recent	years,	and	because	they	have	the	potential	
to	provide	a	unique	contribution	to	the	understanding	
of	treatment	engagement	in	outpatients	with	SMI.	
 One	of	the	most	influential	models	of	motivation	
and	 change	 is	 the	 Transtheoretical	 model	 (TTM)	
developed by Prochaska and DiClemente 44. TTM has 
also been called the stages of change model, and 
is	 typically	 regarded	 as	 a	 model	 for	 motivation	 for	
change,	 as	 the	 motivation	 to	 engage	 in	 behaviour	
change increases with each progressive stage 37,52. 
That	is,	clinicians	should	aim	to	identify	their	patients’	
readiness to change by specifying in which one of 
five	 stages	 the	 patient	 is	 in:	 precontemplation	 (not	
planning to change or even resistant to change), 
contemplation	 (considering	 change	 but	 not	 yet	
planning	it),	preparation	(preparing	to	change	soon),	
action	(behaviour	change	has	recently	been	achieved)	
or maintenance (long-term behaviour change has 
been achieved) 53. When the appropriate stage is 
identified,	specific	interventions	should	be	offered	to	
help	patients	progress	to	the	next	stage	or	to	maintain	
changes made 54. The TTM has frequently been used 
as a basis for the development of health behaviour 
interventions,	especially	 in	 the	field	of	addictions	 55. 
It	 is	 estimated	 that	 around	 25%	 to	 35%	 of	 patients	
with SMI have co-occurring substance use problems56, 
which explains why the TTM has gained popularity in 
the	 psychiatric	 treatment	 of	 patients	 who	 have	 co-
occurring	 mental	 and	 addiction	 problems.	 Current	
studies suggest that TTM constructs can explain 
outcomes	for	patients	with	a	dual	diagnosis	57-59, and 
that the TTM constructs are associated with physical 
activity	 in	 patients	 with	 schizophrenia	 spectrum	
disorders 60,61	 and	 with	 drop-out	 from	 dialectical	
behavioural	 therapy	 for	 patients	 with	 borderline	
personality disorder 62. A meta-analysis on the 
relations	 between	 stages	 of	 change	 and	 processes	
of change applied to psychotherapy, found that 
“the majority of published research concerns health 
behaviours	 and	 addictive	 disorders,	 as	 contrasted	
with the wide range of Axis I disorders” (p. 151)63. 
It appears that the TTM has been understudied 
regarding	 motivation	 for	 changing	 psychiatric	
problems	 in	 outpatient	 treatment	 for	 patients	 with	
SMI,	despite	its	potential	in	this	domain.	Considering	
the above, the TTM was therefore chosen as one of 
the three theories for inclusion in the research of the 
current study. In Chapter 2 of this thesis, the TTM is 
described in more detail.
	 As	mentioned	previously,	 the	Theory	of	Planned	
Behaviour is also one of the most widely used 
theories in health behaviour research. This theory 
proposes	 that	 motivation	 and	 behaviour	 results	
from	 a	 rational	 process	 of	 decision	 making.	 Key	
constructs	 are	 subjective	 norms,	 intentions	 to	
perform	 specific	 actions	 and	 perceived	 behavioural	
control.	More	 recently,	 a	 derivative	 of	 the	 TPB	was	
specifically	developed	by	Drieschner	and	Boomsma37 
for	 application	 in	 forensic	 psychiatric	 care,	 called	
the	 Integral	 Model	 of	 treatment	 motivation37 (IM). 
The IM revolves around six factors that predict the 
level	 of	motivation	 to	 engage	 in	 treatment,	 namely	
problem	 recognition,	 distress,	 perceived	 legal	
pressure, perceived costs of treatment, perceived 
suitability of treatment, and outcome expectancy. 
The IM has a strong focus on individual beliefs, 
subjective	 norms	 and	 self-efficacy	 as	 the	 proximal	
predictors	 of	 motivation,	 similar	 to	 TPB.	 In	 IM,	 the	
level	of	motivation	 is	 considered	 to	be	predictive	of	
subsequent treatment engagement. Although the IM 
was	specifically	developed	as	a	model	 for	treatment	
motivation	in	forensic	psychiatric	care,	its	framework	
may	 also	 be	 applicable	 to	 outpatients	 with	 severe	
mental	 illness.	 To	 evaluate	 its	 utility	 in	 this	 context,	
it was selected as one of the three theories to be 
investigated	in	the	current	thesis.	Chapter	2	describes	
the IM in more detail.
 Finally, Self-Determination Theory 64 (SDT) is a 
motivation theory that has gained much interest in 
the literature in the last two decades. SDT describes 
different types of motives or reasons why a person 
may engage in behaviour, that fall along a continuum 
of self-determination between intrinsic and 
extrinsic motivation 65. To date, several studies have 
found support for the utility of SDT’s motivational 
constructs in relation to cognitive and psychosocial 
functioning in patients with schizophrenia spectrum 
disorders 66-69. For example, studies show that 
intrinsic motivation in schizophrenia spectrum 
disorders can change over time 66,68,70, predicts 
improvements in learning and psychosocial 
functioning 66,71,72, and mediates the relationship 
between negative and disorganized symptoms of 
schizophrenia and psychosocial functioning 69. At the 
start of the current research project, no empirical 
studies had investigated the basic process model 
of SDT as applied to the treatment of patients with 
SMI, whereas the theory may be useful as a basis for 
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psychosocial	 interventions	 in	this	context	73,74. It was 
therefore decided to incorporate SDT as the third 
theory	 to	 be	 investigated	 in	 the	 current	 thesis,	 and	
additionally,	 it	was	 decided	 to	 use	 SDT	 as	 the	 basis	
for	 the	development	 of	 a	motivational	 intervention.	
Chapter 2 describes SDT in more detail and Chapter 
3	describes	how	SDT	was	applied	in	the	motivational	
intervention	that	was	tested	in	a	cluster-randomised	
controlled trial. 
Outline of the thesis
As	 mentioned	 previously,	 Chapter	 2	 provides	 an	
overview	 of	 the	 three	 motivation	 theories	 that	
constitute	 the	main	 focus	of	 the	 research	described	
in	 this	 thesis:	 Self-Determination	 Theory	 (SDT),	 the	
TransTheoretical	Model	(TTM)	and	the	Integral	Model	
of	 Treatment	Motivation	 (IM).	 Central	 to	 Chapter	 2	
was to evaluate the main concepts, hypotheses, and 
the research that was available at the start of this 
project	 regarding	 the	applications	of	 each	 theory	 to	
the	mental	health	care	for	patients	with	severe	mental	
illness. At the end of Chapter 2, a research agenda 
regarding these theories is summarised, which was 
used as a guideline for the subsequent chapters and 
research described in this thesis. In Chapter 3, the 
research agenda from Chapter 2 is translated to a 
specific	design	and	to	specific	methods.	This	chapter	
describes	 the	 rationale	 and	 details	 of	 the	 cluster-
randomised controlled trial that was chosen as the 
overarching	 design.	 Specific	 research	 questions	 that	
are addressed in subsequent chapters are indicated 
below (see bullet points).
•  Can we assess the core constructs from the three 
motivation theories in a reliable and valid manner in 
outpatients with SMI? 
• To which extent is each motivation theory applicable 
to outpatient treatment engagement in patients 
with SMI? 
  
As	 the	 testing	 of	 theories	 is	 founded	 on	 the	
proper	 assessment	 of	 theoretical	 constructs,	 the	
research	 described	 in	 this	 thesis	was	 firstly	 focused	
on	 investigating	 the	 psychometric	 properties	 of	
questionnaires	 from	the	different	 theories.	Chapters	
4,	 5,	 6	 and	 7	 report	 on	 psychometric	 properties	 of	
questionnaires	 from	 each	 motivation	 theory,	 while	
subsequently we investigate	 for	 each	 motivation	
theory	 how	 the	 theory-specific	 motivational	
constructs	 relate	 to	 the	 patient’s	 treatment	
engagement,	psychosocial	functioning	and	quality	of	
life.	Chapters	5,	6	and	7	focus	on	testing	SDT,	IM	and	
TTM,	 respectively.	 These	 chapters	 have	 in	 common	
that	they	focus	on	testing	whether	the	process	models	
as described by the originators of the theories are 
plausible	in	the	reality	of	clinical	practice	for	patients	
with SMI. It is tested whether the original models 
are	robust	across	time	and	across	patient	diagnostic	
groups	 and	 it	 is	 investigated	 how	much	 variation	 in	
treatment engagement and outcomes is explained. 
•  Is Motivation Feedback – based on SDT – effective 
in improving treatment engagement and outcomes 
in outpatients with SMI? 
This question is addressed in Chapter 8, where the 
results of the cluster-randomised controlled trial 
(RCT) are reported. The primary aim of the trial was 
to test the effectiveness of a motivation feedback 
intervention based on SDT on treatment engagement 
and outcomes. Secondary, it is explored whether 
the effectiveness of the intervention is dependent 
on the type of disorder, namely whether there are 
differences in effectiveness between patients with 
primarily psychotic disorders versus those with 
primarily personality disorders. 
•  To which extent are clinicians, who provide regular 
care to patients with SMI, able to estimate the 
patient’s motivation for engaging in treatment? 
To which extent do clinicians and patients agree 
on the patient’s motivation? Which factors are 
associated with estimation and agreement on 
treatment motivation? 
In	a	further	attempt	to	understand	differences	between	
patients	and	clinicians	on	their	reports	on	motivation,	
comparisons	 between	 patient-reported	 and	 clinician-
reported	motivation	are	addressed	 in	Chapter	9.	This	
chapter	 includes	 measures	 of	 all	 three	 motivation	
theories	 to	 explore	 whether	 the	 associations	 differ	
between the three theories, and which factors are 
associated	with	(dis)agreement	on	motivation	between	
patients	and	clinicians.	
•  Which motivation theory – or elements from these 
theories- provides the best explanation of treatment 
engagement and outcomes in outpatients with SMI?
•  How do the three theories relate to each other 
(empirically)?
Chapter 10 addresses the two final questions above. 
It provides a general discussion of the research 
findings described in the previous chapters and 
attempts to integrate the findings regarding the 
tests of the three motivation theories. This chapter 
reports on the contributions of this entire thesis 
to the understanding of motivation for engaging in 
treatment in outpatients with SMI. Implications for 
theory, research and practice are discussed.
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H. J. 2011. A critical analysis of the utility and compatibility 
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Objective
The TransTheoretical Model (TTM), Self-Deter-
mination Theory (SDT), and the Integral Model of 
Treatment Motivation (IM) provide distinct but not 
incompatible conceptualisations of motivation. The 
utility of these theories as a basis for the improvement 
of psychiatric treatment engagement and treatment 
outcomes in patients with severe mental illness is 
evaluated. 
Methods
The current study is a literature review that provides 
a qualitative overview of three motivation theories, 
including their empirical support for and challenges 
to application in psychiatric treatment for patients 
with severe mental illness.
Results
The TTM provides a temporal framework for 
motivation as represented by the stages of change, 
in which cognitive and behavioural components 
have been recognised while IM disentangles the 
determinants of motivation from its effects. SDT 
appears to differentiate itself from these two theories 
with its postulation of basic psychological needs 
that determine the development of specific types 
of motivation for particular behaviours. It appears 
that all three theories have gained support for their 
predictions of outcomes in patients with severe 
mental illness, but important questions remain 
unanswered, such as which of these theories provides 
the best prediction of treatment engagement and 
treatment outcomes. It is explained how these three 
theories could complete each other, based on their 
strong and unique assets. A model is presented to 
visualize possible interrelations that can be tested in 
future research. 
Conclusion
It is imperative that the theories are empirically 
tested and compared to confirm their utility, and 
to this end we propose several important research 
questions that should be addressed in future 
research. Theory comparisons can advance what is 
currently known about intrapersonal changes and 
interpersonal differences in treatment engagement 
and outcomes in severely mentally ill patients. 
Ch. 2
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Introduction
Although numerous theories of motivation and 
health behaviour exist today, it has been noted by 
several authors that real innovations and advances 
in understanding health behaviour have been quite 
modest 75,76. One of the contributing factors to this 
lack of advancement in health behaviour theory is 
said to be that theories are seldom compared with 
each other in order to determine whether one theory 
offers a superior explanation of health outcomes 
than another theory 75-77. Noar and Zimmerman 75 
have further argued that this absence of empirical 
comparisons between different models, induces 
fragmented rather than accumulative knowledge 
regarding the prediction of (health) behaviour. The 
importance of empirically comparing theories is 
evident from the fact that we cannot truly know 
which theories are most accurate in explaining or 
predicting health behaviour if we do not test this. 
Clinicians faced with decision making regarding 
the optimal interventions should be able to rely 
on theory comparison studies that point out which 
theories (and accompanying intervention strategies) 
are best for which patients in which circumstances. 
We also agree with Noar and Zimmerman (2005) 
that: “The fact that theories have so many similar 
constructs demands that we (1) try and discover 
what the best conceptualization of those constructs 
is, and (2) compare theories to discover how these 
constructs combine and result in the enactment of 
health behaviour” (p.282). 
 The current chapter aims to provide an 
overview of three leading theories of motivation 
and conceptually relates these theories to each 
other in order to understand their common and 
unique contributions to the motivation concept. 
Also, the strengths and limitations of the theories 
are discussed in light of empirical evidence that 
these theories have gathered in their prediction and 
explanation of treatment engagement in patients 
with (severe) mental illness. This specific context 
was chosen since patients with severe mental illness 
(SMI) are generally considered problematic with 
regard to motivational issues and show high rates 
of drop-out and attrition from psychiatric treatment 
24, which in turn has been shown to deteriorate 
treatment outcomes 23,28,29. The current article 
serves to raise important research questions and 
critical thought with which we expect to stimulate 
research in testing and comparing these theories. 
First, we will explain how we arrived at the choice of 
these three specific theories before discussing the 
theories and how they relate to each other. 
Three motivation theories
One	 of	 the	 most	 influential	 models	 of	 motivation	
and change, widely used in psychiatric treatment 
facilities	 and	 particularly	 in	 the	 treatment	 of	
addiction,	 is	 the	 Transtheoretical	 model	 (TTM)	
developed by Prochaska and DiClemente 44. TTM 
has also been called the stages of change model, 
and	 is	 typically	 regarded	 as	 a	model	 for	motivation	
for	change,	as	the	motivation	to	engage	in	behaviour	
change increases with each progressive stage 37,52. 
The TTM has frequently been used as a basis for 
the	development	of	health	behaviour	 interventions,	
especially	in	the	field	of	addictions	55. A fundamental 
assumption	 in	 TTM	 (or	 any	 stage	 model)	 is	 that	
matching	interventions	to	specific	stages	will	increase	
the likelihood that change will occur, as opposed to 
mismatching or not matching to stages. However, the 
TTM has been the subject of several conceptual and 
empirical	critiques	37,78-80.	Interestingly,	Drieschner	et	
al. 37	have	developed	their	own	motivational	model	in	
response	to	the	TTM,	as	these	authors	have	criticised	
TTM (among other things) for its limited coverage 
of	 motivational	 factors.	 The	 model	 developed	 by	
Drieschner et al. 37 is called the Integral Model of 
Treatment	 Motivation	 (IM)	 and	 revolves	 around	
six so-called internal determinants that predict the 
level	 of	motivation	 to	 engage	 in	 treatment.	 The	 IM	
has	 a	 strong	 focus	 on	 individual	 beliefs,	 subjective	
norms	 and	 self-efficacy	 as	 the	 proximal	 predictors	
of	 motivation,	 and	 the	 level	 of	 motivation	 would	
be	 predictive	 of	 subsequent	 behaviour	 (e.g.	 taking	
medication).	 The	 TTM	 and	 IM	 differ	 from	 each	
other, in that the TTM is a stage model while the 
IM	 is	 a	 continuous	 model,	 according	 to	 the	 typical	
classification	 by	Weinstein,	 Rothman	 and	 Sutton	 81. 
Stage models assume that behaviour change takes 
place	 in	discrete	stages	and	that	there	 is	a	different	
equation	 for	 every	 stage	 that	 predicts	 progression	
to	 the	 next	 stage.	 Hence,	 interventions	 based	 on	
stage	 models	 include	 different	 interventions	 for	
people	 in	 different	 stages.	 Continuous	 models	
on the other hand, focus on predictors (such as 
attitudes	 or	 motivation)	 of	 the	 patient’s	 decision	
to	 perform	 certain	 health	 behaviours.	 Continuous	
models	combine	these	predictors	 in	a	–	often	linear	
-	 prediction	 equation	 that	 places	 individuals	 along	
a	 continuum	 of	 behaviour	 likelihood.	 If	 one	 scores	
higher	on	either	predictor	 in	 the	equation	 then	 the	
likelihood of behaviour or behaviour change is also 
increased.	 The	 question	 now	 rises,	 which	 theories	
–	 stage	 or	 continuous	 -	 are	most	 valuable	 in	 terms	
of	their	explanatory	and	predictive	power	regarding	
treatment engagement and treatment outcomes in 
patients	 with	 (severe)	 mental	 illness.	 The	 current	
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article	 will	 discuss	 the	 strengths	 and	 limitations	 of	
the TTM and IM as prototypical examples of these 
theory	 types,	 to	 see	 what	 contributions	 they	 have	
made	to	the	prediction	and	explanation	of	treatment	
engagement	and	outcomes	in	patients	with	SMI.	
 Although the TTM and IM differ from each other 
with respect to the type of framework they are 
composed of, they appear to have in common that the 
focus is upon predicting the level of motivation. That 
is, both models employ a quantitative motivation 
concept where the motivation that an individual 
may hold can range from a low level/stage to higher 
levels or stages. Contrasting such a quantitative 
viewpoint would be a qualitative viewpoint, where 
motivation is not so much characterised by its level 
but by its underlying reasons for performing certain 
behaviour, or to put it in other words, by a type of 
motivation. One such theory is Self Determination 
Theory (SDT) 48,64, a theory that has gained much 
interest in the literature in the last two decades. 
SDT postulates different types of motivation, 
where a central distinction is made between 
autonomous (i.e. self-determined) motivation and 
controlled (i.e. externally determined) motivation. 
Specifically, SDT predicts that autonomous 
motivation leads to a higher quality of treatment 
engagement (that is, self-determined treatment 
engagement) and as a consequence, to a better 
maintenance of healthy behaviour and more 
well-being 82. Furthermore, controlled motivation 
would be related to a poorer quality of treatment 
engagement and as a consequence, to poorer 
maintenance and well-being 82. It should be noted 
however, that although SDT is primarily concerned 
with	 the	 quality	 of	 motivation,	 it	 is	 also	 concerned	
with	 the	 quantification	 of	 motivation	 across	 the	
self-determination continuum. Amotivation stands 
at one end of the self-determination continuum, 
characterised	 by	 the	 lowest	 intentions	 for	 action,	
whereas motivation stands at the other end of the 
continuum, characterised by clear intentions for 
action, whether they are extrinsic or intrinsic. The 
addition of SDT as a theory to compare to TTM and 
IM leads to a second question concerning whether 
the level of motivation or the type of motivation 
(or a combination of these) is most important for 
the	prediction	of	treatment	engagement	and	clinical	
outcomes. This is another issue that will be addressed 
in	the	current	article.
	 Thus,	 we	 have	 now	 arrived	 at	 the	 selection	 
of the following three theories for our discussion: 
the	 TransTheoretical	 Model	 44, the Integral Model 
of	 treatment	 motivation	 37	 and	 Self-Determination	
Theory 64. These models, their definitions and 
measurements of the motivation concept and 
the way in which they predict treatment engagement 
and treatment outcomes will be described.
Transtheoretical Model (TTM)
TTM describes how individuals pass along five stages 
towards behaviour change 44,55,83,84. These stages 
are known as precontemplation, contemplation, 
preparation, action and maintenance. Precon-
templation is the stage at which the individual has no 
intention to change his behaviour in the foreseeable 
future, usually defined as the next 6 months 84. In 
this stage, patients are unaware of their problems 
or avoid reading or thinking about their problems. 
They are therefore considered unmotivated to 
change at this stage. Contemplation is the stage 
in which the individual is aware that a problem 
exists and is seriously thinking about overcoming it 
over the next six months, but has not yet made a 
commitment to take action 84. An important aspect 
of the contemplation stage is the weighing of the 
pros and cons of the problem and the solution to 
the problem. Moving on to the preparation stage, 
individuals in this stage intend to take action in the 
next month 84. Then, in the action stage, the individual 
modifies his behaviour, experiences, or environment 
in order to overcome his problems in the preceding 
six months. Maintenance is regarded as the stage 
in which the individual works to prevent relapse 
and consolidate the gains attained during action 84. 
Maintenance is considered a continuation of change 
that extends from six months to an indeterminate 
period (although estimated to about five years) past 
the initial action 84. Interestingly, within each of the 
five different stages specific problems may occur, 
depending on specific situations and disorders. For 
example, patients who suffer from schizophrenia 
often have impaired insight into their illness 85 
which might prevent them from progressing from 
precontemplation towards the contemplation 
stage. Figure 1 shows the stages of change and their 
relations with other constructs in TTM. 
According to TTM, individuals progress through 
the stages sequentially, but relapsing and recycling 
through the stages is common 55. Figure 1 shows 
three possible relapse moments between the stages. 
Due to the explicit notion of relapsing and recycling, 
it has been argued that TTM has been successful 
in promoting a less pejorative view of people who 
are not ready for change and that the model has 
heuristic appeal 79. TTM describes how fourteen 
constructs, including two decisional balance 
constructs, two self-efficacy constructs and ten 
processes of change determine transitions between 
the stages 83,87. These ten processes of change can be 
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divided into two categories: experiential processes 
and behavioural processes. Experiential processes 
include activities related to thinking about the 
health behaviour change (e.g. consciousness raising, 
self-re-evaluation, environmental re-evaluation), 
while behavioural processes are categories of 
behaviours that are supposed to be helpful for the 
achievement of the behaviour change (e.g. stimulus 
control, reinforcement management) 44. Prochaska 
et al. 54 have argued that the ten processes of change 
are “like independent variables that people need to 
apply to move from stage to stage” (p.63). However, 
several problems with both the stages of change and 
processes of change have been noted 88-90, as we 
shall discuss in the following.
Definition and measurement of the constructs 
in the TTM
A basic and substantial problem with the TTM is the 
way in which the stages of change are defined and 
measured. Several measures have been developed 
to assess the stages of change, including categorical 
stage assignments based on stage algorithms 55 
and continuous measures (e.g. the Readiness to 
Change Questionnaire (RCQ) 91 the University of 
Rhode Island Change and Assessment (URICA) Scale 
38, Motivation for Treatment Questionnaire 92). 
Continuous measures have the advantage that they 
have been shown to have relatively good agreement 
between different scales and between clients and 
clinicians 93, but a disadvantage is that they do not 
provide a representation of all five stages of the 
model. For example, the RCQ only distinguishes 
between the precontemplation, contemplation 
and action stages, while the URICA incorporates 
these three and the maintenance stage but not the 
preparation stage. The URICA has been modified 
into the URICA-M to suit the needs of people 
with SMI 57. The URICA-M contains the same four 
subscales as the URICA, but includes reading items 
aloud to accommodate individuals who cannot read, 
modified language to make it simpler and includes 
only 24 items 57. Overall, in a sample of patients with 
SMI and co-occurring substance use all subscales of 
the	URICA-M	showed	good	reliability	(i.e.	α	=	.72	or	
higher), except for the maintenance subscale that 
showed	 moderate	 reliability	 (α	 =	 .67	 to	 α	 =	 .70).	
When reanalysed within diagnostic and substance 
use groups, the results suggested that the URICA-M 
was more reliable for schizophrenia and substance 
dependent groups than for non-psychotic affective 
groups and substance remitted groups 57. It appears 
that, compared to other TTM measures (e.g. of the 
processes of change, self-efficacy and decisional 
balance) that were also studied by Nidecker et al. 
57, the URICA-M showed inferior reliability, especially 
for patients with affective disorders and those 
in remission . Furthermore, a disadvantage that 
remains with the URICA-M (and other continuous 
measures of the stages) is that participants can 
endorse items representing at least two different, 
sometimes nonadjacent stages. If participants 
turn out to be in multiple stages at the same time 
however, the validity of discrete stages is called into 
question 79,90. 
 Where most continuous measures for the stages 
of change do not represent all five stages of the 
model, algorithms enable placing individuals in 
either of five stages and have been used extensively 
in diverse populations and research areas 55,87,93. The 
algorithm approach involves a series of questions 
that ask about attempts and intentions to change 
behaviour within certain time frames that correspond 
to a particular stage. A disadvantage of most of the 
staging algorithms, as pointed out by Sutton 88, 
is that the time periods are arbitrary and in some 
cases, the staging algorithms are logically unsound. 
Using different time periods would lead to a different 
stage allocation and a different stage attribution 88. 
Furthermore, studies have shown low concordance 
between these different stage measures 88 and in 
different studies, there have been inconsistencies 
in the definitions of the stages 89. Obviously, the 
practical utility of the TTM is called into question if 
the stages cannot be assessed readily. Some authors 
have even argued that the problems with the TTM 
are so serious that the theory should be discarded 
entirely 78 or that the model should not be regarded 
as a descriptive model but as a prescriptive model – 
a model of ideal change 90. However, supporters of 
the model favour its practical utility and argue that 
the shortcomings of the TTM still pale in comparison 
to other models that have traditionally excluded 
unmotivated individuals, whereas TTM has been 
dedicated to specifically also include unmotivated 
individuals who need the most help 94. 
 Furthermore, the TTM does not appear 
to differentiate between the determinants of 
motivation and the motivation concept itself, for 
which it has been criticised 37. Drieschner et al. 
37 have interpreted the stages of change within 
TTM not as temporally ordered levels of a single 
dimension (motivation to engage in the process 
of behaviour change) but instead argue that the 
stages conceptually encompass two underlying 
components. The first consists of the cognitive 
determinants of motivation to change and the second 
consists of behaviour that results from a certain 
level of treatment motivation. In his criticism upon 
the TTM, Sutton 88 has also noted this, and he states 
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that the stages of precontemplation, contemplation 
and preparation may be seen as the “planned time 
to action” (p.176). Looking at the TTM this way, the 
level of motivation to engage in treatment then rises 
as one moves from the precontemplation stage to 
the preparation stage, and leads to actual behaviour 
changes from the action stage onwards. 
 Other constructs of the TTM, such as the 
decisional balance constructs and self-efficacy 
constructs, are typically measured with Likert scales 
that ask patients about the relative importance given 
to pros and cons when making the decision to engage 
in the relevant health behaviour and how they judge 
their own capacity to perform certain behaviour. A 
decisional balance scale has also been constructed 
95. For the assessment of the processes of change, 
the Processes of Change Inventory was developed 
for individuals trying to quit smoking 96. A revised 
processes of change inventory (a shortened version 
of the original 40-item scale) has been validated in a 
sample of SMI patients with co-occurring substance 
disorder 57. However, the processes of change remain 
the least studied dimension of the TTM. This is rather 
strange, since the processes of change represent a 
core assumption of TTM: that movement between 
stages is predicted by the use of the processes of 
change. Besides the little empirical attention that 
the processes of change have been given, there are 
other problems. For example, some of the processes 
seem more like procedures than processes (e.g. 
stimulus control) 89 and Dunlap 97 has noted that 
although TTM establishes the processes of change as 
important variables that facilitate stage movement, 
it does not clarify how the processes are initiated or 
once activated, how they can be stimulated further. 
Prediction of treatment engagement and 
outcomes
The different stages of change are hypothesised to 
predict treatment engagement, dropout, efficacy 
and long-term maintenance of behaviour changes 
83,98. More specifically, the amount of progress that 
patients make following treatment is predicted 
to be a function of their pretreatment stage of 
change 55, where patients in lower stages (i.e. 
precontemplation and contemplation) would make 
least progress and show higher rates of dropout. 
Additionally, the processes of change would predict 
transitions between stages, where the experiental 
processes should be employed in the early stages to 
progress to higher stages, and behavioural processes 
should be endorsed in the action and maintenance 
stages of change. 
 It has been noted that the available longitudinal 
evidence for TTM’s prediction of change is mixed 
at best 79,89. Studies have shown inconsistencies 
as to which stage predicts drop-out or behaviour 
change. In a comprehensive review of the stages 
of change model (not the entire TTM), Littell and 
Girvin 79 concluded that there was “scant evidence 
of sequential movement through discrete stages 
in studies of specific problem behaviours, such 
as smoking and substance abuse” (p.223). On the 
other hand, it has been noted by Hutchison, Breckon 
and Johnston 99 that “the majority of interventions 
reported to be based on the TTM fail to accurately 
represent all dimensions of the model. Therefore, 
until interventions are developed to accurately 
represent the TTM, the efficacy of these approaches 
and the appropriateness of the underpinning 
theoretical model cannot be determined” (p.829). 
Furthermore, few prospective studies have been 
conducted to investigate the TTM constructs in 
patients with severe mental illness. In a study by 
Rogers et al. 100 it was examined how baseline stages 
of change scores were prospectively related to 
retention in a vocational intervention with patients 
with SMI. At three months, none of the stages were 
significantly related to retention, and at six months 
only the contemplation stage was a significant 
predictor of better retention while at nine months 
again none of the stages had predictive value 100. 
A study by Pantalon and Swanson 101 showed that, 
contrary to TTM’s predictions, dually diagnosed 
patients in lower stages of change (measured 
with the URICA) had greater treatment adherence 
one month after discharge from hospital than 
patients in higher stages, in that they attended a 
greater proportion of therapy groups and clinical 
appointments. Also, patients in lower stages 
were more likely to attend all of their scheduled 
appointments than those in higher stages 101. Cross-
sectional studies have also shown inconsistent 
findings with respect to the validity and utility of 
the TTM stages of change (e.g., 60,102-104). Since it has 
been shown that the TTM constructs can be reliably 
measured in patients with SMI (and co-occuring 
substance use disorders) 57,105,106, researchers should 
now aim to (prospectively) investigate the utility and 
validity of TTM in patients with SMI. 
Intervention strategies and evidence for these 
strategies
Being a stage model, the TTM implies that 
interventions should be matched to the stage a 
patient is in. Project MATCH (Matching Alcoholism 
Treatment to Client Heterogeneity) was a large 
multisite clinical trial designed to test the matching 
hypothesis 107. One of the three treatment arms in 
this trial, called Motivational Enhancement Therapy, 
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was grounded in the TTM 108. Of the 16 hypotheses 
tested in Project MATCH, only one hypothesis 
was statistically significant: that clients with few 
psychiatric symptoms would respond better to 
Twelve-Step facilitation than Cognitive Behavioural 
Coping Skills Therapy 109. These negative findings 
leave us to wonder whether matching patients to 
stage-specific interventions is worth the effort. 
However, in a re-examination of the motivation 
matching hypothesis support was found for the 
matching hypothesis in the outpatient sample, 
where individuals with lower baseline motivation 
had better outcomes if assigned to Motivational 
Enhancement Therapy compared to those in 
Cognitive Behavioural Coping Skills Therapy 110. 
Overall, evidence for the matching hypothesis and 
prospective power of TTM is mixed 80,111,112 and it is 
still unclear how the matching hypothesis applies to 
patients with SMI. Furthermore, regarding the use 
of the TTM in clinical practice, it has been noted by 
Patterson, Wolf & Buckingham 113 that: “working with 
the stages of change seems to require the dedicated 
attention to that central, one and only, specifically 
identified problem. (…) The individual and therapist 
then, have one problem and five different stages to 
monitor. The multiple challenged clients however, 
could have up to five equally serious problems to 
address (i.e. housing, employment, alcohol or drug 
use, medical conditions, and criminal justice). This 
would require monitoring five co-evolving problems 
with five different TTM stages” (p.54). This would 
be almost impossible to achieve, since the therapist 
would then have to keep track of five problems and 
five stages per problem, resulting in 25 possible 
interventions. It would thus seem that stage-
based interventions are less suited for individuals 
with SMI – a population that almost by definition 
faces multiple problems. As Littell and Girvin 79 
have noted: “Stage-matched interventions seem 
premature and ill advised. A more realistic approach 
is taken by Miller and Tonigan (1996), who provided 
clients with feedback on their SOCRATES scores as a 
starting point for discussion about their motivation 
for change” (p. 255).
Integral Model of treatment 
motivation (IM)
The Integral model of treatment motivation (IM) was 
developed by Drieschner et al. 37 in an attempt to 
disentangle the determining factors and behavioural 
consequences of the concept of treatment 
motivation. The IM defines treatment motivation 
as “the patient’s motivation to engage in their 
treatment (MET)” (37, p. 1130). According to the 
authors, the proximal predictors of the level of MET 
are six cognitive and emotional factors, called internal 
determinants of MET. The IM and related concepts 
is shown in Figure 2. The six internal determinants 
include problem recognition, level of suffering, 
perceived external pressure, perceived costs of 
treatment, perceived suitability of treatment, and 
outcome expectancy 37. It is indeed plausible that a 
distressed patient who recognises his problems, has 
a high level of perceived legal pressure, combined 
with optimism about the effect of treatment will 
have a higher level of MET than a patient with 
lower levels on these factors. According to IM, 
the internal determinants mediate the influence 
of external factors (such as the type of treatment 
and demographic features) on MET. As the internal 
determinants are expected to determine the MET, 
MET in turn would determine the level of treatment 
engagement. However, the authors argue that this 
association is not perfect, since patients may lack 
the cognitive or neuropsychological capacity to do 
what the treatment requires 37. Finally, treatment 
engagement would determine treatment outcome, 
along with other factors (i.e. external determinants) 
such as the treatment effectiveness and the 
persistence of the patients’ problems 37. 
 The IM seems psychologically plausible in that 
it leaves room for external factors to influence the 
relation between MET and TE. Indeed, studies have 
shown that the association between motivation 
and behaviour is imperfect 114,115. The authors of IM 
themselves found that self-reported MET by patients 
explained 32 percent of the variance of subsequent 
therapist-rated treatment engagement 116. Although 
this percentage compares favourably to values 
found in other fields of research, it still leaves a large 
percentage of the variance in treatment engagement 
to be explained by other factors. The IM is not clear 
about which exact factors – apart from cognitive 
functioning – are needed to ‘bridge the gap’ 
between MET and TE. It could be an improvement 
on IM to add intermediary factors between the level 
of motivation and the actual treatment engagement. 
Although including such factors will not increase the 
size of the effect of motivation upon behaviour, it will 
generally improve the prediction of the behaviour 
115 and thus create opportunities to beneficially 
influence the pathway to behaviour change and 
maintenance.
Definition and measurement of the constructs 
in the IM
Two instruments have been developed to specifically 
measure the constructs in the IM: the Treatment 
Motivation Scales for Forensic Outpatient Treatment 
(TMS-F) to measure the internal determinants and the 
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Figure 2. The Integral Model of treatment motivation and related concepts, adapted from Drieschner et al. 117
Figure 3. Self-Determination Theory, adapted from Deci and Ryan 48 and Ryan, Patrick, Deci and Williams 123
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level of motivation, and the Treatment Engagement 
Rating Scale (TER). The patient population in which 
the theory and its measures were tested consisted of 
individuals with psychiatric and personality problems 
being treated in a correctional outpatient treatment 
facility. In several studies with this population, the 
measurement instruments were found to be reliable 
and valid 116,118,119. Although the sample in which the 
instruments were validated was a heterogeneous 
one (e.g. 70% had a axis I DSM-IV diagnosis of which 
8% had a psychotic disorder, and 80% has substantial 
characteristics of personality disorders) it remains to 
be determined whether the TMS-f and TER are also 
reliable and valid instruments for use in samples of 
patients with SMI, not necessarily being offenders. 
Prediction of treatment engagement and 
outcomes
In the IM, motivation is regarded as the outcome of 
the combined effects of the internal determinants 
and it can therefore vary in amount, depending on 
the values of the internal determinants. According 
to IM, a higher motivation for treatment induces 
higher treatment engagement and, as a result, a 
better treatment outcome. In several studies in 
forensic psychiatric outpatient centres, Drieschner 
et al. 116,118,119 have generally found support for the 
theory that the internal determinants predict the 
MET which in turn predicts treatment engagement. 
Outcome expectancy was found to be the best 
predictor of MET and also predicts engagement in an 
important degree, albeit indirectly 116. Furthermore, 
treatment engagement was found to predict 
treatment completion and treatment outcome 117. 
These findings seem to support the predictions of 
the Integral Model of the relations between the 
internal determinants, MET, treatment engagement 
and treatment outcome. However, there were also 
some findings that were not in line with IM. For 
example, treatment engagement was best predicted 
by the MET scale and by the subscale of Perception 
of the Suitability of the Treatment, while subscales 
for Distress and the Perceived Legal Pressure were 
found virtually unrelated to MET and treatment 
engagement 116. Also, the perceived suitability of 
the treatment was found to predict the treatment 
engagement directly, beyond the mediated effect 
of MET. These findings indicate that the patient’s 
appraisal of the treatment is most important for 
treatment motivation and treatment engagement, 
while problem recognition, distress and perceived 
legal pressure are not so much. Actually, as we shall 
see later on, these findings seem to fall in line with 
SDT’s postulation that when an individual reports 
motives that are more internalised (such as perceiving 
the treatment as suitable) this is more predictive of 
treatment engagement than external motives (such 
as legal pressure). It appears that the IM is at least 
partially supported, but more research is needed to 
clarify the relationships between the core constructs 
of the IM since the overall empirical attention 
that the IM has been given is still very modest. As 
mentioned before, the IM was developed and tested 
in forensic psychiatric patients indicating the need 
for further testing in other patient populations. 
Intervention strategies and evidence for these 
strategies
As the IM is a continuous model with multiple 
determinants forming the basis for the level of 
motivation, interventions based on this model 
would include influencing these determinants. 
Drieschner and Verschuur 117 have argued that most 
of the internal determinants can be influenced by 
interventions such as motivational interviewing and 
its derivative motivational enhancement therapy, a 
general motivational style or by adherence to the 
responsivity principle (i.e. adapting the treatment 
to a patient’s learning style, cultural background 
and cognitive capacity). The authors of IM have 
not proposed their own specific intervention based 
on the theory, so evidence for the efficacy of IM-
compatible interventions comes indirectly. For 
example, motivational interviewing has been shown 
to be an effective intervention across different 
health behaviours, including alcohol, drugs and 
exercise 120. At the moment, it is unclear whether 
motivational interviewing should be supported to 
use in treatments of individuals with severe mental 
illness or those with a dual diagnosis since evidence 
from randomised trials is inconsistent 121,122. 
Self-Determination Theory (SDT)
Self-Determination Theory (SDT) was developed 
by Deci and Ryan 48. SDT poses that all humans are 
naturally active organisms, focused on growing, 
mastering challenges and integrating new experiences 
into a coherent sense of self 48,64. The social context 
is seen as a crucial influence upon the direction of 
this growth; it can either support it or hinder/stop it. 
According to SDT, this interplay between the active 
human and the social context determines behaviour 
and development. More specifically, SDT uses the 
concept of basic psychological needs for autonomy, 
competence and relatedness as the core ingredients 
for a healthy physical and mental development. If 
these basic psychological needs are not met, certain 
types of psychopathology may develop 82. Figure 3 
visualises how SDT is modelled. 
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According	 to	 SDT,	 autonomous	 motivation	 may	
vary	 from	 intrinsic	 motivation	 to	 types	 of	 extrinsic	
motivation	in	which	people	have	identified	with	the	
value of a change and have integrated this change into 
their sense of self 82. SDT poses that autonomously 
motivated	 people	 experience	 greater	 ownership	
of	 the	 behaviour	 and	 feel	 less	 conflict	 about	
behaving	 in	 accord	 with	 regulations	 and	 external	
demands. For example, an individual who remains 
in a programme or treatment because he feels that 
following	the	treatment	itself	is	exciting	and	pleasant	
(e.g. in a physical exercise programme), would 
be	 an	 autonomously	 motivated	 client.	 Obviously	
not many clients, if any, will present with such a 
motivation	 for	 psychiatric	 treatment,	 as	 treatment	
is	 usually	 followed	 with	 the	 goal	 of	 finding	 relief	
of symptoms or resolving problems and is usually 
not considered to be pleasant in itself. In contrast, 
controlled	motivation	consists	of	external	regulation,	
in which behaviour is regulated by external rewards 
or punishments. When people have a controlled 
motivation,	 they	 experience	 pressure	 to	 behave	 in	
particular	ways.	SDT	then	differentiates	four	types	of	
extrinsic	motivation:	external	regulation,	introjected	
regulation,	 identified	 regulation	 and	 integrated	
regulation.	 External	 regulation,	 in	 which	 people	
engage	 in	 an	 activity	 out	 of	 social	 pressure	 or	 to	
obtain an external reward or avoid punishment, is the 
least	self-determined	form	of	extrinsic	motivation.	In	
this	case,	the	patient	following	psychiatric	treatment	
would	be	motivated	to	remain	in	treatment	because	
he feels pressured by others to do so (e.g. they 
advised	him	 to	do	 so).	Next,	 introjected	motivation	
is	a	more	self-integrated	form	of	extrinsic	motivation.	
Instead	of	being	motivated	by	external	contingencies	
and forces, a person who behaves due to introjected 
motivations	 is	 driven	 by	 internal	 drives	 such	 as	
feelings	of	guilt,	 shame,	and	anxiety.	A	patient	with	
such a drive would feel disappointed in himself or 
ashamed if he would not remain in treatment. SDT 
states	 that	 these	 motivational	 forces	 still	 remain	
external to person’s self, because the individual 
does not fully endorse them. Moving further along 
the	 continuum,	 identified	 motivation	 is	 the	 third	
form	of	extrinsic	motivation,	in	which	the	individual	
recognises and accepts the underlying value of 
certain behaviour. As Deci and Ryan 48 state it: “By 
identifying	 with	 a	 behaviour’s	 value,	 people	 have	
more	fully	internalized	its	regulation;	they	have	more	
fully	accepted	 it	as	 their	own”(p.236).	The	resulting	
behaviour would be more autonomous, although 
still	 instrumental	 rather	 than	 integrated	 into	 the	
individual’s sense of self. Finally, the most complete 
form	 of	 internalisation	 of	 extrinsic	 motivation	 is	
integrated	 motivation.	 Integrated	 motivation	 not	
only	 involves	 identifying	 with	 the	 importance	 of	
the	 behaviour,	 but	 is	 also	 about	 integrating	 those	
identifications	 with	 other	 aspects	 of	 the	 self.	 A	
separate	 category	 of	 motivation	 exists	 for	 people	
who	experience	no	regulation	at	all	(neither	external	
nor internal) over their behaviour, and therefore lack 
any	intention	to	behave	in	a	certain	way.	This	state	is	
called	amotivation.	 In	 this	 case,	 the	patient	 is	 likely	
to reject or drop out from treatment soon. According 
to	SDT,	amotivation	may	be	caused	by	a	lack	of	self-
efficacy	and	an	external	locus	of	control	48. 
 Theoretically, SDT is appealing because of its 
addition of a qualitative aspect to the motivation 
concept. The differentiation between different types 
of motivation, especially different types of extrinsic 
motivation, could prove beneficial and relevant 
for use in a context of patients with motivational 
issues such as those with SMI. To know not only 
the level of motivation of the patient but also the 
reasons behind it, could help clinicians to better 
guide patients towards resolutions of possible 
motivational conflicts while moving towards the 
desired behaviour change. However, as we shall 
discuss in the following, SDT has not (yet) been able 
to produce a measure that can assess all six types of 
motivation to engage in treatment. 
Definition and measurement of the constructs 
in SDT
Within SDT, different constructs are operationalised 
by different measures. A separate scale was 
developed to study motivation for entering 
psychiatric treatment. This scale, called the 
Treatment Motivation Questionnaire (TMQ), has 
been studied in patients with alcohol addiction 35, 
in a study of people attending a methadone clinic 
124 and among people with severe and persistent 
mental illness 125. In this latter study, adult patients 
with a psychotic disorder or with a major mood 
disorder with psychotic features were assessed 
with an adapted version of the original TMQ. The 
original TMQ consists of 26 items reflecting four 
theoretical constructs: intrinsic motivation, extrinsic 
motivation, help-seeking and confidence in success 
of treatment. In the adapted version of the TMQ 
for the population of people with SMI, a five-factor 
solution was found in which an additional introjected 
motivation	 subscale	 was	 identified	 125. This version 
of	 the	 TMQ	 still	 provided	 support	 for	 the	 SDT	
framework	 in	 which	 external	 motivation	 was	 found	
to be an overarching construct comprising several 
sub-dimensions	 of	 emotion	 regulators	 (i.e.	 external	
motivation	and	introjected	motivation).	Furthermore,	
Wild, Cunningham and Ryan 126 have developed the 
Treatment	Entry	Questionnaire	 (TEQ)	 for	patients	 in	
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addiction treatment. The TEQ is an adapted version 
of the TMQ, including more items to be able to more 
clearly discriminate between identified, introjected 
and external motives for treatment. The TEQ formed 
internally	 consistent	 dimensions	 for	 external	 (α	 =	
.89),	 introjected	(α	=	.89)	and	identified	motivation	
(α	 =	 .85).	 As	mentioned	previously,	 a	 disadvantage	
of using the TMQ or TEQ is that it does not assess 
all six types of motivation. Also, the TMQ and TEQ 
have thus far not become commonly used with 
any population and studies supporting the use of 
these questionnaires come primarily from the same 
source, the people who have developed SDT 127. 
Although the TMQ appears to be a valid measure 
to use in a population of patients with SMI 125, it is 
unclear whether this is also the case for the extended 
version (the TEQ). 
Prediction of treatment engagement and 
outcomes
According to SDT, the more internal (i.e. autonomous) 
perceived cause of a person’s behaviour, the more 
likely the person is to persist in this behavioural 
activity, and in case of treatment, to adhere to a 
therapeutic regimen. Conversely, the more external 
perceived cause of behaviour, or the more a person’s 
reasons for entering treatment are based on 
external regulators (controlled motivation), the less 
persistence and adherence are expected. Several 
studies have supported these predictions from SDT, 
although only few studies have been conducted 
among patients with (severe) mental illness. A 
study by Zuroff et al. 128 showed that autonomous 
motivation was a stronger predictor of outcome in 
depressed outpatients than therapeutic alliance, 
predicting higher probability of achieving remission 
and lower posttreatment depression scores across 
three different treatments (interpersonal therapy, 
cognitive-behavioural therapy and pharmacotherapy 
with clinical management). Also, patients who 
reported their therapists as more autonomy 
supportive also reported higher levels of autonomous 
motivation 128. A study by Pelletier, Tusson and 
Haddad 129 showed that the more autonomous 
patients were in their motivation for psychotherapy, 
the more satisfied they were with treatment, the 
greater their intention to persist and the lower 
their level of depressive symptoms. In contrast, 
controlled motivation was related to tension, and 
negatively predicted the importance of therapy and 
intention to persist 129. Another study showed that 
higher need satisfaction for autonomy was related 
to improved outcomes in group psychotherapy for 
anxious and depressed patients, and this relation 
was presumably mediated by more treatment 
engagement and a reduction in negative thinking 
induced by cognitive behavioural therapy 130. In a 
study with patients entering addiction treatment, 
Wild et al. 126 showed that external motivation was 
positively correlated with legal referral and social 
network pressures, while identified motivation was 
positively correlated with self-referral. Furthermore, 
it appeared that identified motivation predicted 
attempts to reduce drinking and drug use, more 
strongly than external motivation. Since patients 
with (severe) mental illness frequently have a co-
occuring substance use disorder 58, these findings 
from SDT show promise for its use in this population. 
 However, empirical evidence is still scarce, 
largely cross-sectional and the use of SDT within 
psychotherapy has mainly been promoted by the 
theorists (e.g. by Ryan & Deci 65). Furthermore, two 
studies have produced results that were not predicted 
by SDT. In a study by Ryan et al. 35 among patients 
with alcohol dependence, results revealed an 
interaction effect between internalised and external 
motivations, indicating that those with both high 
internal and high external reasons were most likely 
to persist in treatment. Another study replicated 
this in a methadone treatment programme, where 
it was found that external motivation accompanied 
by internal motivation may aid recovery of addiction 
124. This interaction between internal and external 
motivation is a finding that was not predicted by 
SDT, since the theory holds that external motivation 
would be related to less persistent engagement and 
poorer health outcomes. In fact, these results might 
be better explained by a quantitative motivation 
theory such as IM, where a higher level of motivation 
(i.e. a combination of high external and internal 
motives) is related to better outcomes. 
Intervention strategies and evidence for these 
strategies
SDT	holds	that	social	contexts	that	support	satisfaction	
of the basic psychological needs facilitate the 
internalisation	of	extrinsic	motivations	48. That is, the 
social	 environment	 can	 facilitate	 satisfaction	 of	 the	
basic needs of autonomy, competence and relatedness 
by providing autonomy support, structure, and 
involvement,	 respectively.	For	example,	 competence	
is	facilitated	when	patients	are	helped	to	develop	clear	
and	realistic	expectations	and	goals	about	behaviour	
change, they are encouraged to believe that they 
are capable of engaging in appropriate behaviours, 
and are given positive feedback regarding their 
progress 82. However, providing support for only 
one basic need such as competence is insufficient 
to promote internalisation of motivation 48. A 
motivationally supportive environment provides 
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support for autonomy, competence as well as 
relatedness 48. The need for autonomy is supported 
when patients are helped to develop a personally 
meaningful rationale for engaging in behaviour, 
by minimising external controls and contingencies 
upon the behaviour, by providing opportunities 
for active participation and choice and by 
acknowledging negative feelings associated with 
engaging in appropriate behaviour that is difficult 
to accomplish 131. In SDT the role of relatedness 
and involvement has received less attention than 
autonomy and competence, but involvement 
describes the extent to which patients perceive that 
significant others are genuinely interested in them 
and their well–being, understand the difficulties 
they are facing, and are emotionally supportive 48. 
 Several studies have found support for SDT’s 
prediction that perceived autonomy support 
facilitates the development of more autonomous 
motives for change 124,132-136. However, of the 
randomised controlled trials that have been 
conducted to investigate this hypothesis from 
Criterion Description TTM IM SDT
Clarity Has well-defined terms that are 
operationalised and explicit and 
internally consistent. Explicit 
propositions are preferred.
+  Explicit terms are operationalised
-  Debate about the 
operationalisation of the stages 
of change 
-  Propositions regarding processes 
of change not always clear (e.g. are 
they mediators or moderators?)
+ Explicit terms are operationalised
-  Unclear proposition about role of 
‘external factors’ 
+ Explicit terms and propositions
-  Not all terms operationalised (e.g. 
all types of motivation)
-  No proposition for the combination 
of high autonomous and high 
external motivation
Consistency The components do not contradict 
each other. There is fit between 
concepts, propositions and clinical 
exemplars.
+  Good fit between concepts and 
clinical exemplars
+  Good fit between concepts and 
propositions
+  Good fit between concepts and 
propositions
Parsimony Explains the phenomenon in the 
least complex manner possible. 
+  Separate constructs easy to 
understand 
-  Complex model with many 
interrelations between constructs
+  Distinction between determinants 
and consequences of motivation
-  Large number of determinants
+ Simple model, easy to understand
Testable The propositions can be tested, 
with the potential to be falsifiable 
or refuted.
+ + +
Empirical validity The theoretical claims are congruent 
with evidence. 
+  Many studies have been done 
across different life domains
-  Mixed evidence is found
-  Little research has been done in 
populations of patients with SMI
+  Predictive power confirmed in 
forensic psychiatric patients
-  Few amount of studies
-  No research has been done outside 
forensic setting
+  Many studies have been done 
across different life domains
-  Little research has been done in 
populations of patients with SMI
Productivity Reveals new phenomenon or 
relations among those already 
known. Generates new questions 
and ideas and adds to the knowledge 
base.
+  Generates new ideas and has 
added to knowledge base
+  Heuristic value
-  Small addition to knowledge base 
(relatively new theory)
+  Generates new ideas and has 
added to knowledge base
Generalisable Generalises to other situations, 
places and times. Extends far beyond 
particular observations and laws that 
it was designed to explain.
+  Applied to broad range of 
behaviours (e.g. smoking, diet, 
exercise, condom use, drug abuse)
-  Specific theory about motivation 
for psychiatric treatment 
+  Applied to broad range of 
behaviours (e.g. parenting, 
education, exercise, work, health)
Integration A set of constructs are combined in 
systematic and meaningful patterns, 
first conceptually, then empirically, 
and ideally mathematically.
+ Meaningful conceptualisation
+  The initial model was adjusted to 
empirical evidence 
+  Strong and weak principle 
(mathematical pattern)
-  Empirical pattern of processes of 
change less clear
+  Meaningful conceptualisation
+  The initial model was adjusted to 
empirical evidence
-  No mathematical principle
+ Meaningful conceptualisation
+  The initial model was adjusted to 
empirical evidence
- No mathematical principle
Utility Provides service and is useable. +  One of the most widely used and 
influential models
+  Provides service to specific 
population 
-  Few empirical tests
+  Utility has increased the last two 
decades
Practical A theory-based intervention is 
demonstrated to have significant 
efficacy, producing greater behaviour 
change than a placebo or control.
+  Appeals to clinicians and is most 
commonly used theory across a 
broad range of behaviours
-  Mixed evidence is found
-  No evidence for practical use in 
patients with SMI
-  Theory does not imply a specific 
intervention
+  Theory-based intervention 
efficacious for tobacco 
dependence, physical activity and 
dental hygiene
-  No evidence for practical use in 
patients with SMI
Table 1. Evaluation criteria applied to the three motivation theories in the context of psychiatric treatment motivation, showing their 
strong (+) and weak/not sufficiently determined (-) points
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SDT, none have so far focused upon patients with 
(severe) mental illness. Therefore, SDT is in need of 
prospective investigations and randomised trials to 
see whether the theory’s predictions hold for this 
population. 
Critical reflection upon the three 
theories
Table 1 shows the most common evaluation criteria 
that are used to evaluate the quality of theories, which 
we adapted from Prochaska, Wright and Velicer 137. 
Several points that are noted in this table should be 
explained. For example, although all three theories 
have clear and well-defined concepts, the TTM and 
SDT have issues pertaining to the operationalisation 
of constructs (i.e. how the stages of change should 
be measured and that not all motivational types are 
present in current measures, respectively) and some 
of the propositions of the IM and TTM are unclear. 
All three theories are productive and provide ideas 
that generate research. For example, TTM provides 
a temporal framework for motivation as represented 
by the stages of change, whereby engaging in 
the processes of change would predict stage 
movements. The IM disentangles the determinants 
of motivation from its effects (different from TTM) 
and views motivation as a primarily quantitative 
concept (similar to TTM). Finally, SDT appears to 
differentiate itself from these two theories with 
its postulation of basic psychological needs that 
determine the development of specific types of 
motivation (amotivation, external, introjected, 
identified, integrated and intrinsic motivation) 
which in turn predict treatment engagement and 
outcomes. All models are testable but as far as 
empirical tests of the theories have been conducted 
among individuals with SMI, it appears that the 
findings show mixed evidence for the theories’ 
predictive and explanatory strengths. 
 Taking these critical points together, it is difficult 
to conclude which theory is overall currently superior 
to the other theories in the context of psychiatric 
treatment motivation and engagement. For TTM, 
long-standing issues pertaining to the measurement 
and distinctiveness of the stages of change and the 
relatively little empirical attention that has been 
dedicated to the processes of change currently appear 
to stand in the way of theoretical advancement 
for this theory. Also, empirical support for the 
hypothesis that matching interventions to specific 
TTM stages is beneficial appears to be lacking 79,108,111 
and application of stage-matched interventions to 
patients with SMI thus seems premature. The IM has 
only been studied in a forensic psychiatric setting 
and although these findings show promise for its 
application in other populations, the current value 
for patients with SMI is unknown. Regarding SDT, the 
scarce empirical evidence that is available regarding 
patients with mental illness shows general support 
for the theory, but no longitudinal studies have yet 
been conducted among patients with SMI indicating 
the need for further investigations. 
 The question whether a continuous model (i.e. 
IM or SDT) or a stage-based theory (i.e. TTM) is most 
valuable to use as a basis for the improvement of 
treatment engagement and treatment outcomes in 
patients with (severe) mental illness appears to fall 
in favour of continuous models, although it should 
be noted that all three theories have been scarcely 
investigated among individuals with SMI. Littell and 
Girvin 79 have argued that: “Although a stage model 
may have greater intuitive appeal, a continuous 
model of readiness for change is more parsimonious 
and may be more easily integrated with related 
concepts from other theories. (…) A continuous 
model may fit the data better than a stage model, 
although continuous measures of readiness for 
change have not yet been thoroughly tested” 
(p. 253). 
 The question whether a quantitative approach 
or qualitative approach to motivation is superior for 
the prediction of treatment engagement remains to 
be answered, since all three theories have thus far 
shown mixed findings. For example, we have shown 
that research findings that were not well predicted 
by IM could be explained by SDT and vice versa. One 
study by Vansteenkiste et al. 138 has readily addressed 
the question of quantity versus quality of motivation 
in a sample of high school and college students, to 
see which approach best predicted optimal learning 
patterns. Four motivation profiles were constructed 
from a SDT perspective: a good quality motivation 
group (i.e., high autonomous, low controlled); a poor 
quality motivation group (i.e., low autonomous, 
high controlled); a low quantity motivation group 
(i.e., low autonomous, low controlled); and a high 
quantity motivation group (i.e., high autonomous, 
high controlled). The authors compared predictions 
from qualitative and quantitative perspectives 
on motivation and found that compared with the 
other profiles, the good quality motivation group 
showed the most optimal learning pattern 138. Such 
an approach adapted to motivation for treatment in 
patients with (severe) mental illness could shed more 
light on the qualitative versus quantitative debate 
with respect to the prediction of treatment 
engagement and outcomes. 
 In the following, we intend to relate the 
three theories to each other, in order to further 
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disentangle their common and unique contributions 
to the motivation concept. In doing so, we hope 
to demonstrate that the theories are generally 
compatible with each other and can be studied 
simultaneously to address relevant research 
questions.
Compatibility of constructs within the 
theories
The core constructs of the TTM, IM and SDT can 
be disentangled into seven common domains: 
(1)	 attitudinal	 beliefs,	 (2)	 self	 efficacy	 beliefs,	 (3)	
reinforcements	 and	 environmental	 influences,	 (4)	
emotional	 responses,	 (5)	 motivation,	 (6)	 behaviour	
and (7) outcome. These domains have been 
summarised in Table 2 where similar constructs 
across the theories are compared in the rows. For 
example, when the decisional balance construct of 
TTM	 is	 specifically	 applied	 to	 psychiatric	 treatment	
engagement,	where	patients	evaluate	whether	or	not	
to engage in their treatment, decisional balance is 
comparable to the constructs called ‘perceived costs 
of treatment’ and ‘outcome expectancy’ in IM, since 
they	 are	 concerned	 with	 appraisal	 of	 the	 positive	
Concept Integral Model of treatment 
motivation
TransTheoretical Model Self-Determination Theory
Attitudinal beliefs
Appraisal of the positive and negative aspects 
of the behaviour and expected outcome of the 
behaviour
Outcome expectancy and perceived 
costs of treatment
(internal determinant)
Pros and cons 
(decisional balance)
-
Problem recognition; awareness about one’s 
problem behaviour
Problem recognition (internal 
determinant)
Consciousness raising (experiential 
process of change)
-
Beliefs about the efficacy of the treatment Perceived suitability of treatment - -
Self-efficacy beliefs
Belief in one’s ability to perform the behaviour; 
confidence
Self-efficacy
(as a part of outcome expectancy within 
the internal determinants)
Self-efficacy Perceived competence*
Reinforcements and environmental influences
External contingencies Perceived external pressure
(internal determinant)
Reinforcement management
(behavioural processes of change)
External regulation
(type of regulation)
Support and responses of others Social network 
(external determinant)
Helping relationships (behavioural 
process of change)
Environmental reevaluation and social 
liberation (processes of change)
Environment that is supportive of 
autonomy, competence and relatedness 
Emotional responses
Experiencing negative emotions due to the problem 
behaviour and coping with these emotions
Distress
(internal determinant)
Dramatic relief and Self-re-evaluation
(experiential process of change)
Introjected regulation 
(type of regulation)
Motivation
Not intending to perform the behaviour, not 
making commitments to change
Low motivation to engage in treatment Precontemplation 
(stages of change)
Amotivation
Intending to or planning to perform the behaviour; 
setting goals or making a commitment to perform 
the behaviour
High motivation to engage in treatment Contemplation/preparation (stages of 
change) 
and self-liberation (behavioural process 
of change)
High extrinsic and high intrinsic 
motivation**
Behaviour
Performing the healthy behaviour; engaging in 
treatment 
Treatment engagement Action 
(stages of change)
(Non-)Self-determined treatment 
engagement ***
Outcome
Long-term outcome of the behaviour Treatment outcome Maintenance and termination
(stages of change)
Treatment outcome
Table 2. Comparing core constructs across the three motivation theories
Variable names in parentheses indicate that the variable(s) above it are part of that larger category, according to the theory
*  SDT maintains that the self-efficacy theory view stands in contrast to the need for competence, which implies that the experience of 
competence in and of itself is a source of satisfaction and a contributor to well-being over and above any satisfaction resulting from 
the outcomes that competence might yield.
**  SDT states that when the source of motivation is external, the behaviour resulting from this type of motivation will show poor transfer 
once contingencies and external pressure are withdrawn.
***  SDT states that the more self-determined the behaviour (e.g. treatment engagement) the better the maintenance of this behaviour 
will be, while non-selfdetermined behaviour is associated with poor maintenance. 
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and	 negative	 aspects	 of	 treatment	 engagement.	
Furthermore,	 it	 appears	 that	 self-efficacy,	 broadly	
defined	as	the	belief	that	one	is	capable	or	competent	
in achieving desirable behaviour, is incorporated in all 
three	 theories	albeit	 in	different	ways.	For	example,	
SDT	 holds	 that	 self-efficacy	 needs	 to	 be	 combined	
with a sense of autonomy in order to achieve the 
most	positive	outcomes	 48 whereas the IM and TTM 
do	not	appear	to	make	such	a	distinction.	
 Also interesting is that within SDT, a distinction 
is made between short-term and long-term effects 
of reinforcements. According to SDT, reinforcements 
facilitate external motivation which may lead to 
short-term behaviour change but will show poor 
maintenance and transfer once contingencies and 
external pressure are withdrawn. SDT states that 
rewards and threats undermine autonomy and thus 
lead to decreased intrinsic motivation and more 
negative outcomes 48. Contrasting this is the view 
of TTM, where reinforcement management would 
predict movement from the action to the maintenance 
stage. Thus, interventions based on TTM would 
include rewarding the patient for making beneficial 
changes and stimulate the patient to reward himself 
for making changes. Interventions based on SDT 
would not include reinforcements as these external 
regulations are often experienced as controlling 
one’s behaviour 139 and are counterproductive for 
the development of intrinsic motivation, leading 
to poor maintenance of the behaviour change. 
Interestingly, DiClemente (1999) has noted that 
intrinsic and extrinsic motivation types differ with 
regard to their long-term outcomes and that: 
“personal pros and cons are more important than 
external incentives in the long run. Sustained change 
must be reinforced by incentives that are owned by 
the individual, so that they become integrated into 
the life of that individual” (p.211). Nevertheless, this 
insight has not yet established itself in the form of 
an adaptation of TTM. It appears that both TTM and 
IM expect that the level of motivation will increase 
when strategies such as rewards (reinforcements) 
and threats (legal pressure) are applied, whereas SDT 
predicts differential effects on the type of motivation 
(and subsequent behaviour) that will result from 
these strategies. These different predictions call 
for empirical tests, as do other research questions 
regarding the three theories (summarised in Table 3).
Compatibility of the three theories
In Figure 4, we have visualised how all three models 
might relate to each other. To start at the top of the 
figure with the IM, this model clearly distinguishes 
the determining factors of motivation to engage 
in treatment (MET) from its manifestation into 
behaviour. This way, the model provides reasons 
as to why an individual has a certain level of 
motivation for treatment. TTM does not incorporate 
the determinants of allocations to certain stages, 
although based on the descriptions of stages one 
could extract some. Rather, TTM describes when 
individuals change by engaging in change processes. 
It could be argued that at a conceptual level, moving 
from precontemplation through contemplation 
to preparation in TTM, the level of MET in the IM 
increases as we come closer to the actual action 
(active manifestation of the behaviour). For example, 
a low level of MET might correspond with either the 
precontemplation or contemplation phase, where 
patients are unwilling or not ready to engage in 
behaviour change, but have been thinking about it. 
Also, a high level of MET could correspond with later 
stages such as the preparation or action stage.
 In SDT, the motivation concept revolves 
primarily around the type of motivation. This 
conceptualisation of motivation is clearly distinct 
from the other models. Nevertheless, some authors 
have hypothesised links between SDT and TTM and 
have proposed SDT’s internalisation process to be 
associated with stage movement within TTM (e.g. 
Dunlap 97,	 Kennedy	 &	 Gregoire	 127, Vansteenkiste, 
Soenens and Vandereycken 140 and Abblett 141). 
Vansteenkiste et al. 140 have argued that TTM seems 
compatible with the concept of internalisation 
of change and thus with the idea of the types 
of motivation within SDT. However, from an SDT 
perspective the critical question would not be to 
which extent patients find themselves in a certain 
stage, but why they are in that stage. There is 
some preliminary evidence that as internalisation 
increases, so does the individual’s advancement 
along the TTM stages142. For example, it has been 
found that people entering drug abuse treatment 
with high levels of internal motivation were more 
likely to be in the action stage than people with high 
levels of external motivation 127. In another study, 
it was found that the use of more identified and 
intrinsic forms of behaviour regulation distinguished 
those in action and maintenance stages from those 
in contemplation and preparation stages 143. These 
findings suggest that the level of internalisation 
differs for people in different stages of change, where 
amotivated or externally regulated individuals might 
be more prevalent in the precontemplation stage, 
whereas individuals who have an integrated form of 
motivation might be more prevalent in action and 
maintenance stages. In Figure 4, this relationship 
between the models is represented by the dotted 
lines between the precontemplation phase in TTM 
and amotivation in SDT, and the dotted line between 
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Figure 4. Visualisation of the three motivation theories and their potential interrelations
IM: Integral Model; TTM: TransTheoretical Model; POC1: Processes of change (consciousness raising, dramatic relief); POC2: Processes of 
change (self-reevaluation); POC3: Processes of change (self-liberation); POC4: Processes of change (reinforcement management, helping 
relationships, counterconditioning, stimulus control); S: Self-efficacy; DB: Decisional Balance; SDT: Self Determination Theory.
Table 3. Possible research questions pertaining to TTM, IM and SDT in the context of psychiatric treatment for patients with severe 
mental illness
Theory Research questions
TTM Do stage algorithms or continuous measures of the stages of change provide better prediction of treatment engagement and outcomes?
Do the processes of change predict stage transitions for patients with SMI?
Do SMI patients in psychiatric treatment in lower stages show higher rates of drop-out than patients in higher stages?
IM Are the TMS-f and TER valid and reliable measures in patients with SMI?
What factors, apart from the level of motivation to engage in treatment, are predictive of actual treatment engagement in patients with SMI?
Does the level of motivation to engage in treatment have predictive value for treatment engagement and outcome in patients with SMI?
SDT Is it possible to distinguish the six types of motivation as postulated by SDT?
Is the TEQ a valid and reliable measure for patients with SMI?
Do the motivational types from SDT have predictive value regarding treatment engagement and treatment outcomes in patients with SMI?
Does the support of the basic psychological needs predict internalisation of motivation in patients with SMI?
Theory comparisons Does the stage-based TTM or the continuum-based IM provide better prediction of treatment engagement and outcomes in patients with SMI?
Does a quantitative approach to motivation provide better prediction of treatment engagement than a qualitative approach?
Is there a difference between self-efficacy (TTM and IM) and perceived competence (SDT)?
Are similar constructs from the different theories (see table 2) actually identical?
Is reinforcement management predictive of the quantity and quality of motivation?
Is reinforcement management predictive of long-term treatment engagement and outcomes?
Are the relations between the three theories as proposed by figure 4 in this article supported by empirical evidence? For example;
- Is the level of MET (IM) related to the stages of change (TTM)?
- Is the level of treatment engagement (IM) related to stages of change (TTM)?
- Is SDT’s internalisation process related to the stages of change (TTM)?
- Are the internal determinants (IM) related to different motivational types (SDT)?
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the preparation stage and intrinsic motivation, 
respectively. Abblett 141 describes SDT as providing 
the molecular mechanisms of how motivation is 
created, and TTM as providing an infrastructure for 
understanding the processes of change. Also, where 
in the IM and TTM it seems relatively important that 
a person engages in treatment, in SDT it is important 
how (self-determined) a person engages in his/her 
treatment. Some interesting research questions 
pertaining to these three theories and their 
interrelations are presented in Table 3. It should 
be noted that Noar and Zimmerman 75 have also 
suggested important theory comparison questions 
which could be applied to these three theories.
Conclusion
The TTM, IM and SDT provide distinct, but in our 
view compatible conceptualisations of treatment 
motivation. The TTM provides a temporal 
framework for motivation as represented by the 
stages of change, in which cognitive and behavioural 
components have been recognised 37,88 while 
IM disentangles the determinants of motivation 
from its effects. SDT appears to differentiate itself 
from these two theories with its postulation of 
basic psychological needs that determine the 
development of specific types of motivation for 
particular behaviours. The theories include several 
common theoretical constructs such as self-efficacy 
and reinforcement strategies, but sometimes predict 
different effects of these constructs upon treatment 
engagement and outcomes. For example, although 
all three theories acknowledge that reinforcement 
strategies have an effect upon motivation and 
treatment engagement, TTM and IM predict that 
reinforcements lead to a higher level of treatment 
motivation and better maintenance of the desired 
behaviour, while SDT holds that reinforcements 
undermine the development of more autonomous 
motivation and thus ultimately to poor maintenance 
of the desired behaviour. 
At present it remains unclear which theory is 
most effective in predicting behaviour change and 
maintenance, and also which theory is best suited 
for use within clinical practice. Future research 
should focus upon empirical comparisons of these 
(and other) theories, in order to aid optimal decision 
making on which theories are most plausible and 
most useful for clinical practice. A comparison of 
theories is a complex challenge, but several authors 
have reflected upon this and provided guidelines 
75-77,144. To reduce patient burden, comparable 
constructs from different theories could be assessed 
with a single measure. For example, this could apply 
to the decisional balance constructs and problem 
recognition, and possibly also for the patients 
perception of external pressures and social relations. 
The unique aspects of the theories ask for theory-
specific measures, such as the stages of change 
within TTM, perceived suitability of treatment 
within IM, and different motivational types within 
SDT. To conclude, it is of particular interest to design 
and conduct theory comparison studies among 
subgroups of patients, such as those with severe 
mental illness, to advance what is currently known 
about how well the TTM, IM and SDT account for 
intrapersonal changes and interpersonal differences 
in treatment engagement and treatment outcome. 
In turn, this could aid in the development of effective 
interventions to improve treatment retention and 
outcome.
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Objective
This chapter describes the study protocol for a 
cluster randomized controlled trial that serves three 
purposes: 1) to determine whether a feedback 
intervention based on the patients’ motivation 
for treatment is effective at improving treatment 
engagement (TE) of severe mentally ill patients 
in outpatient psychiatric treatment, 2) to gather 
insight into motivational processes and possible 
mechanisms regarding treatment motivation 
(TM) and TE in this patient population and 3) to 
determine which of three theories of motivation is 
most plausible for the dynamics of TM and TE in this 
population.
Methods
The Motivation and Treatment Engagement 
Intervention Trial (MotivaTe-IT) is a multi-
center cluster randomized trial investigating the 
effectiveness of feedback generated by clinicians 
regarding their patients’ treatment motivation upon 
the patients’ TE. The primary outcome is the patients’ 
TE. Secondary outcomes are TM, psychosocial 
functioning and quality of life. Patients whose 
clinicians generate monthly motivation feedback 
(additional to treatment as usual) will be compared 
to patients who receive treatment as usual. An 
estimated 350 patients, aged 18 to 65 years, with 
psychotic disorders and/or severe personality 
disorders will be recruited from outpatient 
community mental health care. The randomization 
will be performed by a computerized randomization 
program, with an allocation ratio of 1:1 (team vs. 
team or clinician vs. clinician) and patients, but not 
clinicians, will be blind to treatment allocation at 
baseline assessment. Due to the nature of the trial, 
follow-up assessment can not be blinded. 
Conclusion
The current study can provide important insights 
regarding motivational processes and the way 
in which motivation influences the treatment 
engagement and clinical outcomes. The 
identification of possible mechanisms through which 
changes in the outcomes occur, offers a tool for the 
development of more effective future interventions 
to improve TM and TE.
Trial registration: Current Controlled Trials NTR2968
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Introduction
This chapter describes the study protocol for the 
Motivation and Treatment Engagement Intervention 
Trial (MotivaTe-IT). MotivaTe-IT serves two purposes: 
1) to determine whether a feedback intervention 
based on the patients’ motivation for treatment is 
effective at improving treatment engagement (TE) of 
severe mentally ill patients in outpatient psychiatric 
treatment, and 2) to gather insight into motivational 
processes and possible mechanisms regarding 
motivation for treatment and treatment engagement 
in this patient population. In the following, we will 
describe why we chose to use motivation feedback 
as the intervention in this study.
Motivation feedback intervention
Studies employing feedback to clinicians have shown 
that monitoring and informing clinicians of their 
patients’ treatment progress in psychotherapy is 
effective in enhancing retention and outcome 145-
150. Providing systematic feedback can be seen as an 
addition to regular treatment and may guide changes, 
prolongation or termination of treatment. It ensures 
that the attempts to resolve the problems can be 
evaluated, and if necessary, adjusted 151. In several 
studies by Lambert et al. 145,146,148 in a psychotherapy 
setting, progress feedback was based upon four 
domains of functioning, including psychological 
disturbance (mainly depression and anxiety), 
interpersonal problems, social role functioning 
and quality of life 149. The effects of feedback were 
most pronounced in patients who showed a poor 
initial response to treatment 147. Feedback is also 
increasingly being researched in other settings. 
In a study in patients with psychotic disorders in a 
community mental health setting, patients were 
asked to rate their quality of life and satisfaction 
with treatment, which was fed back to clinicians and 
discussed 152.When compared to control patients 
(who did not make use of feedback) after 12 months, 
patients in the feedback condition reported better 
quality of life, fewer unmet care needs and higher 
satisfaction with treatment. However, the groups 
showed no statistically significant difference on 
psychopathology scores (i.e. positive, negative or 
general symptoms of schizophrenia). In another study 
conducted among SMI patients receiving community 
care, where clinicians received feedback on their 
patients’ care needs, a significant improvement 
was found in patient satisfaction, but not on 
psychopathology, social functioning and quality of 
life 153 when compared to controls. A study conducted 
in the Netherlands among patients with severe 
mental illness, found that systematic monitoring of 
patients’ care needs in combination with feedback 
provision was associated with global improvement 
in depression and anxiety symptoms, but not with 
improvement in manic excitement and positive 
symptoms 154. It seems that structured feedback 
has positive effects on some central outcomes of 
community mental health care (e.g. quality of life 
and patient satisfaction) but not on others (e.g. 
level of symptoms or functioning), depending on the 
setting and the content of the feedback. In a study by 
Whipple et al. 148 a more extensive form of feedback 
was used when compared to the Lambert et al. 
studies 145,146, where the authors found that using 
clinical support tools (CSTs) additional to feedback 
upon the client’s progress resulted in clients staying 
in therapy longer, and that these clients were twice 
as likely to show superior outcomes. These CSTs 
incorporated measures to assess the therapeutic 
relationship, the motivation to change and the social 
support network. These results line up with other 
studies about feedback to clinicians and point out 
that the use of support tools is of additional value 
148. However, a limitation of Whipple’s study was that 
it was not possible to determine the effects of the 
individual components (e.g. motivation to change) 
in the CSTs upon outcome. Some studies have 
compared the effects of personalized feedback with 
the effects of motivational interviewing including 
personalized feedback, and found that feedback 
only is less effective than motivational interviewing 
with feedback in achieving behaviour change 155-
157. Therefore, next to providing feedback, it seems 
important to apply additional strategies in order 
to improve the motivation of patients to engage in 
treatment.
 The aforementioned clinician feedback research 
has focused primarily upon treatment progress and 
was unable to determine which specific element(s) 
from the clinical support tools provided the 
mechanism(s) of action. Since treatment motivation 
has been found to be of crucial importance in this 
matter 29,35-37, the current study set out to place 
treatment motivation in a central position. The 
feedback that will be provided to the clinicians in 
the current study revolves around the patients’ 
motivation to engage in their treatment. Therefore, 
our feedback intervention is labelled motivation 
feedback. The feedback to clinicians will be based 
upon the current motivational state of their patients 
regarding their motivation for remaining and 
engaging in treatment. Furthermore, solely providing 
feedback to clinicians of patients with severe 
mental illness might not be sufficiently intensive 
to improve treatment engagement 148. To aid 
clinicians in addressing motivational problems that 
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become evident from the feedback, clinicians will 
be educated in motivation enhancement strategies 
based on Self-Determination Theory 48,64. Despite 
the differences between the Transtheoretical Model 
44, the Integral Model of Treatment Motivation 37, 
and Self-Determination Theory 48 on the concept 
of treatment motivation, these theories may 
complement each other 86. A detailed discussion 
of similarities and differences in how these three 
theories predict treatment engagement and 
outcomes can be found in Jochems et al. 86. 
 We chose Self-Determination Theory (SDT) 64 as 
the basis of our motivation feedback intervention, 
since this theory encompasses both a qualitative 
and quantitative view of motivation and the 
intervention strategy that it implies seems suitable 
for patients with SMI. In brief, SDT postulates 
different types of motivation, where the most 
central distinction is made between autonomous 
(i.e. self-determined) motivation and controlled (i.e. 
externally determined) motivation. Autonomous 
motivation may vary from intrinsic motivation to 
types of extrinsic motivation in which people have 
identified with the value of a change and have 
integrated this change into their sense of self 82. 
SDT poses that autonomously motivated people 
experience greater ownership of the behaviour, will 
have greater intention to persist in treatment and 
have better mental health outcomes 65,82. In contrast, 
controlled motivation consists of external regulation, 
in which behaviour is regulated by external rewards 
or punishments, and introjected regulation, where 
the drive for behaviour is partially internalised and 
energised by avoidance of shame, guilt and anxiety 
64. When people have a controlled motivation, they 
will show poorer health outcomes according to 
theory 82. Furthermore, SDT states that fulfilling the 
patients’ basic psychological needs of autonomy, 
competence and relatedness during treatment will 
facilitate internalization of motivation for treatment, 
leading to better health outcomes 82. 
Methods/Design
Aims
The study has three main objectives. The primary 
objective is to determine the effects of the motivation 
feedback intervention on treatment engagement 
(TE) of patients with psychotic and/or personality 
disorders. Secondary outcomes are the patient’s 
treatment motivation, psychosocial functioning and 
quality of life. To this end, clinicians will be randomly 
assigned to either of two groups; one group will 
generate SDT-based feedback on the motivation of 
their patients while the other group will not. 
The second objective is to determine the factors 
associated with the effect of our motivation 
feedback intervention upon the primary and 
secondary outcomes. Several demographic and 
clinical factors as well as factors that have a theory-
based and/or empirically established relationship 
with the outcomes will therefore be assessed. At the 
moment, it is unclear which exact factors are most 
important so this will be studied explorative. 
 The third and final objective of the study is 
to determine which theory of motivation is most 
plausible for the dynamics of TE and treatment 
motivation in patients with psychotic disorders and 
personality disorders in outpatient treatment. The 
models selected here are the Transtheoretical Model 
(TTM) 44, the Integral model of treatment motivation 
(IM) 37 and Self-Determination Theory (SDT) 64. In a 
literature review that we have performed earlier, we 
have described these theories in detail, including 
their differences and similarities 86. We will explore 
which of three theories (i.e. TTM, SDT, and IM) is 
most supported by the data in predicting treatment 
motivation and engagement. It is possible that 
different subcomponents of these theories will be 
integrated in a novel theoretical-empirical model 
tailored to this specific population. 
Hypotheses
It is hypothesized that motivation feedback to 
clinicians on the treatment motivation of their 
patients will lead to an increase in both the quantity 
and quality of treatment motivation and treatment 
engagement of these patients. The patient’s self-
reported motivation and the clinician-reported 
motivation of the patient are expected to induce 
more awareness regarding motivational issues that 
are at play during treatment, and subsequently to 
more suitable (motivational) interventions leading 
to better outcomes (i.e. treatment engagement 
and	 psychosocial	 functioning).	 More	 specifically,	
we expect the increase in quantity and quality of 
motivation will follow the patterns shown in Figure 
1. For example, in the intervention group we expect 
a larger increase in autonomous motivation (concept 
from SDT), a larger proportion of patients making 
forward shifts in the stages of change (concept 
from TTM) and a larger increase in motivation to 
engage in treatment (concept from IM) relative to 
the control group. As a consequence, we expect 
the intervention group to show a higher level of 
treatment engagement than the control group at the 
time	of	follow-up,	as	demonstrated	by	higher	clinician-
rated	treatment	engagement,	less	no-shows	and	better	
antipsychotic	 medication	 adherence	 in	 the	 patients	
with	psychotic	disorders.	
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Control Condition: Treatment as Usual
The control condition consists of patients who are 
provided treatment as usual (TAU). These patients 
receive care that is guided by their individual 
symptoms, problems and needs. Treatment may 
consist of assertive outreach, medication, cognitive 
(behavioural) therapy, stress-management, family 
therapy, and/or supportive structured therapy. 
Assertive outreach is provided by Flexible Assertive 
Community Treatment (FACT) teams. FACT is a team 
treatment model that aims to provide community-
based, assertive, outreaching and supportive 
psychiatric services to individuals with SMI 14,15. 
Besides assertive outreach, which is the key feature 
of Assertive Community Treatment (ACT), there 
is an emphasis on out-of-office interventions and 
home visits, but when patients constitute a danger 
to themselves or others and are not motivated for 
treatment, clinicians can start a procedure for them 
to be committed to a psychiatric hospital 14. During 
hospitalisations, the ACT team keeps into contact 
with the patient to secure continuity of care. In 
the Netherlands, a special type of ACT teams exist, 
called Flexible-ACT (FACT). Van Veldhuizen (2007) 
has described Dutch FACT as follows: “FACT is a 
rehabilitation-oriented clinical case management 
model, which is based on the ACT model but is more 
flexible	and	able	to	serve	a	broader	range	of	clients	
with severe mental illness. FACT offers the original 
ACT as one of several treatment or care models. The 
FACT team is a case management team with partly an 
individual approach and partly a team approach; the 
approach varies from patient to patient, depending 
on the patient’s needs. For more stable long-term 
patients FACT provides coordinated multidisciplinary 
treatment and care by individual case management. 
Unstable patients at risk of relapse, neglect and 
readmission are provided with intensive assertive 
outreach care by the same team, working with a 
shared caseload for this subgroup. (p.422)” Patients 
and clinicians in the TAU condition will be assessed at 
baseline and at 12 months follow-up. Type, duration 
and frequency of TAU will be monitored. 
Intervention Condition: Motivation Feedback 
Patients randomized to the motivation feedback 
condition will receive treatment as usual (TAU) 
Figure 1. Visualization of the three motivation theories and their potential interrelations
IM: Integral Model; TTM: TransTheoretical Model; POC1: Processes of change (consciousness raising, dramatic relief); POC2: Processes of 
change (self-reevaluation); POC3: Processes of change (self-liberation); POC4: Processes of change (reinforcement management, helping 
relationships, counterconditioning, stimulus control); S: Self-efficacy; DB: Decisional Balance; SDT: Self Determination Theory.
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and additionally, their clinicians will generate 
information regarding the patient’s motivation to 
engage in treatment. Patients and clinicians in the 
intervention group will fill in a short motivation 
feedback questionnaire every month up to twelve 
months after baseline assessment that provides 
the clinicians with motivation feedback. The short 
motivation feedback questionnaire includes eight 
statements that relate to the level and type of the 
patient’s treatment motivation, based on two types 
of motivation as distinguished by SDT. The individual 
items of both clinician and patients are rated on a 
10-point continuous scale and can be plotted against 
each other in a graph to represent visual motivation 
feedback to the clinician. This graph then shows 
both the patient’s rating and the clinician’s rating 
of the current level of autonomous and controlled 
motivation of the patient. Figure 2 presents a 
hypothetical motivation profile and graphs of a 
possible course of the motivation over time. 
 Previous pilot testing with the short motivation 
feedback questionnaire among 55 patients with 
primarily anxiety and depressive symptoms receiving 
outpatient treatment showed that the list was 
comprehensible and easy to use in clinical practice. 
Clinicians appreciated the brevity and clarity of the 
items, which could function as a starting point for 
the discussion with the patient regarding his/her 
current motivation to engage in treatment. 
 Clinicians will be asked to fill in the short 
motivation feedback questionnaire just before the 
appointment with the patient. After having filled 
in the questions, the clinician will ask the patient 
at the beginning of the appointment to also fill in 
the questions on motivation for treatment. This 
information will be used by the clinician as a starting 
point for the discussion with the patient regarding 
his/her motivation for treatment. Clinicians 
randomized to the feedback condition, are expected 
to measure and discuss the current motivational 
status of their patients monthly. The clinician may 
use the information from the questionnaire and the 
subsequent conversation with the patient about this 
as feedback and apply an intervention tailored to the 
patients’ current motivation. Clinicians will be free 
to decide for themselves how they will structure this 
discussion with the patient (e.g. discuss only one 
item or several, discuss differences between patient 
and clinician vision) and how long this will take. In 
case the patient is unable or unwilling to indicate 
his/her motivation, the clinician may still use his 
own judgment of the motivation of the patient and 
use this as self-generated feedback. Additionally, 
the motivation of the clinician to keep treating 
the particular patient is also measured monthly by 
asking the clinician to rate two other motivation 
items.
 Before commencing the study, clinicians will be 
trained	by	the	principal	investigator	how	to	read	and	
interpret	 the	 motivation	 feedback	 graphs.	 During	
this	training,	they	are	given	a	presentation	about	the	
principles	of	Self	Determination	Theory,	the	different	
types	 of	motivation	 postulated	 by	 SDT	 and	 perform	
exercises	 to	 learn	 how	 to	 distinguish	 the	 needs	 for	
autonomy, competence and relatedness in discussions 
with	 the	 patient.	 Clinicians	 also	 perform	 feedback	
assessments on each other during this training, to 
familiarize themselves with the feedback and how 
to	 introduce	 it	 to	 their	 patients.	 During	 the	 course	
of the study (i.e. one year) clinicians will be regularly 
contacted	 by	 the	 principal	 investigator	 to	 evaluate	
the	motivation	 feedback	 intervention	and	 to	discuss	
their progress and experiences together with other 
colleagues	 who	 also	 participate	 in	 the	 motivation	
feedback	intervention.	During	the	evaluation	sessions	
with	 the	 principal	 investigator,	 it	 can	 be	 checked	
whether	 the	 feedback	 is	 still	 being	 used	 properly	
(and	if	not,	actions	can	be	taken).	To	aid	clinicians	in	
remembering to perform SMFL assessments monthly, 
they	 will	 be	 given	 MotivaTe-IT	 bookmarks	 to	 use	
in their paper planners, electronic reminders will 
regularly be placed in the electronic planners, and the 
principal	 investigator	will	 send	emails	 to	 remind	 the	
clinicians	of	the	motivation	feedback.	
 In case a patient is transferred to another 
clinician during the course of the study (e.g. in case 
of treatment by a FACT-team where several clinicians 
cooperate to provide services to patients), the 
feedback generated by the patient will be provided 
to the clinician who is currently the primary clinician 
(i.e. case-manager) involved with the patient. The 
feedback generated by clinicians who have been 
engaged with the patient at an earlier moment in 
time will be provided to the clinician who is currently 
the primary clinician, so that it remains possible to 
keep monitoring the development of the patient’s 
motivation over time. 
Development of the Motivation Feedback 
Intervention
The	 guidance	 provided	 by	 the	 UK’s	 Medical	
Research Council on developing and evaluating 
complex interventions (www.mrc.ac.uk/
complexinterventionsguidance) states that the 
identification of evidence base and theory, the 
modelling of process and outcomes, assessing 
feasibility and piloting methods are important 
steps towards successful evaluations of complex 
interventions. The motivation feedback intervention 
under study here, although new in it’s emphasis on 
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motivation for treatment as the content of feedback 
(as opposed to care needs or quality of life), is 
otherwise fairly similar to previously trialled clinician 
feedback where it was found that feedback improved 
SMI patient outcomes in community mental health 
settings 152-154. As Self-Determination Theory is the 
theoretical basis for the intervention, this ensures 
that the effects (or potentially no effects) of the 
intervention can be viewed in light of the processes 
of change proposed by this theory. Pilot testing with 
the novel short motivation feedback questionnaire 
in a group of patients with depressive and anxiety 
disorders showed that the list was comprehensible 
and easy to use, for both patients and clinicians. The 
clinicians reported that the questionnaire gave rise 
to interesting discussions with patients about drives 
and motivations that the clinician was unaware of, 
such as partners or children being more important 
drives to remain in treatment than levels of distress, 
or patients expressing that they felt very much 
coerced to enter treatment at first (sometimes even 
traumatic) but felt that this had progressed to more 
internal drives during the course of treatment. These 
pilot evaluations strengthened our belief that the 
intervention could be executed as intended. Due to 
time limitations however, no piloting was done with 
patients with SMI and the psychometric properties 
of this questionnaire remain to be determined. 
These issues will therefore be addressed during the 
course of the trial. 
Design and setting
This study is a multicenter randomized controlled 
study with two treatment conditions: treatment as 
usual (TAU) and motivation feedback (additional 
to TAU). There will be two extensive measurement 
occasions for both groups: at baseline and follow-up 
at 12 months. Twelve departments within the Mental 
Health Center West North Brabant (MHC WNB), and 
the Mental Health Center BreBurg (MHC Breburg) 
Figure 2. Hypothetical motivation feedback: the motivation profile by the clinician and patient (top parts) and the course of motivation 
(bottom graphs). The top part shows that although the clinician and patient agree that the patient is currently in treatment to solve 
problems and aim for a better life, the patient indicates that he also finds it important to feel proud of himself and to not disappoint 
himself. This could be a starting point for the discussion. In the lower graphs, it can be seen that the autonomous motivation had risen 
in the first three measurements and then dropped in the subsequent two measurements, at which point the clinician might choose to 
intervene.
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located in the south west of the Netherlands, were 
approached to participate in the study. The MHC 
WNB and MHC Breburg provide mental health care to 
varying patient populations, including patients with 
a primary diagnosis of psychotic and/or personality 
disorder who will be targeted for this study. The 
current study will take place at several treatment 
locations of the MHC WNB and MHC Breburg, and 
represents a partnership between these centers and 
the Epidemiological and Social Psychiatric Research 
institute (a research center within the Erasmus 
Medical Center in Rotterdam, the Netherlands). 
Study population: Inclusion and 
exclusion criteria
The current study aimed for patients with severe 
mental illness treated in outpatient community 
mental health care, and although there are several 
definitions of severe mental illness, most definitions 
include a diagnosis of severe psychiatric disorder, 
a treatment duration or illness duration of at least 
two years and several disabilities 6,158. Since patients 
with psychotic disorders constitute the majority 
of patients treated in assertive community mental 
health teams in the Netherlands 14,159 and patients 
with severe personality disorders constitute another 
significant part of the caseload, combined with 
clinical observations that these two diagnostic groups 
may especially benefit from interventions aimed 
at improving treatment motivation and treatment 
engagement, it was decided to incorporate both 
patient groups into the study.
 The research participants will consist of patients 
with a primary diagnosis of a psychotic disorder 
and/or a personality disorder, and their clinicians. 
Patients are eligible for participation if they are 
aged between 18 and 65 years old and receive 
individual outpatient treatment for their psychotic 
and/or personality disorder. Exclusion criteria are 
insufficient command of the Dutch language and/or 
a documented diagnosis of organic psychosyndrome 
(e.g. dementia or chronic toxic encephalopathy). 
 Clinicians will be eligible for participation if they 
are the primary health care practitioner involved 
with the patient, meaning that he/she is the one that 
has the most frequent contacts with this patient. 
It is expected that the resulting group of clinicians 
will mainly consist of specialized social workers, 
specialized psychiatric nurses and psychologists 
with relevant treatment experience with this patient 
population.
Methods
In order to test the three motivational theories while 
also trying to limit the level of response burden for 
study participants in our intervention trial, proper 
choices for instruments had to be made. To ensure 
that we measure constructs appropriately for each 
theory, we tried to stay as close as possible to the 
original measures used by Ryan and Deci 64 for SDT, 
Prochaska and DiClemente 55 for TTM and Drieschner 
et al.160 for IM. Priority was given to readily available 
Dutch versions of measurement instruments, 
but in case these were not available we chose 
to apply a translation procedure to the original 
English versions. Since our motivation feedback 
intervention is based on SDT, the primary outcome 
analysis is focused on this theory. Subsequently we 
will investigate how well the other two theories 
explain the effects of the intervention. Table 1 gives 
an overview of the instruments – questionnaires 
and interviews – that will be applied at baseline, 
monthly (for the intervention condition only) and at 
12 months follow-up to patients and clinicians. It is 
estimated that the total duration of the assessment 
for clinicians takes 25 minutes per measurement 
occasion, while for patients this is 70 minutes.
Primary and secondary outcomes 
The primary outcome in this study is actual 
treatment engagement, as measured with the 
Service Engagement Scale (see paragraph on 
treatment engagement). Secondary outcomes in this 
study are treatment motivation, as measured with 
the Treatment Entry Questionnaire (see paragraph 
on SDT instruments), administrative data on 
missed appointments (see paragraph on treatment 
engagement), psychosocial functioning and quality 
of life (see paragraph on secondary outcomes). 
Treatment engagement
Treatment engagement will be measured with the 
Service Engagement Scale (SES) that was constructed 
by Tait, Birchwood & Trower 161. The SES has 14 
items that are rated on a 4-point scale ranging 
from 0 (not at all) to 3 (most of the time). The four 
subscales refer to availability, collaboration, help 
seeking and treatment engagement. The scale will 
be administered to clinicians. The original English 
version of the SES has shown good psychometric 
properties 161. As a more objective measure of 
treatment engagement, data from the patients’ 
files will be collected on the frequency of missed 
appointments with the main clinician, percentage of 
missed appointments over all appointments in the 
past year, reasons for discontinuation of care or drop-
out (if applicable) and the number of admissions in 
the past year (voluntary and involuntary).
 Furthermore, the Morisky Medication 
Adherence Scale (MMAS) 162 will be administered to 
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only to patients with psychotic disorders to measure 
the level of antipsychotic medication adherence. 
The MMAS is a self-report scale that consists of 8 
items asking about a specific medication-taking 
behaviour. The total scale score can range from 0 
to 8, which will be discretized into high adherence 
(score of 8), medium adherence (score of 6 or 7) 
or low adherence (score below 6) 162. The scale was 
found	reliable	(Cronbach’s	α=	0.83)	as	a	measure	for	
blood pressure medication adherence in patients 
with hypertension 162 and has been adjusted to 
fit our study population of psychotic patients. 
Additionally, the psychiatrists of the patients with 
psychotic disorders will be asked every six months 
to indicate whether they believe the patient adheres 
to the antipsychotic medication and if not, to give 
reasons for the patient’s nonadherence. 
Psychosocial functioning
Psychosocial functioning will be measured with the 
Dutch version of the Health of the Nations Outcome 
Scales (HoNOS) 163,164. The HoNOS form is completed 
via a semi-structured interview with the patient. The 
HoNOS quantifies health and social problems during 
the previous two weeks and contains 12 items 
that refer to behavioural problems, impairment, 
symptoms, alcohol and drug abuse, and social (dis)
functioning. Three HoNOS addendum items are 
also administered. These refer to manic symptoms, 
treatment motivation and compliance with 
medication. The items are rated from 0 (no problem) 
to 4 (very severe problem). The HoNOS has shown 
to be reliable and sensitive to change 164. In order 
to obtain a more differentiated understanding of 
the psychotic symptoms, five items from the Brief 
Psychiatric Rating Scale 165 will be administered 
additionally to the HoNOS items in the interview 
with the patient. These include suspiciousness, 
unusual thought content, grandiosity, hallucinations 
and blunted affect. The BPRS has been used in 
various settings and has shown good psychometric 
properties 166.
Quality of Life
The Manchester Short Assessment of Quality of Life 
(MANSA) 167 will be used to measure quality of life. The 
MANSA is a self-report questionnaire administered 
to the patient to measure how satisfied the patient 
is in the following life domains: living situation, 
social relationships, physical health, mental health, 
safety, financial situation, work situation and life as a 
whole. Each question is answered on a 7-point scale 
(1	=	not	satisfied,	7	=	very	satisfied)	and	a	composite	
(mean) score is calculated. The psychometric 
properties are satisfactory 167, and the scale has 
also been validated in a population of patients with 
severe mental illness 168.
Table 1. Instruments used at two research contacts and monthly
Patients
T0
(Baseline) Monthly
T1
(12 months)
TMS-f x x
URICA-D x x
SoC Algorithm x x
PCS x
TEQ x x
HCCQ x x
IS x x
Zoo Map test x x
HAQ x x
TCI x
MMAS x x
HoNOS x x
BPRS* x x
MANSA x x
SDT graph* x
Therapists
T0
(Baseline) Monthly
T1
(12 months)
TMS-f x x
URICA-D x x
SoC Algorithm x x
HAQ x x
SES x x
SDT graph* x
Therapist motivation** x
*  Only patients and therapists in the motivation feedback 
condition fill in the SDT graph.
**  Only therapists in the motivation feedback condition fill in two 
items regarding their motivation to treat the patient.
HoNOS: Health of the Nations Outcome Scales, BPRS: Brief 
Psychiatric Rating Scale, MANSA: Manchester Short Assessment 
of Quality of Life, TMS-f: Treatment Motivation Scale for 
forensic patients, SoC algorithm: Stages of Change algorithm, 
URICA-D: University of Rhode Island Change Assessment – Dutch 
version, PCS: Processes of Change Scale, TEQ: Treatment Entry 
Questionnaire, HCCQ: Health Care Climate Questionnaire, SIPP-SF: 
Severity Indices of Personality Problems – Short Form, IS: Insight 
Scale, HAQ: Helping Alliance Questionnaire, TCI: Temperament 
and Character Inventory, MMAS: Morisky Medication Adherence 
Scale, SDT graph: Self-Determination graph, SES: Service 
Engagement Scale.
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SDT instruments
The types of motivation that are distinguished by 
SDT will be measured with the Treatment Entry 
Questionnaire (TEQ) 35,126. It was shown that the TEQ 
was reliable ( i.e. internally consistent) for external 
(Cronbach’s	α	=	.89),	introjected	(Cronbach’s	α	=	.89)	
and	identified	motivation	(Cronbach’s	α	=	.85)	126. To 
our knowledge, the TEQ has not been studied in a 
Dutch population before. Therefore, we translated 
the original TEQ by Wild et al. 126 and adapted the 
wording to fit a population of patients with severe 
mental illness in psychiatric treatment (e.g. words 
that referred specifically to addiction treatment 
were replaced by words that reflected more general 
treatment by a mental health center). Two translators 
performed independent forward translations of the 
original TEQ into Dutch and adapted the wording 
to fit its application to outpatient psychiatric 
treatment. A consensus version was established, 
consisting of 27 items that can be rated on a 7-point 
Likert-scale ranging from 1 (strongly disagree) to 7 
(strongly agree). The psychometric properties of this 
Dutch TEQ are to be investigated in this study.
 The Health Care Climate Questionnaire (HCCQ) 
will be used to measure the degree to which 
clinicians are perceived to be autonomy supportive. 
Items are scored on a Likert scale, ranging from 1 
(strongly disagree) to 7 (strongly agree). The HCCQ 
has 15 items that have been used in studies of weight 
loss 134	(Cronbach’s	α	=.92)	and	smoking	cessation	169 
(Cronbach’s	α	=	.96).	Application	of	a	Dutch	HCCQ	is	
not known to us. Therefore, the original HCCQ was 
translated into Dutch by two independent translators 
who subsequently established a consensus version. 
This consensus version was back translated into 
English by two independent expert translators to 
check for discrepancies between the original version 
and the backtranslation. On the basis of consensus 
between all translators, the final Dutch questionnaire 
was achieved. The psychometric properties of the 
Dutch HCCQ will be determined in this study. 
TTM instruments
The stages of change will be measured by staging 
algorithms and the University of Rhode Island 
Change Assessment – Dutch version (URICA-D). 
Algorithms are capable of placing individuals in 
one of five stages and have been used extensively 
in diverse populations and research areas 55,87,93. 
The algorithm approach involves several questions 
that ask about attempts and intentions to change 
behaviour within certain time frames corresponding 
to a particular stage. Both patients and clinicians will 
be asked to judge whether the patient is currently in 
the precontemplation, contemplation, preparation, 
action or maintenance stage with regard to the 
patients’ motivation to change his psychiatric 
problems and specific problem behaviours if 
relevant (e.g. alcohol abuse, drug abuse and criminal 
behaviours). Precontemplation is defined as ‘not 
planning to work on my problems in the next six 
months’. Contemplation is defined as ‘planning to 
work on my problems within the next six months, but 
not within 30 days from now’. Preparation is defined 
as ‘planning to work actively on my problems within 
the next 30 days’. Action is defined as ‘having worked 
on my problems actively for the last 30 days, but no 
longer than six months’. Maintenance is defined as 
‘having worked actively on my problems for the last 
six months’. These definitions are similar to other 
stage algorithms from TTM 88. 
 The URICA-D is the Dutch version of the URICA 
38, which is a self-report scale that asks the patient 
to first enter a problem and then to indicate on a 
five	 point	 Likert	 scale	 (1	 =	 strongly	 disagree	 to	
5	 =	 strongly	 agree)	 how	 much	 he	 agrees	 with	 a	
particular statement. The URICA-D consists of four 
subscales which represent four stages of change: 
precontemplation, contemplation, action and 
maintenance. The reliabailities (i.e. Cronbach’s 
alpha) for the subscales have been found to range 
from 0.84 to 0.95 170. 
 The processes of change will be measured by 
asking patients to indicate how often they make 
use of the strategies described in 20 statements, 
where each process of change is represented by 
two statements. The statements are rated on a 
five point Likert scale, ranging from 1 (never) to 5 
(repeatedly), consistent with other measures of the 
processes of change in TTM 96,171,172. Application of 
the processes of change scale in a Dutch psychiatric 
patient population is not known to us. Therefore, 
we developed a questionnaire based on the original 
English questionnaire by Prochaska et al. 96 and 
adapted it to a population of people with mental 
illness in psychiatric treatment. Two translators 
performed independent forward translations of the 
Processes of Change Scale (PCS) 96 into Dutch and 
adapted the wording to fit its application to change 
processes in psychiatric treatment. From the 40 items 
generated in this translation procedure, a consensus 
version was established from which 20 items were 
chosen (two items per process) as most relevant 
to create a short form of the processes of change 
inventory, consistent with other short forms of the 
processes of change inventory (e.g. in the studies 
of 57,171). The psychometric properties of our scale 
are to be investigated in this study. The decisional 
balance constructs and self-efficacy constructs are 
incorporated in the Treatment Motivation Scale 
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for forensic patients 160, a scale that will be used to 
measure the constructs of the IM (see next section). 
IM instruments
The constructs within the IM will be measured by 
the	Treatment	Motivation	Scale	 for	 forensic	patients	
(TMS-f) 160. The TMS-f consists of eight subscales, one 
scale	for	the	motivation	to	engage	in	treatment	(MET)	
and six scales for variables that are summarized as 
Internal	Determinants	 of	MET:	 problem	 recognition,	
distress, perceived legal pressure, perceived costs 
of treatment, perceived suitability of treatment and 
outcome	 expectancy.	 An	 additional	 scale	 assesses	
the	patients’	tendency	to	respond	according	to	social	
desirability. The items within the scale of ‘perceived 
legal	 pressure’	 were	 adapted	 to	 fit	 a	 more	 broadly	
defined	 concept	 of	 perceived	 External	 Pressure,	 in	
order	 to	 fit	 all	 patients	 in	 our	 research	 population.	
The	 TMS-f	 has	 a	 patient	 version	 (86	 items)	 and	 a	
clinician version (7 items), and both will be used in 
our study. The TMS-f has been found to be a reliable 
and	 valid	 operationalisation	 of	 the	 constructs	 in	 IM	
116,118,160. However, the TMS-f has only been used in 
a	 forensic	 psychiatric	 setting	 and	 it	 remains	 to	 be	
determined whether the scale is also applicable 
outside	 this	 setting.	 In	 the	 total	 patient	 population	
in which the scale was validated, it was found that 
61%	of	the	patients	had	axis-I	disorders,	while	strong	
characteristics	of	personality	disorders	were	prevalent	
in	78%	of	patients	 118,119. The composite reliability of 
the	scale	ranges	between	α	=	.83	and	α	=	.91	160.
Covariables
Socio- demographic factors of patients and 
clinicians
Socio-demographic data on gender, age, ethnicity, 
marital status, living situation, housing, distance 
from the treatment location, educational 
background, income, treatment history, treatment 
duration, no-shows in the treatment in the previous 
twelve months, legal status, medication use, and 
DSM-IV diagnosis will be collected at baseline from 
the patient’s medical record. In case of missing 
information in the medical record, the patient will 
be asked to provide the information. Information 
on clinician sex, age, years of clinical working 
experience, and treatment team was collected from 
clinicians. 
Insight into illness
Impaired insight has been associated with reduced 
treatment engagement and increased symptoms, 
as well as higher rates of involuntary detention 
173. The Insight Scale 174 will be used to measure a 
patients’ insight into illness. This 8-item self-report 
scale produces a total score that ranges between 0 
and 12. It was found to be a reliable, valid and easily 
applicable measure 174. 
Executive functions
There is considerable evidence for cognitive 
dysfunctioning, especially impaired executive 
functioning, in patients with severe mental illness 
175-177. Executive dysfunctioning has been found to 
contribute to poor insight in psychosis and might 
be related to poor treatment engagement 177. As a 
measure for executive functions, planning ability was 
chosen. Although the Wisconsin Card Sorting Test 
(WCST; 178) is typically administered as a measure for 
executive functioning 177, the inclusion of this test to 
our study instruments would increase the burden to 
the patients such that we decided it was unsuitable 
for administration. Alternatively, planning ability will 
be measured with the Zoo Map test, a subtest of the 
Behavioural Assessment of Executive Functioning 
(BADS) 179,180. The Zoo Map test asks the patient to 
draw a route on a map of a zoo and to visit specific 
sites in the zoo while applying specific rules (e.g. 
‘you can use the dotted pathways as often as you 
want, but the white pathways only once’). There 
are two subtests within the Zoo Map test: the first 
is unstructured, forcing the patient to plan his route 
independently. This indicates the extent to which 
the patient is capable of spontaneous planning. 
The second condition is structured and indicates a 
specific order in which the patient should visit the 
specific sites. This indicates the ability of a patient 
to follow a concrete, externally demanded strategy. 
Theoretically, it is expected that patients who find 
it difficult to develop logical strategies on the Zoo 
map test also have more difficulties with following 
a (complex) treatment regimen. The time used for 
planning and execution of the task and the number 
of mistakes (breaking a rule) are scored, and a profile 
score ranging from 0 to 4 for each subtest is then 
derived. The BADS has shown adequate validity and 
test-retest stability 180,181. 
Therapeutic alliance
The therapeutic relationship is measured with the 
Helping Alliance Questionnaire (HAQ). The Dutch 
version of the HAQ comprises 11 items that are rated 
on a 5-point scale (completely disagree, disagree, 
neither agree nor disagree, agree, completely agree) 
182. Both a patient and a clinician version have been 
developed (example items include “I feel the clinician 
understands me”; “I understand the patient”). The 
HAQ contains two scales: Cooperation (Cronbach’s 
α	 =	 0.88)	 and	 Helpfulness	 (Cronbach’s	 α	 =	 0.76)	
182. Modest associations have been found between 
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the therapeutic alliance and client outcomes in 
community mental health for patients with severe 
mental illness 183,184. However, it has been noted 
that most studies performed in these settings have 
been limited by a lack of power and standardized 
measures 183. Possibly, the current study can improve 
on these limitations.
Experienced stigma
Stigma will be measured using the 12-item 
‘perceived devaluation and discrimination’ subscale 
of the self-report Stigma-Scale 185. This subscale 
refers to the perception of common opinions 
about psychiatric patients, such as ‘Most people 
stay friends with someone who has had a mental 
illness’ and ‘Most people look down on people 
who have been hospitalized for mental illness’. 
The items are scored on a scale from 1 (strongly 
disagree) to 4 (strongly agree). A higher total scale 
score means more perceived stigmatization. The 
scale had acceptable reliability (Cronbach’s alpha 
=	 .78)	 and	 construct	 validity	 was	 demonstrated	 in	
studies	 predicting	 associations	 between	 stigma	 (as	
measured	with	the	subscale	of	‘perceived	devaluation	
and	 discrimination’)	 and	 self-esteem,	 employment,	
demoralization,	quality	of	life	and	treatment	seeking	
in	patients	with	mental	illness	186,187. 
Personality characteristics
The temperament dimensions from the Temperament 
and Character Inventory (TCI) 110,188 will be used to 
measure	 personality	 characteristics,	 in	 order	 to	
explore	 the	 relationship	 between	 temperament	 and	
motivation	to	engage	in	treatment.	The	temperament	
dimensions from Cloninger’s theory called novelty 
seeking, harm avoidance, persistence and reward 
dependence 110,189 are used in this study. Convergent 
validity exists in the form of studies comparing the TCI 
scales with other similar scales of validated personality 
tests 110. The internal consistencies (i.e. Cronbach’s 
alphas) of the novelty seeking, harm avoidance, 
persistence and reward dependence subscales varied 
between	α	=0.62	and	α	=0.90	 in	psychiatric	patients	
recruited from community mental health care 110. The 
temperament dimensions are measured by items that 
can be scored as true or false. 
Procedures and randomization
Figure 3 shows the study procedures. Eligible 
clinicians	and	patients	will	mainly	be	approached	via	
specific	treatment	programs	that	provide	FACT	(for	a	
description	of	FACT	see	the	section	on	Treatment	As	
Usual). Clinicians who are willing to cooperate in this 
study	 will	 be	 informed	 by	 the	 principal	 investigator	
regarding the goals and procedures of the study and 
receive	 an	 information	 brochure.	 Two	 weeks	 after	
having	 received	 the	 information	brochure,	 clinicians	
will	be	contacted	to	ask	for	participation	and	to	sign	
informed consent. 
 After having received informed consent from 
the clinicians, randomization will be performed 
at either clinician-level or team-level. Where 
clinicians work in FACT-teams, randomization will 
be performed at team-level so that a whole team 
(all clinicians working in this team) will be allocated 
to either the TAU condition or motivation feedback 
condition. As teams often work with a shared 
caseload between clinicians in the same team, this 
decision was made in order to prevent possible 
cross-over of the feedback-condition to the TAU 
condition within teams. Where clinicians work in an 
outpatient clinic on a one-to-one basis (individual 
case-management) then randomization will be 
performed at the clinician-level. The allocation ratio 
is 1:1 (i.e. therapist vs. therapist and team vs. team, 
respectively). Stratification for diagnosis in advance 
was considered unrealistic and impractical, as we 
would then have to achieve equal numbers of each 
patient diagnosis in each treatment condition, while 
our randomization is at team-level and clinician-
level. Therefore, we chose to use multivariate 
modelling with diagnosis as a covariate (see section 
2.9 ‘Statistical analyses’). Randomisation will be 
performed by assigning each randomization unit 
(e.g. a team or a clinician) a unique number, which 
is entered in a computerized randomization program 
(www.randomization.com) that randomizes each unit 
to a single treatment by using randomly permuted 
blocks. The randomization is single-blind, as both the 
principal investigator and clinicians need to know 
which condition the clinicians are in, in order for the 
clinicians to receive the necessary training for the 
intervention condition (or not). As a consequence, 
only patients will be blind to treatment allocation at 
baseline assessment, while clinicians are not. Due to 
the nature of the trial, follow-up assessment can not 
be blinded. 
 Subsequently, clinicians are asked to provide 
a list of their entire caseload to the principal 
investigator (PI). The PI will remove patients from 
this list who do not fulfil the inclusion criteria or fulfil 
the exclusion criteria and subsqequently, the PI will 
randomly select 10 eligible patients from this list to 
be asked for participation in the study. Clinicians will 
inform their selected patients about the objectives 
of the study, and provide a full explanation of all 
procedures for the study. If patients are willing to 
participate, an appointment is scheduled for the 
administration of the HoNOS.
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At the beginning of the appointment, again all 
procedures of the research study are explained to the 
patient and signed informed consent will be obtained 
by the research assistant. Written information will 
also be provided to the patient, which explains the 
nature of the intervention and provides contact 
details of the research team. Following the informed 
consent procedure, baseline assessment will take 
place. The HoNOS will be administered by the 
case-manager of the patient accompanied by an 
independent research assistant, who will assist in the 
interview and scoring of the HoNOS. This decision 
was made for several reasons. The first is that the 
case-managers have been trained to administer the 
HoNOS for Routine Outcome Monitoring, which is 
primarily used in clinical practice to guide treatment 
plans and evaluations and is now secondary used 
as an outcome in the current research study. 
Combining the two approaches ensures that 
Routine Outcome Monitoring procedures can be 
maintained (by the case-manager) while research 
requirements can be met (by the independent 
research assistant monitoring the administration 
and scoring of the HoNOS). Secondly, the response 
rates for the interviews is expected to be higher if 
the patient is approached by a familiar person (the 
case-manager). This might typically be the case 
for the more paranoid or anxious patients. Third, 
the presence of an independent research assistant 
who is also trained in the administration of the 
Figure 3. Flowchart of MotivaTe-IT procedures
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HoNOS likely ensures that the HoNOS is scored 
appropriately, to minimise a possible bias that might 
occur if the case-manager alone would do this. The 
self-report questionnaires will be administered by 
research assistants, only sometimes in the presence 
of the case-manager when the patient is seen at 
home to ensure the safety of the research assistant 
or to minimise feelings of anxiety with patients (who 
might feel intimidated by an unfamiliar person), but 
always ensuring the confidentiality and anonymity 
of the collected data. 
 Assessments of the HoNOS and self-report 
questionnaires will take place at baseline and follow-
up at 12 months. Baseline assessment will take place 
after randomization to reduce the variation in the 
time between baseline assessment and the start of 
the intervention. Measuring baseline status close 
to the start of the intervention ensures that the 
information obtained at baseline assessment is still 
up to date at the start of the intervention. A limitation 
to this approach is that clinicians are aware of the 
treatment allocation, which may bias their responses. 
This possible information bias can not be eliminated 
since clinicians in the motivation feedback condition 
have to be trained in the relevant procedures before 
baseline assessment, since shortly after they will 
start employing the feedback intervention. Patients 
however, will not be informed about their treatment 
allocation at baseline assessment and are therefore 
blind to treatment allocation at the start of the 
study. In case patients drop-out from treatment or 
complete their treatment before these 12 months 
have passed, information regarding the reason for 
ending the treatment and total treatment duration 
will be obtained.
Sample size and power calculations
The RCT was designed to enrol an average of 6 
patients for each of 56 participating clinicians. 
The sample size was calculated on the basis of our 
primary hypothesis, that the intervention group 
(motivation feedback) would be more effective than 
the control group (treatment as usual) in enhancing 
treatment engagement, as measured with the 
Service Engagement Scale (primary outcome) at 12 
months after baseline assessment. The difference 
between the motivation feedback group and control 
group for the primary outcome is based on a power 
of 0.80 and an alpha of 0.05 (two-tailed). Earlier 
studies regarding differences between feedback and 
treatment as usual (control) conditions have shown 
effect sizes (standardized mean differences) ranging 
from 0.34 to 0.92 148,149, but were based on treatment 
progress and not (solely) on treatment motivation. 
One RCT studying the effects of treatment adherence 
therapy in patients with psychotic disorders used 
the SES as outcome measure and found an effect 
size of 0.39 190. Therefore, we expect an effect size 
of approximately 0.40. Using an unpaired t-test 
statistic, this resulted in a minimum of 123 subjects 
per condition. However, as patients are clustered 
within clinicians, and clinicians are clustered in 
teams, the patient and clinician observations can 
not be considered as independent of each other. The 
sample size was therefore adjusted by the (variance 
inflation)	factor	f	=	1	+	(m	–	1)ρ,	to	account	for	the	
variance that would have been achieved had there 
been no clustering. The cluster size (m) is 6 (patients 
per	 clinician)	 and	 the	within-cluster	 correlation	 (ρ)	
was estimated from a previous study to be around 
0.07 153. Thus, the computed sample size was inflated 
by 1.35 to be at least 166 subjects per condition 
(minimally 332 in total). The SES is rated by clinicians 
and so we expect minimal loss to follow-up on the 
primary outcome, but to be on the safe side we will 
aim for 350 patients as the total sample size. 
Statistical analyses
The data of the RCT will be analysed according to the 
intention-to-treat principle. Baseline comparability 
between the intervention group and control group in 
demographic and clinical variables will be evaluated 
with independent samples t-tests and chi-square 
tests. Furthermore, non-responders (i.e. eligible 
patients who chose not to participate in the study) 
will be compared to responders with respect to 
background demographic and clinical variables with 
independent samples t-tests and chi-square tests. 
Logistic regression analysis will be applied to test 
for differences between the motivation feedback 
and control group with respect to the primary 
and secondary outcomes that are dichotomous 
variables, while (multiple) linear regression analysis 
will be used in case of continuous outcome variables. 
For individual categorical outcome variables, the 
effectiveness will be determined by odds ratios, 
including p-values (two-tailed). The effectiveness 
of the variables combined will be determined 
by ROC-curves (for categorical outcomes) and 
the individual odds ratios, R2 and the individual 
regression coefficients (for continuous outcomes). 
The Hosmer and Lemeshow goodness-of-fit test 
will be used in case of logistic regression. In case of 
multiple regression analysis the classical regression 
diagnostics will be applied for normality, (non)
linearity, heteroscedasticity, (influential) outliers and 
interaction. A subgroup analysis will be performed 
for patients with psychotic disorders for the effects of 
the intervention upon their antipsychotic medication 
adherence. The analyses will be performed both 
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unadjusted and adjusted for baseline differences of 
the distributions between the two treatment groups. 
In analyzing a specific outcome variable, the baseline 
score of that variable will be used as covariate. The 
analysis will be extended using multilevel analyses 
that takes the nesting of measurements into account. 
A clustering of outcomes is likely since a single 
clinician may treat several patients, and clinicians 
are clustered into teams. Multilevel modelling will 
be performed to check for any clustering effects 
on the primary outcome. In the multilevel analyses 
we consider the two measurements as the first 
level and the patient as the second level. We will 
explore whether the different treatment locations 
(FACT teams) and institutions (MHC Breburg and 
MHC WNB) can be considered as random factors 
in the modeling. We will identify predictive factors 
in estimating the outcome and whether there 
are predictive factors dependent on the type of 
treatment condition (interaction between baseline 
variables and treatment effect). Furthermore, we 
will take into account to what extent patients were 
exposed to the intervention by analyzing the dose-
effect relationship. We expect (as is the case in 
most empirical studies in a psychiatric setting) that 
missing data will occur. We expect that the data will 
be Missing At Random (MAR), which is allowed to be 
a function of the observed variables (both covariates 
and outcome variables). If the assumption of MAR 
is violated, the pattern mixture model approach will 
be applied. In case predictor variables are missing, 
the method of multiple imputations or the maximum 
likelihood estimation method will be applied. 
 For monthly measurements (i.e. the motivation 
feedback graph for patient and therapist, and the 
therapist motivation) the method of mixed modelling 
will be applied. This highly flexible method enables 
two level models: repeated measurements (level 1) 
and patient level (level 2). The three motivational 
theories will be modelled with Structural Equation 
Modelling (SEM), in order to study their fit to the 
empirical data, their predictive power and parsimony 
(i.e. whether the model can be simplified without 
substantially reducing the model fit and predictive 
power). The three motivational theories will be 
studied exploratively to determine which theoretical 
constructs are most plausible (i.e. clinically relevant 
and statistically significant) for the prediction of the 
outcome variables. The difference of the two -2log-
likelihood tests (including the difference of degrees 
of freedom) will be used for testing differences 
between nested models, and information criteria 
will be used for differences between non-nested 
models (i.e. Akaike Information Criterion/AIC, 
Bayesian Information Criterion/BIC and adapted 
BIC). Where relevant, the 95% confidence intervals 
and/or P-values (two-tailed) will be reported.
Ethical considerations
The current research protocol was endorsed by the 
Medical Ethical Committee for Mental Health Care 
Institutions (METiGG) and by the committees for 
scientific research within the two mental health 
institutions where the data will be collected (MHC 
WNB and MHC Breburg). The collected data are 
treated according to the Medical Confidentiality 
Rules, and are kept in locked files cabinets. Every 
patient will be assigned a patient number, so that 
processing of the data will occur anonymously. 
Access to data is limited to members of the research 
group and the medical ethical committee (METiGG). 
The study will be conducted in accordance with 
the Helsinki Declaration. As mentioned previously, 
written informed consent will be obtained for all 
clinicians and patients that are entered into the 
study. Patients and clinicians are free to refuse 
participation at any time during the research period, 
without having to disclose any reason why.
 Patients that are included in the study will 
receive an incentive of € 15, - after every completion 
of an extensive measurement (baseline and 
follow-up). Thus, if a patient has completed both 
measurement occasions, he or she will have received 
€ 30, - in appreciation of his/her cooperation. These 
incentives are introduced in order to increase 
the response rate, since it is expected that in this 
patient population with severe mental illness and 
possibly with motivational problems, the response 
rate would otherwise turn out too low. The effects of 
the intervention are unknown at this moment, and 
therefore we think it is justified to allocate patients 
randomly over the two conditions. 
Discussion
The central research question in this study is whether 
the motivation feedback intervention is able to 
increase the treatment engagement of patients in 
outpatient psychiatric treatment for severe mental 
illness. The secondary research question is whether 
the intervention improves treatment motivation, 
psychosocial functioning (health and functioning 
in several life domains) and quality of life. Thirdly, 
three theories of motivation will be assessed on 
their core theoretical constructs to investigate 
which theoretical constructs and which theory is 
best able to predict the outcomes in this patient 
population. The identification of possible mediating 
and moderating mechanisms through which 
changes in the outcomes occur, offer a tool for the 
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development of future interventions. The study has 
several strengths and limitations.
Limitations
The main limitation of the design is that patients and 
clinicians are not blind for the treatment condition 
to which they are randomized. Clinicians will be 
informed about their treatment condition, since it 
is required that clinicians in the motivation feedback 
condition receive training. Patients are blind for 
treatment condition at the baseline assessment, but 
not at follow-up assessment since they will realize 
what condition they are in once their clinician starts 
asking them to fill in the feedback questionnaires 
monthly after baseline assessment – or not. This could 
lead to information bias, as patients and clinicians 
in the intervention group may be more actively 
involved in the treatment as they expect it to work, 
which may enhance the effect of the intervention 
we find. This would especially be the case for the 
subjective (i.e. self-report) outcome measures that 
are administered to patients and clinicians, but less 
so for the objective outcome measures (e.g. number 
of no shows and drop-out as registered by the 
institution’s administrative system). Regarding the 
HoNOS, which is administered by the patient’s case-
manager and an independent research assistant, 
we have weighed the possible bias that could occur 
due to the presence of the case-manager with the 
advantage of achieving higher response rates for 
the study, thereby minimising a possible selection 
bias (that would occur if the more severe mentally 
ill group would decline participation if asked by an 
unfamiliar person). We believe that the presence 
of the independent research assistant during the 
administration and scoring of the HoNOS ensures that 
the HoNOS is scored appropriately and will minimise 
the former bias. A second limitation is that it is not 
possible to determine which exact component of 
motivation feedback contributed to the effect, since 
it might be possible that measuring patient progress 
systematically in itself is key to the effects – whether 
you measure the patient’s motivation or the patient’s 
symptoms or any other patient characteristic – or 
the fact that the intervention includes reminders 
to the clinician to keep in contact with the patient 
for the measurement of the motivation. In order to 
have some idea of which elements contributed to 
the effect of the intervention, we will monitor the 
number of times the feedback was used, the amount 
of time that was spent on discussing the feedback, 
characteristics of clinicians using the feedback and 
the motivation of the clinician to treat the patient. 
Thirdly, the DSM-IV diagnosis is not established with 
structured diagnostic interviews, but is obtained 
from the patients’ medical records. This choice was 
made to reduce patient burden, since structured 
interviews were considered too extensive and 
time-consuming in combination with the other 
instruments used in this study. 
Strengths
The strengths of this study include the design and 
the clinical relevance. The patients in the study are 
retrieved from a general population of severe mental 
illness (i.e. psychotic disorders and personality 
disorders), representing a ‘real-life’ population 
including patients with a variety of comorbid 
disorders rather than a more narrow selection of 
patients. Therefore we will be able to generalize 
our findings to a large group of outpatients with 
psychotic disorders and personality disorders. The 
design of the motivation feedback intervention is 
based upon empirical evidence of interventions 
that have proven efficacious in lowering treatment 
non-completion and drop-out. Most of the studies 
concerning feedback have been based upon self-
report measures from the perspective of the 
patients. The current study also incorporates the 
clinicians’ perspective upon the patients’ motivation 
for treatment. Also, past research concerning the 
effects of feedback has largely included patients with 
relatively mild problems and non-specific disorders 
(for example, the studies by Lambert et al. 145,146 
were based on data from a university outpatient 
clinic). The current study will focus upon patients 
with severe psychiatric problems. 
 Regarding the theory comparisons it should 
be noted that SDT will be tested most rigorously 
in this study, since this theory will be used as the 
basis for the intervention in this study and its core 
theoretical components will be manipulated (i.e. 
the basic psychological needs will be supported by 
clinicians, and motivational types will be known and 
responded to by clinicians). Although the other two 
theories are not tested so rigorously (i.e. they are 
not part of the intervention), the core theoretical 
constructs of IM and TTM are followed prospectively 
over the course of 12 months in order to determine 
if the constructs behave as the theories suggest 
and to see if they are able to predict treatment 
motivation and treatment engagement at follow-up. 
The design of our study fulfils most of the criteria 
that have been suggested by Noar and Zimmerman 
75 for theory comparison studies. The criteria are: 
1) having a longitudinal design, 2) using Structural 
Equation Modelling, 3) including past behaviour and 
(4) demographics in the model tests, 5) including 
non-college participants in the sample, 6) having 
a strong sample size (N>200), 7) utilizing multiple 
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samples in model testing, 8) utilizing samples 
from more than one country, 9) having more than 
one dependent variable (e.g. motivation and 
behaviour), 10) examining more than one behaviour, 
11) comparing more than two theories and (12) 
empirically examining an integrated model 75. All 
criteria except 8 and 10 are fulfilled by our design. 
Furthermore, most previous studies employing the 
TransTheoretical Model have only measured the 
stages of change, while the model also incorporates 
other constructs. The current study measures both 
the stages of change, the processes of change, self-
efficacy and the decisional balance constructs. Thus, 
a strong aspect of this study is that it includes all 
core theoretical constructs of the three motivational 
theories.
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Measures of motivation for 
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on Self-Determination 
Theory
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Cornelis CM, & van Dam A. 2014. Measures of Motivation for 
Psychiatric Treatment Based on Self-Determination Theory: 
Psychometric Properties in Dutch Psychiatric Outpatients. 
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Objective
Self-Determination Theory is potentially useful for 
understanding reasons why individuals with mental 
illness do or do not engage in psychiatric treatment. 
The current study examined the psychometric 
properties of three questionnaires based on Self-
Determination Theory. 
Methods
The psychometric properties of the Treatment 
Entry Questionnaire (TEQ); Health Care Climate 
Questionnaire (HCCQ); and the Short Motivation 
Feedback List (SMFL) were investigated in a sample of 
348 Dutch adult outpatients with primary diagnoses 
of mood, anxiety, psychotic and personality disorders 
using Structural Equation Modeling.
Results
Structural equation modeling showed that the 
empirical factor structures of the TEQ and SMFL 
were adequately represented by a model with three 
intercorrelated factors. These were interpreted as 
identified, introjected and external motivation. The 
reliabilities of the Dutch TEQ, HCCQ and SMFL were 
found to be acceptable but can be improved upon; 
congeneric estimates ranged from 0.66 to 0.94 
depending on the measure and patient subsample. 
Preliminary support for the construct validities 
of the questionnaires was found in the form of 
theoretically expected associations with other 
scales, including therapist-rated motivation and 
treatment engagement and with legally mandated 
treatment.
Conclusion
The results of the current study suggest that the 
TEQ, SMFL and HCCQ could be valuable instruments 
for research on SDT in psychiatric outpatients and 
for clinical purposes such as discussing the patient’s 
motivation to engage in treatment. Additionally, the 
study provides insights into the relations between 
measures of motivation based on Self-Determination 
Theory, the Transtheoretical Model and the Integral 
Model of Treatment Motivation in psychiatric 
outpatients with severe mental illness.
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Introduction
Self-Determination Theory (SDT) is a theory on 
human motivation, which has been applied in 
various life domains including health-related 
behavior changes, such as tobacco dependence, diet 
and physical activity 64,65. Several studies suggest 
that SDT could also be useful for understanding why 
individuals with mental illness do or do not engage 
in psychiatric treatment 65,124,128,129. The primary 
aim of this study was to translate three measures 
based on SDT into Dutch and to investigate their 
psychometric properties in a population of patients 
with various primary psychiatric disorders in 
outpatient treatment. Additionally, we aimed to 
provide insights into the relations between measures 
of motivation based on Self-Determination Theory, 
the Transtheoretical Model and the Integral Model 
of Treatment Motivation in psychiatric outpatients 
with severe mental illness. In the following, we 
will first describe SDT and its potential utility 
for application in Dutch outpatient psychiatric 
treatment and secondly, we will describe some of 
the measurement issues regarding SDT measures. 
Finally, our hypotheses regarding the relationships 
between SDT measures and criterion measures will 
be described.
Applying Self-Determination Theory to 
psychiatric treatment
SDT distinguishes between different types of 
motivation that fall along a continuum of self-
determination in the following order from most to 
least self-determined: intrinsic, integrated, identified, 
introjected, external and amotivation 65,123. The 
most self-determined form of motivation is intrinsic 
motivation, where people feel that a certain activity 
or behaviour is pleasant in itself. For example, this 
would be the case for a patient who enters therapy 
purely for the pleasure of gaining a deeper personal 
understanding of himself 129. Psychiatric professionals 
would like to see that their patients present with 
such intrinsic willingness to change their problems 
and participate in treatment processes, as this is 
thought to lead to positive and lasting results 65,139. 
However, not many patients will present with such 
motivations for treatment, as treatment is usually 
followed with the intent to find relief of psychiatric 
symptoms as opposed to it being pleasant in itself 
or highly valued 191. Thus, more controlled forms 
of motivation seem to be applicable. According to 
SDT, the most self-determined form of controlled 
motivation is integrated motivation, where a 
patients identifies with the importance of behaviors 
but also integrates this into aspects of the self 48. An 
example is a patient who has completed treatment 
but now wants to reenter a treatment program to 
help him maintain changes, as he has internalized 
the value of sustaining mental health. That is, 
sustaining mental health is consistent (integrated) 
with his current identity 129. Less self-integrated is 
identified motivation, in which a patient recognizes 
and accepts that treatment is useful for achieving 
personally relevant goals 65. An example would be a 
patient who engages in treatment because he thinks 
it is the best way to help him live a healthy life, or a 
patient who finds it important to take medications as 
a way of preventing relapse into psychoses. This type 
of motivation is thus more instrumental to achieving 
a goal, as opposed to integrated motivation which 
is more aligned with the person’s perception of the 
self. An even less self-integrated form of motivation 
is introjected motivation, where a patient is driven 
by feelings of guilt, shame or anxiety, and might feel 
ashamed or disappointed if he did not remain in 
treatment. An example would be a man who seeks 
treatment because he is overwhelmed by feelings 
of shame, as he feels that he is a bad husband for 
having repeatedly battered his wife. Engaging in 
treatment is driven by his introjected motive to 
improve his relationship and family situation. Finally, 
the most externally determined form of motivation 
is when a patient remains in treatment because he 
feels pressured to do so 65. This could be the case for 
a patient who is court-ordered into treatment or a 
patient who enters treatment because his wife has 
pressured him to change his drinking problem or else 
seek out a divorce attorney 129. A separate category 
of motivation is called “amotivation”, where people 
experience no regulation at all over their behaviour 
and are very likely to drop out or reject treatment 
192. A patient who is amotived to engage in treatment 
is characterised by not having a clear understanding 
of why he does so and has a sense of hopelessness, 
believing that treatment will undoubtedly lead to 
failure and disappointment 129. 
 According to SDT, engaging in treatment for a 
long period of time and maintenance of changed 
behaviours over time requires that patients 
internalize values and skills for change 123. That is, 
patients with a more internalized form of motivation 
will experience greater ownership of the behaviour 
and be more self-determined. SDT predicts that 
people with more internalized motives for engaging 
in treatment and engaging in behaviour changes will 
have better mental and psychical health outcomes, 
compared to those with more externalized motives 
123. The rationale is that behaviours that are more 
self-determined and intrinsically rewarding are most 
likely to be performed again, whereas behaviours 
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that are primarily driven by external motives will 
only be performed again in the presence of such 
external pressures. As Ryan and Deci 65 put it: “This 
is so because, to the extent that people experience 
treatment or change as a function of external 
factors, they will experience conflict and division in 
the process of change, rendering it unstable. Unless 
the client internalizes responsibility for the process 
of change, there can be little hope for long-term 
success.” (p. 187). 
 According to SDT, the different types of 
motivation become manifest due to the (lack 
of) support for three basic psychological needs; 
autonomy, competence and relatedness. Autonomy 
refers to the need to be the originator of one’s 
actions and the desire for volition and choice. 
Competence refers to the need to feel capable of 
achieving desired outcomes, while relatedness is 
the need to feel close to and understood by others 
48. SDT predicts that patients who feel that their 
therapeutic environment is supportive of their basic 
psychological needs, will more easily go through the 
process of internalization and identify with adhering 
to treatment processes and engaging in behaviour 
changes, leading to better treatment outcomes 
compared to those patients who feel thwarted in 
their needs 65. 
Measurement issues
Several studies have found that autonomy support 
is positively related to treatment outcomes in 
psychotherapy 126,128,193, but the evidence is still 
rather scarce and no previous studies have reported 
on the utility of SDT in patients with SMI 86. One of 
the reasons for this may be that there is a lack of 
psychometrically adequate instruments that enable 
the measurement of these types of motivation 
in mental health care services for patients with 
SMI. Although a scale for intrinsic motivation was 
developed for patients with schizophrenia by Choi, 
Mogami and Medalia 70, this scale has several 
limitations. It measures subjective experiences 
of interest/enjoyment, effort, value/usefulness, 
pressure/tension, relatedness and perceived choice, 
and it thus seems conceptually ambiguous since it 
encompasses concepts that are in fact psychological 
needs (such as relatedness) and behavior resulting 
from motivation (such as effort). Furthermore, 
although psychiatric patients may experience 
intrinsic motivation for many activities in life, it is 
questionable whether this applies to engaging in 
psychiatric treatment 86,191. 
 The Treatment Entry Questionnaire (TEQ) 
developed by Wild, Cunningham and Ryan 126 
seems to represent SDT’s types of motivation more 
adequately and was developed specifically for 
treatment settings. It formed internally consistent 
dimensions for identified motivation, introjected 
motivation and external motivation 126 and consists 
of 27 items. Although the TEQ does not measure 
all six different types of motivation postulated by 
SDT (which are intrinsic, integrated, identified, 
introjected, external and amotivation), its extension 
to more external forms of motivation might prove 
valuable and insightful for the treatment of patients 
with severe mental illness, such as those with 
psychotic disorders. Thus, the TEQ is in need for 
further theoretical and empirical investigation. In 
line with the development of a shortened 12-item 
version of the English TEQ 107, we developed a short 
version of the Dutch TEQ that could be easily applied 
in clinical practice, for example during treatment 
sessions as a way of discussing the patient’s current 
motivation for treatment. This short motivation 
feedback list (SMFL) was also in need of psychometric 
testing. To measure the extent to which health care 
providers are autonomy supportive, the health care 
climate questionnaire (HCCQ) was developed 134, 
but application of this scale to a Dutch psychiatric 
outpatient population is not known to us. 
 Therefore, we were interested in determining the 
empirical factor structures of the patient-rated SMFL 
and TEQ, and examine the reliabilities and construct 
validities of the TEQ, HCCQ and SMFL in a Dutch 
outpatient sample. Convergent and discriminant 
validities for the TEQ and SMFL were determined 
by using clinician ratings of the TEQ and SMFL. The 
use of observer-rated motivation questionnaires 
is rare in SDT-literature, which is regretful as self-
report questionnaires may be influenced by socially 
desirable response bias and insight into illness, 
especially for patients with psychiatric problems. 
According to Campbell and Fiske 194 convergent 
validity is determined by correlations between 
different measures for similar traits, the so-called 
monotrait-heteromethod correlations, while 
discriminant validity is supported when monotrait-
heteromethod correlations exceed the heterotrait-
monomethod correlations and the heterotrait-
heteromethod correlations. The validities of the 
TEQ, SMFL and HCCQ were investigated further 
by using several criterion measures. For example, 
the TEQ was investigated in relation to clinician-
rated treatment engagement and legally mandated 
treatment assessed at the same time, as well as 
to two other measures of motivation to engage in 
treatment. The first was a measure for motivational 
concepts within the Integral Model of Treatment 
Motivation (IM) 37. The IM postulates six proximal 
predictors of the patient’s motivation to engage in 
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treatment (MET) and is conceptually clear about 
the distinction between predictors of motivation, 
treatment motivation itself (having an intention) 
and treatment engagement (actual behavior) 86. The 
second was based on the Transtheoretical Model 
(TTM) 38,44, which asserts that patients move through 
certain stages in the process of behavior change, 
and these stages are generally seen as different 
levels of motivation 37,86. In a previous theoretical 
exploration, we have argued that the IM and TTM 
are mainly concerned with a quantification of the 
motivation concept (low or high motivation) while 
SDT is concerned with a more differential motivation 
concept (types or quality of motivation) 86. 
 The HCCQ and SMFL were subjected to similar 
tests as the TEQ. That is, the SMFL was expected 
to show the theoretically expected associations 
with the patient-rated and clinician-rated TEQ 
scales and substantial associations with the IM and 
TTM motivation scales, clinician-rated treatment 
engagement and with legally mandated treatment. 
For the HCCQ, the Helping Alliance Questionnaire 
(HAQ) was used as a criterion measure. The helping 
alliance refers to the patient’s experience of the 
relationship with the therapist as helpful 195 and 
more specifically, to perceptions of the patient 
regarding cooperation (such as working together 
with the clinician to achieve goals and perception of 
the influence of the clinician on the healing process) 
and helpfulness (such as the patient’s confidence in 
his clinician, the treatment in general and his own 
capacities).
Hypotheses
We hypothesized that more internalized forms of 
motivation measured within the SDT-framework 
would be associated with higher levels of motivation 
measured within the TTM and IM frameworks 
86 and more positively associated with clinician-
rated treatment engagement 126 compared to more 
externalized forms of motivation. We expected 
that patients with a legal mandate for psychiatric 
treatment would show higher levels of external 
motivation than patients without a legal mandate 
for treatment. It should not necessarily be so 
that patients with a legal mandate show lower 
levels of identified motivation, as these different 
motivational types do not exclude each other and 
different types may co-occur at high levels at the 
same time 196. For the HCCQ, we hypothesized that 
the cooperation-subscale of the HAQ would be more 
strongly associated with autonomy support than the 
helpfulness-subscale, because both cooperation and 
autonomy support specifically refer to the patient’s 
perception of the clinician, while helpfulness refers 
to a more broad perception of the usefulness of the 
treatment in general and the patient’s competence.
 
Methods
Participants and procedures
We invited eleven function assertive community 
treatment teams (FACT teams), one outpatient 
forensic psychiatric team and one treatment program 
applying cognitive behavioral therapy to patients 
with mood and anxiety disorders from the Western 
North Brabant Mental Health Center and the Breburg 
Mental Health Center to participate in this study. 
FACT is a team treatment model where individuals 
with severe mental illness are offered community-
based, assertive, outreaching and supportive 
psychiatric services 14,15. Besides assertive outreach, 
the emphasis is on out-of-office interventions and 
home visits 14. First, clinicians who provided care 
to patients with a primary diagnosis of mood or 
anxiety, psychotic or personality disorder were 
approached for participation. Second, participating 
clinicians were asked to provide a list of their 
caseload to the primary researcher, to select eligible 
patients. Patients were eligible for participation if 
they were aged at least 18 years or older, were in 
outpatient treatment and had a primary diagnosis 
of anxiety, mood, psychotic or personality disorder. 
Comorbid psychiatric disorders were allowed as 
long as the anxiety, mood, psychotic or personality 
disorder was the primary diagnosis. These diagnoses 
were obtained from the patient’s medical records. 
Exclusion criteria were a poor understanding of 
the Dutch language, mental retardation and a 
documented history of dementia or chronic toxic 
encephalopathy. Eligible patients were informed 
and asked for their consent. Patients were asked 
to fill in questionnaires and provide some socio- 
demographic data (e.g. age, gender, education level) 
and information regarding their treatment (e.g. age 
of first contact with mental health, legal mandate, 
previous admissions). Clinicians were asked to fill 
in questionnaires regarding this patient. To study 
the test-retest reliabilities of the TEQ and HCCQ, 70 
patients with psychotic disorders and/or personality 
disorders were re-administered the TEQ and HCCQ 
one year after the first measurement. These 70 
patients were in the treatment as usual arm (control 
condition) of the randomized controlled trial in 
which the data of the current study were gathered 
197. The SMFL was administered at a later time point 
than the TEQ and HCCQ, as the TEQ and HCCQ were 
administered during the baseline assessment of 
the previously mentioned trial 197 while the SMFL 
was	administered	sometime	after	this	(median	=	65	
days). Additionally, four repeated measures with the 
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SMFL were available for 52 patients with psychotic 
disorders and/or personality disorders, with a 
median of 43 days apart. The current research was 
approved by an official medical ethical committee 
and by the committees for scientific research within 
the two mental health institutions where the data 
were collected.
Measures
SDT - Treatment Entry Questionnaire
The types of motivation that are distinguished 
by SDT were measured with the Treatment Entry 
Questionnaire (TEQ) 35,126. It was shown that the 
original English TEQ was reliable for external 
(Cronbach’s	 α	 =	 0.89),	 introjected	 (Cronbach’s	 α	
=	 0.89)	 and	 identified	 motivation	 (Cronbach’s	 α	 =	
0.85) in a study of patients seeking substance abuse 
treatment 126. Construct validity for the English 
TEQ exists in the form of theoretically expected 
correlations between TEQ subscales and referral 
source (i.e. legal mandate or self-referral), social 
network pressures to seek treatment and problem 
severity 126,198. The original TEQ consists of 27 items 
rated on a scale from 1 (strongly disagree) to 7 
(strongly agree), and subscale scores are computed 
by averaging the item scores. Higher scale scores 
denote higher levels of that type of motivation.
 For the translation of the 27 items of the original 
TEQ, we first adapted the wording to fit a population 
of patients with mental illness in psychiatric 
treatment. For example, where in the original TEQ 
the focus was upon substance abuse treatment and 
included items such as ‘I plan to go through with a 
treatment program because I’ll hate myself if I don’t 
get my habit under control’, we focused on a more 
general psychiatric treatment and adapted the item 
to ‘I plan to go through with a treatment program 
because I’ll hate myself if I don’t get my problems 
under control’. Two translators performed forward 
translations of the original TEQ independently 
into Dutch and adapted the wording to fit its 
application to outpatient psychiatric treatment. A 
consensus version based on these two translations 
was established. This consensus version was back 
translated by a native English speaker (second 
language Dutch, also native level) and compared to 
the original English version. Only minor adaptations 
were necessary to establish the final Dutch items. 
SDT - Short Motivation Feedback List
The Dutch TEQ items served as the basis for item 
creation and selection in the short motivation 
feedback list (SMFL). The SMFL contains only eight 
items (three items intended to measure identified 
motivation, two items for introjected motivation and 
three items for external motivation). The eight items 
were selected based on the highest factor loadings 
in the study by Wild et al. 126 on the original TEQ. The 
items were shortened and simplified where possible, 
to aid patients and clinicians in understanding them. 
All items begin with the phrase: ‘Currently, I remain 
in treatment because…’ followed by a specific 
ending (e.g. ‘I can solve my problems this way’ for 
identified motivation, ‘I may not disappoint myself’ 
for introjected motivation and ‘other people think 
that I should’ for external motivation). After these 
adjustments, none of the SMFL items were identical 
to TEQ items anymore, although they resembled 
them. The items are rated on a scale from 0 (totally 
disagree) to 10 (totally agree). Higher scale scores 
denote higher levels of that type of motivation. 
Preliminary impressions of the use of the SMFL 
among 13 patients with primarily anxiety and 
depressive symptoms receiving outpatient treatment 
showed that the list was comprehensible and easy 
to use in clinical practice. Clinicians appreciated the 
brevity and clarity of the items, which could function 
as a starting point for the discussion with the patient 
regarding his/her current motivation to engage in 
treatment. 
SDT - Health Care Climate Questionnaire
The Health Care Climate Questionnaire (HCCQ) 134 
was administered to patients to assess the degree 
in which clinicians were perceived to be autonomy 
supportive. Autonomy support consists of providing 
choices to the patient, being open to the perspective 
of the patient and minimizing pressure and control 
65. The HCCQ has 15 items that are scored on a 
Likert scale, ranging from 1 (strongly disagree) to 7 
(strongly agree). The items are summed up to obtain 
a total scale score, with higher scores reflecting 
higher perceived autonomy support. The HCCQ was 
found to be reliable in a study on psychotherapy 
for	 depressed	 outpatients	 (Cronbach’s	 α	 =	 .88)	 128. 
The original HCCQ was translated into Dutch by 
two independent translators who subsequently 
established a consensus version. This consensus 
version was back translated into English by two 
independent expert translators to check for 
discrepancies between the original version and the 
back-translation. On the basis of consensus between 
all translators, the final Dutch HCCQ was constructed.
IM - Motivation to Engage in Treatment (MET) 
scale
The scale for motivation to engage in treatment 
(MET) that is part of the Treatment Motivation 
Scale for forensic patients (TMS-f) 118 is a self-report 
questionnaire that was administered to patients to 
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measure their motivation for outpatient treatment. 
Although the TMS-f was developed within Dutch 
forensic psychiatric outpatient treatment, we 
felt that the items on the MET subscale were 
sufficiently general for application outside a forensic 
setting. The MET subscale measures commitment 
for treatment engagement, session attendance, 
treatment completion and readiness to make 
sacrifices necessary for treatment (e.g. money, 
emotional burden and lifestyle changes)116. The MET 
subscale has 16 items that are rated on a scale from 
1 (totally agree) to 5 (totally disagree). The TMS-f 
has been found to be reliable and valid measure in 
a population of Dutch (forensic) outpatients with a 
variety of psychiatric disorders 116,118. 
TTM - University of Rhode Island Change 
Assessment
The Dutch version of the University of Rhode Island 
Change Assessment (URICA-D) 170 is a self-report 
scale that asks a patient to rate the agreement with 
a particular statement reflecting a specific stage of 
change. It has 24 items rated on a scale from 1 (totally 
disagree) to 5 (totally agree) representing four stages 
of change: precontemplation, contemplation, action 
and maintenance. A total readiness for change score 
was calculated by subtracting the precontemplation 
scale score from the sum of the other three scale 
scores, as in a previous study in patients with severe 
mental illness where it was found to be sufficiently 
reliable and valid 57. Higher scores reflect more 
readiness to change.
Helping Alliance Questionnaire
The Helping Alliance Questionnaire (HAQ) contains 
two subscales that refer to cooperation (5 items) and 
helpfulness (5 items) that are rated on a 5-point scale 
(completely disagree to completely agree)182. Both a 
patient and a clinician version have been developed. 
The patient version (HAQ-P) includes items such as 
“I feel the clinician understands me”. The clinician 
version (HAQ-C) has similar items but worded 
differently, such as “I understand the patient”. The 
HAQ was found to be reliable and construct validity 
was supported by positive correlations between the 
HAQ and other relationship scales and outcomes 
such as length of stay in detox treatment programs 
and noncompliance with treatment 182. 
Service Engagement Scale
The Service Engagement Scale (SES) was used to 
assess the patient’s engagement with outpatient 
psychiatric treatment 199. This scale was developed 
specifically for assessing engagement with services 
in community mental health settings. It has four 
subscales that refer to availability, collaboration, 
help seeking and treatment engagement (including 
medication adherence). The 14 items of the SES are 
rated by clinicians on a 4-point scale ranging from 0 
(not at all) to 3 (most of the time). For the current 
study, the total scale score was used. In case patients 
were not prescribed medications, these items were 
replaced with the total mean of the other items to 
compute the total scale score. A higher score on the 
SES reflects higher levels of treatment engagement. 
The SES has shown good psychometric properties in 
patients with psychotic disorders 190,199. 
Statistical Analyses
The analysis strategy consisted of four steps: 1) 
Exploratory Factor Analysis (EFA), 2) Confirmatory 
Factor Analysis (CFA), 3) estimating reliabilities and 4) 
determining construct and criterion validity. Although 
Wild et al. 126 have reported on the structure of the 
English TEQ, several items referring to substance or 
drug abuse problems were rewritten in the Dutch 
translation to fit a population of outpatients with 
primarily psychiatric problems and these alterations 
might influence the structural model. Thus, EFA 
was first conducted to empirically determine the 
number of factors that would be appropriate for the 
Dutch TEQ. The fit of structural models with varying 
numbers of latent factors (i.e. from one factor up to 
four factors) was compared using robust maximum-
likelihood approaches (MLR) and the chi-square 
statistic	(χ2). Also, the scree plot was inspected and 
the	Kaiser	criterion	(eigenvalues	>	1)	was	considered.	
Additionally, theoretical psychological interpretation 
guided the decision making, informed by the study 
with the original English TEQ by Wild. et al 126 in 
which three latent factors were retained. 
 Subsequently, CFA was performed on the latent 
factors that were identified by EFA, to establish 
whether the factor structure of the Dutch TEQ was 
similar to the original English TEQ. Although the 
theoretical constructs defined by SDT are distinct, 
it is likely that these constructs are related when 
translated in empirical statistical terms. Therefore, 
we decided to analyze all constructs simultaneously 
by determining the relative fits of four different 
models to the TEQ data. First, an uncorrelated factors 
model (27 items loading on three uncorrelated 
factors) and an intercorrelated factors model (27 
items loading on three intercorrelated factors) were 
tested to see if three factors underlie the measured 
items and if these should be correlated. Thirdly, a 
bifactor model (27 items simultaneously loading on 
three uncorrelated factors and one general factor) 
was specified to test if a model with an independent 
general motivation factor and three additional 
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more specific motivation factors was appropriate. 
Although it is unlikely with EFA to obtain a bifactor 
model (since the aim of EFA is to obtain simple 
structure and the number of factors), bifactor 
models can be appropriate for psychological scales 
200. Finally, a second order factor model (27 items 
loading on three factors which loaded on a single 
higher order factor) was specified to test if the three 
motivation factors had a common underlying (higher 
order) construct (i.e. motivation in general). It is of 
great importance to identify which of these different 
factor models is most plausible, both clinically/ 
theoretically and empirically/statistically. It is an 
important preliminary step before conducting larger 
structural models that also include relationships 
between predictors/determinants and outcome 
variables. For example, CFA can help to determine 
if there are specific motivation factors that could be 
used as unique predictors of treatment outcomes 
(in case we find most support for the uncorrelated 
or intercorrelated factor model), or if there are 
both specific factors and an independent general 
motivation factor, which may be hierarchically 
ordered (in case we find most support for the 
second-order factor model) or not (in case of most 
support for the bifactor model). 
 The quality of the models was evaluated in two 
steps. First, the analyses were rerun if the models 
were improperly specified. Individual fit was assessed 
by evaluating individual estimated parameters (e.g. 
no	 negative	 variances	 or	 correlations	 of	 ≥	 |1.00	
|	 and	 no	 parameter	 estimates	 with	 values	 that	
contradicted psychological theoretical interpretation 
were allowed). Second, overall fit was assessed by 
using	 the	 chi-square	 statistic	 (χ2),	 χ2/df,	 Bentler’s	
Comparative Fit Index (CFI), Tucker Lewis Index (TLI) 
and the root mean square error of approximation 
(RMSEA). The following rules of thumb were used to 
specify cutoff points for fit indices 201: CFI/TLI > 0.95 
(good fit), 0.90-0.95 (borderline fit) and <0.90 (poor 
fit); RMSEA <0.06 (good fit), 0.06 - 0.08 (fair fit), 
0.08-0.10 (borderline fit) and >0.10 (poor fit). Also, 
the fit indices of Akaike Information Criterion (AIC), 
Bayesian Information Criterion (BIC) and Sample-
Size Adjusted Bayesion Information Criterion (S-BIC) 
were inspected. Furthermore, in search for the 
most parsimonious assessment with the TEQ, the 
TEQ items with a substantial loading on a certain 
factor	(i.e.	≥	|0.40|)	and	 low	loadings	on	the	other	
factors	 (i.e.	≤	|	0.20	|)	were	considered	as	“factor-
pure” items. We performed secondary (and similar) 
Confirmatory Factor Analyses on only these factor-
pure items to determine the final structural model 
of the Dutch TEQ. For all models, robust maximum 
likelihood estimation (MLR) as implemented in 
Mplus 202 was used because of non-normality of 
the frequency distribution of the items. The factor 
structure of the SMFL was established with the same 
procedure, by first conducting EFA to determine the 
number of factors. The relative fits of models with 
one, two or three latent factors were evaluated. 
Subsequently, we fitted the following models in 
CFA: a general factor model; an uncorrelated factors 
model; an intercorrelated factors model; a bifactor 
model and a second order factor model.
 The reliabilities of the TEQ, SMFL and HCCQ were 
determined	by	the	computation	of	Cronbach’s	α	and 
either tau-equivalence or congeneric estimates of 
reliability. The reliability of the composite of items 
is a function of the square of the sum of the factor 
loadings on one factor, as this decomposes the 
observed variance into a systematic and an error 
component. Although	 Cronbach’s	 α	 is	 the	 most	
commonly used measure of internal consistency, it 
only yields an unbiased estimate of the reliability if 
the factor loadings and error variances of the items 
are equal 203. If however, only factor loadings are 
equal but error variances are not, a tau-equivalence 
estimate for reliability is more appropriate and 
if both factor loadings and error variances are 
heterogeneous, the congeneric reliability estimate 
is most appropriate 203. Therefore, additional to 
reporting	 traditional	 Cronbach’s	 α’s,	 either	 tau-
equivalent or congeneric estimates of reliability will 
be reported where appropriate. Also, test-retest 
correlations were computed for the TEQ. For the 
interpretation of the reliability coefficients, we 
used the guidelines of Nunnally and Bernstein 204 
who stated that a value of 0.70 is sufficient for early 
stages of research but a reliability coefficient of 
0.80 or higher should be attempted, while reliability 
coefficients of 0.90 or higher are desirable when 
important decisions are to be made with the test 
scores. Test-retest reliabilities for the scales were 
explored by computing Pearson correlations (in 
case of normally distributed data) or Spearman rank 
correlations (for non-normally distributed data) 
between the first and second assessment. For the 
SMFL, intraclass correlation coefficients (ICCs) were 
computed to estimate the test-retest stability over 
four consecutive SMFL assessments, using a two-
way random model of consistency. 
	 Validity	 was	 investigated	 by	 computing	 Pearson	
correlations	 (in	 case	 of	 linear	 normally	 distributed	
data)	or	Spearman	rank	correlations	(for	non-normally	
distributed	 data)	 between	 all	 patient-rated	 and	
clinician-rated	 scales.	 The	 conventional	 guidelines	
by Cohen 205	were	used	for	the	 interpretation	of	the	
correlation	coefficients:	r	≤	|0.29|	as	weak,	|0.30	to	
0.49|	as	moderate	and	r	≥	|0.49|	as	large.
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Furthermore, the mean scores on the TEQ subscales 
were compared between patients who were rated 
by their clinicians as having high levels of treatment 
engagement (measured by the SES) to those with low 
levels, and between patients with and without legally 
mandated treatment. Since the SES scores showed 
a skewed distribution, the SES was dichotomized 
at	 the	 median	 score.	 SES	 ≤30	 was	 interpreted	 as	
low treatment engagement and SES >30 as high 
treatment engagement. Logistic regression analyses 
were performed using the TEQ scales as predictors 
for the dichotomized SES and legally mandated 
treatment (yes/no). Statistical tests were performed 
using SPSS version 21 for Windows (SPSS Inc., 
Chicago, IL, USA) and Mplus version 7.0 202. 
Results
A total of 72 clinicians agreed to participate of which 
49 were female (68%). Their mean age was 43 years 
old	(SD	=	10.81)	and	they	had	a	mean	of	15.4	years	
of clinical working experience in mental health 
services	 (SD	 =	 9.32).	 From	 their	 caseloads,	 a	 total	
of 349 patients agreed to participate. Table 1 shows 
an overview of the patient characteristics. Within 
the subsample of patients with psychotic disorders, 
the majority of patients were diagnosed with 
schizophrenia (48%), schizoaffective disorder (16%) 
or psychotic disorder not otherwise specified (24%). 
Within the subsample of personality disorders, 
40% had a borderline personality disorder, 13% 
had antisocial personality disorder and 26% had a 
personality disorder not otherwise specified. Within 
the subsample of patients with mood and anxiety 
disorders, 46% had an anxiety disorder. 
Exploratory Factor Analyses
EFA analyses on the 27 items of the TEQ revealed 
superior fit for a structural model with three latent 
factors	 (χ2=534.64,	 df=273,	 p=0.0000,	 χ2/df=1.96,	
CFI=0.90;	 TLI=0.87;	 RMSEA=0.05),	 as	 opposed	
to	 a	 model	 with	 one	 latent	 factor	 (χ2=1762.74,	
df=324,	 p=0.0000,	 χ2/df=5.44,	 CFI=0.46;	 TLI=0.42;	
RMSEA=0.11)	 or	 two	 latent	 factors	 (χ2=693.50,	 df=	
298,	 p=0.0000,	 χ2/df=2.33,	 CFI=0.85;	 TLI=0.83;	
RMSEA=0.06). A three factor model was most 
consistent with the original English version of the 
TEQ 126 and these three factors could theoretically be 
interpreted as representing identified, introjected 
and external motivation. 
 The SMFL was subjected to EFA, in which a 
superior	fit	for	a	model	with	three	latent	factors	was	
also	 found	 (χ2=7.16,	 df=7,	 p=0.4127,	 χ2/df=1.02,	
CFI=0.99;	TLI=0.99;	RMSEA=0.01),	as	opposed	to	two	
latent	factors	(χ2=35.91,	df	=13,	p=0.0006,	χ2/df=2.76,	
CFI=0.92;	TLI=0.83;	RMSEA=0.11)	or	one	latent	factor	
(χ2=113.14,	df=20,	p=0.0000,	χ2/df=5.66,	CFI=0.68;	
TLI=0.55;	 RMSEA=0.19).	 Theoretically,	 SMFL-items	
1 and 2 were interpreted as identified motivation, 
items 3, 5, and 7 were interpreted as introjected 
Table 1. Patient characteristics for the total sample and diagnostic groups 
Total patient sample
n = 349
Psychotic disorders
n= 199
Personality disorders
n = 95
Mood and Anxiety disorders
n = 55
Age, mean (SD) 43.3 (10.6) 43.0 (10.2) 46.0 (10.2)* 39.8 (11.5)*
Male gender, n (%) 200 (57.5) 133 (66.2)* 46 (50.0)* 21 (38.5)* A
Education level, n (%)
- No education/elementary
- Secondary school
- Upper high school and over
- Unknown
129 (37.1)
144 (41.4)
67 (19.3)
8 (2.3)
76 (37.8)
77 (38.3)
47 (23.4)
1 (0.5)
31 (33.7)
47 (51.1)
12 (13.0)
2 (2.2)
22 (40.0)
20 (36.4)
8 (14.5)
5 (9.1)
Country of birth, n (%)
- Netherlands
- Morocco
- Netherlands Antilles
- Other
- Unknown
286 (82.2)
15 (4.3)
6 (1.7)
39 (11.2)
2 (0.6)
158 (78.6)
10 (5.0)
5 (2.5)
28 (13.9)
0 (0)
81 (88.0)
1 (1.1)
1 (1.1)
9 (9.8)
0 (0)
47 (85.5)
4 (7.3)
0 (0)
2 (3.6)
2 (3.6)
Treatment duration (months)
mean (SD)
median (IQR)
34.3 (25.5)
29 (17 to 48)
37.3 (24.2)*
30 (20.5 to 52)
42.1 (25.9)*
37.5 (26.3 to 53)
8.3 (8.47)*B
5.5 (3 to 12)
GAF-score, mean (SD) 57.6 (8.3) 56.7 (9.0) 58.3 (7.5) 59.7 (6.2)
Legal mandate, N (% yes) 24 (6.9) 13 (6.5) 11 (12.0)* 0 (0)*
One or more previous admissions, n, (% yes) 234 (67.2) 162 (80.6)* 65 (70.7)* 7 (12.7)*B
Note:	percentages	reflect	column	percentages.	*	p	<	0.017	(The	conventional	p-value	of	α	=	0.05	was	divided	by	the	number	of	groups	
(3) in the comparison). A All three diagnostic groups significantly differed from each other. B Patients with mood and anxiety disorders 
significantly differed from the other two diagnostic groups. 
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motivation and items 6 and 8 as external motivation. 
Item 4 was discarded as it did not load substantially 
on any of the retained factors and could not be 
interpreted theoretically as belonging to any of 
these three factors. In the following analyses, these 
three SMFL-subscales were used. 
Confirmatory Factor Analyses 
CFA analysis of the 27 items of the TEQ (see Table 
2) revealed superior fit for the bifactor model 
(χ2=613.30,	df=	299,	p=0.0000,	χ2/df=2.05;	CFI=0.85;	
TLI=0.82;	 RMSEA=0.06),	 compared	 to	 the	 other	
models. CFA did not converge for the second 
order factor model, even after a loosening of 
constraints on the model and enlarging the number 
of iterations. Secondly, only the TEQ items with a 
substantial	 loading	on	a	relevant	factor	(i.e.	≥	 .40|)	
and	 low	 loadings	on	 the	other	 factors	 (i.e.	≤	|.20|)	
were brought into a secondary (and similar) CFA 
(see Table 2). A total of 18 items were selected, 6 
items per factor. Again, the bifactor model showed 
superior	fit	(χ2	=	249.65,	df	=	118,	p	=	0.0000,	χ2/df	=	
2.12;	CFI	=	0.90;	TLI	=	0.87;	RMSEA	=	0.06),	compared	
to the other models. The information criteria (AIC, 
BIC, S-BIC) were also lowest for the bifactor model, 
which supports that this model was most plausible. 
However, subsequent reliability analysis on the 
bifactor model revealed that several subscales had 
inadequate reliability estimates for both the total 
sample and subsamples (e.g. congeneric estimates 
of 0.10 and 0.18). Since our goal was to establish 
reliable sum scores for the subscales of the TEQ, we 
chose to continue with the next best fitting model, 
which was the intercorrelated factors model. This 
model	 had	 borderline	 acceptable	 fit	 (χ2=315.18,	
df=135,	 p=0.0000,	 χ2/df=2.33;	 CFI=0.86;	 TLI=0.84;	
RMSEA=0.06)	 but	 was	 theoretically	 more	 plausible	
than the bifactor model solution and reliability 
estimates for all patient samples were acceptable 
(see Table 3). The item cross-loadings were inspected 
for all confirmative analyses and no indication was 
found for any cross-loading. Standardized coefficients 
(factors loadings) between the observed measures 
(18 TEQ items) and latent variables (motivation 
factors) for the intercorrelated factors model are 
shown in Figure 1. The three factors in the final 
model were interpreted as identified motivation, 
introjected motivation and external motivation. The 
average variance explained (R2) by the final model 
was 35% (R2 for the items ranging from 11% to 56%). 
In all subsequent analyses, the TEQ 18-item-version 
was used.
Regarding the structure for the SMFL, CFA on the 
seven items revealed that the intercorrelated 
factors model had relatively better fit compared to 
the other models.
Reliability 
Internal consistencies of the three questionnaires 
for the total patient sample are summarized in Table 
3. As the assumptions for tau-equivalence estimates 
of reliabilities were never met, these were not 
reported. We found acceptable reliabilities for the 
TEQ subscales of identified motivation (congeneric 
estimate	=	0.78),	introjected	motivation	(congeneric	
estimate	=	0.72)	and	external	motivation	(congeneric	
estimate	=	0.75)	in	the	total	sample.	Reliabilities	did	
not vary substantially between subgroups, except for 
the external motivation subscale that was lower for 
the patients with personality disorders (congeneric 
estimate	=	0.69).	Test-retest	reliability	of	the	TEQ	was	
determined by correlating the first measurement 
with the measurement after 12 months of community 
mental health treatment in a sample of patients 
with	 psychotic	 and	 personality	 disorders	 (N=	 70).	
The test-retest correlations for the subscales were 
acceptable;	r	=	0.58	(p<0.01)	for	internal	motivation,	
r	 =	 0.60	 (p<0.01)	 for	 introjected	 motivation	 and	 
r	=	0.45	(p	<0.01)	for	external	motivation.	
 The short motivation feedback list had adequate 
internal consistency in the total sample for identified 
motivation	(congeneric	estimate	=	0.81),	introjected	
motivation	 (congeneric	 estimate	 =	 0.93)	 and	
external	motivation	(congeneric	estimate	=	0.84)	at	
the first administration. The reliability for external 
motivation varied between subgroups; it was 
questionable for patients with mood and anxiety 
disorders. For 52 patients with personality and/or 
psychotic disorders, the SMFL was administered four 
times with a median of 43 days apart. The ICCs for 
identified, introjected and external motivation were 
0.69, 0.89 and 0.91, respectively. Table 4 shows 
that the Spearman correlations increased with 
the number of times the SMFL was administered. 
Furthermore, the introjected and external motivation 
scales consistently showed strong intercorrelations 
over time, while identified motivation only showed 
moderate correlations to introjected motivation 
when it was assessed at the same time.
 The HCCQ showed excellent internal consistency 
for	the	total	sample	(congeneric	estimate	=	0.93),	and	
also for all subsamples. The test-retest correlation 
for	the	HCCQ	after	one	year	was	r	=	0.58	(p<0.01).
67
Table 2. Confirmatory Factor Analyses for the TEQ and SMFL
Note:	TEQ	=	Treatment	Entry	Questionnaire;	SMFL	=	Short	Motivation	Feedback	List;		χ2 =	chi-square	statistic;	df	=	degrees	of	freedom;	 
CFI	 =	Comparative	 Fit	 Index;	 TLI	 =	Tucker	 Lewis	 Index;	RMSEA	=	 root	mean	 square	error	of	 approximation;	AIC	=	Akaike	 Information	
Criterion;	BIC	=	Bayesian	Information	Criterion;	S-BIC	=	Sample-Size	Adjusted	Bayesion	Information	Criterion;	d.n.c.	=	did	not	converge.
Questionnaire Model χ2 df p-value χ2 / df CFI TLI RMSEA 90% C.I. for 
RMSEA
AIC BIC S-BIC
TEQ
(27 items)
Uncorrelated factors 984.96 325 0.0000 3.03 0.68 0.66 0.08 0.071 to 0.082 37810.51 38118.46 37864.67
Intercorrelated factors 830.65 322 0.0000 2.58 0.76 0.74 0.07 0.062 to 0.073 37638.04 37957.54 37694.23
Bifactor 613.30 299 0.0000 2.05 0.85 0.82 0.06 0.049 to 0.061 37409.43 37817.46 37481.20
Second order factor d.n.c.
TEQ 
(18 items)
Uncorrelated factors 423.86 138 0.0000 3.07 0.78 0.75 0.08 0.069 to 0.086 24898.85 25095.16 24933.37
Intercorrelated factors 315.18 135 0.0000 2.33 0.86 0.84 0.06 0.053 to 0.071 24779.37 24987.23 24851.93
Bifactor 249.65 118 0.0000 2.12 0.90 0.87 0.06 0.047 to 0.066 24724.88 24998.18 24772.95
Second order factor 360.59 135 0.0000 2.67 0.83 0.80 0.07 0.061 to 0.078 24828.60 25036.46 24865.16
SMFL 
(7 items)
Uncorrelated factors d.n.c.
Intercorrelated factors 24.55 9 0.0035 2.72 0.92 0.82 0.11 0.060 to 0.167 4464.64 4540.37 4458.12
Bifactor 23.42 7 0.0014 3.35 0.92 0.75 0.13 0.075 to 0.192 4468.43 4549.98 4461.40
Second order factor d.n.c.
Figure 1. Standardized coefficients (factor loadings) obtained with the intercorrelated factors model for the Treatment Entry 
Questionnaire (TEQ).
Note: To avoid complexity of the figure, the error variances are not shown here. Numbers between brackets represent the range of 
the item loadings.
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Validity 
Table 5 shows Spearman correlations that were 
computed between the subscales of the TEQ, HCCQ, 
SMFL and the MET, RTC, HAQ and SES for the total 
sample. To emphasize that the MET and RTC scales 
were based on theoretical perspectives different 
from SDT, we will use their theory abbreviations in 
front of the scale names from this point onward. 
That is; IM-MET for the motivation scale based on 
the Integral Model of Treatment Motivation and 
TTM-RTC for the motivation scale based on the 
Transtheoretical Model. 
Concurrent and discriminant validity
Table 5 shows the patterns of monomethod 
correlations (gray cells) and the heteromethod 
correlations (black cells) for the TEQ and SMFL. 
The inter-correlations of the TEQ subscales 
showed similar patterns for both methods. That is, 
identified and external motivation were moderately 
negatively correlated and introjected motivation 
showed stronger positive correlation with identified 
motivation than with external motivation. For the 
SMFL, the general patterns for both methods were 
also comparable, although the correlations were 
stronger for clinician-ratings than patient-ratings. 
Contrary to theoretical expectations however, 
identified and external motivation were not 
negatively correlated but marginally positive. 
 The convergent validities for the TEQ and SMFL 
are represented by the correlations on the diagonal 
of the black boxes within Table 5. These monotrait-
heteromethod correlations generally showed 
moderate	 correlations	 (between	 r	 =	 0.26	 and	 
r	 =	 0.30),	 although	 the	 TEQ	 introjected	 scale	
showed	 weak	 correlation	 (r	 =	 0.15).	 Discriminant	
validities for the TEQ and SMFL were supported by 
the finding that generally, higher correlations were 
found between similar motivation concepts than 
between different motivation concepts. That is, all 
monotrait-heteromethod correlations exceeded the 
heterotrait-heteromethod correlations except for 
the external motivation scale of the SMFL rated by 
the clinician, which showed higher correlation with 
patient-rated introjected than external motivation. 
Criterion validity for the TEQ
Regarding	associations	between	the	TEQ	and	measures	
for	 the	quality	of	 the	 therapeutic	 relationship,	most	
theoretically	 expected	 associations	 were	 confirmed.	
It was found that identified motivation showed 
substantial positive correlation with autonomy 
support measured by the HCCQ and with both 
subscales of the patient-rated HAQ. Correlations 
were stronger for patient-rated TEQ than clinician-
rated TEQ. Introjected motivation rated by patients 
showed	weak	positive	correlation	with	HCCQ	(p=0.13,	
p<0.05) and the external motivation subscale showed 
moderate negative association with the HCCQ 
(rs	 =	 -0.24,	 p<0.01).	 The	 correlations	 of	 clinician-
rated TEQ with the therapeutic relationship scales 
showed a similar pattern but were less pronounced. 
 The TEQ scores were also correlated with 
motivation measures based on the two other 
theories. Regarding associations with the IM-MET-
scale, TEQ identified motivation showed weak 
positive correlation and introjected motivation 
showed no association for both methods. External 
motivation showed weak negative association with 
IM-MET (rs	=	-0.21,	p<0.01)	when	rated	by	patients,	
but no association between clinician-rated external 
motivation and IM-MET was found. Furthermore, 
for both TEQ methods it was found that identified 
motivation showed strongest positive correlation 
with TTM-RTC, introjected motivation showed less 
strong positive association and external motivation 
showed moderate negative association.
 In line with theoretical expectations, treatment 
engagement as measured with the SES was 
positively correlated with clinician-rated TEQ 
identified motivation (rs	=	0.58,	p<0.01),	less	strong	
with introjected motivation (rs	 =	 0.18,	 p<0.01)	 and	
negatively with external motivation (rs	 =	 -0.15,	
p<0.05). For patient-rated TEQ scales however, 
neither introjected motivation nor external 
motivation was associated with SES. The means of 
the TEQ scales were compared between those who 
were rated by their clinicians as having high levels 
of treatment engagement (i.e. SES-score > 30) 
to those who were rated as having low levels (i.e. 
SES-score	 ≤	 30).	 Table	 6	 shows	 that	 patients	 who	
rated themselves higher on identified motivation 
were rated by their clinicians as having high levels 
of treatment engagement at the same time (mean 
difference -2.61, p < 0.01). 
Table 7 shows results from independent samples 
T-tests that were performed to investigate the 
relationship between means on the TEQ subscales 
and legal mandate for treatment. Patients who had 
a legal mandate for psychiatric treatment scored 
significantly lower on identified motivation and 
significantly higher on external motivation, both for 
clinician-rated and patient-rated TEQ scales. 
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Questionnaires Total patient sample
n= 348
Psychotic disorders
n = 201
Personality disorders
n = 92
Mood and Anxiety disorders
n = 55
TEQ identified motivation 
- Mean (S.D.)
- Internal consistency 
   - Cronbach’s α 
   - Congeneric estimate
- Test-retest reliability (one year) 
34.5 (7.13)
0.78
0.78
0.58** (n = 70)
33.53 (7.56)
0.78
0.75
0.60** (n = 48)
34.6 (6.77)
0.76
0.82
0.53* (n = 22)
37.9 (4.71)
0.74
0.86
TEQ introjected motivation 
- Mean (S.D.) 
- Internal consistency 
   - Cronbach’s α
   - Congeneric estimate
- Test-retest reliability (one year) 
22.2 (9.24)
0.77 
0.72
0.60** (n = 70)
22.3 (9.37)
0.76 
0.71
0.58** (n =48)
23.1 (9.33)
0.78 
0.73
0.62** (n = 22)
20.3 (8.48)
0.78 
0.76
TEQ external motivation 
- Mean (S.D.) 
- Internal consistency
   - Cronbach’s α
   - Congeneric estimate
- Test-retest reliability (one year) 
15.85 (8.41)
0.74
0.75
0.45** (n = 70)
18.4 (8.39)
0.71 
0.74
0.48** (n = 48)
14.5 (7.73)
0.69 
0.69
0.30 (n = 22)
8.7 (3.57)
0.58 
0.74
SMFL identified motivation 
- Mean (S.D.) 
- Internal consistency 
   - Cronbach’s α
   - Congeneric estimate
13.54 (4.02)
0.76
0.81
13.24 (3.86)
0.85
0.89
13.19 (4.24)
0.72
0.85
14.00 (4.07)
0.71
0.85
SMFL introjected motivation 
- Mean (S.D.) 
- Internal consistency 
   - Cronbach’s α
   - Congeneric estimate
14.01 (7.14)
0.63
0.93
14.20 (7.75)
0.67
0.90
11.38 (6.65)
0.63
0.92
15.33 (6.53)
0.54
0.91
SMFL external motivation 
- Mean (S.D.) 
- Internal consistency 
   - Cronbach’s α
   - Congeneric estimate
6.89 (5.18)
0.70
0.84
8.28 (5.93)
0.84
0.88
6.16 (4.46)
0.56
0.74
6.04 (4.63)
0.54
0.66
HCCQ total scale score
- Mean (S.D.) 
- Internal consistency
   - Cronbach’s α
   - Congeneric estimate
Test-retest reliability (one year) 
88.56 (15.06)
0.93
0.93
0.58**(n= 131)
86.02 (16.17)
0.93 
0.94
0.58** (n = 84)
89.73 (14.01)
0.92
0.93
0.56** (n = 47)
95.85 (8.82)
0.91
0.91
Table 3. Descriptive statistics and reliabilities for the SDT measures in the total client sample and diagnostic groups
*	p	<	0.05,	**	p	<	0.01	TEQ	=	Treatment	Entry	Questionnaire;	SMFL	=	Short	Motivation	Feedback	list;	HCCQ	=	Health	Care	Climate	Questionnaire.
IDEN 1 IDEN 2 IDEN 3 IDEN 4 INTRO 1 INTRO 2 INTRO 3 INTRO 4 EXT 1 EXT 2 EXT 3 EXT 4
IDEN 1 - 0.06 to 0.44 0.05 to 0.52 -0.03 to 0.56 0.20 to 0.53 -0.17 to 0.29 -0.22 to 0.25 -0.26 to 0.31 -0.03 to 0.35 -0.17 to 0.27 -0.26 to 0.20 -0.25 to 0.33
IDEN 2 0.26* - 0.14 to 0.62 0.07 to 0.64 0.07 to 0.48 0.18 to 0.57 -0.19 to 0.34 -0.32 to 0.35 -0.22 to 0.24 0.01 to 0.43 -0.09 to 0.43 -0.44 to 0.16
IDEN 3 0.31* 0.40* - 0.22 to 0.68 0.28 to 0.64 -0.03 to 0.45 0.05 to 0.52 -0.03 to 0.41 -0.09 to 0.41 -0.22 to 0.28 -0.07 to 0.40 -0.24 to 0.28
IDEN 4 0.30* 0.37** 0.48** - 0.03 to 0.60 -0.21 to 0.43 -0.20 to 0.15 0.03 to 0.62 -0.29 to 0.23 -0.46 to 0.15 -0.31 to 0.28 -0.17 to 0.40
INTRO 1 0.37* 0.28** 0.48** 0.32* - 0.33 to 0.69 0.31 to 0.74 0.36 to 0.81 0.49 to 0.74 0.23 to 0.63 0.36 to 0.74 0.35 to 0.76
INTRO 2 0.06 0.39** 0.21 0.09 0.53** - 0.46 to 0.79 0.49 to 0.87 0.26 to 0.63 0.51 to 0.79 0.63 to 0.86 0.37 to 0.81
INTRO 3 0.02 0.08 0.30* 0.08 0.54** 0.65** - 0.45 to 0.87 0.26 to 0.66 0.34 to 0.73 0.54 to 0.84 0.43 to 0.82
INTRO 4 0.03 0.03 0.21 0.33* 0.63** 0.72** 0.69** - 0.09 to 0.61 0.22 to 0.74 0.48 to 0.84 0.64 to 0.90
EXT 1 0.17 -0.00 0.18 -0.03 0.63** 0.45** 0.48** 0.37** - 0.38 to 0.71 0.42 to 0.79 0.38 to 0.78
EXT 2 0.04 0.22* 0.03 -0.17 0.45** 0.67** 0.56** 0.49** 0.56** - 0.54 to 0.83 0.44 to 0.82
EXT 3 -0.04 0.16 0.17 -0.02 0.57** 0.77** 0.71** 0.70** 0.63** 0.71** - 0.69 to 0.93
EXT 4 0.04 -0.13 0.02 0.12 0.60** 0.62** 0.66** 0.80** 0.61** 0.67** 0.84** -
Table 4. Test-retest spearman correlations (below diagonal) and corresponding 95% confidence intervals (above diagonal) of four assessments 
with the patient-rated SMFL scales 
*	p	<	0.05,	**	p	<	0.01	(two-tailed).	IDEN	=	identified	motivation,	INTRO	=	introjected	motivation,	EXT	=	external	motivation.	
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Criterion validity for the SMFL
Not all of the theoretically expected associations 
between the SMFL and the TEQ subscales were 
confirmed. For example; looking at patient-rated 
scales it can be seen that while SMFL identified 
motivation correlated most positive with TEQ 
identified motivation (rs	 =	 0.24,	 p<0.01)	 and	 the	
SMFL introjected scale showed strongest positive 
association with TEQ introjected motivation 
(rs	 =0.46,	 p<0.01),	 these	 correlational	 patterns	
were not found for clinician-rated scales. Other 
mixed findings include that patient-rated SMFL 
scales showed almost no significant associations 
with clinician-rated TEQ scales, although they were 
positively associated with most clinician-rated 
SMFL-scales. For both methods it was found that 
the SMFL external scale was most strongly positively 
associated with TEQ introjected motivation instead 
of with TEQ external motivation. Clinician-rated SMFL 
scales showed an unexpected pattern of correlations 
with patient-rated TEQ scales as clinician-rated SMFL 
introjected motivation was positively correlated with 
patient-rated TEQ identified motivation (rs	 =	 0.30,	
p<0.01) and clinician-rated SMFL external motivation 
was weakly positively correlated with patient-rated 
introjected motivation (rs	=	0.17,	p<0.01).	
 Looking at associations between the SMFL 
and measures for the therapeutic relationship, the 
findings were generally consistent with expectations. 
For the HCCQ, both patient-rated and clinician-rated 
SMFL identified motivation showed significantly 
positive correlations and, additionally, so did 
clinician-rated introjected motivation. Three positive 
correlations were found of patient-rated SMFL with 
patient-rated HAQ, but no positive correlations were 
found with clinician-rated HAQ. Vice versa, clinician-
rated SMFL scales showed several significant positive 
correlations with clinician-rated HAQ but only one 
with patient-rated HAQ. 
 Finally, regarding associations between the 
SMFL and motivation scales from the other two 
theories it was found that patient-rated identified 
motivation was positively associated with TTM-
RTC (rs	 =	 0.31,	 p<0.01)	 and	 so	 was	 clinician-rated	
PATIENT RATED SCALES CLINICIAN RATED SCALES
SDT IM TTM SDT
TEQ
ID
TEQ
IN
TEQ
EX HCCQ
SMFL
ID
SMFL
IN
SMFL
EX MET RTC HAQ c HAQh
TEQ
ID
TEQ
IN
TEQ
EX
SMFL
ID
SMFL
IN
SMFL
EX
HAQ c HAQh
PA
TI
EN
T-
RA
TE
D 
SC
AL
ES
TEQ ID -
TEQ IN 0.35* -
TEQ EX -0.34* 0.16* -
HCCQ 0.49* 0.13* -0.25* -
SMFL ID 0.24* 0.05 -0.15 0.22* -
SMFL IN 0.22* 0.46* 0.05 0.04 0.34* -
SMFL EX -0.05 0.36* 0.33* -0.11 0.09 0.58* -
MET 0.18* 0.04 -0.21* 0.34* 0.16 -0.04 -0.09 -
RTC 0.50* 0.25* -0.30* 0.33* 0.31* 0.18 -0.01 0.13* -
HAQc 0.47* 0.21* -0.12* 0.67* 0.25* 0.18 0.15 0.26* 0.34* -
HAQh 0.25* 0.03 -0.03 0.43* 0.25* 0.24* 0.13 0.19* 0.13* 0.59* -
CL
IN
IC
IA
N-
RA
TE
D 
SC
AL
ES
TEQ ID 0.29* 0.13* -0.10 0.30* 0.07 -0.10 -0.08 0.17* 0.21* 0.29* 0.18* -
TEQ IN 0.16* 0.15* -0.04 0.17* 0.22* 0.01 0.03 0.08 0.14* 0.15* 0.05 0.43* -
TEQ EX -0.20* 0.03 0.30* -0.05 0.03 0.16 0.09 -0.09 -0.24* -0.00 0.14* -0.30* 0.12 -
SMFL ID 0.15 -0.06 -0.21* 0.22* 0.28* 0.18* -0.06 0.16 0.16 0.10 0.02 0.27* 0.33* 0.05 -
SMFL IN 0.30* 0.07 -0.11 0.20* 0.24* 0.26* 0.11 -0.01 0.23* 0.15 0.13 0.30* 0.29* 0.09 0.56* -
SMFL EX 0.15 0.17* 0.07 0.07 0.17* 0.33* 0.28* -0.10 0.09 0.12 0.22* 0.12 0.03 0.25* 0.20* 0.55* -
HAQc 0.14* 0.01 0.02 0.24* 0.13 -0.10 -0.10 0.16* 0.05 0.24* 0.16* 0.47* 0.16* -0.11 0.27* 0.26* 0.02 -
HAQh 0.19* 0.04 0.03 0.17* 0.04 -0.10 -0.21* 0.18* 0.06 0.22* 0.25* 0.50* 0.23* -0.08 0.21* 0.19* 0.01 0.61* -
SES 0.25* 0.04 -0.05 0.21* 0.13 -0.11 -0.16 0.28* 0.09 0.29* 0.30* 0.58* 0.18* -0.15* 0.25* 0.16 -0.04 0.55* 0.54*
Table 5. Spearman correlations between SDT measures and criterion measures rated by patients and clinicians
*	p	<	0.05,	 (two-tailed).	Gray	cells	 represent	monomethod	correlations.	Black	cells	 represent	heteromethod	correlations.	SDT	=	Self-Determination	
Theory,	IM	=	Integral	Model	of	treatment	motivation,	TTM	=	Transtheoretical	Model,	TEQ	=	Treatment	Entry	Questionnaire,	ID	=	identified	motivation,	
IN	 =	 introjected	motivation,	 EX	 =	 external	motivation,	HCCQ	=	Health	 Care	 Climate	Questionnaire,	 SMFL	 =	 Short	Motivation	 Feedback	 List,	MET	 =	
Motivation	 to	Engage	 in	Treatment	scale,	RTC	=	Readiness	 to	Change,	HAQc	=	Helping	Alliance	Questionnaire	cooperation,	HAQh=	Helping	Alliance	
Questionnaire	helpfulness,	SES	=	Service	Engagement	Scale.	
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introjected motivation (rs	=	0.23,	p<0.05).	However,	
neither patient-rated nor clinician-rated SMFL scales 
were associated with IM-MET.
Criterion validity for the HCCQ
The HCCQ showed exceptionally strong positive 
association with the patient-rated HAQ cooperation 
(rs	=	0.71,	p	<0.01)	and	strong	correlation	with	patient-
rated HAQ helpfulness (rs	=	0.47,	p<0.01).	The	HCCQ	
showed weaker associations with the clinician-rated 
HAQ; rs	=	0.24	(p	<0.01)	for	cooperation	and	rs	=	0.18	
(p<0.01) for helpfulness, which suggests that the 
correlations between patient-rated scales are likely 
inflated due to common method variance. Consistent 
with theoretical expectations, the HCCQ showed 
somewhat stronger association with patient-rated 
TEQ identified motivation (rs	 =	 0.49,	 p<0.01)	 than	
with the IM-MET-scale (rs	 =	 0.34,	 p<0.01)	 and	 the	
TTM-RTC score (rs	=	0.33,	p<0.01).	Finally,	the	HCCQ	
showed a positive association with the SES (rs	=	0.23,	
p<0.01), which was less strong than the associations 
between the different HAQ-scales and the SES. 
Discussion
The current study investigated the psychometric 
properties of the TEQ, HCCQ and SMFL in a Dutch 
sample of psychiatric outpatients and generally 
found support for the use of these instruments for 
further research applications. 
Factor structures
The factor structure for the TEQ was best represented 
by an intercorrelated factors model with three 
factors, which were interpreted as identified, 
introjected and external motivation. This structure 
was consistent with the original English TEQ 126. In 
search for the most parsimonious assessment with 
the TEQ, it was found that a scale with 18 items 
(as opposed to the original 27 items), represented 
by 6 items per subscale showed best fit. All 18 
items loaded onto the same factors as the original 
English TEQ, except the item ‘I remain in treatment 
because I want others to see that I am really trying 
to deal with my problems’. In our solution this item 
Treatment Engagement (SES)
TEQ subscale
Means (S.D.)
Low 
(SES ≤ 30 )
N = 130
High 
(SES > 30 )
N = 113
Mean difference
(95% C.I.)
T df p-value
Patient-rated TEQ
Identified motivation 32.89 (7.65) 35.50 (6.30) -2.61 (-4.40 to -0.82) -2.92 240 0.004
Introjected motivation 23.25 (9.13) 23.31 (9.70) 1.20  (-2.45 to 2.30) -0.06 232 0.952
External motivation 18.15 (8.76) 17.48 (8.21) 0.67 (-1.49 to 2.82) 0.61 240 0.540
Clinician-rated TEQ
Identified motivation 26.67 (7.01) 32.97 (4.76) -6.29 (-7.70 to -4.87) -8.77 259 0.000
Introjected motivation 20.36 (7.28) 22.09 (6.58) -1.72 (-3.39 to -0.05) -2.03 270 0.043
External motivation 21.34 (7.93) 19.09 (7.47) 2.24 (0.39 to 4.09) 2.39 270 0.018
Legal mandate
TEQ subscale
Means (S.D.)
Yes
(N = 24)
No
(N = 267)
Mean difference
(95% C.I.)
T df p-value
Patient-rated TEQ
Identified motivation 29.83 (8.83) 34.24 (7.08) 4.41 (1.37 to 7.44) 2.86 289 0.005
Introjected motivation 19.83 (8.85) 22.83 (9.37) 2.99 (-0.91 to 6.91) 1.51 289 0.133
External motivation 20.45 (7.22) 16.89 (8.42) -3.57 (-7.06 to -0.07) -2.01 289 0.045
Clinician-rated TEQ
Identified motivation 23.68 (9.71) 30.09 (6.30) 6.41 (2.04 to 10.77) 3.04 23 0.006
Introjected motivation 19.54 (9.98) 21.31 (6.83) 1.76 (-2.71 to 6.26) 0.81 23 0.425
External motivation 26.95 (5.87) 19.70 (7.64) -7.25(-10.00 to -4.51) -5.42 27 0.000
Table 6. Relationship between TEQ subscales and clinician-rated treatment engagement
Table 7. Relationship between TEQ subscales and legal mandate for treatment
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was incorporated into the introjected motivation 
subscale, while for the original English version 
it loaded highest onto the external motivation 
subscale 126. 
 The analysis for the SMFL revealed that this 
questionnaire had a similar factor structure as the 
TEQ. The SMFL item ending on ‘I find it interesting’ 
did not fit adequately within the internal/external 
approach/avoidance matrix, which was consistent 
with SDT since this form of motivation represents 
a truly internal motive that does not seem to apply 
to psychiatric treatment engagement 65,86. That 
is, generally patients do not feel that engaging in 
psychiatric treatment is ‘interesting’ or ‘pleasurable’ 
in itself, but rather see this as instrumental to the 
goal of achieving relief from symptoms and/or 
resolving problems that result from the psychiatric 
illness and disabilities. 
Reliability
The reliabilities of the Dutch TEQ subscales were 
generally found to be acceptable, although there is 
still room for improvement as they ranged between 
0.66 (external motivation scale for patients with 
mood and anxiety disorders) and 0.86 (identified 
motivation scale for patients with mood and 
anxiety disorders). Possibly, this could be due to 
heterogeneity of diagnoses and other patient 
characteristics within these subsamples. Also, it 
is likely that a selection bias occurred in the study 
sample as participation in this study was voluntary 
and it is plausible to assume that the less motivated 
or more extrinsically motivated patients were less 
likely to participate. The found reliabilities are not 
sufficient for the scale to be used for assessment 
at the individual level but may currently be used to 
interpret the sum scores at the level of groups. The 
test-retest reliabilities after one year were generally 
adequate. The SMFL subscales showed adequate 
congeneric estimates of reliability, although the 
external motivation scale for patients with mood 
and anxiety disorders was too low. The test-retest 
correlations were generally good. Future studies 
using larger samples of more homogenous patient 
groups are needed to determine if the reliabilities of 
the TEQ and SMFL can be improved upon for use of 
assessments at the individual level. 
 The HCCQ revealed excellent internal consistency 
for all subsamples and the total sample, and 
acceptable test-retest reliability. It should be noted 
however that the HCCQ showed a ceiling effect, such 
that there was a restriction of range to high scores 
as most patients were very satisfied regarding their 
relationship with their clinician. This was a limitation 
to the correlational analyses.
Validity
The construct validities of the questionnaires were 
generally supported by correlations between the 
different scales and methods, although this was 
less so for the SMFL. The associations between the 
three TEQ scales and the HCCQ were consistent with 
theoretical expectations, as the different types of 
motivation were differentially related to perceived 
autonomy support in the manner that SDT predicted. 
Also, the association between the HCCQ and TEQ 
identified motivation was relatively stronger than 
the associations with the IM-MET-scale and the 
TTM-RTC score. Correlations between the TEQ scales 
and the IM-MET scale and TTM-RTC score suggest 
that the more broad external-internal distinction 
of SDT is linked with the quantitative motivation 
concepts of the TTM and with the IM (although less 
so) in the manner hypothesized by Jochems et al. 86; 
namely that higher levels of identified motivation 
are associated with higher levels of IM-MET and 
TTM-RTC while higher levels of external motivation 
are associated with lower levels of IM-MET and 
TTM-RTC. 
 Theoretically, it was expected that when 
clinicians scored their patients as high on the SES, 
thereby implicating that patients are available 
for appointments, seek help when needed and 
actively engage in treatment (including taking 
prescribed medications), this would be positively 
associated with identified motivation and negatively 
with external motivation. This hypothesis was 
only partially supported, since it was found that 
the patient-rated identified motivation scale 
was significantly associated with clinician-rated 
treatment engagement, but neither patient-
rated introjected nor external motivation was. It 
did not matter if we treated the SES-scores as a 
continuous variable (in correlational analyses) or 
as a dichotomous variable (in t-tests and logistic 
regression analyses) or if we looked at subscales of 
the SES (results not presented). Looking at clinician-
rated TEQ, the associations with SES were stronger 
and more consistent with theory, which was probably 
due to their common method. The TEQ subscales of 
identified and external motivation were associated 
with legally mandated treatment in the theoretically 
expected manner, regardless of who rated the TEQ. 
 Little support was found for the validity of 
the patient-rated SMFL scales when looking at the 
associations with criterion measures. Most support 
was found for SMFL identified motivation, which 
showed positive association with TTM-RTC, the 
HCCQ and with HAQ cooperation and helpfulness as 
rated by the patient, but not with clinician-rated HAQ 
subscales or the SES. The implications of the findings 
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on the SMFL are less clear and deserve further 
study as we face multiple possible explanations for 
these findings. A plausible explanation is that the 
correlations were low due to the fact that the SMFL 
was not administered at the same time as the TEQ 
and HCCQ. Other explanations are that perhaps 
the SMFL is an inadequate measure, the criterion 
measures might have been inadequate, the design of 
this study could be inappropriate, or a combination 
of the above. At the moment, it seems that the 
SMFL might be useful as a short and simple way to 
communicate with patients about different types of 
motivation for treatment, as it slightly resembles the 
TEQ, but it is far from assessment applications at the 
individual level. 
 The HCCQ showed moderate to strong 
association with the HAQ, depending on the rater 
(patient or clinician) and the subscale (cooperation or 
helpfulness). As expected, the strongest correlation 
was found between the HCCQ and the cooperation 
subscale of the HAQ when rated by the patient 
(rs	 =	 0.71,	 p<0.01).	 This	 is	 an	 exceptionally	 high	
correlation when considering that Hemphill 206 found 
that correlations of 0.50 or higher correspond to the 
89th percentile of most psychological assessment 
studies. Also, a similar correlation pattern with the 
TEQ was found for the HCCQ and HAQ cooperation 
scale when all were rated by the patient. Both 
the HCCQ and the HAQ were moderately strongly 
related to clinician-rated treatment engagement. It 
seems that the scales (and underlying concepts) are 
not completely interchangeable but they seem to be 
perceived highly similar, implying a need for a better 
differentiation of the concept of ‘clinician autonomy 
support’ from other (perhaps more broadly defined) 
positive clinician behaviors. 
Strengths, limitations and implications
Both a strength and a limitation of this study is the 
heterogeneity of our study sample that included 
outpatients with varying primary psychiatric 
diagnoses and comorbid psychiatric disabilities. 
Within the three diagnostic groups that we have 
specified, it is likely that heterogeneity exists 
between patients with different disorders, such as 
differences between types of personality disorders, 
psychotic disorders or mood disorders. These 
differences might influence the motivational profiles 
on the questionnaires. This heterogeneity was 
ignored to obtain adequate sample sizes for each 
subgroup, but future studies are needed to replicate 
the findings. On the other hand, the heterogeneity 
strengthens the generalizability of the findings to a 
broad psychiatric outpatient population. 
Currently, we feel that the SMFL should not be 
used for assessment purposes, but might be used 
for structured communication purposes, such as 
discussing the patient’s current motivation for 
engaging in psychiatric treatment. This is relevant 
considering that our findings seem to suggest that 
patients and clinicians have different views on 
the patient’s motivation, which was in line with 
another study that we recently performed207. In 
an exploratory analysis on the patient-rated SMFL, 
where we looked at the proximities of the items, we 
saw that the items formed an ellipse shape rather 
than clearly distinct clusters of items (results not 
reported). We felt that the interpretation of this 
solution could be understood by consideration of 
both Self Determination Theory and approach-
avoidance theories of motivation 208. One axis 
within the SMFL represents the internal-external 
continuum proposed by SDT and appeared to 
be the most important one, while the other axis 
represents approach-avoidance motives which 
operates orthogonally to the internal-external axis. 
Several items can be interpreted as representing 
approach (‘I will feel proud of myself if I do so’) or 
avoidance motives (‘I may not disappoint myself’ 
and ‘I may not disappoint others’). Using the SMFL 
as a starting point for a discussion between the 
patient and clinician regarding the patient’s current 
motivation for treatment, these external/internal 
and approach/avoidance motives can be explored. 
It should be noted that theoretically, patients can 
endorse all these motives simultaneously as they 
are not mutually exclusive. A high score for one 
type of motivation does not preclude a high score 
for another type. As an example, Silverstein (2010) 
mentions supported employment for patients with 
schizophrenia, where the intrinsically motivating 
psychological benefits of work (e.g. sense of 
competence and having a valued social role, sense 
of autonomy) are combined with the benefits of 
earning money 196. 
 Investigating the construct validity of the scales is 
an ongoing iterative evaluation process 209 that should 
be continued after this study, preferably with other 
criterion measures and in other (larger and more 
homogenous) patient populations. The predictive 
utility of the scales should be investigated with 
longitudinal data, with other measures of treatment 
engagement and other outcomes such as drop-out, 
psychosocial functioning and the patient’s quality of 
life. These criterion measures should include more 
objective measures of treatment engagement, such 
as percentage of no-shows in clinical practice and/
or blood levels of (antipsychotic) medication use. 
Nevertheless, the preliminary results of this study 
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are promising and suggest that the TEQ, SMFL and 
HCCQ could be valuable instruments for research 
on SDT in psychiatric outpatients or for clinical 
purposes such as discussing the patient’s motivation 
to engage in treatment. 
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Objective
Currently, it is unclear whether Self-Determination 
Theory (SDT) applies to the mental health care of 
patients with severe mental illness (SMI). Therefore, 
the current study tested the process model of SDT in 
a sample of outpatients with SMI. 
 
Methods
Participants were 294 adult outpatients with a 
primary diagnosis of a psychotic disorder or a 
personality	 disorder	 and	 their	 clinicians	 (n=57).	
Structural equation modelling was used to test the 
hypothesized relationships between autonomy 
support, perceived competence, types of motivation, 
treatment engagement, psychosocial functioning 
and quality of life at two time points and across the 
two diagnostic groups. 
Results
The	expected	relations	among	the	SDT	variables	were	
found,	but	additional	direct	paths	between	perceived	
competence and clinical outcomes were needed to 
obtain	good	model	fit.	The	obtained	process	model	
was	 found	 to	 be	 stable	 across	 time	 and	 different	
diagnostic	 patient	 groups,	 and	 was	 able	 to	 explain	
18% to 36% of variance in treatment engagement, 
psychosocial	functioning	and	quality	of	life.
Conclusion
It is concluded that SDT can be a useful basis 
for interventions in the mental health care for 
outpatients with SMI. Additional experimental 
research is needed to confirm the causality of the 
relations between the SDT constructs and their 
ability to influence treatment outcomes.
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Introduction
Background and rationale
Self-Determination Theory (SDT) 48 claims to 
provide a universal framework for understanding 
the individual and environmental factors that 
produce and shape certain types of motivation and 
subsequent engagement with behaviour 48. SDT 
describes different types of motives or reasons why 
a person may engage in behaviour, that fall along 
a continuum of self-determination in the following 
order from most to least self-determined: intrinsic, 
integrated, identified, introjected, external and 
amotivation 65,123. For example, identified motivation 
is evident when a patient recognizes and accepts that 
treatment is useful for achieving personally relevant 
goals 65, which is more internalized than introjected 
motivation, which is evident when a patient is driven 
by feelings of guilt, shame or anxiety, and might 
feel ashamed or disappointed if he did not remain 
in treatment. To date, several studies have found 
support for the utility of SDT’s motivational constructs 
in relation to cognitive and psychosocial functioning 
in patients with schizophrenia spectrum disorders 66-
69.	For	example,	studies	show	that	intrinsic	motivation	
in schizophrenia spectrum disorders can change over 
time	 66,68,70, predicts improvements in learning and 
psychosocial	functioning	66,71,72,	is	positively	associated	
with	physical	activity	210	and	mediates	the	relationship	
between	 negative	 and	 disorganized	 symptoms	 of	
schizophrenia and psychosocial functioning 69. 
 It has been suggested that SDT may be useful as a 
basis for psychosocial interventions for patients with 
severe mental illness (SMI) 73,74. In line with this, we 
have recently conducted and reported on a cluster-
randomized controlled trial in which a motivation 
feedback intervention based on SDT was investigated 
in outpatients with SMI 211. In this study, clinicians 
were trained in the principles of SDT and the use of 
a short questionnaire as a communication tool with 
patients about their motivation for treatment (i.e. 
providing them with motivation feedback). It was 
expected that the motivation feedback would help 
to internalize the patient’s motivation resulting in 
a higher level of treatment engagement, compared 
to treatment as usual. After one year of treatment, 
however, no statistically significant differences 
between the intervention group and control group 
on treatment engagement, psychosocial functioning 
and quality of life were found 211. Although the 
results of the trial were negative, this was not taken 
as decisive evidence against SDT, as the motivation 
feedback may not have been able to successfully 
affect SDT-constructs such as patient autonomy 
and competence. We argued that the motivational 
constructs of SDT might still be able to predict 
clinical outcomes in both treatment conditions. The 
aim of the current study therefore, is to investigate 
the basic process model of SDT in the patient sample 
of the trial. In the following, we will briefly describe 
SDT, it’s hypotheses and the specific objectives 
regarding the testing of this theory in outpatients 
with SMI. 
 
Self-Determination Theory
Central to SDT is the notion of the basic human 
needs for autonomy, competence and relatedness 
that, when supported, facilitate the internalization 
of motivation 48. Internalization is the process 
through which reasons for change and motivations 
for particular behaviours are integrated to different 
degrees into the sense of self 48. The environmental 
context, which may include the mental health care 
system, can support autonomy by acknowledging 
the patient’s perspective, offering choice (about 
treatment options) and support initiative while 
minimizing pressure and control 65. Further, when 
patients are additionally afforded the skills and 
tools for change and are helped to experience 
mastery and control over their behaviour, they may 
gain a sense of competence 123. Relatedness may 
be supported by involvement with others in an 
empathic, affectionate and dedicated manner 212. It 
is argued that regardless of the motivational starting 
point, the support for the basic needs is essential for 
internalization of motivation, which in turn would 
lead to the instigation and sustainment of treatment-
related behaviours such as engagement, but also to 
better health and higher quality of life 65. 
 According to SDT, the more internal the perceived 
cause of a person’s behaviour 82, the more likely the 
person is to persist in this behavioural activity, and 
in case of treatment, to adhere to a therapeutic 
regimen. Conversely, the more external perceived 
cause of behaviour, or the more a person’s reasons for 
entering treatment are based on external regulators, 
the less persistence and adherence are expected 
48. In line with this, it is generally found that initial 
increases in target behaviours in response to token 
economy systems, which involve rewarding patients 
for specified target behaviours, are not sustained 
after reinforcements are withdrawn 213. Alternatively, 
other authors have suggested that external 
motivation may be beneficial and even necessary 
to optimally enhance motivation and outcomes in 
patients with motivational deficits 196,214. For example, 
when individuals present with low baseline levels 
of intrinsic motivation for engaging in treatment, 
extrinsic rewards such as praise by a mental health 
worker or receiving help for financial problems, may 
help to achieve short-term desired goals and provide 
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a sense of self-competency and relatedness which 
may	 in	 time	 stimulate	 internalization	 of	 motivation	
196,214. In a study by Ryan et al. 35	 among	patients	 in	
alcohol	 treatment,	 outcomes	 were	 most	 beneficial	
for those with both high intrinsic and high extrinsic 
motivation,	 which	 suggests	 a	 potential	 synergistic	
effect	 of	 different	motivational	 types.	 In	 a	 study	 by	
Wild et al. 126	involving	patients	seeking	treatment	for	
addiction	problems,	introjected	treatment	motivation	
was	 positively	 related	 to	 both	 perceived	 benefits	 of	
reducing alcohol or drug use and to perceived costs 
of	 reducing	 alcohol	 or	 drug	 use.	 Currently,	 it	 is	 still	
unclear	 how	 different	 types	 of	 motivation	 affect	
the psychosocial treatment of individuals with SMI, 
including	 the	way	 through	which	 the	different	 types	
of	 motivation	 affect	 treatment	 engagement	 and	
treatment outcomes.
 The current study aims to determine whether the 
basic	process	model	of	SDT	 is	applicable	 in	a	setting	
of	 outpatients	 with	 SMI.	 The	 basic	 process	 model	
that will be tested in the current study, is based on 
previous studies of SDT in health care contexts 215-217 
and	on	our	 own	previous	work	on	 the	 relationships	
between	autonomy	support	and	motivation	types	 in	
the	 current	patient	 sample	 218. In the meta-analyses 
by Ng et al. 217 on studies of SDT in health care 
contexts, support was found for a model in which 
autonomy support predicted perceived competence 
as	 well	 as	 motivational	 regulations,	 which	 were	 in	
turn predicted health outcomes. Further, in a previous 
study in which we examined the factor structure of a 
SDT	questionnaire	for	motivation	types	218, we found 
support for a model with three intercorrelated factors 
which	were	interpreted	as	identified,	introjected	and	
external	motivation.	This	structure	was	incorporated	
into the larger structural model which will be tested in 
the current study, as shown in Figure 1. 
Hypotheses
1:  It was hypothesized that the process model as 
outlined in Figure 1 would be plausible. If this 
model does not turn out to be plausible, we 
will evaluate which alternative model is more 
plausible. 
2:  It was hypothesized that the model would be 
stable across time (i.e. baseline and one year 
later) and across patient groups (i.e. patients with 
primarily a personality disorder versus those with 
primarily a psychotic disorder).
3:  It was hypothesized that the model would 
show	 clinical	 utility	 by	 explaining	 observed	
variance in clinical outcomes, including clinician-
rated treatment engagement, interviewer-rated 
psychosocial	 functioning	 and	 patient-reported	
quality of life. 
Methods
Study Design
The current longitudinal study constitutes a 
secondary analysis of a cluster randomized clinical 
trial 197. The study was approved by an official 
medical ethical committee as well as by the scientific 
committees of the two specialty mental health 
institutions where the data were collected.
Setting 
Data were collected between May 2011 and October 
2013 from 12 outpatient treatment programs, 
including a forensic psychiatric outpatient clinic, three 
specialized psychotic outpatient treatment programs 
and eight several flexible assertive community 
treatment teams (FACT-teams 14) of two specialty 
Dutch mental health treatment centres. FACT-teams 
provide assertive, outreaching, community-based, 
and supportive psychiatric services to individuals 
with SMI 14, such as those with psychotic disorders 
and severe personality disorders. 
Participants and procedures
Inclusion criteria for patients were: a primary 
diagnosis of psychotic or personality disorder, aged 
18 to 65 years, undergoing individual outpatient 
treatment and having a sufficient command of 
the Dutch language. A clinician was eligible for 
participation if he or she was the primary health 
care provider involved with the patient and saw 
the patient most frequently. Eligible patients on 
the clinicians’ caseload lists were approached and 
informed by researchers and asked for their signed 
consent. Both patients and clinicians were asked 
to fill in questionnaires at baseline and follow-
up assessment (12 months after baseline) and 
additionally, patients were interviewed regarding 
their functioning in several life domains by 
independent research assistants at these assessment 
moments. To enhance the likelihood of participation, 
patients were given an incentive of 15 euro for the 
baseline and follow-up assessment in the trial. 
Measures
All measures for the current study were assessed 
at baseline and at follow-up (12 months after 
baseline) in the trial in which the current data were 
collected 197,211. Baseline assessment took place after 
randomization at clinician-level, such that patients 
but not clinicians were blind to treatment allocation 
at baseline assessment. 
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Clinical outcomes: Treatment engagement, 
psychosocial functioning and quality of life
Treatment engagement was measured with the 
Service Engagement Scale (SES) that was filled out 
by clinicians. The SES was developed to measure 
engagement with community mental health services 
199. It comprises 14 items that assess availability, 
collaboration, help seeking and treatment 
engagement behaviours (including medication 
adherence). The items are rated on a 4-point scale 
ranging from 0 (not at all) to 3 (most of the time). 
The SES has good internal consistency (Cronbach’s 
α	=0.87,	congeneric	estimate	of	reliability	=	0.91	 in	
the current sample) and validity 199,218. The SES total 
scale score was used as the outcome measure in this 
study, where higher scores denote higher treatment 
engagement. 
 The patient’s psychosocial functioning was 
measured with the Dutch version of the Health of 
the Nations Outcome Scales (HoNOS)163,164. The 
HoNOS is a semi-structured interview with the 
patient in which health and social problems of the 
previous two weeks are quantified. It contains 12 
items that refer to behavioural problems, cognitive 
and physical impairments, symptoms, and social 
functioning. HoNOS items are scored on a scale from 
0 (no problem) to 4 (severe problem). The total scale 
score is computed by adding the 12 items. For ease 
of interpretation, we recoded the total score such 
that higher scores reflected better psychosocial 
functioning. The administration of the HoNOS was 
performed by independent research assistants 
(mostly graduate students in psychology and 
medicine) who had no involvement in the patient’s 
treatment. The psychometric properties of the 
total scale score were shown to be acceptable 164. 
Internal consistency was acceptable in the current 
study	 (Cronbach’s	α	=	0.70,	 congeneric	estimate	of	
reliability	=	0.77).	
 The patient’s quality of life was assessed with 
the Manchester Short Assessment of Quality of 
Life (MANSA)167,168. The MANSA is a self-report 
questionnaire that asks the patient how satisfied he/
she is in the following life domains: living situation, 
social relationships, physical health, mental health, 
safety, financial situation, work situation and life as 
a whole. The 12 items are scored on a Likert scale 
from 1 (couldn’t be worse) to 7 (couldn’t be better), 
which are summed to calculate a total score. Higher 
scores denote a higher perceived quality of life. The 
scale	is	shown	to	be	reliable	(i.e.	Cronbach’s	α	=	0.82	
and	 congeneric	estimate	of	 reliability	=	0.92	 in	 the	
current sample) and other psychometric properties 
are considered satisfactory 167. 
Core theoretical constructs of SDT: types of 
motivation and need support 
Motivation for engaging in treatment as postulated 
by SDT was measured with the Treatment Entry 
Questionnaire (TEQ)126,218 that was administered to 
patients. The TEQ contains three subscales (external, 
introjected and identified motivation), each with 6 
items rated on a scale from 1 (strongly disagree) 
to 7 (strongly agree). The congeneric estimates of 
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Figure 1. Hypothesized conceptual model based on Self-Determination Theory
Note: Thick lines represent theoretically expected regression paths, dotted lines represent theoretically expected intercorrelations of 
variables. A plus indicates a hypothesized positive relationship between the constructs, a minus indicates a negative hypothesized 
relationship. Variables reflect patient-rated constructs unless indicated otherwise.
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reliability for TEQ subscales ranged from 0.72 to 0.78, 
which was considered adequate218. In a previous 
study, we found support for the construct validity of 
the TEQ 218. Higher scale scores denote higher levels 
of that type of motivation.
 The Health Care Climate Questionnaire (HCCQ) 134 
was administered to patients to assess the degree to 
which patients perceived their clinician as autonomy 
supportive. The HCCQ has 15 items that are scored 
on a Likert scale, ranging from 1 (strongly disagree) 
to 7 (strongly agree). The items are summed up to a 
total scale score, with higher scores reflecting higher 
perceived autonomy support. Internal consistency 
was	 found	 to	 be	 good	 (Cronbach’s	 α	 =	 0.93,	
congeneric	 estimate	 of	 reliability	 =	 0.93)218 and the 
scale was shown to be valid for patients with SMI 218. 
 The subscale ‘Outcome Expectancy’ from the 
Treatment Motivation Scales for Forensic patients 
(TMS-F) was administered to patients as a measure 
for the patient’s perceived competence in being able 
to finish the treatment and making and sustaining 
the behaviour changes learned during treatment. 
Example items include ‘I am absolutely certain that I 
will be able to maintain my new behaviour after the 
treatment’, ‘I probably do not have enough patience 
for this treatment’ and ‘I think that my problem 
behaviour will never really change’. The scale consists 
of 9 items rated on a 5-point Likert scale from 0 
(totally agree) to 5 (totally disagree). Several items 
are reverse scored after which the items are summed, 
such that a higher score on the subscale reflects a 
higher perceived competence. Internal consistency 
was	 good	 in	 the	 current	 sample	 (Cronbach’s	 α	 =	
0.82,	 congeneric	 estimate	 of	 reliability	 =	 0.86)	 and	
previous studies in forensic psychiatry have provided 
support for convergent and discriminant validity of 
the scales of the TMS-f 116,118.
Statistical analyses
The analyses were performed in several steps. 
First, the bivariate relations of variables were 
estimated using Spearman correlations. Structural 
equation modelling (SEM) as implemented in Mplus 
version 7.3 [32] was used to test the hypothesized 
relationships between autonomy support, perceived 
competence, types of motivation, treatment 
engagement, psychosocial functioning and quality of 
life as depicted in Figure 1.
Latent variables
Both at baseline and at follow-up we evaluated 
the plausibility of the SDT process model using 
latent path analysis as outlined in Figure 1. 
Classical reliability theory reformulated in terms 
of confirmatory factor analysis enabled to identify 
latent variables. Congeneric reliability estimates 203,219 
were obtained as both the common factors loadings 
and the residuals turned out to differ. Subsequently, 
a factor analysis model for each observed variable 
was defined , in which the factor loading was fixed 
at 1.0 and the residual variance of that factor (i.e. 
1- reliability) was multiplied by the variance of the 
variable at issue. In doing so, the observed variables 
were corrected for unreliability resulting in the latent 
variables. 
Model testing
As the type of design was complex (patients clustered 
within teams) and, in addition, the distributions of 
the variables were considered to be non-normal, the 
estimation method used was MLR. This maximum 
likelihood	 estimates	 standard	 errors	 and	 χ2 test 
statistic that are robust to non-normality and non-
independence of observations. The MLR standard 
errors were estimated using a sandwich estimator. 
Multilevel analyses were performed to adjust for 
potential clustering of the data within teams (i.e. the 
variable ‘team’ was included as an additional level in 
the analyses).
 First, the model as depicted in Figure 1 was fitted 
to the data for the full sample using the baseline and 
follow-up measurements separately. The following 
measures were used to test for adequacy of the 
model	 fit:	 χ2 for model fit (low and non-significant 
values	of	 the	χ2	were	desired;	P-value	>	0.05);	 χ2/df 
ratio (a value <2.0 was considered to be acceptable); 
information criteria including Akaike (AIC), Bayesian 
(BIC), sample-size adjusted BIC (SS-BIC) (the smaller 
the better); Comparative Fit Index (CFI), and Tucker-
Lewis Index (TLI) (high values are desired (> 0.95), 
values > 1.0 point to over identification 220,221); Root 
Mean Square Error of Approximation (RMSEA: a 
value < 0.05 indicates a close fit 222; and Standardized 
Root Mean Squares of Residuals (SRMR: a value of 
< 0.05 indicates a reliable fit)201. Explained variances 
(R2) were used to describe the performances of the 
determinants for the individual dependent variables. 
It was tested whether the baseline model showed 
a good overall fit. If not, it was evaluated how it 
could be adapted such that the fit would improve or 
alternatively, whether the model could be simplified 
while not threatening the overall model fit. The most 
plausible model was obtained by evaluating the 
model fit criteria and standardized residuals. Further, 
the	MLR	 χ2 difference test 223 was used to compare 
different models which were nested. 
 The invariance of the most plausible path model 
across time was evaluated by testing the invariance 
of the regression estimates of the latent variables, 
by comparing those assessed at baseline with those 
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assessed	 at	 follow-up	 using	 the	 MLR	 χ2 difference 
test. Fitting both latent path models (baseline and 
follow-up) jointly was used to evaluate whether the 
regression estimates of both time points could be 
considered invariant. Specifically, a non-significant 
MLR	 χ2 difference test between the model with all 
regression estimates constrained to be equal for the 
corresponding measurements versus all regression 
estimates unconstrained was considered statistical 
evidence for the latent path model being invariant 
across time. Individual estimates were regarded 
statistically significant if the two-sided P-values 
were < 0.05. The correlations of the latent variables 
between the corresponding measurements were 
allowed to be free as the measurements were 
repeated. It should be noted that it was decided not 
to analyse the data longitudinally (e.g. correlated 
change analysis or cross-lagged analyses) because 
the motivational intervention was conducted in 
between the two assessment moments and may 
have affected the ‘natural’ change between the two 
time points. 
 A similar procedure was applied to test whether 
the	model	was	invariant	across	different	patient	groups	
(personality	disorders	versus	psychotic	disorders).	To	
test	to	what	extent	the	process	model	has	utility	for	
clinical	practice,	it	was	evaluated	how	much	variance	
was explained on the dependent variables in the 
model, namely treatment engagement, psychosocial 
functioning	and	quality	of	life.	
Results
Participants and descriptive data
The enrolment of participants took place from May 
2011 to September 2012, at which time a total of 57 
clinicians and 294 eligible patients were enrolled in 
the study. Table 1 shows an overview of the patient 
characteristics. Within the subsample of patients with 
psychotic disorders, the majority of patients were 
diagnosed with schizophrenia (48%), schizoaffective 
disorder (16%), or psychotic disorder not otherwise 
specified (24%). Within the subsample of personality 
disorders, 40% had a borderline personality disorder, 
13% had antisocial personality disorder, and 26% 
had a personality disorder not otherwise specified. 
Most clinicians were female (63%), their mean age 
was	44	years	(SD	=	10.70)	and	they	had	a	mean	of	16	
years of clinical working experience in mental health 
services	 (SD	 =9.30).	 At	 12	 months,	 253	 patients	
(86%) were re-assessed. The group that was lost to 
follow-up was significantly more often of non-Dutch 
ethnicity (48% versus 26%, p<0.01) and more often 
had a legal mandate for treatment (18% versus 7%, p 
=	0.03)	compared	to	completers.
Total patient sample
n = 294
Psychotic disorders
n= 199
Personality disorders
n = 95
Age, mean (SD) 44 (10.3) 43 (10.3) 45 (10.0)
Male gender, n (%) 179 (60.9) 132 (66.3) 47 (49.5)
Dutch ethnicity, n (%) 208 (70.7) 140 (70.4) 68 (71.6)
Education level, n (%)
- No education/elementary
- Secondary school
- Upper high school and over
108 (36.7)
124 (42.2)
59 (20.1)
76 (38.2)
75 (37.7)
47 (23.6)
32 (33.7)
49 (51.6)
12 (12.6)
Comorbid substance use problemsA, n (% yes) 74 (25.2) 42 (21.1) 32 (33.7)
Legal mandate, n (% yes) 24 (6.9) 13 (6.5) 11 (12.0)
One or more previous admissions, n, (% yes) 227 (77.2) 159 (79.9) 68 (71.6)
Perceived competence, median (IQR) 31 (28 to 39) 34 (29 to 39) 32 (26 to 38)
Perceived autonomy support, median (IQR) 91 (78 to 100) 90 (75 to 100) 92 (81 to 100)
Identified motivation, median (IQR) 36 (30 to 40) 36 (29 to 39) 36 (30 to 40)
Introjected motivation,
median (IQR) 23 (16 to 30) 23 (16 to 30) 23 (17 to 30)
External motivation, 
median (IQR) 16 (11 to 24) 18 912 to 25) 13 (7 to 21)
Treatment engagement, 
median (IQR) 31 (24 to 36) 32 (25 to 37) 28 (24 to 35)
Psychosocial functioning,
median (IQR) 9 (6 to 13) 8 (5 to 12) 10 (8 to 15)
Quality of life, 
median (IQR) 5 (4 to 5) 5 (4 to 5) 4 (4 to 5)
Table 1. Baseline characteristics of participating patients, stratified by primary diagnosis
A  Substance abuse problem was defined as having a DSM-IV diagnosis of substance abuse and/or dependence 
in the medical record.
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The correlations between SDT constructs and 
clinical outcomes are shown in Table 2. Most of the 
correlations between baseline psychological needs 
(autonomy and competence) and other variables 
at baseline and follow-up were medium to high, 
in the expected direction and reached statistical 
significance at p<0.05 (two-tailed). 
Path analyses
Test of the SDT process model
First, all observed variables were linearly transformed 
by a factor of 10 to reduce their variances 
which allowed Mplus to reach convergence202. 
Subsequently, the observed variables were corrected 
for unreliability resulting in the latent variables. The 
latent variables were used in the subsequent path 
analysis, where the process model as depicted in 
Figure 1 was fitted to the data at baseline (Model 
1a) and at follow-up (Model 2a). As can be seen in 
Table	3,	Model	1a	provided	bad	fit	to	the	data	(χ2 / df 
=	7.64,	RMSEA	=	0.15,	CFI	=	0.92,	TLI	=	0.61,	SRMR	=	
0.03)	as	did	Model	2a	(χ2 /	df	=	14.44,	RMSEA	=	0.22,	
CFI	=	0.81,	TLI	=	0.09,	SRMR	=	0.04).	The	modification	
indices and standardized residuals suggested that 
the misfit was most likely due to lacking direct 
effects between perceived competence and clinical 
outcomes (treatment engagement, psychosocial 
functioning and quality of life). Such direct effects 
were also theoretically plausible 217. When these three 
paths were added, model fit for both measurement 
occasions improved substantially as can be seen in 
Table 3. Other rivalling models, including those with 
the regression path between autonomy support and 
perceived competence in the opposite direction, 
additional direct regression paths from autonomy 
support to clinical outcomes and a model in which 
autonomy support and perceived competence were 
simply inter-correlated either provided worse fit to 
the data or did not improve the fit. Therefore, it 
was decided to retain models 1b and 2b for further 
analyses, which included testing the obtained SDT 
process model for invariance across time.
Test of the SDT process model across time
Testing the process model across time was done by 
testing the invariance of the regression estimates 
of the latent variables across the two measurement 
occasions. A model was created in which both 
baseline and follow-up latent path models were 
included simultaneously (Model 3). In the first 
version of this model the regression weights were 
allowed to be free (unconstrained) for the baseline 
and follow-up measurements (Model 3a), which 
resulted	 in	 borderline	 fit	 to	 the	 data	 (χ2/df=2.39,	
RMSEA=0.07,	 CFI=0.94,	 TLI=0.89,	 SRMR=0.08).	
Subsequently, a second version of this model was 
created (Model 3b) in which the regression weights 
for the corresponding paths at baseline and follow-
up were constrained to be similar. Model 3b provided 
good	 fit	 to	 the	 data	 (χ2/df	 =2.19,	 RMSEA=0.06,	
CFI=0.93,	TLI=0.90,	SRMR=0.08).	
The test for invariance across time was represented 
by	the	MLR	χ2 difference test between the model with 
all regression estimates constrained to be equal for 
the corresponding measurements (Model 3b) versus 
all regression estimates unconstrained (Model 3a), 
where	 a	 non-significant	 χ2-test was considered 
statistical evidence for the latent path model being 
invariant	 across	 time.	 The	 χ2-test did not reach 
statistical	 significance	 (Δχ2=30.67,	 Δdf=21,p=0.08),	
which provided support for the hypothesis that 
the SDT process model was invariant across time. 
Model 3b was accepted as a plausible model for 
the representation of SDT and was used in the 
subsequent analyses. This model is shown in Figure 
2, including standardized regression coefficients for 
the baseline and follow-up measurements. It can 
be seen in Table 4 that around 26% of the variance 
of psychosocial functioning and between 31% and 
36% of the variance of quality of life was explained 
depending on the time of measurement.
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Baseline assessment Follow-up assessment
CO AS ID IN EX TE PF QL CO AS ID IN EX TE PF QL
Baseline assessment
Perceived competence (CO)
Autonomy support (AS) 0.45
Identified motivation (ID) 0.27 0.53
Introjected motivation (IN) -0.02 0.22 0.43
External motivation (EX) -0.16 -0.15 -0.28 0.13
Treatment engagement (TE) 0.30 0.26 0.26 0.06 -0.04
Psychosocial functioning (PF) 0.33 0.19 0.08 -0.06 0.07 0.38
Quality of life (QL) 0.45 0.29 0.11 -0.03 0.10 0.37 0.57
Follow-up assessment
Perceived competence (CO) 0.61 0.35 0.14 -0.03 -0.10 0.23 0.23 0.41
Autonomy support (AS) 0.41 0.60 0.28 0.09 -0.12 0.32 0.16 0.34 0.58
Identified motivation (ID) 0.28 0.38 0.54 0.34 -0.11 0.27 0.14 0.13 0.22 0.38
Introjected motivation (IN) 0.04 0.07 0.27 0.62 0.18 0.14 0.03 0.01 -0.05 0.01 0.40
External motivation (EX) -0.17 -0.19 -0.17 0.14 0.52 -0.03 -0.03 -0.03 -0.21 -0.25 -0.15 0.33
Treatment engagement (TE) 0.26 0.27 0.26 0.10 -0.02 0.65 0.24 0.28 0.34 0.38 0.29 0.09 -0.18
Psychosocial functioning (PF) 0.30 0.15 0.08 -0.03 -0.04 0.28 0.44 0.36 0.37 0.21 -0.02 -0.06 -0.05 0.25
Quality of life (QL) 0.39 0.26 0.04 -0.04 0.00 0.21 0.28 0.58 0.49 0.32 -0.02 -0.13 -0.11 0.21 0.61
Model C or U χ2 df χ2/df p-value RMSEA 90% C.I. for 
RMSEA
CFI TLI SRMR AIC BIC SS-BIC
1a. Baseline process model 
(Figure 1)
- 45.85 6 7.64 <0.01 0.15 0.11 to 0.19 0.92 0.61 0.03 4156 4296 4175
1b. Baseline process model (as 1a plus 
additional paths between perceived competence 
and outcomes)
- 1.87 3 0.62 0.60 0.00 0.00 to 0.08 1.00 1.02 0.01 4133 4284 4154
2a. Follow-up process model 
(Figure 1)
- 86.64 6 14.44 <0.01 0.22 0.18 to 0.26 0.81 0.09 0.04 3272 3410 3290
2b. Follow-up process model (as 2a plus 
additional paths between perceived competence 
and outcomes)
- 9.75 3 3.25 0.02 0.09 0.03 to 0.15 0.98 0.85 0.02 3238 3388 3258
3a. Baseline and follow-up jointly 
(as 1b and 2b)
U 143.55 60 2.39 <0.01 0.07 0.05 to 0.08 0.94 0.89 0.08 6829 7168 6876
3b. Baseline and follow-up jointly 
(as 1b and 2b)
C 177.59 81 2.19 <0.01 0.06 0.05 to 0.08 0.93 0.90 0.08 6814 7075 6850
4a. Baseline process model (as 1b) for psychotic 
versus personality disorders
U 75.32 6 12.55 <0.01 0.28 0.23 to 0.34 0.86 -0.35 0.02 4134 4436 4176
4b. Baseline process model (as 1b) for psychotic 
versus personality disorders
C 33.13 27 1.23 0.19 0.04 0.00 to 0.08 0.99 0.97 0.05 4111 4336 4142
5a Follow-up process model (as 2b) for psychotic 
versus personality disorders
U 29.38 6 4.90 <0.01 0.17 0.11 to 0.23 0.95 0.50 0.03 3252 3552 3292
5b Follow-up process model (as 2b) for psychotic 
versus personality disorders
C 55.47 27 2.05 <0.01 0.09 0.05 to 0.12 0.94 0.86 0.10 3242 3465 3271
Table 3. Model fit information
Note:	 C	 or	 U	 =	 Model	 with	 either	 constrained	 (C)	 or	 unconstrained	 (U)	 regression	 coefficients	 for	 corresponding	
measurements at baseline and follow-up. The grey and white shading indicates models that are rivaling (nested) models 
(similar	shading	indicates	rivaling	models).	χ2 =	chi-square	statistic;	df	=	degrees	of	freedom;	RMSEA	=	root	mean	square	
error	of	approximation;	CFI	=	Comparative	Fit	 Index,	TLI	=	Tucker-Lewis	 Index,	SRMR	=	standardized	root	mean	square	
residual;	AIC	=	Akaike	Information	Criterion,	BIC	=	Bayesian	Information	Criterion,	SS-BIC	=	Sample	size	adjusted	BIC.
Table 2. Spearman intercorrelations of variables in the model 
Boldface indicates p < 0.05 (two-tailed).
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Test of the SDT process model across patient 
groups
To further test the robustness of the SDT process 
model, it was tested whether the model could be 
considered	invariant	across	different	diagnostic	groups	
of	patients.	The	two	groups	consisted	of	those	with	a	
primary	 diagnosis	 of	 a	 psychotic	 disorder	 and	 those	
with a primary diagnosis of a personality disorder. First, 
it was tested whether the process model at baseline 
(Model	1b)	could	be	considered	invariant	across	patient	
groups	by	evaluating	 the	χ2-test, which did not reach 
statistical	significance	(Δχ2=16.91,	Δdf=21,p=0.73)	and	
thus provided support for the hypothesis that the SDT 
process	 model	 was	 invariant	 across	 different	 patient	
groups at the baseline measurement. 
 The same procedure was repeated for the 
process model at follow-up (model fit is shown 
in	 Table	 3).	 Here,	 it	was	 found	 that	 the	 χ2-test	 for	
nested models did reach statistical significance 
(Δχ2=34.85,	Δdf=21,	p=0.03),	which	was	interpreted	
as the SDT process model being variant across the 
patient groups at follow-up. It was explored whether 
these differences could be explained by loss-to-
follow-up (e.g. differences between the sample at 
baseline and the sample at follow-up) but this was 
not the case. Therefore, the regression estimates 
for models 5a and 5b were inspected and several 
discrepancies were found between the two patient 
groups at the follow-up assessment, including the 
associations between autonomy support and all 
three motivation types. These are shown in Figure 
3. For example, patients with psychotic disorders 
showed a stronger positive association between 
autonomy support and identified motivation 
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Figure 2. Testing the SDT process model across time on clinical outcomes of treatment engagement, psychosocial functioning and quality 
of life
Note: The figure represents Model 3b, with all regression coefficients constrained for the corresponding measurements at baseline 
and follow-up (i.e. indicating that these are invariant across time). Numbers represent standardized regression coefficients for the 
corresponding path (baseline / follow-up), where boldface indicates that the estimate is statistically significant at p<0.05. Thick lines 
represent regression paths, dotted lines represent intercorrelations of variables. Variables reflect patient-rated constructs unless 
indicated otherwise. The intercorrelations between the motivation scales and between the patient’s psychosocial functioning and quality 
of	life	were	as	follows:	ID	with	IN	=	0.32/0.32,	ID	with	EX	=-0.24/-0.03	,	IN	with	EX	=	0.04/0.28,	PF	with	QL	=	0.42/0.61.	
Model Variance (R2)
CO ID IN EXT TE PF QL
1b. Baseline 0.26 0.39 0.10 0.04 0.18 0.26 0.36
2b. Follow-up 0.38 0.22 0.01 0.10 0.24 0.26 0.31
Table 4. Variances explained by the SDT process model
Note:	 CO	 =	 perceived	 competence;	 ID	 =	 identified	 motivation;	 IN	 =	 introjected	 motivation;	 EX	 =	 external	 motivation;	 TE	 =	 treatment	
engagement;	PF	=	psychosocial	functioning;	QL	=	quality	of	life.	N.a.	=	not	applicable.	Boldface	indicates	p<0.05	(two-tailed).
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compared to those with personality disorders 
(β=	 0.62	 versus	 β=0.25,	 respectively),	 and	 a	 less	
strong negative association between autonomy 
support	and	external	motivation	(β=	-0.19	versus	β=-
0.31, respectively). Also, regarding the associations 
between SDT constructs and treatment engagement, 
it was found that patients with psychotic disorders 
showed a stronger positive association between 
perceived competence and treatment engagement 
(β=	 0.39	 versus	 β=0.03,	 respectively),	 and	 stronger	
negative association between external motivation 
and	treatment	engagement	(β=	-0.17	versus	β=0.04,	
respectively), compared to patients with personality 
disorders. 
Discussion
Key findings and interpretation
The results of the current study show that the SDT 
process model specified to motivation for psychiatric 
treatment in a sample of outpatients with SMI: 1) 
shows good fit, 2) is stable across time and different 
patient groups and 3) is able to explain and predict 
clinical outcomes such as treatment engagement, 
psychosocial functioning and quality of life to a 
substantial degree. These findings suggest that SDT 
might be a useful foundation for interventions in the 
mental health care for outpatients with SMI. 
 Regarding the first hypothesis, it should be 
noted that although the results supported all the 
hypothesized paths in the model, additional paths 
were required between perceived competence 
and clinical outcomes which were not a-priori 
hypothesized. The necessity of such direct effects 
between competence and outcomes suggest that 
the patient’s perception of being able to do what 
the treatment requires is important in achieving 
actual treatment engagement and realizing 
favourable psychosocial outcomes and quality of 
life, independent of the quality of their motivation 
for engaging in treatment. Alternative models in 
which autonomy support was directly related to 
clinical outcomes were not supported by the data. 
This suggests that the model with indirect effects 
through competence and motivational regulations 
was most appropriate. Further, neither did we find 
support for a model in which the path between 
perceived competence and autonomy support 
was reversed, which suggests that gaining a sense 
of competence is facilitated by autonomy. Thus, it 
seems that once patients experience a high degree 
of choice, respect and relevance of treatment, they 
are then most likely to also experience competence 
to learn and do what the treatment requires. 
These findings are consistent with previous studies 
in other health-related contexts, which have 
also found support for the indirect link between 
perceived autonomy support and health outcomes 
via perceived competence 217. The strengths of the 
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Figure 3. Testing the SDT process model across diagnostic groups at follow-up
Note: The figure represents Model 5a, with all regression coefficients unconstrained for the corresponding measurements of each 
diagnostic group at follow-up. Numbers represent standardized regression coefficients for the corresponding path (psychotic disorders 
/ personality disorders), where boldface indicates that the estimate is statistically significant at p<0.05. Thick lines represent regression 
paths, dotted lines represent intercorrelations of variables. Variables reflect patient-rated constructs unless indicated otherwise.
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relationships between SDT constructs and clinical 
outcomes suggest that especially the patient’s 
perceived competence is imperative for engaging 
with treatment and achieving a better quality of life.
 Considering the second hypothesis, we found 
that the process model was relatively stable 
across different time points and across different 
diagnostic groups of SMI patients (i.e. psychotic 
disorders and personality disorders). This provided 
further empirical support for the robustness of 
the SDT process model. The model was, however, 
slightly different at follow-up assessment for the 
two patient groups (model 5a compared to model 
5b). After inspecting the regression estimates, 
it was found that both patients groups generally 
showed the theoretically expected associations 
between SDT constructs, yet to a different degree. 
For example, the finding that autonomy support 
was found to show a stronger and more stable 
relationship to identified motivation in patients 
with psychotic disorders compared to personality 
disorders, may indicate that patients with psychotic 
disorders show more stable continuous benefit 
from autonomy support in terms of their motivation 
whereas this may be more fluctuant in patients with 
primarily personality disorders. Also, looking at the 
strengths of the different regression estimates, it 
seems that treatment engagement in patients with 
psychotic disorders was most strongly associated 
with perceived competence (independent of the 
type of motivation), whereas for patients with 
personality disorders, treatment engagement was 
most strongly related to identified motivation. 
These findings may reflect differential effects of the 
motivational intervention in patients with primarily 
psychotic disorders compared to patients with 
primarily psychotic disorders 211, or alternatively, 
may be a reflection of different ‘natural’ courses 
of motivational changes in these groups over 
time. Either way, these findings could argue for a 
differential approach to motivational interventions 
in these two patient groups. 
 Further, although the current study shows 
preliminary support that SDT constitutes a robust 
framework for patterns through which patients 
become motivated to engage in treatment, future 
studies should investigate potential moderators of 
the processes described by SDT. The association 
between SDT constructs and various outcomes 
may vary in strength as a function of, for example, 
treatment duration, duration of illness, patient age, 
and type of treatment. These analyses were beyond 
the scope of the current study, but the detection 
of such moderators may have implications for the 
design of future SDT-based studies and interventions. 
Regarding the third hypothesis, it was found that the 
SDT process model explained around 18% to 24% 
of the variance of treatment engagement, around 
26% of the variance of psychosocial functioning 
and around 31% to 36% of the variance of quality 
of life. Although it is apparent that most variance in 
the clinical outcomes remains unexplained, these 
findings compare favourably to most other studies 
investigating models that include attitude-behaviour 
relationships 224. All in all, these findings provide 
preliminary support for the use of SDT principles 
such as support of the patient’s autonomy and 
competence to improve treatment engagement 
and achieve better mental health outcomes in 
outpatients with SMI. 
Strengths and limitations
Strengths of the current study include the 
longitudinal component which allowed for testing of 
the process model at two time points, demonstrating 
that SDT is a robust model that has potential as the 
basis for interventions in outpatients with SMI. 
Other strengths included a relatively large sample 
size considering the often difficult to engage patient 
population, that it was a multi-center study, the 
correction for unreliability of measurements and 
testing of rivalling models. 
 Several limitations of the current study should 
be acknowledged. First, there is the possibility of 
misspecification of the SDT process model. For 
example, misspecification of the model may have 
occurred if (some of) the relations in the model 
were in fact bidirectional. These alternatives were 
not tested as this is not in line with SDT, but it has 
been noted that for example, a patient who shows 
better psychosocial functioning (in terms of better 
cognitive, social and behavioural functioning) 
would likely experience more competence in doing 
what the treatment requires 217. However, other 
alternative models were adequately tested such that 
model misspecification is unlikely. 
 Second, several variables were not available in 
the current data set, such as perceived relatedness, 
other types of motivation such as intrinsic, integrated 
and amotivation and/or causality orientations 
which are also part of the larger holistic theoretical 
framework of SDT 48. Nevertheless, we feel that the 
constructs that have been recognized as the core 
constructs of SDT, namely autonomy support and 
perceived competence 65,123,217 and different types of 
motivation, were included in this study.
 Third, the tests in the current study represent 
cross-sectional associations which cannot be 
used to infer causality. The actual utility of SDT in 
clinical practice for SMI patients should be proven 
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in experimental studies, preferably by randomized 
clinical trials that aim to effectively influence 
patient autonomy and competence. Furthermore, 
the process model that was tested in the current 
study was based on previous studies, including a 
meta-analysis 217, that have modelled the effects of 
SDT constructs disjointly, or in other words, have 
examined each construct separately in relation 
to the other constructs. Although our approach 
adds to the comparability of the current study to 
previous studies and is a preliminary step towards 
more research into SDT in this context, the disjoint 
approach does not take into account possible 
combinations of different levels of motivation in 
association with the outcomes. Future studies could 
benefit from a conjoint analytic approach. Such 
analyses, could for example include motivational 
profiles of patients who show high ratings on all 
types of motivation compared to patients who show 
low ratings on several or all types of motivation, 
or including the conjoint effects of high and low 
autonomy and competence, such that we could 
further clarify the potential synergistic, additive or 
antagonistic effects between these constructs. 
 Finally, our sample largely represents a broad 
population of outpatients with diagnoses of 
psychotic and personality disorders with a variety of 
co-morbid psychiatric disorders, which strengthens 
the generalizability of the study. The incentive of 
15 euro was introduced with the aim to improve 
recruitment and follow-up of less motivated and less 
engaged patients. However, patients with relatively 
high levels of motivation for treatment, treatment 
engagement and psychosocial functioning may still 
have been more likely to participate in and complete 
the study compared to patients with low motivation, 
low engagement and poor functioning [28]. Also, the 
patients included in the current study were already 
engaged with services for some time, whereas future 
studies may aim to include patients who have just 
entered or who are in need for help but not yet in 
contact with services, who are likely to present with 
a different motivational profile and more variety in 
levels of functioning and quality of life. 
Conclusion and implications
The current study showed that the relations 
between perceived autonomy support, perceived 
competence, types of motivation for engaging 
in treatment and clinical outcomes were in the 
directions hypothesized by SDT. These relations 
were found to be consistent across time and patient 
diagnostic groups and showed explanatory value, 
which suggests that SDT can be a useful basis 
for interventions in the mental health care for 
outpatients with SMI. The results seem to confirm 
that the motivational feedback intervention that 
was tested in the randomised controlled trial 211 
was insufficient in improving patient autonomy and 
competence compared to usual care. Potentially 
fruitful future interventions might include (a 
combination of) more extensive training and 
monitoring of clinicians in the application of SDT, 
techniques from motivational interviewing that align 
with SDT 191,225, accounting for potential problems 
in (social) cognitive functioning of patients, as 
well as feedback components. Specific techniques 
that clinicians may use to support the needs for 
autonomy, competence and relatedness have been 
described in other papers (see for example 65,123,212). 
Experimental studies based on SDT in outpatients 
with SMI are still scarce, which underlines the need 
for additional research to confirm the causality of 
the relations between the SDT constructs and their 
ability to influence treatment outcomes. 
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Objective and Methods
The Integral Model of treatment motivation (IM) 
is the theory underlying the Treatment Motivation 
Scales for Forensic patients. The current study 
tested the IM using structural equation modelling 
in a sample of 294 outpatients with severe mental 
illness (SMI).
Results
Congeneric estimates of reliability for the seven 
subscales of the TMS-f ranged from 0.61 to 0.91 in the 
current sample. The obtained structural model was 
not consistent with original theory, nor was the model 
invariant across time and patient groups (psychotic 
disorders and personality disorders). The patient’s 
perceived suitability of treatment, perceived costs 
of treatment and outcome expectancy were most 
strongly associated with motivation and treatment 
engagement. The model explained between 22% 
and 86% of variance in clinical outcomes, depending 
on the timing of the assessment.
Conclusion
Currently, the IM does not constitute a robust 
framework for patterns through which patients 
become motivated to engage in treatment, but 
does explain substantial amounts of variance in 
clinical outcomes. The future potential of IM as a 
basis for interventions in the mental health care 
for outpatients with SMI is discussed, including 
suggestions for subsequent research and potential 
alterations of the IM to improve its utility for 
application in clinical practice.
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Introduction
Background and rationale
The Integral Model of treatment motivation (IM) 
is a health behavior theory that was specifically 
developed for application in mental health treatment 
to understand patients’ motivation for engaging in 
treatment 37. The IM holds that six cognitive and 
emotional factors, called internal determinants 
37, predict the patient’s motivation for engaging 
in treatment. The patient’s motivation is seen as 
the mediator between the internal determinants 
and actual treatment engagement. The Treatment 
Motivation Scales for forensic outpatient treatment 
(TMS-f) was developed by the founders of IM to 
assess the constructs in the theory 118. A series of 
studies using the TMS-f in a forensic psychiatric 
setting showed support for its hypothesized 
factorial structure and showed adequate reliability 
and validity116,118. The studies also found support for 
the general tenets of the IM, such that three out of 
six internal determinants were indeed statistically 
significantly related to the patient’s motivation for 
engaging in treatment, which in turn was predictive 
of treatment engagement 116-118. However, the 
relationships between the core constructs of the IM 
are in need for further empirical testing, including 
the plausibility and utility of the model outside 
a forensic psychiatric population. Therefore, the 
current study aimed to test the IM in a sample of 
Dutch adult outpatients with severe mental illness 
using a slightly adapted version of the TMS-f. The 
following describes the general tenets of IM and our 
study objectives.
The Integral Model of treatment 
motivation
The IM is theoretically affiliated with Ajzen and 
Fishbein’s theory of planned behaviour 45, with a 
strong focus on attitudes toward the behaviour, 
subjective norms, and perceived behavioural 
control. The theory of planned behaviour however, 
does not account for other factors that can influence 
motivation, such as distress, past experience or 
environmental factors, which are relevant in the 
context of motivation for engaging in treatment(-
related behaviours)37. The IM does take into account 
these factors more explicitly and may therefore be 
more useful in the context of mental health care. 
The IM holds that the patients’ MET depends on the 
six internal determinants (IDs), which in turn are 
determined by external factors such as treatment 
characteristics, external circumstances and patient 
factors. These external factors are thought to have 
their effect on motivation only through the IDs 37. 
The IDs comprise problem recognition, distress, 
perceived costs of the treatment, perceived 
suitability of the treatment, outcome expectancy 
and perceived legal pressure. Problem recognition 
refers to the recognition that one has a problem, the 
willingness to admit to the presence of a problem 
and the recognition that one must change to prevent 
recidivism. Distress is the level of suffering that might 
result from symptoms, social problems or having fear 
of deterioration in any area of life. Perceived costs of 
the treatment are the fee and the time the patient 
feels is spent on treatment, and the psychological 
costs resulting from exposure to unpleasant emotions 
and changes in lifestyle. Perceived suitability of the 
treatment encompasses three facets: the patient’s 
perception of appropriateness and effectiveness 
of the therapy, the patients’ agreement with the 
goals of treatment and the patients’ perception of 
the therapeutic relationship. Outcome expectancy 
refers to the patient’s expectancy of being able to 
finish the treatment, have success and believe in the 
ability to change 37,116,118,160. Finally, perceived legal 
pressure is the patient’s perception of the external 
pressure through the legal system. As the current 
study will explore whether the IM is also applicable 
outside a forensic psychiatric setting, the current 
study decided to adapt the construct of perceived 
legal pressure into a more broad perceived external 
pressure by others. This adjustment can be justified by 
considering that only a subgroup of outpatients with 
SMI will be referred to or pressured into psychiatric 
treatment via the legal system, while (most) others 
will likely experience other pressures that drive their 
motivation for engaging with treatment (i.e. family, 
friends, partner, assertive outreaching clinicians). 
 Further, MET is thought to predict treatment 
engagement, which in turn is a predictor of treatment 
outcome. However, the relationship between MET 
and treatment engagement is not presumed perfect, 
because of the possibility that patients may lack 
the capacity to do what the treatment requires 
due to cognitive, neuropsychological and other 
limitations37. Also, treatment outcome may depend 
on the effectiveness of the treatment approach and 
the persistence of the patients’ problems 37,117 which 
may result in only a modest relationship between 
treatment engagement and treatment outcome. 
 Figure 1 shows the IM as applied to the current 
study, including additional clinical outcomes and 
using perceived external pressure as one of six 
IDs as opposed to perceived legal pressure. In 
evaluating whether a motivation theory such as 
the IM is a “good theory”, we argued that a good 
theory would be applicable in multiple settings (i.e. 
different patients groups), robust against changes 
across time and would be able to explain clinical 
94
Chapter 6 } A test of the IM
outcomes. Regarding the second criterion, it should 
be noted that, although patients may change in 
their respective levels of motivation and outcome 
expectancy and perceived external pressure etc. 
over time, the associations between the constructs 
in the theory should remain constant across time if 
the theory is correctly specified. The objectives for 
the current study were based on these criteria.
Objectives
1: It will be tested whether the IM-model as outlined 
in Figure 1 is plausible. We hypothesized that the 
model in Figure 1 would show good fit to the 
reality, as represented by the data. However, if this 
model does not turn out to be plausible, we will 
test which alternative model is most plausible. 
2:  It will be tested whether the most plausible model 
can be considered invariant across time (i.e. 
baseline and one year later) and across patient 
groups (i.e. patients with primarily a personality 
disorder versus those with primarily a psychotic 
disorder). 
3:  The clinical utility of the model will be evaluated 
by investigating to which extent the IM model 
explains observed variance in clinical outcomes. 
Methods
Study Design
The current longitudinal study constitutes a 
secondary analysis of a cluster randomized clinical 
trial 197. The design of this trial and the intention-
to-treat analyses were reported elsewhere 197. 
Findings are reported according to the STROBE 
guidelines 226. The current study was approved by 
the Medical Ethical Committee for Mental Health 
Care Institutions (Dutch Trial Registry NTR2968) 
as well as by the scientific committees of the two 
specialty mental health institutions where the data 
were collected.
Setting 
Data were collected between May 2011 and October 
2013 from 12 outpatient treatment programs, 
including a forensic psychiatric outpatient clinic, 
three specialized psychotic outpatient treatment 
programs and eight several function-assertive 
community treatment teams (FACT-teams 14) of 
two Dutch treatment centres: GGZ Westelijk Noord 
Brabant and GGz Breburg. FACT-teams provide 
assertive, outreaching, community-based, and 
supportive psychiatric services to individuals with 
SMI 14, such as those with psychotic disorders and 
severe personality disorders. 
Participants and procedures
Inclusion criteria for patients were: a primary 
diagnosis of psychotic or personality disorder, aged 
18 to 65 years, undergoing individual outpatient 
treatment and having a sufficient command of 
the Dutch language. A clinician was eligible for 
participation if he or she was the primary health 
care provider involved with the patient and saw 
the patient most frequently. Eligible patients on 
the clinicians’ caseload lists were approached and 
informed by researchers and asked for their signed 
consent. Both patients and clinicians were asked 
to fill in questionnaires at baseline and follow-
up assessment (12 months after baseline) and 
additionally, patients were interviewed regarding 
their functioning in several life domains by 
independent research assistants at these assessment 
moments. To enhance the likelihood of participation, 
patients were given an incentive of 15 euro for the 
baseline and follow-up assessment in the trial. 
Measures
Core theoretical constructs of IM: Internal 
Determinants and motivation for engaging in 
treatment
Treatment	motivation	and	the	six	internal	determinants	
were	measured	 by	 the	 Treatment	Motivation	 Scales	
for	Forensic	patients	(TMS-f).	The	items	were	rated	on	
a	5-point	Likert	scale	(0	=	totally	agree	to	5	=	totally	
disagree). The subscale scores were calculated 
in such a way that a higher score on the subscale 
represented more perception of that respective 
scale, including the subscale perceived costs of the 
treatment (i.e. higher scores represented higher 
perceived costs of the treatment). The subscale of 
perceived legal pressure was adapted to represent a 
more broad perceived external pressure by others. 
For example, where in the original TMS-f an item is 
‘I feel a strong pressure from the legal system’, this 
was substituted for ‘I feel a strong pressure from 
others’. The entire modified scale and additional 
psychometric properties of the adapted subscale 
can be found in the online supplementary material. 
The congeneric estimates of reliability for the seven 
subscales of the TMS-f for the baseline and follow-
up assessment in the current study were as follows: 
problem	recognition	=	0.80	and	0.80,	distress	=	0.90	
and	0.91,	external	pressure	=	0.61	and	0.68,	costs	of	
treatment	=	0.77	and	0.79,	 suitability	of	 treatment	
=	 0.86	 and	 0.89,	 outcome	 expectancy	 =	 0.86	 and	
0.85,	 and	 motivation	 for	 engaging	 in	 treatment	 =	
0.82 and 0.86, respectively. The TMS-f was found 
to be a reliable and valid operationalisation of the 
constructs in the Integral Model in previous studies 
116,118. In a previous study in outpatients with severe 
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mental illness, we found statistically significant low 
to moderate correlations between the motivation 
subscale of the TMS-f and motivation scales derived 
from other motivation theories 218.
Clinical outcomes: Treatment engagement, 
psychosocial functioning and quality of life
Treatment engagement was measured with the 
Service Engagement Scale (SES) that was filled out 
by clinicians. The SES was developed to measure 
engagement with community mental health 
services 199. It comprises 14 items that assess 
availability, collaboration, help seeking and treatment 
engagement behaviours, including medication 
adherence. The items are rated on a 4-point scale 
ranging from 0 (not at all) to 3 (most of the time). 
The SES has good internal consistency (Cronbach’s 
α	=0.87,	congeneric	estimate	of	reliability	=	0.91	 in	
the current patient sample) and validity is supported 
by discrimination between criterion groups 199 and 
significant associations with therapeutic alliance 
and motivation for engaging in treatment 218. The SES 
total scale score was used as the outcome measure 
in this study, where higher scores denote higher 
treatment engagement. 
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Figure 1. Hypothesized model for IM
Note: The figure depicts latent variables, the observed variables and accompanying measurement errors underlying the latent variables 
were left out to avoid a cluttered presentation.
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The patient’s psychosocial functioning was measured 
with the Dutch version of the Health of the Nations 
Outcome Scales (HoNOS)163,164. The HoNOS is a 
semi-structured interview with the patient in which 
health and social problems of the previous two 
weeks are quantified. It contains 12 items that refer 
to behavioural problems, cognitive and physical 
impairments, symptoms, and social functioning. 
HoNOS items are scored on a scale from 0 (no 
problem) to 4 (severe problem) . The total scale 
score is computed by adding the 12 items. For ease of 
interpretation, we reversed the total score such that 
higher scores reflected higher levels of psychosocial 
functioning. The administration of the HoNOS was 
performed by independent research assistants 
(mostly graduate students in psychology and 
medicine) who had no involvement in the patient’s 
treatment. Patients were interviewed at the team 
office or at home, depending on their preference. 
The psychometric properties of the total scale score 
were shown to be acceptable and sensitive to change 
164. Internal consistency was acceptable in the current 
study (Cronbach’s α	 =	 0.70,	 congeneric	 estimate	 of	
reliability	=	0.77).	
 The patient’s quality of life was assessed with 
the Manchester Short Assessment of Quality of 
Life (MANSA)167,168. The MANSA is a self-report 
questionnaire that asks the patient how satisfied he/
she is in the following life domains: living situation, 
social relationships, physical health, mental health, 
safety, financial situation, work situation and life as 
a whole. The 12 items are scored on a Likert scale 
from 1 (couldn’t be worse) to 7 (couldn’t be better), 
which are summed to calculate a total score. Higher 
scores denote a higher perceived quality of life. The 
scale is shown to be reliable (i.e. Cronbach’s α	=	0.82	
and	 congeneric	 estimate	 of	 reliability	 =	 0.92	 in	 the	
current patient sample) and other psychometric 
properties are considered satisfactory 167. 
Socio-demographic factors and clinical 
diagnosis
The DSM-IV diagnosis as made by the psychiatrist of 
the team was obtained from the patients’ medical 
record, as well as socio-demographic data such as 
gender, age, ethnicity, age of onset and legal status. 
If these data were missing in the medical record, the 
patient was asked to provide this information. 
Statistical analyses
The analyses were performed in several steps. First, 
the bivariate relations of variables were estimated 
using Spearman correlations. Structural equation 
modelling (SEM) as implemented in Mplus version 
7.3 202 was used to test the hypothesized relationships 
between autonomy support, perceived competence, 
types of motivation, treatment engagement, 
psychosocial functioning and quality of life as 
depicted in Figure 1.
Latent variables
Both at baseline and at follow-up we evaluated the 
plausibility of the IM- model using latent path analysis 
as outlined in Figure 1. Classical reliability theory 
reformulated in terms of confirmatory factor analysis 
enabled to identify latent variables. Congeneric 
reliability estimates 203,219 were obtained as both the 
common factors loadings and the residuals turned 
out to differ. Subsequently, a factor analysis model 
for each observed variable was defined as a basis 
for deriving latent variables, in which the factor 
loading was fixed at 1.0 and the residual variance of 
that factor (i.e. 1- reliability) was multiplied by the 
variance of the variable at issue. In doing so, the 
observed variables were corrected for unreliability 
resulting in the latent variables. This process was 
included in each SEM-analysis.
Testing the invariance of the structural model
As the type of design was complex (patients clustered 
within teams) and, in addition, the distributions of 
the variables were considered to be non-normal, the 
estimation method used was MLR. This maximum 
likelihood estimates standard errors and χ2 test 
statistic that are robust to non-normality and non-
independence of observations. The MLR standard 
errors were estimated using a sandwich estimator. 
Additionally, the variable ‘team’ was included as an 
additional level in the analyses to adjust for potential 
clustering of the data within teams.
 First, the model as depicted in Figure 1 was fitted 
to the data for the full sample using the baseline and 
follow-up measurements separately. The following 
measures were used to test for adequacy of the 
model fit: χ2 for model fit (low and non-significant 
values of the χ2 were desired; P-value > 0.05); χ2/df 
ratio (a value <2.0 was considered to be acceptable); 
information criteria including Akaike (AIC), Bayesian 
(BIC), sample-size adjusted BIC (SS-BIC) (the smaller 
the better); Comparative Fit Index (CFI), and Tucker-
Lewis Index (TLI) (high values are desired (> 0.95), 
values > 1.0 point to over identification 220,221); Root 
Mean Square Error of Approximation (RMSEA: a 
value < 0.05 indicates a close fit 222; and Standardized 
Root Mean Squares of Residuals (SRMR: a value of 
< 0.05 indicates a reliable fit)201. Explained variances 
(R2) were used to describe the performances of the 
determinants for the individual dependent variables. 
 Subsequently, it was tested whether the baseline 
model showed a good overall fit. If not, it was 
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evaluated how it could be adapted such that the fit 
would improve or alternatively, whether the model 
could be simplified while not threatening the overall 
model fit. The most plausible model was obtained 
by evaluating the model fit criteria and standardized 
residuals. Further, the MLR χ2 difference test 
was used to compare different models which 
were nested. The χ2 difference was based on log-
likelihood values and scaling correction factors 
obtained with the MLR estimator, using the formula 
Δχ2=	 -2*(L0	 -	 L1)/cd	where	 L0	 is	 the	 log	 likelihood	
of the constrained (nested) model, L1 is the log 
likelihood of the unconstrained model and cd is the 
difference test scaling correction (which is based on 
scaling correction factors (c0 and c1) and number 
of parameters (p0 and p1) for the constrained and 
unconstrained models, respectively). 
 The invariance of the most plausible path model 
across time was evaluated by testing the invariance 
of the regression estimates of the latent variables, 
by comparing those assessed at baseline with those 
assessed at follow-up using the MLR χ2 difference 
test. Fitting both latent path models (baseline and 
follow-up) jointly was used to test whether the 
regression estimates of both time points could be 
considered invariant. Specifically, a non-significant 
MLR χ2 difference test between the model with all 
regression estimates constrained to be equal for the 
corresponding measurements versus all regression 
estimates unconstrained was considered statistical 
evidence for the latent path model being invariant 
across time. Individual estimates were regarded 
statistically significant if the two-sided P-values 
were < 0.05. The correlations of the latent variables 
between the corresponding measurements were 
allowed to be free as the measurements were 
repeated.
 The next step was to test the invariance of the 
model with the regression estimates of the identified 
latent path models jointly at baseline and follow-up 
further. This was done by comparing whether this 
model was also invariant across different patient 
groups (personality disorders versus psychotic 
disorders). The MLR χ2 difference test was used to 
test equality constraints between nested models.
Explained variance of clinical outcomes
To test to what extent the obtained IM- model has 
utility for clinical practice, it was evaluated how much 
variance was explained on the dependent variables 
in the model, including treatment engagement, 
psychosocial functioning and quality of life. 
Results
Participants and descriptive data
A total of 294 patients and 57 clinicians were included 
between May 2011 and September 2012. Patient 
characteristics are shown in Table 1. The majority 
of patients with psychotic disorders were diagnosed 
with schizophrenia (48%), schizoaffective disorder 
(16%), or psychotic disorder not otherwise specified 
(24%). In the group with primarily personality 
disorders, 40% had a borderline personality disorder, 
13% had antisocial personality disorder, and 26% 
had a personality disorder not otherwise specified. 
Most clinicians were female (63%), their mean age 
was	44	years	(SD	=	10.70)	and	they	had	a	mean	of	16	
years of clinical working experience in mental health 
services	(SD	=9.30).	
 After 12 months, 253 patients (86%) were re-
assessed. The group that was lost to follow-up was 
significantly more often of non-Dutch ethnicity (48% 
versus 26%, p<0.01) and more often had a legal 
mandate	 for	 treatment	 (18%	 versus	 7%,	 p	 =	 0.03)	
compared to completers.
 Table 2 shows Spearman correlations between 
variables that were included in the IM model. MET 
was most strongly correlated with the subscales 
perceived costs of treatment, suitability of 
treatment and outcome expectancy. The correlation 
between motivation for treatment with treatment 
engagement	was	moderate	for	both	time	points	(r	=	
0.28	and	r	=	0.30,	respectively).	Further	descriptive	
statistics of the TMS-f scales, including results from 
confirmatory factor analyses on each subscale and 
on the model including the six IDs as predictors for 
motivation, are presented in the supplementary 
material online. Based on these analyses, it was 
decided that the adapted version of the TMS-f, 
as used in the current study, was suitable for 
subsequent analyses. 
Path analysis
Establishing a plausible structural model
The observed variables were divided by a factor 
of 10 to reduce their variances which allowed 
Mplus to reach convergence with less uncertainty. 
The observed variables were then corrected for 
unreliability resulting in the latent variables, which 
were used in the subsequent path analyses. Table 
3 shows the model fit information of the models 
that were subjected to latent path analyses. The IM- 
model as depicted in Figure 1 was fitted to the data 
at baseline (Model 1a) and at follow-up (Model 2a). 
Model 1a provided a bad fit to the data (χ2/df=8.30,	
RMSEA=0.16,	 CFI=0.88,	 TLI=0.71,	 SRMR=0.13)	 and	
Model 2a provided a borderline fit (χ2/df=3.94,	
RMSEA=0.10,	CFI=0.95,	TLI=0.86,	SRMR=0.09).	
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Total patient sample
n = 294
Psychotic disorders
n= 199
Personality disorders
n = 95
Age, mean (SD) 44 (10.3) 43 (10.3) 45 (10.0)
Male gender, n (%) 179 (60.9) 132 (66.3) 47 (49.5)
Dutch ethnicityA, n (%) 208 (70.7) 140 (70.4) 68 (71.6)
Education level, n (%)
- No education/elementary
- Secondary school
- Upper high school and over
108 (36.7)
124 (42.2)
59 (20.1)
76 (38.2)
75 (37.7)
47 (23.6)
32 (33.7)
49 (51.6)
12 (12.6)
Comorbid substance use problemsB, n (% yes) 74 (25.2) 42 (21.1) 32 (33.7)
Legal mandate, n (% yes) 24 (6.9) 13 (6.5) 11 (12.0)
One or more previous admissions, n, (% yes) 227 (77.2) 159 (79.9) 68 (71.6)
Problem recognition, mean (SD) 30.2 (7.7) 28.6 (7.7)
Distress, mean (SD) 25.7 (9.6) 23.6 (9.1) 33.8 (6.7)
External pressure, mean (SD) 30.4 (5.9) 30.2 (6.0) 30.0 (9.2)
Perceived costs of treatment, mean (SD) 19.9 (6.9) 19.8 (7.1) 30.9 (5.8)
Suitability of treatment, mean (SD) 35.0 (7.2) 35.1 (7.3) 20.3 (6.4)
Outcome expectancy, mean (SD) 31.9 (8.1) 32.5 (8.2) 34.7 (7.0)
Motivation to engage in treatment, mean (SD) 47.2 (11.7) 47.4 (11.7) 46.9 (12.0)
Treatment engagement, median (IQR) 31 (24 to 36) 32 (25 to 37) 28 (24 to 35)
Psychosocial functioning, median (IQR) 9 (6 to 13) 8 (5 to 12) 10 (8 to 15)
Quality of life, median (IQR) 5 (4 to 5) 5 (4 to 5) 4 (4 to 5)
Baseline assessment Follow-up assessment
PR DS EP CT ST OE MET TE PF QL PR DS EP CT ST OE MET TE PF QL
PR  
DS 0.54
EP 0.54 0.28
CT 0.02 0.35 0.01
ST 0.12 -0.34 0.24 -0.59
OE -0.11 -0.55 0.08 -0.61 0.68
MET 0.10 -0.18 0.07 -0.50 0.38 0.51
TE 0.03 -0.24 0.17 -0.26 0.30 0.30 0.30
PF -0.30 -0.56 -0.17 -0.27 0.20 0.37 0.18 0.35
QL -0.19 -0.57 -0.02 -0.32 0.33 0.45 0.26 0.37 0.57
Follow-up assessment
PR 0.58 0.38 0.43 0.02 0.09 -0.05 0.17 0.09 -0.19 -0.13
DS 0.40 0.68 0.19 0.25 -0.29 -0.40 -0.16 -0.19 -0.37 -0.46 -0.56
EP 0.44 0.25 0.57 0.00 0.16 0.06 0.14 0.18 -0.08 -0.05 0.63 0.37
CT 0.05 0.26 0.00 0.58 -0.48 -0.49 -0.34 -0.22 -0.25 -0.35 0.14 0.40 0.04
ST 0.03 -0.28 0.19 -0.46 0.66 0.54 0.38 0.31 0.20 0.36 0.07 -0.37 0.19 -0.67
OE -0.10 -0.42 0.06 -0.43 0.51 0.61 0.33 0.23 0.27 0.41 -0.25 -0.60 -0.04 -0.70 0.70
MET 0.01 -0.16 0.08 -0.37 0.36 0.38 0.61 0.28 0.17 0.27 -0.02 -0.28 0.04 -0.49 0.49 0.54
TE 0.18 -0.07 0.23 -0.26 0.28 0.24 0.26 0.63 0.21 0.25 0.09 -0.13 0.23 -0.35 0.41 0.33 0.32
PF -0.22 -0.48 -0.14 -0.22 0.21 0.34 0.20 0.30 0.52 0.40 -0.34 -0.60 -0.20 -0.27 0.27 0.37 0.22 0.23
QL -0.24 -0.52 -0.11 -0.30 0.34 0.39 0.21 0.21 0.33 0.58 -0.33 -0.73 -0.21 -0.39 0.38 0.49 0.25 0.19 0.61
Table 1. Baseline characteristics of participating patients, stratified by primary diagnosis
A The definition of Dutch Ethnicity was based on the definition by the Dutch Bureau of Statistics.
B Substance abuse problem was defined as having a DSM-IV diagnosis of substance abuse and/or dependence in the medical record.
Table 2. Spearman intercorrelations of variables in the model for the total study sample
Boldface indicates p < 0.05 (two-tailed). Problem recognition, Distress, External pressure, Perceived costs of treatment, Perceived 
suitability of treatment, Outcome expectancy , Motivation to engage in treatment, Treatment engagement, Psychosocial functioning, 
Quality of life. 
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In search for a more plausible model, modification 
indices and, in particular, standardized residuals 
were inspected. These did not provide theoretically 
plausible nor unequivocal suggestions for improving 
model fit. That is, the indices pointed to several 
lacking direct effects between internal determinants 
and clinical outcomes (treatment engagement, 
psychosocial functioning and quality of life), some 
of which were opposite to theoretical expectations. 
Therefore, it was decided to investigate whether the 
structural model that was empirically obtained by 
Drieschner and Boomsma 160 would show better fit 
to the data than the originally hypothesized model. 
 The empirically derived model by Drieschner 
and Boomsma 160 was tested across both time 
points and labelled as model 1b (baseline) and 
model 2b (follow-up) in Table 3. This model included 
indirect paths from problem recognition, outcome 
expectancy and costs of treatment to treatment 
engagement via MET (while the paths between 
the remaining three internal determinants and 
MET were constrained to 0), and direct paths from 
suitability of treatment, external pressure and MET 
to treatment engagement. Additionally, psychosocial 
functioning and quality of life were determined by 
both treatment engagement and MET. In a second 
version of this model, psychosocial functioning and 
quality of life were also determined by suitability of 
treatment and external pressure (models 1c and 2c). 
The results in Table 3 show that model fit improved 
slightly but remained borderline for baseline 
assessment (models 1b and 1c), whereas it became 
worse for the follow-up assessment (models 2b and 
2c) compared to the model depicted in Figure 1. 
Thus, these models did not show acceptable fit to 
the data.
 In search for a more plausible model, a model 
was chosen which included paths from all predictors 
to all subsequent variables in the model. The fit of 
this model (which we labelled ‘start-model’) was 
perfect for both assessment moments (see models 
1d and 2d in Table 3). Subsequently, a backward 
elimination procedure was applied to the start-
model to obtain a more constrained model while 
not statistically significantly reducing model fit. 
The MLR χ2 difference test was used to compare 
nested rivalling models on model fit. The backward 
procedure started with the constriction of paths from 
the internal determinants to the distal outcomes 
(psychosocial functioning and quality of life) as these 
paths were least in line with theory 37. Specifically, 
the regression paths were sequentially constrained 
to zero between each internal determinant and the 
two distal outcomes to determine which constrictions 
were acceptable, i.e. did not statistically significantly 
reduce model fit. It was found that all paths between 
the internal determinants and two distal outcomes 
could be constrained to zero except for the path 
between distress and both outcomes. The fit for this 
model for both assessment moments is presented in 
Table 3 (models 1e and 2e) and Table 4a shows the 
results of the MLR χ2 difference test between the 
start-model (models 1d and 2d) and the constrained 
models (models 1e and 2e). 
Model χ2 df χ2/df p-value RMSEA 90% C.I. 
for RMSEA
CFI TLI SRMR AIC BIC SS-BIC
1a. Baseline (as in Figure 1) 149.40 18 8.30 <0.01 0.16 0.14 to 0.18 0.88 0.71 0.13 4567 4740 4591
1b. Baseline (as obtained by Drieschner & Boomsma116, version 1) 141.93 19 7.47 <0.01 0.15 0.13 to 0.17 0.89 0.74 0.12 4560 4730 4584
1c. Baseline (as obtained by Drieschner & Boomsma116, version 2) 77.97 15 5.20 <0.01 0.12 0.09 to 0.15 0.94 0.83 0.05 4497 4681 4522
1d. Baseline (start-model) 0.00 0 - <0.01 0.00 0.00 to 0.00 1.00 1.00 0.00 4448 4688 4482
1e. Baseline (constricted paths between IDs and PF/QL) 14.68 10 1.47 0.14 0.04 0.00 to 0.08 1.00 0.98 0.02 4441 4644 4469
1f.  Baseline (model 1e plus additional constricted paths between 
IDs and TE)
19.57 14 1.40 0.14 0.04 0.00 to 0.07 1.00 0.98 0.02 4436 4624 4462
2a. Follow-up (as in Figure 1) 71.00 18 3.94 <0.01 0.10 0.08 to 0.13 0.95 0.86 0.09 -1256 -1083 -1232
2b.  Follow-up (as obtained by Drieschner & Boomsma116,  
version 1)
109.02 19 5.74 <0.01 0.13 0.10 to 0.15 0.91 0.78 0.09 -1243 -1074 -1220
2c.  Follow-up (as obtained by Drieschner & Boomsma116,  
version 2)
101.39 15 6.76 <0.01 0.14 0.12 to 0.17 0.91 0.73 0.07 -1251 -1066 -1225
2d. Follow-up (start-model) 0.00 0 - <0.01 0.00 0.00 to 0.00 1.00 1.00 0.00 -1317 -1078 -1284
2e. Follow-up (constricted paths between IDs and PF/QL) 12.71 10 1.27 0.24 0.03 0.00 to 0.07 1.00 0.99 0.02 -1321 -1118 -1293
2f.  Follow-up (model 1e plus additional constricted paths 
between IDs and TE)
18.19 14 1.30 0.20 0.03 0.00 to 0.07 1.00 0.99 0.02 -1321 -1133 -1295
Table 3. Model fit information
Note:	χ2 =	chi-square	statistic;	df	=	degrees	of	freedom;	RMSEA	=	root	mean	square	error	of	approximation;	CFI	=	Comparative	Fit	Index,	
TLI	=	Tucker-Lewis	Index,	SRMR	=	standardized	root	mean	square	residual;	AIC	=	Akaike	Information	Criterion,	BIC	=	Bayesian	Information	
Criterion,	SS-BIC	=	Sample	size	adjusted	BIC.
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Subsequently, it was investigated if the path from 
MET to the distal outcomes could be constrained 
to zero, which was acceptable for the baseline 
model but not for the follow-up assessment. It was 
therefore decided to retain this path in the model 
unconstrained. Then, it was investigated which 
paths from the internal determinants to treatment 
engagement could be constrained to zero without 
significant loss of model fit. It was found that all 
paths from internal determinants to treatment 
engagement could be constrained to zero, except 
for the paths from distress and external pressure 
to treatment engagement (see Table 4a for the 
MLR χ2 difference test between the start-model 
and models 1f and 2f). This model was accepted 
as the final model, as further constrictions (e.g. 
between the IDs and MET) would hinder the testing 
of the ‘core’ of the original theory which consists of 
the mediating role of motivation between the six 
internal determinants and treatment engagement 37. 
Figure 2 shows the accepted final structural model, 
in which it can be seen that the strongest positive 
associations were found from perceived suitability 
of treatment, perceived costs of treatment and 
outcome expectancy to motivation for engaging in 
treatment, whereas strong negative associations 
were found between distress and treatment 
engagement, psychosocial functioning and quality 
of life.
Test of the IM process model across time and 
across patient groups
Testing the obtained process model across time was 
done by testing the invariance of the regression 
estimates of the latent variables across the two 
measurement occasions. A model was created 
in which both baseline and follow-up latent path 
models were included simultaneously (Model 3). In 
the first version of this model the regression weights 
were allowed to be free (unconstrained) for the 
Table 4a. Model comparisons to test for constrictions of the start-model
Model C or 
U
χ2 df χ2/ df Δ Χ2 Δ df Δ Χ2 / Δ df p-value Interpretation based on 
statistical inference
1d. Baseline (start-model) U 0.00 0 -
14.68 10 1.47 0.14
The more constricted model can 
be retained without significant 
loss of model fit
1e. Baseline (constricted paths between IDs and PF/QL) C 14.68 10 1.47
1d. Baseline (start-model) U 0.00 0 -
19.57 14 1.40 0.14
The more constricted model can 
be retained without significant 
loss of model fit
1f. Baseline (model 1e plus additional constricted paths between IDs 
and TE)
C 19.57 14 1.40
2d. Follow-up (start-model) U 0.00 0 -
12.71 10 1.27 0.24
The more constricted model can 
be retained without significant 
loss of model fit
2e. Follow-up (constricted paths between IDs and PF/QL) C 12.71 10 1.27
2d. Follow-up (start-model) U 0.00 0 -
18.19 14 1.30 0.20
The more constricted model can 
be retained without significant 
loss of model fit
2f. Follow-up ((model 1e plus additional constricted paths between 
IDs and TE)
C 18.19 14 1.30
Table 4b. Model comparisons to test for robustness of the obtained model across time and patient groups
Model C or U χ2 df χ2/ df Δ Χ2 Δ df Δ Χ2 / Δ df p-value Interpretation based on 
statistical inference
3a. Baseline and follow-up jointly (as 1f and 2f ) U 244.94 86 2.85 247.47 15 16.50 <0.01 The model is variant across 
time3b. Baseline and follow-up jointly (as 1f and 2f ) C 589.39 101 5.84
4a. Baseline process model 
(as 1f ) for psychotic versus personality disorders
U 31.11 28 1.11
17.57 15 1.17 0.29 The model is invariant across 
patient groups at baseline4b. Baseline process model 
(as 1f ) for psychotic versus personality disorders
C 48.92 43 1.13
5a Follow-up process model 
(as 2f ) for psychotic versus personality disorders
U 50.67 28 1.81
38.00 15 2.53 <0.01 The model is variant across 
patient groups at follow-up5b Follow-up process model 
(as 2f ) for psychotic versus personality disorders
C 87.25 43 2.03
Note:	C	or	U	=	Model	with	either	constrained	(C)	or	unconstrained	(U)	regression	coefficients	for	corresponding	measurements	at	baseline	
and follow-up. The constrained (nested) model is the more constrictive model with more degrees of freedom than the comparison model. 
The	grey	and	white	shading	indicates	models	that	are	rivalling	(nested)	models	(similar	shading	indicates	rivaling	models).	χ2 =	chi-square	
statistic;	df	=	degrees	of	freedom;	Δ	χ2	=	chi-square	value	of	the	MLR	difference	test,	Δ	df	=	difference	in	degrees	of	freedom	between	
the	models	being	compared.	IDs	=	internal	determinants;	PF	=	psychosocial	functioning;	QL	=	quality	of	life;	TE	=	treatment	engagement.
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baseline and follow-up measurements (Model 3a), 
which resulted in borderline fit to the data (χ2 / df 
=	2.85,	RMSEA	=	0.08,	CFI	=	0.94,	TLI	=	0.86,	SRMR	
=	 0.08).	 Then,	 a	 second	 version	 of	 this	model	 was	
created in which the regression weights for the 
corresponding paths at baseline and follow-up were 
constrained to be similar (Model 3b). Compared to 
Model 3a, Model 3b provided much worse fit to the 
data (χ2/df	=	5.84,	RMSEA=0.13,	CFI=0.80,	TLI=0.63,	
SRMR=0.17).	The	test	for	invariance	across	time	was	
represented by the MLR χ2 difference test between 
Models 3a and 3b, where a non-significant χ2-test 
was considered statistical evidence for the latent 
path model being invariant across time. As can be 
seen in Table 4b, the χ2-test reached statistical 
significance (Δχ2=247.47,	 Δdf=15,	 p=<0.01),	
implying that the IM model was not invariant across 
time. That is, the regression coefficients between 
variables in the model could not be considered 
similar for the baseline and follow-up assessments, 
as at least some of these were significantly different 
for the two time points. Model 3a is shown in Figure 
2, including standardized regression coefficients for 
the baseline and follow-up measurements.
 Additionally, it was tested whether the IM 
model could be considered invariant across 
different patient groups. To this end, the IM model 
was tested for differences between the group of 
patients with a primary diagnosis and patients 
with a primary diagnosis of a personality disorder. 
First, it was tested whether this model at baseline 
(Model 1f) could be considered invariant across 
patient groups by evaluating the χ2-difference test, 
which compared the model with all corresponding 
Distress
Problem
recognition
Perceived
external pressure
Perceived costs
of treatment
Perceived
suitability of
treatment
Outcome
expectancy
Motivation to
engage in
treatment
Treatment
engagement
Psychosocial
functioning
Quality of life
-0.46 /
-0.36
-0.49 /
-0.51
0.27 /
-0.24
0.25 /
-0.51
0.09 /
0.90
-0.03 /
0.67
0.19 /
0.89
-0.42 /
0.03
0.36 /
-0.05
0.14 /
0.01
0.23 /
-0.06
-0.02 /
0.00
-0.60 /
-0.09
-0.47 /
0.70
0.53 /
0.12
Figure 2. Testing the obtained process model for IM across time on clinical outcomes
Note: The figure represents Model 3a, with all regression coefficients left unconstrained for the corresponding measurements at 
baseline and follow-up (i.e. indicating that these are variant across time). Numbers represent standardized regression coefficients 
for the corresponding path (baseline / follow-up). Thick lines represent regression paths, dotted lines represent intercorrelations of 
variables. Boldface indicates statistical significance at p<0.05 (two-tailed). The figure depicts latent variables, the observed variables and 
accompanying measurement errors underlying the latent variables were left out to avoid a cluttered presentation.
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regression estimates constrained to be equal for the 
two patient groups (Model 4b) to the model where 
all regression estimates were unconstrained for 
the two patient groups (Model 4a). Table 4 shows 
the results for this comparison and it can be seen 
that the χ2-test did not reach statistical significance 
(Δχ2=17.57,	 Δdf=	 15,	 p=0.29),	 which	 provided	
support for the hypothesis that the IM model was 
invariant across these different patient groups at the 
baseline measurement.
 The same procedure was repeated for the IM 
process model at follow-up. Here, it was found that 
the χ2-test for nested models did reach statistical 
significance (Δχ2=38.00,	 Δdf=	 15,	 p<0.01),	 which	
was interpreted as the IM process model being not 
invariant across the patient groups at follow-up. 
That is, although the two patient groups could be 
described by a similar structural model at baseline 
(i.e. the regression coefficients between variables in 
the model at baseline were not significantly different 
between the groups), this was not the case for the 
follow-up assessment. Further testing of differences 
between patient groups with models that included 
both time points simultaneously also showed that 
the two patient groups were not invariant. In sum, 
these tests of the obtained IM process model suggest 
that this model is not stable across time nor across 
patient groups. 
Variance explained and predictive 
value of the IM process model
It can be seen in Table 5 that the obtained IM process 
model explained between 22% to 86% of treatment 
engagement, between 38% to 43% of psychosocial 
functioning and between 31% to 42% of quality of 
life, depending on the timing of the assessment. 
Table 5. Variances explained by the IM process model
Variance (R2)
Model MET TE PF QL
1. Baseline 0.44 0.22 0.38 0.42
2. Follow-up 0.73 0.86 0.43 0.31
Note:	MET	=	motivation	to	engage	in	treatment;	TE	=	treatment	
engagement;	PF	=	psychosocial	 functioning;	QL	=	quality	of	 life.	
N.a.	=	not	applicable.	Boldface	indicates	p<0.05	(two-tailed).	
Discussion
Key findings and interpretation
Regarding the first objective, the hypothesized 
mediational effect of motivation for engaging in 
treatment between internal determinants and 
treatment engagement was only partially supported. 
It was found that motivation fully mediated the effects 
of problem recognition, suitability of treatment, costs 
of treatment and outcome expectancy on treatment 
engagement. However, the model did not show a 
good model fit until additional direct paths between 
distress and all clinical outcomes were incorporated. 
Also, perceived external pressure was found to 
be of direct influence on the patient’s treatment 
engagement, independent of a mediational effect 
by motivation. Thus, the final structural model 
was not in line with original hypothesized theory 
nor similar to the obtained empirical model which 
was previously found by Drieschner and Boomsma 
in a forensic psychiatric research population 116, 
in which the patient’s motivation for engaging in 
treatment mediated the relations between problem 
recognition, outcome expectancy, costs of treatment 
and treatment engagement.
 Regarding the second objective, the obtained 
plausible model was not stable across time nor 
across different patient groups. These findings 
indicate that this theory in its current form does not 
constitute a robust framework for patterns through 
which patients become motivated to engage in 
treatment. On the one hand, it is not surprising that 
the identified model differs between patients with 
psychotic disorders and personality disorders, or that 
this is different for forensic psychiatric outpatients 
compared to outpatients with severe mental illness 
(with or without a history of offending). On the 
other hand, it would have strengthened the utility 
and generalizability of the theory if similar patterns 
of associations between motivational variables 
would appear across time and across different 
patient populations. Future studies should aim to 
replicate the current study in other populations 
and aim to explain (if and) why these differences 
occur. In addition, since the patient’s quality of life 
and psychosocial functioning are of great interest 
to treatment outcomes, future studies may aim to 
explore subdomains within these outcomes and how 
this affects the fit of the model. 
 Despite these findings regarding the structure 
and stability of the IM, the current study does 
provide insight into which factors are most 
relevant for the patient’s motivation and treatment 
engagement. Both our work and that of Drieschner 
and Boomsma 160 showed that perceived suitability 
of treatment, perceived costs of treatment and 
outcome expectancy were most strongly associated 
with motivation and treatment engagement. These 
determinants comprise the patient’s perception of 
the treatment and relationship with the clinician, 
the perception of the investment that is needed and 
the perceived competence in being able to do what 
the treatment requires, and the findings underscore 
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their importance in relation to motivation and 
treatment outcomes. 
 Further, the level of distress is generally regarded 
an important determinant of treatment motivation, 
such that more (symptomatic) suffering makes 
patients more motivated to engage in treatment 227. 
Indeed, studies have found that treatment-seeking 
patients with personality disorders or substance-use 
disorders reported higher subjective distress than 
those who did not seek treatment 228,229. However, 
others have found a so-called ‘motivation paradox’ 
in patients with SMI, such that those with more 
symptoms and more psychosocial problems are 
less motivated for engaging in treatment 230. This 
latter observation is consistent with the current 
study, where distress showed a negative association 
with treatment engagement and was unrelated to 
motivation for engaging in treatment (controlling 
for the other internal determinants). Drieschner 
and Boomsma found similar results in their studies 
in forensic psychiatric patients 116. This implies that, 
higher distress may withhold outpatients with SMI 
from in engaging with treatment, which may be 
related to the finding that higher distress is also 
associated with lower outcome expectancy and lower 
perceived suitability of treatment (see Table 2). For 
patients where distress is high and other motivational 
determinants are low, this may provide an argument 
for the paternalistic practices as performed by the 
assertive outreach teams, trying to engage patients 
who might otherwise be left untreated 230. These 
patients might be engaged by first increasing the 
external (legal) pressure, as – again similar to the 
findings of Drieschner and Boomsma 116 - we found 
that perceived external (legal) pressure was directly 
related to treatment engagement, whereas no 
significant association between external pressure 
and motivation was found. These findings suggest 
that patients may engage in treatment due to 
external pressures, regardless of how motivated 
they are (by themselves). 
 Regarding the differences between the structural 
models at the two time points, it seems remarkable 
that not only the strengths of the relationships 
between the IDs and motivation were different 
, but also – in some cases – the direction of these 
relationships. For example, the correlation between 
perceived suitability of treatment and motivation 
was positive (see Table 2), but when corrected for 
the influence of the other internal determinants 
resulted in a negative association at baseline, and 
again a positive association at follow-up (see Figure 
2). After ruling out the possibility of multicollinearity 
problems, we interpreted this finding as valid and 
indicating that the interrelations of the internal 
determinants are more complex than the current 
theory suggests. This should therefore be subject of 
subsequent investigations of the IM. 
 Thirdly and finally, the obtained plausible model 
was able to explain substantial amounts of variance 
in treatment engagement, psychosocial functioning 
and quality of life. The model explained between 
22% to 86% of treatment engagement, between 38% 
to 43% of psychosocial functioning and between 31% 
to 42% of quality of life, depending on the timing of 
the assessment. The discrepancy between explained 
variances at baseline and at follow-up may be 
explained by the relative contributions of perceived 
suitability of treatment and motivation, which were 
more pronounced at the follow-up assessment. All in 
all, this suggests that the concepts contained within 
the IM hold potential to predict treatment outcomes, 
which warrants further empirical investigation into 
the IM. 
Strengths and limitations 
Strengths of the current study include the 
longitudinal component which allowed for testing 
of the model at two time points, a relatively large 
sample size considering the often difficult to engage 
patient population, that it was a multi-center study, 
the correction for unreliability of measurements and 
testing of rivalling models.
 Limiting the current study is the possibility 
of model misspecification, which should not be 
underestimated. Misspecification of the model may 
have occurred due to misspecification of the relations 
between the internal determinants or if some of the 
relations in the model were actually bidirectional 
(such as between distress and psychosocial 
functioning and quality of life). These alternatives 
were not tested as these were not in line with IM, but 
the idea of reciprocal relationships between some 
of the variables in the model is actually possible. 
For example, not only may motivation for engaging 
with treatment depend on the patient’s outcome 
expectancy, but in turn the patient’s outcome 
expectancy may depend on (previous) motivation 
for engaging in treatment and previous treatment 
engagement behaviours. Such relations are likely 
for ongoing, repeated behaviours 77 as is the case 
in our study sample, where patients were not new 
to treatment but most had been in treatment for 
many years. Further, although efforts were made to 
compare different structural models and to identify 
a model which was most plausible considering both 
theory and data, our final model was based on a 
backward elimination approach which opens the 
possibility of a ranking and selection problem. That 
is, the constriction of certain paths in the model 
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to zero (i.e. “dropping them”), was based on this 
study sample which might not be generalizable to 
other samples let alone to the entire population of 
outpatients with SMI. 
 It is considered a strength that our sample 
largely represents a broad population of outpatients 
with diagnoses of psychotic and personality 
disorders with a variety of co-morbid psychiatric 
disorders, which strengthens the generalizability 
of the study. However, patients with relatively 
high levels of motivation for treatment, treatment 
engagement and psychosocial functioning may still 
have been more likely to participate in and complete 
the study compared to patients with low motivation, 
low engagement and poor functioning. Therefore, 
the results may not be generalizable to the entire 
population of outpatients with SMI, in particular 
those patients who are not in contact with services. 
Future studies should further investigate the 
generalizability of the TMS-f and the adapted version 
that was used in the current study, to other patient 
populations and nationalities, as the scales and the 
conceptual framework of the IM may prove useful 
in the understanding and communication about 
motivation for engaging with treatment services in 
other mental health contexts as well. 
Conclusion and implications
The current study showed that the relations 
between internal determinants, motivation for 
engaging in treatment, treatment engagement and 
clinical outcomes were not consistent with the 
original theory, nor were they consistent across 
time and different patient diagnostic groups. Future 
studies should aim to test the IM in other clinical 
populations, to further specify the relations between 
constructs in the model and to re-specify (or reject) 
the initially hypothesized principles. Depending on 
the context of these future studies, researchers 
may choose to use the original TMS-f, or to use the 
version that was used in the current study in which 
the legal pressure subscale was adapted to represent 
external pressure. The IM might be improved by 
re-specifying the interrelations of the internal 
determinants and/or by including intermediary 
factors such as action planning between the level 
of MET and the actual treatment engagement 
86,115. Including such intermediary factors might 
create opportunities to beneficially influence the 
pathway to treatment engagement. The constructs 
in the model did show explanatory value, which 
demonstrates the future potential of IM (constructs) 
as a basis for interventions in the mental health 
care for outpatients with SMI. In further testing of 
the theory, it will become more accurate and thus 
more useful for application in clinical practice. 
Clinical implications of our findings include that 
perceived suitability of treatment, perceived costs of 
treatment and outcome expectancy currently seem 
the most interesting targets for interventions aimed 
at improving motivation and treatment engagement.
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in Outpatients with Severe 
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Objective and Methods
The stages of change (SoC) described by the 
TransTheoretical Model (TTM) provide a potentially 
useful framework for evaluating the motivation 
of patients with severe mental illness (SMI) to 
participate in treatment for their psychiatric 
problems, yet no studies to date have evaluated stage 
instruments for such applications. Two assessment 
methods for SoC, namely a staging algorithm and 
the University of Rhode Island Change Assessment, 
were studied using structural equation modelling in 
a sample of 294 SMI outpatients. Convergent validity 
and criterion validity were evaluated.
Results
It was found that the two measures showed low 
convergence and thus seem to assess different 
aspects of motivation to engage with psychiatric 
treatment. For both assessment methods, the 
TTM stages only partially showed the theoretically 
expected associations with other TTM constructs 
and treatment engagement. Further, the instruments 
explained only 3% to 16% of variance in treatment 
engagement.
Conclusion
These findings reveal important problems in the 
applicability of staging measures to the engagement 
of patients with SMI in outpatient psychiatric 
treatment, and currently do not support their use 
in clinical practice. Future studies should focus on 
evaluating other SoC measures as a foundation 
for further research into the utility of the TTM in 
psychiatric treatment services.
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Introduction
Background and rationale
The TransTheoretical Model (TTM) 44 is one of the 
most frequently used models in daily clinical practice 
to assess and address motivation for behaviour 
change 63. According to the TTM, effective health 
behaviour intervention strategies are those which 
are tailored to the patient’s stage of change. That 
is, clinicians should aim to identify their patients’ 
readiness to change by specifying in which one of 
five stages the patient is in: precontemplation (not 
planning to change or even resistant to change), 
contemplation (considering change but not yet 
planning it), preparation (preparing to change 
soon), action (behaviour change has recently been 
achieved) or maintenance (long-term behaviour 
change has been achieved) 53. When the appropriate 
stage is identified, specific interventions should be 
offered to help patients progress to the next stage 
or to maintain changes made 54. Typically, the TTM 
is regarded as a model for motivation for change, 
as the motivation to engage in behaviour change 
increases with each progressive stage until action is 
taken, after which the level of motivation must be 
maintained to consolidate the changes made 86. TTM 
researchers have evaluated two distinct but related 
aspects of motivation: motivation for change and 
motivation for engaging in treatment 53. Although 
related, these two concepts are not equivalent, as 
patients may want to change their health behaviour 
problem without professional help. Vice versa, 
patients can come into treatment and be motivated 
to engage in treatment activities but still be reluctant 
to change their health behaviour problems 53. For 
these latter patients, engaging in treatment may be 
the first step towards behaviour change if they are 
supported in developing motivation, which may take 
months or even years 231.
 The TTM has been applied to numerous health 
behaviours and settings54, and may also be useful 
for application in psychiatric treatment services 
for patients with severe mental illness (SMI), such 
as patients with psychotic disorders, personality 
disorders and co-occurring SMI and substance use-
disorders (dual diagnosis) patients 58,86. Current 
studies suggest that TTM constructs can explain 
outcomes for patients with a dual diagnosis 57-59, and 
that the TTM constructs are associated with physical 
activity in patients with schizophrenia spectrum 
disorders 60,61 and with drop-out from dialectical 
behavioural therapy for patients with borderline 
personality disorder 62. A meta-analysis on the 
relations between stages of change and processes 
of change applied to psychotherapy, found that 
“the majority of published research concerns health 
behaviours and addictive disorders, as contrasted 
with the wide range of Axis I disorders” (p. 151)63. 
It appears that the TTM has been understudied 
regarding motivation for changing psychiatric 
problems in outpatient treatment for patients 
with SMI, despite its potential in this domain. For 
example, it would be relevant for clinicians to 
know whether the stages regarding motivation for 
changing psychiatric problems by engaging with 
treatment can objectively be identified and which 
instrument is most useful for assessing the stages. 
Further, it would be relevant for clinicians to know 
whether the stages are associated with actual 
treatment engagement and clinical outcomes (in the 
manner hypothesized by TTM). 
 Previous studies in patients with substance use 
problems have found that associations between 
stages and clinical outcomes may vary depending 
on the type of stage assessment (e.g. using an 
algorithm versus a continuous scale)93,232. It is 
unknown, however, how the (measures of the) TTM 
model perform in outpatients with SMI, rendering it 
important to evaluate different types of instruments 
for assessing stages of change in clinical practice 
to decide which of the two types has the highest 
predictive power regarding treatment engagement. 
Therefore, the purpose of the current study is to 
examine the plausibility and utility of the TTM stages 
of change regarding the engagement with outpatient 
psychiatric services for patients with SMI, using two 
popular methods of stage assessment to evaluate 
which instrument is most applicable in clinical 
practice.
Hypotheses from the Transtheoretical 
Model
Figure 1 shows how the TTM holds that people 
progress through the five stages to accomplish 
behaviour changes and that this progression is 
cyclical rather than linear (see bottom left of Figure 
1). People may move forward and backward through 
the stages of change, as relapse is common to the 
change process 53. As noted previously, the TTM 
proposes several mechanisms of change, including 
ten processes of change, that guide movement 
through the stages. Prochaska, Redding and Evers 
have noted that: “To help people progress from 
precontemplation to contemplation, such processes 
as consciousness raising and dramatic relief should 
be applied. Applying processes like contingency 
management, counterconditioning, and stimulus 
control to people in precontemplation would 
represent a theoretical, empirical, and practical 
mistake. But for people in action, such strategies 
would represent optimal matching” (p. 106)54. Across 
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the ten processes of change, two higher-order 
constructs have been identified which are referred to 
as experiential and behavioural processes of change 
96. According to the authors of TTM, experiential 
processes are used in early stages and include the 
cognitive, affective, and evaluative processes to 
progress through stages 96. In later stages, people rely 
more on commitments, conditioning, contingencies, 
environmental controls, and support for progressing 
toward maintenance or termination, which together 
make up the behavioural processes of change96. 
Movements through stages are marked by a shift in 
decisional balance, which is the patient’s perception 
of the pros and cons of changing, and by an increase 
in the patient’s self-efficacy 54. In sum, the processes 
of change are considered as mediators between 
stage movements or as predictors of stages 54,80, 
whereas the markers of change - self-efficacy and 
decisional balance - are considered as dependent 
variables or sometimes as mediators 54,80. 
Objectives and hypotheses of the 
current study
1)  Validating the five TTM stages: It will be tested 
whether	the	five	stages	of	change	can	be	empirically	
validated	 regarding	 the	 patient’s	 motivation	 for	
changing	 psychiatric	 problems	 in	 outpatient	
treatment.	Specifically,	it	will	be	tested	if:
a.		the	 experiential	 and	 behavioural	 processes	 of	
change,	 self-efficacy	 and	 decisional	 balance	
discriminate	 between	 the	 identified	 stages	 in	 the	
manner hypothesized by TTM. We hypothesized 
that	the	stages	could	be	distinguished	in	the	manner	
consistent with original theory 54, as shown in 
Figure 1:
1. experiential processes of change are predictive of 
the precontemplation and contemplation stages, 
including stronger positive association with 
contemplation compared to precontemplation. 
Experiential processes are not predictive of 
the action and maintenance stages, or at least 
show less strong positive association with these 
stages compared to the behavioural processes;
2. behavioural processes of change are predictive 
of the action and maintenance stages, showing 
positive associations with both stages. 
Behavioural processes are not predictive of the 
precontemplation and contemplation stages, or 
at least show less strong positive association 
with these stages compared to the experiential 
processes;
3. the decisional balance variables problem 
recognition, distress and perceived suitability 
of treatment will be negatively associated with 
precontemplation, and will show increasingly 
positive associations with contemplation, action 
and maintenance;
4. the decisional balance variables perceived 
external pressure and costs of treatment will 
be positively associated with precontemplation, 
and will show increasingly negative associations 
with contemplation, action and maintenance;
5. self-efficacy will be negatively associated with 
precontemplation, and will show increasingly 
positive associations with contemplation, action 
and maintenance.
b.  the stages show associations with treatment 
engagement. Consistent with TTM 54, we 
hypothesized that precontemplation would show 
negative association with treatment engagement, 
whereas the ‘higher’ stages would all show 
increasingly stronger positive associations with 
treatment engagement. 
2)  Testing the stability of the relations between 
stages and outcomes: we hypothesized that 
the associations between stages and clinical 
outcomes would be stable across time and across 
patient groups, as this would provide support for 
the robustness of the stage construct. 
3)  Testing differences in stability and predictive 
power between two types of stage assessments: 
it will be investigated whether there are 
differences between the staging algorithm and 
continuous assessment regarding their stability 
across time and patient groups and their abilities 
to explain variance in treatment engagement. It 
was hypothesized that the strength of associations 
would vary between the two types of assessment, 
but that the pattern of associations and stability 
across times and groups would be similar. 
Methods
Study Design
The current longitudinal observational study 
(baseline assessment and one-year follow-up) 
constitutes a secondary analysis of a cluster 
randomized clinical trial197. The design of this trial 
and the intention-to-treat analyses were reported 
elsewhere 197. The study was approved by the 
Medical Ethical Committee for Mental Health Care 
Institutions (Dutch Trial Registry NTR2968) as well 
as by the scientific committees of the two specialty 
mental health institutions where the data were 
collected. Findings are reported according to the 
STROBE guidelines 226.
Setting 
Data were collected between May 2011 and October 
2013 from 12 outpatient treatment programs, 
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including a forensic psychiatric outpatient clinic, 
three specialized psychotic outpatient treatment 
programs and eight several function-assertive 
community treatment teams (FACT-teams14) of 
two Dutch treatment centers: the Western North 
Brabant Mental Health Center and the Breburg 
Mental Health Center. FACT-teams provide assertive, 
outreaching, community-based, and supportive 
psychiatric services to individuals with SMI 14, 
such as those with psychotic disorders and severe 
personality disorders. 
Participants and procedures
All of the following inclusion criteria for patients 
had to be fulfilled: a primary diagnosis of psychotic 
or personality disorder, aged 18 to 65 years, 
undergoing individual outpatient treatment and 
having a sufficient command of the Dutch language. 
A clinician was eligible for participation if he or she 
was the primary health care provider involved with 
the patient and saw the patient most frequently. 
Eligible patients on the clinicians’ caseload lists were 
approached and informed by researchers and asked 
for their signed consent. Both patients and clinicians 
were asked to fill in questionnaires at baseline and 
follow-up assessment (12 months after baseline) 
and additionally, patients were interviewed 
regarding their functioning in several life domains by 
independent research assistants at these assessment 
moments. To enhance the likelihood of participation, 
patients were given an incentive of 15 euro for the 
baseline and follow-up assessment in the trial. 
Measures
Core theoretical constructs of TTM: stages of 
change, decisional balance, self-efficacy and 
processes of change
The stages of change were measured by using the 
University of Rhode Island Change Assessment 
(URICA)38,170 and with a staging algorithm. The 
URICA-D is the Dutch version of the URICA 38,170, which 
is a self-report scale consisting of 24 items which 
are rated on a scale from 1 (totally disagree) to 5 
(totally agree) that correspond to one of four stages: 
precontemplation (P), contemplation (C ), action (A) 
or maintenance (M). The version used in the present 
study employs the generic ‘problem’ frame for the 
items, which has allowed the URICA to be used 
with a variety of disorders and behaviours54,62,63, 
by instructing the patients that ‘for all statements 
that refer to your “problem”, answer in terms of 
the most important problem that you are working 
on in your current treatment’. In the current study, 
most patients wrote target goals such as ‘reach 
stability in psychotic symptoms’ or ‘prevent relapse 
in psychoses’. As all patients in our study sample 
were enrolled in treatment, we considered that 
we could generalize the responses to the URICA-D 
as representing ‘willingness to change psychiatric 
problems during outpatient treatment’. Example 
items of the URICA-D are ‘As far as I’m concerned, I 
don’t have any problems that need changing’ (P), ‘I 
have a problem and I really think I should work on it’ 
(C), ‘I am doing something about the problems that 
had been bothering me’ (A) and ‘It worries me that I 
might slip back to a problem I have already changed, 
so I am here to seek help’ (M). Subscale scores were 
calculated based on their original item composition 
170. Congeneric estimates of reliability in the current 
sample were: 0.50 (P), 0.67 (C), 0.84 (A) and 0.68 
(M). 
 The algorithm approach involves several 
questions that ask about attempts and intentions 
to change behaviour within certain time frames 
corresponding to a particular stage. Patients were 
asked to indicate whether they were currently in 
the precontemplation, contemplation, preparation, 
action or maintenance stage with regard to their 
motivation to change psychiatric problems. That 
is, this is a ‘forced-choice’ assessment; patients 
can choose only one stage to be in regarding their 
motivation for changing their psychiatric problems. 
Precontemplation was defined as ‘not planning 
to work on my problems in the next six months’. 
Contemplation was defined as ‘planning to work on 
my problems within the next six months, but not 
within 30 days from now’. Preparation was defined 
as ‘planning to work actively on my problems within 
the next 30 days’. Action was defined as ‘having 
worked on my problems actively for the last 30 days, 
but no longer than six months’. Maintenance was 
defined as ‘having worked actively on my problems 
for the last six months’. These definitions are similar 
to standard stage algorithms from TTM 80,83,96.
 To assess the processes of change, we developed 
a Dutch questionnaire which was based on available 
short questionnaires for the processes of change 
96,171,172, but adapted to fit its application to change 
processes in psychiatric treatment. The processes of 
change were measured by asking patients to indicate 
how often they made use of the strategies described 
in 20 statements 197, reported in the supplementary 
material (Table S1). The statements were rated on 
a five point Likert scale, ranging from 1 (never) to 5 
(repeatedly), consistent with other short measures 
of the processes of change 57,96,171,172. The overarching 
constructs of experiential and behavioural processes 
of change were used for the current study, of which 
the congeneric estimates of reliability were 0.71 
and 0.77, respectively. Additional psychometric 
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properties of this questionnaire are reported in the 
supplementary material (Table S1). 
 Decisional balance and self-efficacy were 
assessed using the Treatment Motivation Scale for 
forensic patients (TMS-f) 118. The original TMS-f 
consists of eight Dutch subscales, of which six 
were considered relevant for the current study: 
problem recognition, distress, perceived external 
pressure, perceived costs of treatment, perceived 
suitability of treatment and outcome expectancy. 
It was considered that patients who are enrolled in 
treatment will evaluate these factors as either high 
or low and that these evaluations can be translated 
into either a pro or a con for treatment. For example, 
a patient who perceives the treatment as highly 
suitable is likely to consider this a pro for treatment, 
whereas high costs in terms of having to invest 
time, energy and recourses in the treatment can 
be considered as a con for engaging in treatment. 
Example items include: ‘I have to learn to deal 
with certain situations in a better way, to prevent 
things going wrong again’ (problem recognition), 
‘My life sucks’ (distress), ‘I feel a strong pressure 
from others to deal with my problems’ (perceived 
external pressure), ‘If you consider the time, money 
and energy that I have to invest in treatment, then it 
comes at a high cost’ (perceived costs of treatment) 
and ‘I totally agree with the goals of this treatment’ 
(perceived suitability of treatment). The subscale 
for outcome expectancy was used as a measure for 
self-efficacy, as this scale addresses the patient’s 
expectancy that he/she will be able to do what 
the treatment requires and to finish it 118. This is 
consistent with the definition of self-efficacy within 
TTM, namely “the situation-specific confidence that 
people can cope with (high-risk) situations without 
relapsing to their former behaviours”(p. 102) 54. All 
items of the TMS-f were rated on a 5-point Likert 
scale	 (0	 =	 totally	 agree	 to	 5	 =	 totally	 disagree).	
The subscale scores were calculated in such a way 
Contemplation
Precontemplation
Psychosocial
functioning
Quality of lifeAction
Maintenance
Treatment
engagement
++
+
-
++
+
+
+
Figure 2. Hypothesized model for the associations between stages of change and clinical outcomes in the current study
Note: It was hypothesized that precontemplation would show negative association with treatment engagement, whereas the other 
‘higher’ stages would show positive and increasingly stronger associations with treatment engagement compared to lower stages, 
consistent with original theory [3]. Thick lines represent theoretically expected regression paths, dotted lines represent expected 
intercorrelations of variables. 
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that a higher score on the subscale represented 
more perception of that respective scale, including 
the subscale perceived costs of the treatment (i.e. 
higher scores represented higher perceived costs of 
the treatment). Congeneric estimates of reliability 
for the six subscales of the TMS-f ranged from 0.61 
to 0.91 in the current sample.
Clinical outcomes: Treatment engagement, 
psychosocial functioning and quality of life
Treatment engagement was measured with the 
Service Engagement Scale (SES) that was filled 
out by clinicians. The SES was developed to 
measure engagement with community mental 
health services 199. It comprises 14 items that 
assess availability, collaboration, help seeking 
and treatment engagement behaviours (including 
medication adherence). The items are rated on a 
4-point scale ranging from 0 (not at all) to 3 (most 
of the time). The SES has good internal consistency; 
the congeneric estimate of reliability was 0.91 in 
the current sample. Its validity is supported by 
discrimination between criterion groups 199 and 
statistically significant associations with therapeutic 
alliance and motivation for engaging in treatment 218. 
The SES total scale score was used as the outcome 
measure in this study, where higher scores denote 
higher treatment engagement. 
The patient’s psychosocial functioning was 
measured with the Dutch version of the Health of 
the Nations Outcome Scales (HoNOS)163,164. The 
HoNOS is a semi-structured interview with the 
patient in which health and social problems of the 
previous two weeks are quantified. It contains 12 
items that refer to behavioural problems, cognitive 
and physical impairments, symptoms, and social 
(dis)functioning. HoNOS items are scored on a scale 
from 0 (no problem) to 4 (severe problem) . The total 
scale score is computed by adding the 12 items. For 
ease of interpretation, we recoded the total score 
such that higher scores reflected better psychosocial 
functioning. The administration of the HoNOS was 
performed by independent research assistants 
(mostly graduate students in psychology and 
medicine) who had no involvement in the patient’s 
treatment. Patients were interviewed at the team 
office or at home, depending on their preference. 
Internal consistency was acceptable in the current 
study;	congeneric	estimate	of	reliability	=	0.77.	The	
psychometric properties of the total scale score were 
shown to be acceptable and sensitive to change in 
previous studies 164,233. 
 The patient’s quality of life was assessed with the 
Dutch version of the Manchester Short Assessment 
of Quality of Life (MANSA)167,168. The MANSA is a 
self-report questionnaire that asks the patient how 
satisfied he/she is in the following life domains: living 
situation, social relationships, physical health, mental 
health, safety, financial situation, work situation and 
life as a whole. The 12 items are scored on a Likert 
scale from 1 (couldn’t be worse) to 7 (couldn’t be 
better), which are summed to calculate a total score. 
Higher scores denote a higher perceived quality of 
life. The congeneric estimate of reliability was 0.92 in 
the current sample. Other psychometric properties 
of the MANSA are considered satisfactory167. 
Statistical analyses
Structural equation modelling (SEM) as implemented 
in Mplus version 7.3 202 was used to investigate the 
research questions. As the type of design was complex 
(patients clustered within teams) and, in addition, 
the distributions of the variables were considered 
to be non-normal, the estimation method used was 
MLR. This maximum likelihood estimates standard 
errors	and	χ2	 test	 statistics	 that	are	 robust	 to	non-
normality and non-independence of observations. 
Additionally, the variable ‘team’ was included as a 
second level in the analyses to adjust for potential 
clustering of the data within treatment teams.
 To evaluate the validity of the stages of 
change, two models were tested. In Model 1, the 
stages of change as assessed with the staging 
algorithm were included as predictors for the 
URICA-D stages to investigate the associations 
between the two assessment methods, to address 
convergent validity. In Model 2, the experiential and 
behavioural processes of change, self-efficacy and 
the trichotomized decisional balance variables were 
used as predictors for the stages of change (both 
the URICA-D and algorithm), to address criterion 
validity. The decisional balance and self-efficacy 
variables were trichotomized to investigate non-
linear relationships between these variables and the 
stages of change, which was feasible, mirrors clinical 
practice and eases the interpretation of results. 
Spearman correlations and analyses of variance were 
conducted to examine the relationships between 
stages of change and mean scores on the patient’s 
treatment engagement, psychosocial functioning 
and quality of life. 
 Subsequently, we evaluated the empirical-
statistical plausibility of the model as outlined in 
Figure 2 at baseline and at follow-up, as well as 
across patient diagnostic groups. This was done 
separately but similar for both the staging algorithm 
and the URICA-D. To make the structural models for 
the staging algorithm and URICA-D comparable, the 
stages contemplation and preparation were merged 
to one stage (labelled ‘contemplation’) in the staging 
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algorithm, such that both assessment methods 
represented the four stages precontemplation, 
contemplation, action and maintenance. An 
extensive description of the model testing using 
SEM, including the criteria used to evaluate model 
fit and the procedure for comparisons between 
models, can be found in the supplementary material 
online.	 Standardized	 regression	 coefficients	 (β)	
and corresponding standard errors (S.E.) as well as 
p-values (two-sided) are reported. 
Results
Participants and descriptive data
A total of 294 patients and 57 clinicians were included 
between May 2011 and September 2012. Patient 
characteristics are shown in Table 1. The majority 
of patients with psychotic disorders were diagnosed 
with schizophrenia (48%), schizoaffective disorder 
(16%), or psychotic disorder not otherwise specified 
(24%). In the group with primarily personality 
disorders, 40% had a borderline personality disorder, 
13% had antisocial personality disorder, and 26% 
had a personality disorder not otherwise specified. 
Most clinicians were female (63%), their mean age 
was	44	years	(SD	=	10.70)	and	they	had	a	mean	of	16	
years of clinical working experience in mental health 
services	(SD	=9.30).	
 After 12 months, 253 patients (86%) were re-
assessed. The group that was lost to follow-up was 
significantly more often of non-Dutch ethnicity (48% 
versus 26%, p<0.01) and more often had a legal 
mandate	 for	 treatment	 (18%	 versus	 7%,	 p	 =	 0.03)	
compared to completers.
 It can be seen in Table 1 that, in accordance 
with expectations, the large majority of patients 
considered themselves to be in maintenance stage 
(83%) as assessed with the staging algorithm. Table 
S2 in the supplementary material shows correlations 
between the stages of change as assessed with the 
URICA-D, processes of change and clinical outcomes, 
at two time points. 
Associations between the stages of 
change and other TTM constructs
Model 1 in Tables 2a and 2b shows the associations 
between the staging algorithm and the URICA-D for 
baseline and follow-up assessments, respectively. 
The algorithm and URICA-D showed low concordance 
for both time points (e.g. contemplation scales for 
both	instruments:	β	=	0.07,	p	=	0.38).	As	there	is	no	
Total patient sample
n = 294
Psychotic disorders
n= 199
Personality disorders
n = 95
Age, mean (SD) 44 (10.3) 43 (10.3) 45 (10.0)
Male gender, n (%) 179 (60.9) 132 (66.3) 47 (49.5)
Dutch ethnicityA, n (%) 208 (70.7) 140 (70.4) 68 (71.6)
Education level, n (%)
  - No education/elementary
  - Secondary school
  - Upper high school and over
108 (36.7)
124 (42.2)
59 (20.1)
76 (38.2)
75 (37.7)
47 (23.6)
32 (33.7)
49 (51.6)
12 (12.6)
Comorbid substance use problemsB, n (% yes) 74 (25.2) 42 (21.1) 32 (33.7)
Legal mandate, n (% yes) 24 (6.9) 13 (6.5) 11 (12.0)
One or more previous admissions, n, (% yes) 227 (77.2) 159 (79.9) 68 (71.6)
Stages of change algorithm, n (%)
  - Precontemplation
  - Contemplation
  - Preparation
  - Action
  - Maintenance
10 (3.5)
2 (0.7)
10 (3.5)
26 (9.2)
234 (83.0)
8 (4.2)
1 (0.5)
6 (3.2)
20 (10.6)
154 (81.5)
2 (2.2)
1 (1.1)
4 (4.3)
6 (6.5)
80 (86.0)
URICA, mean (SD)
  - Precontemplation
  - Contemplation
  - Action
  - Maintenance
2.6 (0.7)
3.7 (1.0)
4.0 (0.8)
3.7 (0.8)
2.6 (0.7)
3.5 (1.1)
3.9 (0.8)
3.6 (0.9)
2.4 (0.7)
4.0 (0.9)
4.1 (0.7)
3.9 (0.7)
Treatment engagement, median (IQR) 31 (24 to 36) 32 (25 to 37) 28 (24 to 35)
Psychosocial functioning, median (IQR) 9 (6 to 13) 8 (5 to 12) 10 (8 to 15)
Quality of life, median (IQR) 5 (4 to 5) 5 (4 to 5) 4 (4 to 5)
Table 1. Baseline characteristics of participating patients, stratified by primary diagnosis
Numbers may not sum to total due to missing data. 
A The definition of Dutch Ethnicity was based on the definition by the Dutch Bureau of Statistics234.
B Substance abuse problem was defined as having a DSM-IV diagnosis of substance abuse and/or dependence in the medical record.
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preparation scale on the URICA-D, it could be argued 
that this might influence the results. To address 
such concerns, we combined the preparation 
stage with the contemplation stage in the staging 
algorithm such that both assessment methods had 
four comparable stages and reran the analyses. This 
procedure resulted in similar results (not shown). 
Model 2 in Tables 2a and 2b shows the associations 
of stages of change (URICA-D and the algorithm) 
with the processes of change, decisional balance 
and self-efficacy. The URICA-D and algorithm did 
not show a similar pattern regarding associations 
with predictor variables, and the patterns were 
not similar for the two time points. Regarding the 
processes of change, only partial support was found 
for the theoretically expected associations with the 
stages. For example, the precontemplation stage 
showed no statistically significant associations with 
the processes, except for the algorithm at follow-up 
which showed negative associations with both the 
experiential and behavioural processes of change. 
Further, at baseline assessment, the URICA-D 
action and maintenance stages showed statistically 
significant associations with behavioural processes 
and non-significant associations with experiential 
processes, consistent with theory. However, this 
pattern was not seen for the algorithm nor for the 
follow-up assessment which showed mixed findings 
regarding the action and maintenance stages and 
the experiential and behavioural processes. 
 Similarly, regarding the associations with 
decisional balance variables, a differential pattern 
across stages emerged and not all associations were 
in line with theoretical expectations. For example, 
perceiving the treatment as highly suitable would 
correspond to a ‘pro’ for engaging with treatment, 
such that positive and significant associations 
with the action and maintenance stages would be 
expected. This is partly supported by our data as 
Model 1
Precontemplation
URICA-D
Contemplation
URICA-D
Action
URICA-D
Maintenance
URICA-D
β (S.E.) p-value β (S.E.) p-value β (S.E.) p-value β (S.E.) p-value
Stages 
algorithm
PRE
CON
PREP
ACT
MAIN
-0.19 (0.12)
-0.19 (0.08)
-0.13 (0.11)
-0.42 (0.18)
-0.50 (0.23)
0.13
0.02
0.20
0.02
0.03
-0.02 (0.09)
0.07 (0.08)
0.29 (0.10)
0.29 (0.11)
0.43 (0.12)
0.81
0.38
<0.01
<0.01
<0.01
0.01 (0.08)
0.02 (0.05)
-0.04 (0.08)
-0.02 (0.14)
0.11 (0.20)
0.92
0.74
0.58
0.86
0.59
-0.07 (0.11)
-0.01 (0.05)
0.06 (0.13)
0.05 (0.18)
0.10 (0.19)
0.55
0.92
0.64
0.80
0.62
Model 2
Precontemplation
URICA-D & algorithm
Contemplation
URICA-D & algorithm
Action
URICA-D & algorithm
Maintenance
URICA-D & algorithm
β (S.E.) p-value β (S.E.) p-value β (S.E.) p-value β (S.E.) p-value
Exp proc -0.03 (0.15) & -0.09 (0.14) 0.82 &0.49 0.13 (0.07) & 0.16 (0.08) 0.05 & 0.03 0.08 (0.08) & 0.02 (0.04) 0.28 & 0.63 0.10 (0.09) & -0.14 (0.07) 0.25 & 0.04
Beh proc 0.03 (0.10) & 0.11 (0.08) 0.74 &0.15 0.26 (0.09) & 0.03 (0.05) <0.01 &0.48 0.23 (0.07) & 0.09 (0.08) <0.01&0.24 0.17 (0.06) & -0.05 (0.08) <0.01 & 0.54
Problem rec
- Middle
- High
-0.17 (0.07)& -0.17 (0.05)
-0.13 (0.08) & -0.12 (0.07)
0.02 &0.01
0.09 &0.09
0.43 (0.07) & 0.08 (0.07)
0.53 (0.09) & 0.15 (0.06)
<0.01 &0.24
<0.01&0.01
0.05 (0.07) & -0.06 (0.05)
0.15 (0.08) & -0.05 (0.08)
0.48 & 0.30
0.05 & 0.49
0.30 (0.07) & 0.15 (0.06)
0.37 (0.08) & 0.05 (0.09)
<0.01 & 0.01
<0.01 & 0.61
Distress
- Middle
- High
-0.02 (0.04) & 0.03 (0.08)
-0.26 (0.09) & -0.04 (0.03)
0.64 &0.75
<0.01 &0.12
0.18 (0.06) & -0.03 (0.06)
0.18 (0.07) & -0.07 (0.09)
<0.01 &0.61
<0.01 &0.43
0.02 (0.06) & -0.04 (0.08)
0.03 (0.08) & 0.06 (0.09)
0.78 & 0.59
0.74 & 0.50
0.26 (0.06) & 0.07 (0.06)
0.18 (0.07) & 0.04 (0.07)
<0.01 & 0.20
<0.01 & 0.56
Ext pressure 
- Middle
- High
-0.11 (0.09) & 0.04 (0.07)
-0.12 (0.12) & 0.10 (0.08)
0.26 &0.52
0.30 &0.19
-0.16 (0.07) & -0.04 (0.07)
-0.02 (0.08) & -0.17 (0.08)
0.03 & 0.60
0.85 & 0.02
-0.03 (0.05) & -0.05 (0.05)
0.07 (0.05) & -0.04 (0.09)
0.63 & 0.34
0.18 & 0.68
0.04 (0.07) & 0.08 (0.07)
0.17 (0.07) & 0.09 (0.12)
0.61 & 0.20
0.01 & 0.43
Costs treat
- Middle
- High
0.10 (0.08) & -0.04 (0.06)
0.03 (0.04) & 0.23 (0.15)
0.20 &0.50
0.47 &0.13
-0.00 (0.06) & -0.05 (0.06)
-0.00 (0.05) & -0.06 (0.02)
0.95 & 0.43
0.96 &<0.01
0.04 (0.06) & 0.08 (0.07)
0.09 (0.04) & -0.03 (0.01)
0.52 & 0.28
0.04 & 0.01
-0.04 (0.06) & 0.03 (0.07)
-0.02 (0.04) & -0.01 (0.07)
0.54 & 0.62
0.58 & 0.87
Suitab treat
- Middle
- High
0.10 (0.10) & -0.09 (0.13)
0.19 (0.06) & -0.13 (0.11)
0.34 &0.51
<0.01 &0.26
0.08 (0.08) & -0.14 (0.08)
0.03 (0.08) & -0.25 (0.08)
0.32 &0.08
0.71 &0.01
0.16 (0.07) & 0.09 (0.07)
0.23 (0.08) & 0.05 (0.10)
0.03 & 0.19
<0.01&0.62
 
0.05 (0.07) & 0.12 (0.07)
0.08 (0.09) & 0.21 (0.08)
0.51 & 0.07
0.36 & 0.01
Self-efficacy
- Middle
- High
-0.11 (0.09) & -0.09 (0.11)
-0.37 (0.12) & -0.08 (0.09)
0.23 &0.38
<0.01 &0.35
-0.03 (0.08) & -0.01 (0.11)
-0.11 (0.08) & 0.05 (0.16)
0.73 & 0.94
0.16 & 0.73
0.04 (0.09) & 0.12 (0.05)
0.24 (0.10) & -0.04 (0.05)
0.65 & 0.02
0.02 & 0.35
-0.11 (0.10) & 0.01 (0.06)
-0.18 (0.14) & 0.09 (0.07)
0.25 & 0.89
0.20 & 0.25
Table 2a. Identification of the stages of change at baseline assessment
β	 =	 standardized	 regression	 coefficient.	 S.E.	 =	 standard	 error	 of	 standardized	 regression	 coefficient.	 PRE	 =	 precontemplation,	 CON	 =	 contemplation,	 
ACT	=	action,	MAIN	=	maintenance,	Exp	proc	=	experiential	processes,	Beh	proc	=	behavioural	processes,	Problem	rec	=	problem	recognition,	Ext	pressure	
=	external	pressure,	Costs	treat	=	perceived	costs	of	treatment,	Suitab	treat	=	perceived	suitability	of	treatment.	Boldface	indicates	p<0.05. 
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demonstrated by the significant positive associations 
with the URICA-D action scale at baseline and the 
algorithm maintenance scale at follow-up. However, 
the significant positive association between 
high suitability of treatment and the URICA-D 
precontemplation at follow-up, as well as the non-
significant associations for the URICA-D action and 
maintenance with suitability of treatment at follow-
up, were not in line with theoretical expectations. 
Also, the patient’s self-reported problem recognition 
showed negative associations with URICA-D 
precontemplation and positive associations with 
URICA-D contemplation and maintenance stages, 
which was consistent with expectations, but this 
pattern was less evident for the algorithm.
 High levels of self-reported treatment-related 
self-efficacy showed theoretically expected negative 
associations with URICA-D precontemplation and 
positive associations with URICA-D action at both 
time points, but not with the maintenance stages 
(as reflected by non-significant associations for both 
methods at both time points). 
Associations between stages of change 
and clinical outcomes
Table S2 in the supplementary material shows 
Spearman correlations between the stages of 
change as assessed with the URICA-D and clinical 
outcomes, at two time points. In sum, it was found 
that the URICA-D action stage showed positive and 
statistically significant association with treatment 
engagement	 at	 all	 time	 points	 (ranging	 from	 r	 =	
0.14	to	r	=	0.31),	whereas	the	other	stages	showed	
mixed findings (e.g. maintenance was negatively 
associated with treatment engagement at baseline, 
but positively at follow-up). Analyses of variance 
were conducted to investigate relationships 
between the stages as assessed with the algorithm 
and all clinical outcomes, at two time points. Figure 
S1 in the supplementary material shows means for 
Model 1
Precontemplation
URICA-D
Contemplation
URICA-D
Action
URICA-D
Maintenance
URICA-D
β (S.E.) p-value β (S.E.) p-value β (S.E.) p-value β (S.E.) p-value
Stages 
algorithm
PRE
CON
PREP
ACT
MAIN
0.01 (0.09)
-0.13 (0.08)
-0.15 (0.10)
-0.40 (0.18)
-0.16 (0.19)
0.91
0.08
0.12
0.03
0.40
-0.11 (0.12)
0.20 (0.09)
0.22 (0.08)
0.50 (0.17)
0.34 (0.20)
0.33
0.03
<0.01
<0.01
0.09
-0.09 (0.08)
-0.09 (0.07)
-0.03 (0.08)
0.15 (0.15)
0.26 (0.17)
0.27
0.19
0.74
0.33
0.12
-0.07 (0.09)
0.13 (0.07)
0.31 (0.08)
0.51 (0.13)
0.38 (0.16)
0.42
0.06
<0.01
<0.01
0.02
Model 2
Precontemplation
URICA-D & algorithm
Contemplation
URICA-D & algorithm
Action
URICA-D & algorithm
Maintenance
URICA-D & algorithm
β (S.E.) p-value β (S.E.) p-value β (S.E.) p-value β (S.E.) p-value
Exp proc -0.17 (0.11) & -0.14 (0.06) 0.14 & 0.03 0.60 (0.07) & 0.04 (0.06) <0.01 & 0.53 0.05 (0.07) & 0.22 (0.08) 0.47 & 0.01 0.48 (0.09) & -0.12 (0.07) <0.01 & 0.07
Beh proc 0.05 (0.08) & -0.10 (0.04) 0.82 & 0.02 0.05 (0.08) & -0.03 (0.07) 0.50 & 0.71 0.44 (0.06) & -0.15 (0.04) 0.00&<0.01 0.06 (0.11) & 0.27 (0.09) 0.58 &<0.01
Problem rec
- Middle
- High
-0.11 (0.23) & -0.04 (0.07)
-0.22 (0.09) & 0.04 (0.08)
0.39 & 0.53
0.01 & 0.62
0.28 (0.07) & 0.07 (0.07)
0.32 (0.07) & 0.06 (0.08)
<0.01 & 0.36
<0.01 & 0.46
0.05 (0.03) & 0.06 (0.07)
0.16 (0.13) & 0.17 (0.08)
0.12 & 0.41
0.23 & 0.03
0.14 (0.07) & 0.03 (0.05)
0.31 (0.08) & -0.18 (0.07)
0.03 & 0.53
<0.01 & 0.01
Distress
- Middle
- High
-0.23 (0.08) & 0.09 (0.06)
-0.42 (0.11) & 0.04 (0.06)
<0.01 & 0.12
<0.01 & 0.45
0.09 (0.07) & -0.04 (0.06)
0.14 (0.05) & 0.15 (0.08)
0.16 & 0.51
0.01 & 0.06
0.16 (0.08) & -0.04 (0.03)
0.02 (0.08) & 0.02 (0.09)
0.05 & 0.19 
0.77 & 0.87
0.12 (0.04) & 0.06 (0.06)
0.03 (0.09) & 0.03 (0.06)
<0.01 & 0.33
0.78 & 0.62
Ext pressure 
- Middle
- High
0.01 (0.09) & -0.16 (0.06)
-0.10 (0.08) & -0.14 (0.04)
0.96 & 0.01
0.23 & <0.01
-0.06 (0.11) & 0.03 (0.08)
0.05 (0.07) & 0.11 (0.10)
0.60 & 0.71
0.48 & 0.26
0.01 (0.08) & -0.01 (0.04)
-0.04 (0.07) & 0.08 (0.08)
0.86 & 0.90
0.60 & 0.32
0.06 (0.09) & 0.05 (0.07)
0.15 (0.06) & -0.04 (0.08)
0.54 & 0.51
0.01 & 0.62
Costs treat
- Middle
- High
0.00 (0.07) & 0.04 (0.06)
-0.07 (0.08) & -0.01 (0.01)
0.98 & 0.46
0.34 & 0.37
-0.17 (0.07) & 0.05 (0.09)
0.04 (0.06) & 0.07 (0.13)
0.01 & 0.57
0.51 & 0.57
-0.12 (0.06) & -0.17 (0.05)
0.03 (0.03) & -0.10 (0.03)
0.07&<0.01
0.36&<0.01
-0.15 (0.05) & 0.10 (0.07)
0.07 (0.03) & -0.07 (0.05)
<0.01 & 0.17
0.04 & 0.16
Suitab treat
- Middle
- High
0.05 (0.10) & -0.09 (0.10)
0.08 (0.14) & -0.03 (0.10)
0.60 & 0.38
0.54 & 0.77
-0.12 (0.07) & -0.33 (0.11)
-0.07 (0.14) & -0.35 (0.14)
0.10 & <0.01
0.63 & 0.02
0.02 (0.08) & -0.08 (0.10)
0.04 (0.12) & -0.10 (0.11)
0.76 & 0.46
0.76 & 0.24
-0.12 (0.07) & 0.24 (0.10)
-0.10 (0.12) & 0.21 (0.08)
0.09 & 0.01
0.42 & 0.01
Self-efficacy
- Middle
- High
-0.26 (0.07) & 0.10 (0.10)
-0.46 (0.12) & 0.03 (0.09)
<0.01 & 0.33
<0.01 & 0.76
0.10 (0.07) & 0.03 (0.04)
0.10 (0.12) & 0.05 (0.08)
0.19 & 0.42
0.44 & 0.53
0.05 (0.07) & -0.10 (0.11)
0.25 (0.06) & -0.09 (0.11)
0.47 & 0.37
<0.01&0.39
0.02 (0.08) & 0.00 (0.08)
0.05 (0.14) & 0.07 (0.10)
0.77 & 0.99
0.70 & 0.48
Table 2b. Identification of the stages of change at follow-up assessment
β	=	standardized	regression	coefficient.	S.E.	=	standard	error	of	standardized	regression	coefficient.	PRE	=	precontemplation,	CON	=	contemplation,	ACT	
=	action,	MAIN	=	maintenance,	Exp	proc	=	experiential	processes,	Beh	proc	=	behavioural	processes,	Problem	rec	=	problem	recognition,	Ext	pressure	=	
external	pressure,	Costs	treat	=	perceived	costs	of	treatment,	Suitab	treat	=	perceived	suitability	of	treatment.	Boldface	indicates	p<0.05.
118
Chapter 7 } A test of the Stages of Change from the TTM
all outcome variables across the stages of change at 
both timepoints. For the staging algorithm, it was 
found that patients in precontemplation showed 
statistically significantly lower treatment engagement 
at baseline compared to patients in maintenance 
(mean	 difference	 =	 7.73,	 95%	CI	 =	 -15.03	 to	 -0.43,	
p	=	0.03),	whereas	no	other	stages	were	statistically	
different from each other at baseline and none of 
the stages showed statistically significant differences 
at follow-up regarding treatment engagement. 
Similarly, no statistically significant differences were 
found between the stages regarding psychosocial 
functioning and quality of life at baseline. At follow-
up, theoretically unexpected differences were found 
between precontemplation and the higher stages, 
such that patients in precontemplation showed 
better psychosocial functioning compared to those 
in	contemplation	and	action	(mean	difference	=	8.66,	
95%CI	=	14.79	to	2.52,	p<0.01	and	mean	difference	
=	6.34,	95%CI	=	11.24	to	1.45,	p<0.01,	respectively).	
In line with theory, patients in the maintenance 
stage showed statistically significant higher quality 
of life at follow-up compared to patients in stages 
of	contemplation	 (mean	difference	=	1.05,	95%CI	=	
0.27	to	1.82,	p<0.01)	and	action	(mean	difference	=	
0.80,	95%CI	=	0.35	to	1.26,	p<0.01).	
 Subsequently, the hypothesized model as 
depicted in Figure 2 was fitted to the data at baseline 
and at follow-up, for both the staging algorithm and 
the URICA-D. The extensive results of the model 
fitting are presented in the supplemental material 
(Tables S3 and S4). Both for the staging algorithm 
and the URICA-D, the model in Figure 2 provided 
borderline fit to the data at both time points. Model 
fit improved somewhat when stages were regressed 
onto the previous stage, as shown in Figure 3. This 
model was therefore retained for further analyses. 
Despite the potential for further improvements of 
model fit, it was decided not to include additional 
paths between stages and clinical outcomes of 
psychosocial functioning and quality of life, as this 
was not in line with theory. 
Testing the stability of the theoretical 
model across time and diagnostic 
groups
The model shown in Figure 3 was tested for stability 
across time and patient diagnostic groups (i.e. 
psychotic disorders and personality disorders), for 
both the staging algorithm and URICA-D, by testing 
the invariance of the paths in the model across the 
two measurement occasions. The extensive results 
of these model comparisons are presented in the 
supplemental material (see Table S4). For both the 
staging algorithm and the URICA-D, it was found 
that the models were invariant (i.e. not statistically 
significantly different) across time and across patient 
diagnostic groups at both time points.
 Figure 3 shows the associations that were found 
between stages, treatment engagement and clinical 
outcomes for both the URICA-D and the staging 
algorithm for the two time points (using the model 
in which these paths were restricted to be equal 
for both time points). It can be seen that both the 
strength and direction of the associations between 
adjacent stages and between stages and treatment 
engagement were not similar for the two assessment 
methods. For example, the precontemplation 
stage of the algorithm showed no associations 
with contemplation and treatment engagement, 
whereas the URICA-D precontemplation showed 
statistically significant negative associations with 
these factors. Further, it can be seen that the staging 
algorithm shows negative associations between 
adjacent stages, whereas the URICA-D shows a 
negative association between precontemplation and 
contemplation but otherwise positive associations 
between adjacent stages. Finally, the associations 
between stages and treatment engagement were 
such that these were increasingly positive for higher 
stages in the staging algorithm, which was in line 
with theoretical expectations, whereas the URICA-D 
showed negative associations for precontemplation 
and contemplation and positive associations for 
action and maintenance with treatment engagement, 
which was not completely in line with theoretical 
expectations. 
Variance explained by the models
It can be seen in Table 3 that the obtained process 
models for the staging algorithm explained around 
7% of treatment engagement, while the URICA-D 
model explained between 6% to 16% of treatment 
engagement. Both methods of assessment explained 
between 8% to 17% of psychosocial functioning and 
between 5% to 15% of quality of life, depending on 
the timing of the assessment.
Discussion
The purpose of the current study was to investigate 
the validity of the TTM stages for motivation to 
participate in psychiatric treatment. Specifically, 
two popular methods of stage assessment, a staging 
algorithm and the URICA-D, were assessed for 
convergent and criterion validity using other TTM 
constructs and treatment engagement. 
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Contemplation
Precontemplation
Psychosocial
functioning
Quality of lifeAction
Maintenance
Treatment
engagement
0.12
/0.1
6
0.15
/0.2
1
0.
17
/0
.2
6
0.
14
/0
.1
9
0.08/0.09
-0.27/-0.37
0.00/0.00
-0.12/-0.15
0.3
4/0
.35
0.3
4/0
.34
0.34/0.27
0.34/0.27
-0.02/-0.03 -0.37/-0.36
-0.06/-0.05 0.44/0.41
-0.62/-0.52 0.11/0.12
Figure 3. Testing the stages of change (using the staging algorithm and the URICA-D) across time on clinical outcomes of treatment 
engagement, psychosocial functioning and quality of life
Note: The figure represents Model 3b, with all regression coefficients restraint for the corresponding measurements at baseline 
and follow-up (i.e. indicating that these are invariant across time). Numbers represent standardized regression coefficients for the 
corresponding path (baseline / follow-up) for the staging algorithm (left of arrows and above the arrows) and for the URICA-D (right of 
arrows and below the arrows). For clarity, the correlations between the stages and between psychosocial functioning and quality of life 
are not shown. 
Model Variance explained (R2)
Treatment engagement Psychosocial functioning Quality of life
Staging algorithm Baseline 0.07 0.16 0.15
Follow-up 0.07 0.08 0.05
URICA-D Baseline 0.06 0.17 0.15
Follow-up 0.16 0.08 0.05
Table 3. Variances explained by the stages of change in clinical outcomes
Boldface indicates p<0.05 (two-tailed). 
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Key findings and interpretation
It was found that the stages, as assessed by two 
standard TTM measures namely a staging algorithm 
and the URICA-D, only partially showed the 
theoretically expected associations with processes 
of change, decisional balance and self-efficacy. That 
is, the stages could neither be uniquely identified 
using the factors proposed by the authors of TTM, 
namely the processes and markers of change, nor 
with external factors such as treatment engagement 
behaviour. Findings were mixed regarding the 
associations between stages and clinical outcomes, 
for both assessment methods, such that the 
majority of the theoretically expected associations 
were not confirmed. Thus, these results point to 
problems in the applicability of staging measures to 
the engagement of patients with SMI in outpatient 
psychiatric treatment. These problems may be 
ascribed to the staging measures itself, to the 
population and/or study sample in which they 
were used, to the underlying theoretical model or a 
combination of these. 
 Regarding the measures it should be noted 
that, even though the current study did not set 
out to evaluate reliability of these two commonly 
used staging methods, there were reliability issues 
for the URICA-D. Only the action scale showed an 
acceptable level of internal consistency, whereas 
the other scales showed poor to questionable 
internal consistencies. An inspection of the item 
statistics and inter-item correlations did not reveal 
specific items that could be eliminated to improve 
consistency. Rather, inter-item correlations were 
generally in the low range overall, implying that the 
items within each subscale did not reflect the same 
underlying construct. It is plausible that the generic 
problem statement ‘willingness to change psychiatric 
problems during outpatient treatment’ was too 
broad, such that patients with different types of 
psychiatric problems and different treatments (e.g. 
with or without medication, additional supportive 
employment, volunteer work opportunities etc.) may 
have had different response tendencies, resulting in 
problems with internal consistency. This possibility 
should be investigated in future studies using more 
homogenous psychiatric patient groups who present 
with similar problems for which they receive similar 
treatments . Even so, it has previously been argued 
that the use of the stage construct in clinical practice 
for patients with SMI is problematic, as these patients 
typically present with multiple problems whereas 
the stage construct seems to require “that central, 
one and only, specifically identified problem” 113 (p. 
54). The current study results seem to affirm these 
problems. Alternatively, studies using the URICA 
in other populations have shown higher internal 
consistencies, such as in patients in methadone 
maintenance treatment 232 and dually diagnosed 
patients 57,101, which may imply that the use of the 
URICA is more suited for treatment settings which 
specifically focus on addiction problems in psychiatric 
outpatients rather than the psychiatric problems 
itself. However, despite showing more acceptable 
internal consistencies in such populations, the URICA 
was found to have questionable external validity in 
those patient groups as well 101,232. 
 A limitation to the current study is that the 
study sample was largely representative of patients 
who were already well engaged with treatment 
services. This has impacted the range of scores on 
the URICA-D and the frequency distributions on 
the algorithm, such that we were likely limited in 
our ability to adequately model the earlier stages 
as numbers of patients were small. Nevertheless, it 
was expected that, in a population of patients who 
receive assertive outreaching psychiatric care, a 
distinction between patients in contemplation and 
those in maintenance should be possible (if these 
stages are indeed present and are a ‘real’ entity). 
However, the results suggest that – at least in so far 
as these stages are assessed with the algorithm or 
the URICA – the stages are difficult to distinguish 
from each other and therefore may not constitute 
clinically identifiable separate stages regarding 
readiness to engage with treatment. Minimally, 
this casts doubt on the potential utility of the stage 
construct from TTM as a framework for motivation 
for engaging with treatment considering that the 
processes, markers and outcomes that are supposed 
to be capable of distinguishing the stages do not 
do so. Acknowledging that the cross-sectional 
design of the current study is limited in its ability to 
identify stages from pseudo-stages or a (nonlinear) 
continuum model 77, the findings of the current 
study do not seem to support a stage theory. 
 Regarding the comparison between the 
algorithm and URICA-D, it was found that the 
algorithm and URICA-D showed low concordance 
and related differently to the processes and 
markers of change. These findings were contrary 
to theoretical expectations but consistent with 
previous TTM-literature 88,232, and suggests that the 
algorithm and URICA-D assess different aspects of 
motivation to engage with psychiatric treatment. 
Their use in research and clinical practice is therefore 
not interchangeable. Furthermore, although both 
assessment methods showed stable associations with 
treatment engagement and clinical outcomes over 
time and across different patient groups, they show 
limited predictive validity as shown by explained 
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variances of 6% to 16% in treatment engagement. 
Of the two methods tested in the current study, the 
algorithm showed the least and weakest theoretically 
expected associations with processes and markers of 
change and with treatment engagement. The results 
for the URICA-D were more in line with theoretical 
assumptions regarding associations with processes 
and markers of change, yet also provided limited 
explanatory power regarding treatment engagement 
behaviour. 
 Taken together, these findings reveal important 
problems in the applicability of staging measures to 
the engagement of patients with SMI in outpatient 
psychiatric treatment, and currently do not support 
their use for such purposes in clinical practice. 
This implies that there remains a need for reliable 
and valid instruments to assess the stages of 
change for engaging with psychiatric services. Such 
staging instruments should be (constructed and) 
evaluated in future studies, such that these can be 
a foundation for further research into the utility of 
the TTM in psychiatric treatment services. Until such 
reliable and valid assessments for the patient’s stage 
of change for engaging with psychiatric services 
are available, essential questions regarding the 
potential utility of the TTM in this context cannot be 
adequately addressed. 
Strengths and limitations
Strengths of the current study include the 
assessment of several central components of the 
TTM (i.e. stages, processes and markers of change) 
and the assessment of the stages by two methods, 
the correction for unreliability of measurements, 
a relatively large sample size considering the often 
difficult to engage SMI patient population, multiple 
centers in the study and the longitudinal component 
which allowed for testing at two time points. 
Further, the current study is novel in its approach 
of testing specific TTM hypotheses in a population 
of outpatients with SMI regarding their motivation 
for engaging with treatment services, and clinically 
relevant considering the widespread use and 
popularity of the model in clinical practice.
 Besides the limitations mentioned previously, 
there are several others that deserve recognition. 
The correlational design provides limited ability to 
decide whether processes and markers of change 
are predictive of the stages of change and also 
whether the stage construct actually predicts 
treatment engagement behaviour. Nevertheless, 
correlational designs are usually considered as 
biasing the results towards overestimations of the 
accuracy of constructs within theories 77, whereas 
the current study found limited and weak support 
for the associations between constructs of the TTM, 
while using instruments that were context-specific 
and similar to standard questionnaires developed 
by the originators of the TTM. Further, although 
the current data provided a possibility to perform 
analyses on transitions in stages and to potentially 
evaluate the predictive validity of baseline stages on 
subsequent treatment engagement, it was chosen 
not to do so because it is plausible to argue that the 
long interval between stage assessments, 12 months, 
is not suitable for evaluating (frequently occurring) 
stage movements and would be responsible for 
the lack of association between predictor variables 
and (movement) of stages. Rather, experiments 
including random assignments using theoretical 
constructs that are each manipulated separately 
yield the least ambiguous results and conclusions 
77, which for the TTM would involve manipulating 
the processes of change in a stage-matched versus 
stage-mismatched manner to evaluate the effects 
on health behaviour changes 54. However, the few 
studies to date that have attempted to do so, have 
found little support for the superiority of matched 
over mismatched interventions 235-237, suggesting 
that the studies showing beneficial effects for 
TTM-based interventions compared to other 
types of interventions may be a consequence of 
other mechanisms and characteristics of the TTM-
interventions, but not a consequence of stage-
matching. 
 As noted previously, the earlier stages (such 
as precontemplation and contemplation) were 
underrepresented in our current research sample, 
while patients with relatively high levels of motivation 
for treatment were over-represented in our sample. 
This is a common limitation in psychotherapy 
research 238, which shows an absence of studies 
conducted among people with SMI who do not 
receive mental health treatment. Consequently, the 
results of the current study may not be generalizable 
to the entire population of outpatients with SMI, 
in particular those patients who are not in contact 
with services and to those who are more ambivalent 
or hesitant to engage with psychiatric treatment 
services. 
 Another limitation to the current study is the 
possibility of model misspecification and/or omitted 
variables. Misspecification of the model may have 
occurred due to misspecification of the relations 
between the stages and treatment engagement. 
Although efforts were made to compare different 
structural models and to include essential constructs 
of TTM such that a model was derived which was 
most plausible considering both theory and data, 
the final model that was tested may not have been 
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the most accurate or complete structural model 
for testing the effects of TTM stages of change on 
treatment engagement. For example, the merging 
of the stages preparation and contemplation into 
one stage using the algorithm, was done to increase 
comparability with the URICA-D models (and the 
limited number of patients in this stage also limited 
our ability to test the model on this stage) but is 
essentially not in line with a theory of five stages. 
Regarding omitted variables, it should be noted that 
the current study did test the ‘complete’ process 
model of TTM, as this was not feasible with the 
current data. Variables such as the ten different 
processes of change, self-efficacy, temptation and 
all five stages may be incorporated into larger and 
more complete SEM-analyses to test essential TTM 
process models, including hypotheses regarding the 
progression from one stage to another. 
Conclusion and implications
Current popular methods for assessing stages of 
change, namely the staging algorithm and the 
URICA, were found to show low convergence 
regarding motivation to engage with psychiatric 
treatment and thus seem to assess different aspects 
of it. Also, both measures generally did not show the 
expected associations with other TTM constructs 
nor were the associations between stages and 
other TTM constructs consistent across two time 
points. Regarding associations between stages and 
treatment engagement, these were consistent across 
time and different patient diagnostic groups, but the 
stages showed limited ability to explain treatment 
engagement behaviour and generally did not show 
the theoretically expected differentiation between 
stages and the mean level of treatment engagement. 
When using existing measures to assess the TTM 
constructs, it seems that we still lack empirical 
support for the validity of the stage construct of 
the TTM model as a way of evaluating the patient’s 
motivation for engaging with the treatment services. 
This is problematic, as the potentially unique and 
useful contribution that the TTM can bring to the 
psychiatric treatment of patients with SMI, can 
only be adequately studied if we can reliably and 
validly assess its main constructs. The current 
study underscores the need for such measures. It 
has been noted that, although the TTM has been 
challenged for its theoretical coherence, it “remains 
one of the few attempts to operationalize different 
change strategies within a common paradigm” 238. 
The questions that TTM raises remain important for 
clinical practice, including whether there are critical 
periods during which specific intervention strategies 
should be applied to facilitate treatment engagement 
and improve clinical outcomes for patients with SMI. 
Future studies should therefore aim to (develop and) 
test other methods of stage assessment, to provide a 
foundation for further research into the utility of the 
TTM in psychiatric treatment services for patients 
with SMI. 
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The effects of Motivation 
Feedback in patients with 
severe mental illness: 
a cluster randomized 
controlled trial
Jochems, E.C., van der Feltz-Cornelis, C.M., van Dam, A., 
Duivenvoorden, H.J., Mulder, C.L. 2015. The effects of 
motivation feedback in patients with severe mental illness: 
a randomized controlled trial. Neuropsychiatric Disease and 
Treatment, 11, 3049-3064. 
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Objective
To evaluate the effectiveness of providing clinicians 
with regular feedback on the patient’s motivation 
for treatment in increasing treatment engagement 
in patients with severe mental illness (SMI).
Methods
Design: Cluster randomised controlled trial (Dutch 
Trials Registry NTR2968). Participants: adult 
outpatients with a primary diagnosis of a psychotic 
disorder or a personality disorder and their clinicians, 
treated in 12 community mental health teams (the 
clusters) of two mental health institutions in the 
Netherlands. Interventions: monthly motivation 
feedback (MF) generated by clinicians additional to 
treatment as usual (TAU) and TAU by the community 
mental health teams. Primary outcome: treatment 
engagement at patient level, assessed at 12 months 
by clinicians. Randomisation: teams were allocated 
to MF or TAU by a computerized randomization 
program that randomized each team to a single 
treatment by blocks of varying size. All participants 
within these teams received a similar treatment.
Results
The 294 randomized patients (148 MF, 146 TAU) 
and 57 clinicians (29 MF, 28 TAU) of 12 teams 
(6 MF, 6 TAU) were analysed according to the 
intention to treat principle. No statistically 
significant differences between treatment groups on 
treatment engagement were found (adjusted mean 
difference=0.1,95%CI=-2.2	 to	 2.3,p=0.96,d=0.00).	
Pre-planned ancillary analyses showed statistically 
significant interaction effects between treatment 
group and primary diagnosis on treatment 
motivation and quality of life (secondary outcomes), 
which were beneficial for patients with a primary 
diagnosis of a personality disorder but not for those 
with a psychotic disorder. There were no reports of 
adverse events.
Conclusion
The current findings imply that monitoring and 
discussing the patient’s motivation is insufficient to 
improve motivation and treatment engagement, and 
suggests that more elaborate interventions for SMI 
patients are needed.
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Introduction
Background
A common consideration in clinical practice is that 
evaluation of the patient’s motivation may help to 
understand how a patient may best be engaged in 
treatment 29,35-37,228. Patients with severe mental 
illness (SMI), such as those with psychotic disorders 
or severe personality disorders, are often considered 
not motivated to seek treatment 239 or fail to adhere 
to treatment programs 240,241. Regular assessment of 
motivation for engaging in treatment and providing 
this as feedback to the clinician might be a promising 
approach to both monitor the patient’s motivation 
and provide a useful structure in the communication 
about it. Such communication may help to improve 
motivation for treatment and treatment engagement 
197. Meta-analyses have shown beneficial effects of 
employing feedback to clinicians on their patients’ 
mental health outcomes 39,49,242. However, most 
clinician feedback research has focused primarily 
upon treatment outcomes 154,243-245 and was unable 
to determine which specific elements from the 
feedback provided the mechanism(s) of action. 
Motivation for treatment has been used as part of 
such feedback systems, yet to our knowledge and 
based on an extensive review 39, no previous study 
has investigated the effects of providing feedback 
that is exclusively based on the SMI patient’s 
motivation for treatment. This warrants the current 
investigation. 
 The theoretical basis of the motivation 
feedback (MF) intervention was founded on Self-
Determination Theory (SDT); a theory of motivation 
that defines several types of motivation that fall along 
a continuum of self-determination and describes 
how social and cultural factors can facilitate or 
undermine people’s sense of self-determination 
48,65. SDT states that the most externally determined 
form of treatment motivation is when a patient 
remains in treatment because he feels pressured to 
do so 65. This external motivation could, for example, 
be present in a patient who is court-ordered into 
treatment 129. Also relatively external yet somewhat 
more autonomous is introjected motivation, where 
a patient is driven by feelings of guilt or shame. A 
patient with introjected motivation might act to avoid 
disapproval or guilt or receive approval or praise 
(eg from the mental health worker or important 
others). More autonomous motivation is present in 
a patient with identified motivation, who recognizes 
and accepts that treatment is useful for achieving 
personally relevant goals 65. An example is a patient 
who finds it important to take medications as a way 
of preventing relapse. According to SDT, engaging 
in treatment for a long time requires that patients 
internalize treatment values since behaviours that 
are more autonomous (ie more self-determined) 
are more likely to be performed again, whereas 
behaviours that are primarily driven by external 
motives will only be performed in the presence of 
such perceived external pressures 65,82.
Objectives and hypothesis
The current study aimed to evaluate the 
effectiveness of a motivation feedback (MF) 
intervention compared to treatment as usual (TAU) 
in outpatients with SMI treated by community 
mental health teams. It was hypothesized that 
SDT-based MF would lead to increased treatment 
engagement (primary outcome), and to a beneficial 
shift in the SDT motivation continuum towards more 
autonomous motivation and improved psychosocial 
functioning and quality of life (secondary outcomes) 
in outpatients with SMI. 
Methods
Trial Design and ethics statement
The current study was a two-center cluster randomized 
trial	 comparing	 Motivation	 Feedback	 (MF)	 to	
treatment	as	usual	(TAU).	Cluster	randomization	was	
chosen	 to	 avoid	 contamination	 bias246. The full trial 
protocol is available elsewhere 197.	Briefly,	the	cluster	
randomized controlled trial was designed with the 
primary	objective	to	determine	the	effectiveness	of	a	
Motivation	Feedback	(MF)	intervention	on	treatment	
engagement	 (primary	 outcome)	 of	 outpatients	
with	 psychotic	 disorders	 and	 personality	 disorders,	
compared to treatment as usual (TAU) in community 
mental health care teams (the clusters). Secondary 
outcomes	include	treatment	motivation,	psychosocial	
functioning	and	quality	of	life.	The	specific	aspects	of	
the	broader	trial	design,	including	details	of	settings,	
interventions, randomization and blinding, are 
addressed in the following paragraphs. Discrepancies 
between the original protocol and the current report 
are described under methods and results; these 
included the handling of skewed outcomes in the 
statistical analyses and the smaller sample size due 
to lower than expected recruitment rate. 
 The current study was approved by the 
Medical Ethical Committee for Mental Health Care 
Institutions (MotivaTe-IT; trial number NTR2968, 
Netherlands Trial Register, http://www.trialregister.
nl/trialreg/admin/rctview.asp?TC=2968)	 as	 well	
as by the scientific committees of the Western 
North Brabant Mental Health Center and Breburg 
Mental Health Center, the speciality mental health 
institutions where the data were collected. The 
authors confirm that all ongoing and related trials 
for this intervention are registered. All procedures 
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were conducted according to the principles 
expressed in the Declaration of Helsinki, including 
the obtainment of written informed consent by the 
participants. Results are presented in accordance 
with the CONSORT statement for cluster randomised 
controlled trials.247.
Setting and participants
The current study was initiated by GGZ Westelijk 
Noord Brabant, a specialty mental health center 
located in a semi-urban area in the south west of the 
Netherlands. GGz Breburg, another specialty mental 
health center in the same semi-urban area, was also 
approached and agreed to join the study. 
 Within these two centers, patients were eligible 
for participation if they had a primary diagnosis of 
a psychotic disorder or a personality disorder (as 
diagnosed by the psychiatrist of the team using the 
DSM-IV-R criteria and obtained from the medical 
record), were aged between 18 and 65 years old 
and received individual outpatient treatment 
for their mental disorder. Exclusion criteria were 
an insufficient command of the Dutch language 
(which was estimated by the clinician who was 
most frequently involved with the patient), and a 
documented diagnosis of dementia or chronic toxic 
encephalopathy. 
 Treatment teams were eligible for participation 
if they provided outpatient assertive community 
mental health care to eligible patients. At the start 
of the study, 12 teams of the two mental health 
centers fulfilled this criterion and were approached 
for participation. Specifically, these teams included 
a forensic psychiatric outpatient clinic, three 
specialized psychotic outpatient treatment programs 
and eight function-assertive community treatment 
teams (FACT-teams 14). FACT-teams provide assertive, 
outreaching, community-based, and supportive 
psychiatric services to individuals with SMI 14. 
Clinicians within the approached teams were eligible 
for participation if they were the primary health care 
practitioner involved with the patient, meaning that 
this clinician had the most frequent contacts with 
the patient. All twelve teams agreed to participate 
in the study and as such, the trial was conducted 
within these teams between May 2011 and October 
2013. 
Interventions: Treatment as Usual 
and Motivation Feedback
Treatment as usual (TAU)
In the TAU group (consisting of six teams or clusters), 
treatment was provided by multidisciplinary 
assertive outreaching community mental health 
teams. TAU was guided by the patient’s individual 
symptoms and needs for care and could include 
assertive outreach, medication, social and financial 
management, job counselling, crisis interventions, 
cognitive (behavioural) therapy, the strengths-based 
approach and/or supportive structured therapy14. 
Individual case management was offered to patients 
who were more stable and needed long-term 
care, but intensive assertive outreach was offered 
to patients at risk of relapse or neglect, often by 
several clinicians working with a shared caseload 
14. We did not seek for uniformity in TAU as such 
diversity reflects reality. Clinicians in the control 
group continued TAU during the course of the study.
Motivation Feedback (MF)
MF was provided in addition to TAU in patients 
randomized to the MF group (consisting of six 
teams or clusters). Patients and clinicians in the 
MF intervention group were asked to fill in a Short 
Motivation Feedback List (SMFL) every month up to 
twelve months after baseline assessment. The SMFL 
consists of eight statements that relate to the level 
and type of the patient’s treatment motivation, based 
on three types of motivation postulated by SDT 65,82: 
external, introjected and identified motivation. The 
SMFL was shown to be reliable for these three types 
of motivation; congeneric estimates of reliability 
ranged from 0.81 to 0.93 203,218. 
 Before commencing the study, clinicians were 
trained by the principal investigator (PI) in the 
principles of SDT and the use of MF. The training 
consisted of a presentation about the principles 
and concepts of SDT, exercises to learn how to 
distinguish the needs for autonomy, competence 
and relatedness, and practicing MF assessments with 
other clinicians (not yet with patients) during this 
training, to familiarize themselves with the feedback 
and how to communicate about it. Clinicians 
received three booster sessions over the course of 
the study to evaluate and discuss their progress and 
experiences together with other colleagues who also 
participated in MF. During the course of the study, 
the PI received filled-out SMFLs from the clinicians 
and subsequently provided the clinician with MF 
graphs via email. An example of such a graph can 
be found in our published research protocol 197. The 
evaluation of the SMFL and the graph could serve 
as a starting point for conversations between the 
patient and the clinician regarding the motivation of 
the patient. Clinicians were instructed to stimulate 
internalization of motivation by supporting the 
patients basic psychological needs of autonomy, 
competence and relatedness, in line with SDT 64. The 
intention was that the conversation would revolve 
around sources of motivation behind treatment 
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goals. Clinicians were free to decide for themselves 
how they would structure this conversation with the 
patient, such as discussing only one item or several, or 
discuss differences between patient’s and clinician’s 
vision, and they were free to decide how long this 
would take. The duration and frequency of SMFL 
assessments were monitored by the research team. 
Both the number of face-to-face contacts between 
patient and clinician and the number of performed 
SMFL assessments were counted, to evaluate how 
many of the possible SMFL assessments were 
actually performed.
 During the course of the study, clinicians were 
regularly contacted by the PI to monitor the MF 
intervention and to discuss progress and experiences 
together with other colleagues who also participated 
in the MF intervention. These evaluation sessions 
took place four times over the course of the study. 
To aid clinicians in remembering to perform SMFL 
assessments, they were given bookmarks to use in 
their paper planners, posters of the study were hung 
up in the team offices, electronic reminders were 
regularly placed in the electronic planners, the PI 
was regularly present in the team office to check up 
on progress and sent emails to remind the clinicians 
of using MF. 
Outcomes
The outcomes of interest were treatment 
engagement (primary outcome) and treatment 
motivation, psychosocial functioning and quality of 
life (secondary outcomes) 197. We also administered 
a comprehensive number of other instruments, 
including measures for baseline characteristics 
used in the current study, for which we refer to 
our research protocol 197. All instruments were 
administered in Dutch language. 
Primary outcomes
Treatment engagement was measured with the 
Service Engagement Scale (SES) that was filled out 
by clinicians. The SES was developed to measure 
engagement with community mental health services 
199. It comprises 14 items that assess availability, 
collaboration, help seeking and treatment 
engagement behaviours (including medication 
adherence). The items are rated on a 4-point scale 
ranging from 0 (not at all) to 3 (most of the time). 
The SES has shown good psychometric properties 
and has previously been used in studies with 
patients with psychotic disorders 161,248,249. The SES 
total scale score was used as the outcome measure 
in this study, where higher scores denote higher 
treatment engagement. Reliability of the total scale 
score in the current sample was considered good, as 
evaluated by a congeneric estimate of reliability of 
0.91. Additionally, we included the number of missed 
appointments (no-shows), as a more objective 
measure of treatment engagement 197. These were 
obtained from the medical records. 
 For patients with a primary diagnosis of a psychotic 
disorder, the Morisky Medication Adherence Scale 
(MMAS)250 was used to assess patient self-reported 
antipsychotic medication adherence. The MMAS is 
a self-report scale that consists of 8 items asking 
about a specific medication-taking behaviour, 
such as “When you feel that your symptoms are 
under control, do you sometimes stop taking your 
medicine?”. The items can be scored ‘yes’ or ‘no’ and 
the total scale score theoretically ranges from 0 to 
8, with higher scores indicating better medication 
adherence. The congeneric estimate of reliability 
was 0.82 in the current sample.
Secondary outcomes
Motivation for engaging in treatment as postulated 
by SDT was measured with the Treatment Entry 
Questionnaire (TEQ) 126,218 that was administered 
to both patients and clinicians. It contains three 
subscales (external, introjected and identified 
motivation), each with 6 items rated on a scale from 1 
(strongly disagree) to 7 (strongly agree) and subscale 
scores are computed by averaging the item scores 
and multiplying this by the number of items. The 
congeneric estimates of reliability for TEQ subscales 
were acceptable in the current study sample as 
evaluated by congeneric estimates of reliability; 
0.78 for identified motivation, 0.72 for introjected 
motivation and 0.75 for external motivation218. 
Construct validity for the TEQ was supported by 
significant associations with therapist-rated service 
engagement (correlations between -0.15 and 0.58 
(p<0.01), depending on the subscale), patient- and 
clinician-rated	 therapeutic	 alliance	 (eg	 r	 =	 0.47	
and	 r	 =	 0.25,	 p	 <0.01,	 respectively	 with	 identified	
motivation) and legally mandated treatment218. 
Higher scale scores denote higher levels of that type 
of motivation.
  The patient’s psychosocial functioning was 
measured with the Dutch version of the Health of 
the Nations Outcome Scales (HoNOS) 163. The HoNOS 
was administered as a semi-structured interview 
with the patient, performed by independent research 
assistants (mostly graduate students in psychology 
and medicine). The researchers had no involvement 
in the patient’s treatment. Patients were interviewed 
at the team office or at home, depending on their 
preference. The HoNOS quantifies health and social 
problems of the previous two weeks and contains 12 
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items that refer to behavioural problems, cognitive 
and physical impairments, symptoms, and social (dis)
functioning. HoNOS items are scored on a scale from 
0 (no problem) to 4 (severe problem) . The total scale 
score is computed by adding the 12 items. A higher 
total score on the HoNOS denotes more severely 
impaired psychosocial functioning. The psychometric 
properties of the total scale score were shown to be 
acceptable and sensitive to change 163. Reliability of 
the total scale score was adequate in the current 
sample, as reflected by a congeneric estimate of 
reliability of 0.77. 
 The patient’s quality of life was assessed with 
the Manchester Short Assessment of Quality of 
Life (MANSA) 167,168. The MANSA is a self-report 
questionnaire that asks the patient how satisfied he/
she is in the following life domains: living situation, 
social relationships, physical health, mental health, 
safety, financial situation, work situation and life as 
a whole. The mean score on the 12 MANSA items 
was used as the outcome measure, of which the 
psychometric properties are considered satisfactory 
168. The congeneric estimate of reliability was 0.91 for 
the MANSA total score in the current sample. Higher 
scores denote a higher perceived quality of life.
Sample size
The sample size was calculated on the basis of our 
primary hypothesis, that MF would be more effective 
than TAU in enhancing treatment engagement, as 
measured with the Service Engagement Scale at 12 
months after baseline assessment. The difference 
between the motivation feedback group and control 
group for the primary outcome was based on a power 
of 0.80, an alpha of 0.05 (two-tailed), and an effect 
size (standardized mean difference) of approximately 
0.40197. The clustering of patients within clinicians 
was accounted for using the variance inflation factor 
formula	 f	 =	1	+	 (m	–	1)ρ,	with	 an	estimated	 cluster	
size (m) of 6 patients per clinician and the within-
cluster	correlation	(ρ)	was	estimated	from	a	previous	
study to be around 0.07 153. Using these parameters 
and including an additional correction for expected 
loss-to-follow-up, it was estimated that the required 
total sample size should be 350 patients 197. 
Randomization 
A computer-generated list of random numbers was 
used to randomly assign each team to a treatment 
condition, such that all clinicians and patients 
in the same team were randomized to a similar 
treatment. The randomization sequence was created 
using software from www.randomization.org with a 1:1 
allocation ratio using random block sizes of 1, 2 and 
3. The random allocation sequence was performed by 
authors ECJ and HJD prior to approaching treatment 
teams, such that treatment teams and its members 
were still unknown and were numbered blindly 
before entering team numbers into the computer 
program.
Blinding
At baseline, patients were unaware (blind) as to which 
treatment condition they had been randomized 
to. Clinicians had to be made aware of treatment 
condition as those randomized to MF needed to 
receive the necessary training prior to baseline 
assessments such that MF could start immediately 
thereafter. This blinding procedure is common in 
psychiatric intervention research 246. At the 12-month 
assessment, clinicians and patients were not blind to 
treatment condition while filling in questionnaires, 
whereas independent research assistants who 
looked up information from the medical record and 
performed interviews with patients were blind to 
treatment allocation.
Procedures
Treatment teams were approached by the PI and 
clinicians working in these teams received oral and 
written information about the study and were asked 
for informed consent. Subsequently, clinicians were 
asked to provide their caseload to the PI, who randomly 
selected 10 eligible patients for participation (or if 
fewer than 10 eligible patients were available, all the 
eligible patients were selected). Clinicians explained 
the selected patients about the contents and 
procedure of the study and asked for participation. 
To enhance the likelihood of participation, patients 
were given an incentive of 15 euro for participating. 
If a patient consented to participate, an appointment 
was made with the PI, sometimes accompanied 
by the clinician for the patient’s comfort and/or 
the investigator’s safety. The patient received oral 
and written information about the contents and 
procedures of the study once more before signing 
informed consent. Subsequently, patients and 
clinicians completed the baseline assessments. 
Independent research assistants accompanied 
patients during the assessment, such that they could 
help if necessary. This could, for example, include 
reading items aloud to accommodate patients with 
concentration problems and/or explaining items that 
were not readily understood. This procedure took 
about two hours for most patients and about 20 
minutes for clinicians. 
 After 12 months, patients and clinicians were 
contacted for the follow-up assessment. Patients 
who had ended treatment or dropped out from 
treatment were nonetheless contacted for a follow-
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up assessment. Clinicians were asked to complete 
their follow-up assessment for all patients who were 
enrolled at start of the study. Furthermore, it was 
assessed to what extent the MF intervention was 
performed by the clinicians.
Statistical Methods
Several outcomes, including the primary outcome 
and the motivation questionnaires, were not 
normally distributed at follow-up assessment and 
transformations were not successful. To deal with 
this, difference scores were calculated as follow-
up assessment minus baseline assessment. The 
difference scores showed normal distributions for all 
outcomes, as evaluated by histograms and normal 
probability plots. Subsequently, they were used as 
outcomes in this study. 
 Differences in demographic and clinical variables 
at baseline between the intervention group and 
control group, and between participants and non-
participants, were evaluated with independent 
samples t-tests and chi-square tests. All analyses 
were conducted using a significance level of p<0.05 
(two-sided) and unstandardized estimates of 
regression	coefficients	(β),	95%	confidence	intervals	
(95%CI), interquartile ranges (IQR), intraclass 
correlation coefficients (ICC) and standardized mean 
differences (SMD) are reported where appropriate. 
Statistical tests were performed using IBM SPSS 
Statistics 21 (SPSS Inc., Chicago, IL, USA) and SAS 
version 9.3 (SAS Institute Inc).
Intention to treat analyses
All outcomes were analysed with multilevel linear 
regression models. As stated in the study protocol197, 
it was explored which and how many levels would be 
appropriate for inclusion in the multilevel analyses. 
Not all available levels (ie mental health institutions, 
teams, clinicians, patients, measurements) could 
simultaneously be included as random effects due 
to singularity problems. Considering the variances 
explained at each level (on average: 81% at patient-
level, 8% at clinician-level, 1% at team-level, 0% at 
mental health institution) and considering that the 
dispersion of patients over teams was larger than 
the dispersion over clinicians (12 to 38 patients per 
team versus 1 to 10 patients per clinician), it was 
decided to include ‘team’ as the second level in the 
analyses. 
 Further, all analyses were performed both 
unadjusted and adjusted for baseline imbalancedness 
between treatment groups. In unadjusted analyses, 
models included treatment as fixed effect and 
clustering at team-level as a random effect. In 
adjusted analyses, models included treatment and 
a multivariate confounder score as fixed effect, 
and clustering at team-level as random effect. The 
multivariate confounders score was calculated using 
a set of observed potential confounders to control 
for the observed differences in the distribution of 
baseline variables between treatment groups 251. The 
multivariate confounder score included: ethnicity, 
sex, educational level, primary diagnosis, addiction 
problems, the clinician’s years of clinical working 
experience and the baseline value of the respective 
outcome (e.g. the baseline score on the SES was 
added to the confounder score in the analyses for 
SES at follow-up). Further, for all models, missing 
data on baseline variables were not imputed; 
only all observed data was used. Missing data on 
outcomes were considered missing at random 
(MAR). Restricted maximum likelihood was used as 
the estimation method. 
Additional analyses
Per protocol analyses
As stated in the study protocol197, we wanted to 
investigate the effect of actual exposure to the 
intervention on outcomes. To this end, a per protocol 
analyses was performed in which a median split was 
performed on the number of SMFL assessments, 
such that patients who performed MF less than 
four times were removed from analyses despite 
their randomization to MF. The modelling approach 
of these per protocol analyses was similar to the 
intention-to-treat analyses. 
 
Test of interaction effects: the role of 
primary diagnosis and age
As stated in the study protocol 197, we were also 
interested in determining whether treatment 
effects were dependent on baseline characteristics 
of the sample. To limit the number of tests (and 
accompanying problems of multiple testing), it was 
decided to test for differences between patients with 
psychotic disorders and patients with personality 
disorders and to test for potential differential 
effects of age. The two diagnostic groups constitute 
the great majority of patients treated in assertive 
outreach teams in the Netherlands 14, yet previous 
studies have largely focused on patients with 
psychotic disorders and ignored the experiences 
of service users with personality disorders in 
motivational interventions and/or outcome feedback 
systems 152,154,252. Therefore, exploratory analyses 
were performed to detect whether the effects of 
treatment on all outcomes were modified by the 
primary diagnosis. Additionally, as previous studies 
in community mental health care for patients with 
SMI in the Netherlands have shown that treatment 
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outcomes such as psychosocial functioning were 
dependent on patient age17, it was decided to explore 
whether the effects of treatment on all outcomes 
were modified by age. We tested these possible 
interactions (treatment group by primary diagnosis 
and treatment group by age) for significance on all 
outcomes.
Results
Participant flow, recruitment and 
numbers analysed
The numbers of participants who were randomly 
assigned, received intended treatment, were lost to 
follow-up and numbers analyzed are shown in the 
flow-chart (Fig. 1). Ultimately, a total of 57 clinicians 
and 294 eligible patients signed informed consent 
and completed baseline assessments between May 
2011 and September 2012. The recruitment process 
was slower and more difficult than expected and 
despite extending the inclusion period by 4 months, 
the inclusion of patients did not reach the estimated 
necessary 350 patients. 
 In total, 58% of the eligible patients (294 out 
of 507) and 80% of clinicians (57 out of 71) actually 
agreed to participate. Of the 155 patients who 
declined participation in the trial, 53 patients (34%) 
did not feel capable of filling in the questionnaires. For 
example,	they	found	it	too	long	or	too	much	(n=	18) 
or they felt they were too ill or incapable at the 
moment	 (n=	 12). Another 51 patients (33%) were 
not interested or did not feel the need to participate 
and 16 patients (10%) said they did not want to 
have anything to do with mental health affiliations. 
Another 18 patients (12%) did not see the use 
of scientific research in general, 9 patients (6%) 
started out with the baseline assessment but quit 
before completing, and 8 patients (5%) did not give 
a reason for declining participation. Additionally, 
58 patients could not be contacted despite several 
attempts. Patients who declined participation 
were significantly more often those with a primary 
diagnosis of a psychotic disorder and less often 
those	 with	 a	 personality	 disorder	 (χ2	 (1,	 N	 =	 470)	
=	 8.70,	 p<0.01). At 12 months, 253 patients (86%) 
were re-assessed. Numbers lost to follow-up were 
not significantly different between intervention 
groups. The group that was lost to follow-up was 
significantly more often of non-Dutch ethnicity (48% 
versus 26%, p<0.01) and more often had a legal 
mandate	 for	 treatment	 (18%	 versus	 7%,	 p	 =	 0.03)	
compared to completers. Clinicians completed their 
follow-up assessments for 278 patients (95%). 
Baseline characteristics
The baseline socio-demographic and clinical 
characteristics of participating patients are shown in 
Table 1. At baseline, several patient characteristics 
were unequally distributed over the two treatment 
groups (see Table 1). Clinicians in the MF group had 
an average of five more years of working experience 
(20 years versus 15 years, p<0.01). 
Adherence to MF intervention
On average, four assessments with the SMFL were 
done	 per	 patient	 (SD=3,	 observed	 range=0	 to	 11),	
representing 45% of the possible SMFL assessments 
that could have been performed considering the 
frequency of contacts with patients. Clinicians 
reported that the median time of discussing the 
SMFL	 with	 the	 patient	 was	 10	 minutes	 (IQR=5	 to	
15 minutes). Eighteen out of 148 patients (12%) 
never completed any SMFL assessments (reasons 
are shown in Figure 1). All clinicians in MF had at 
least one patient that was actively involved in MF, 
so there was no clinician that never performed SMFL 
assessments. 
Intention-to-treat analyses of 
outcomes
Table 2 shows pre- and post-intervention medians 
and the results of intention-to-treat analyses 
for all outcome measures, both unadjusted and 
adjusted for the multivariate confounder score. In 
the following, we will describe the results of the 
adjusted analyses, which are similar to the results of 
unadjusted analyses in terms of interpretation.
 It can be seen in Table 2 that we found no 
statistically significant differences between the MF 
and TAU groups in terms of treatment engagement, 
neither as measured with the SES nor as measured 
by the number of no-shows. Neither did we find 
significant differences between treatment groups 
in patients with primarily psychotic disorders, 
regarding their self-reported medication adherence. 
Regarding motivation for treatment, no statistically 
significant treatment effects were found for patient-
reported motivation, but clinicians reported that MF 
reduced patients’ introjected motives for engaging in 
treatment	more	than	TAU	(AMD=	-4.5,	95%CI=	-6.4	to	
-2.6, p<0.001). Neither any of the other motivation 
scales, nor the patient’s psychosocial functioning nor 
quality of life were significantly differently affected 
between the two treatment groups. 
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Ancillary analyses
Per protocol analyses
The results of the per protocol analyses were 
comparable to the findings of the intention-to-
treat analyses. That is, no statistically significant 
differences between the MF and TAU groups were 
found in terms of treatment engagement (as 
measured with the SES and number of no-shows) 
and patient-reported motivation. The findings 
on clinician-reported introjected motivation 
were confirmed such that clinicians reported 
a significantly higher reduction of introjected 
motivation	 in	MF	 than	 in	 TAU	 (AMD=	 -4.9,	 95%	 CI	
=	 -7.4	 to	 -2.4,	 p<0.001).	 Additionally,	 we	 found	 an	
effect on clinician-reported external motivation such 
that clinicians reported less external motivation in 
MF	compared	 to	TAU	 (AMD=	 -3.2,	95%	CI	=	 -6.2	 to	
-0.3, p<0.03). No statistically significant differences 
between the MF and TAU groups were found for 
psychosocial functioning and quality of life.
Test of interaction effects: the role of 
primary diagnosis and age
Results of the interaction analyses showed no 
statistically significant differential treatment effect 
of the primary diagnosis on changes in treatment 
engagement	as	assessed	by	the	SES	(p	=	0.50)	and	the	
number	of	no-shows	(p=0.09).	No	differential	effects	
on patient-reported treatment motivation were 
found, but the interaction effect between treatment 
group and primary diagnosis was significant 
for clinician-reported identified motivation 
(β	 =-3.77,95%	 CI=-7.12	 to	 -0.42,p=0.03)	 and	 
clinician-reported introjected motivation 
(β	 =-5.07,95%CI=-8.67	 to	 -1.59,p<0.01)	 (see	 Figure	
2 for estimates of accompanying main effects). As 
depicted in Figure 2, clinicians reported opposing 
treatment effects for identified motivation in the two 
diagnostic groups, such that they reported increased 
identified motivation in patients with a primary 
diagnosis of a personality disorder and decreased 
identified motivation in patients with a primary 
diagnosis of a psychotic disorder. For introjected 
motivation, it was found that clinicians reported a 
higher increase in introjected motivation in TAU 
than in MF for both diagnostic groups but more 
pronounced for patients with a psychotic disorder. 
 Further, the interaction effect between 
treatment group and primary diagnosis was 
significant	 for	 patient-reported	 quality	 of	 life	 (β	 =	
-0.62,	 95%	 CI	 =	 -1.08	 to	 -0.15,	 p	 =0.01),	 such	 that	
patients reported opposing treatment effects 
depending on their diagnostic group; those with a 
primary diagnosis of a personality disorder reported 
a significantly higher quality of life in MF whereas 
patients with a primary diagnosis of a psychotic 
disorder reported lower quality of life in MF (see 
Figure 2). No significant interaction effects between 
treatment group and primary diagnosis were found 
on the patient’s psychosocial functioning. Finally, 
none of the interaction effects between treatment 
group and age reached statistical significance, 
suggesting that the effects of treatment were not 
dependent on patient age.
Harms
No	 adverse	 or	 unintended	 effects	 of	 the	 MF	
intervention	nor	of	TAU	were	reported.
Discussion
Main findings
There were no significant differences between 
MF and TAU regarding clinician-rated treatment 
engagement and the number of no-shows (primary 
outcome), and no differences regarding the 
patient’s psychosocial functioning and quality of 
life (secondary outcomes). Regarding the secondary 
outcome motivation for engaging in treatment, 
we found no statistically significant differences 
between the MF and TAU groups on patient-
reported motivation. Clinicians however, did report 
that MF reduced introjected motives for engaging in 
treatment more than TAU, albeit that the effect size 
was small. 
Interpretation and possible 
mechanisms 
Apparently, SMI patients felt that talking about their 
motivation with their clinician did not change their 
motivation nor treatment engagement, and clinicians 
felt that MF did not improve their patient’s treatment 
engagement. These findings thus question whether 
monitoring and discussing the current motivational 
profile of the patient is necessary and sufficient to 
cause beneficial change in treatment motivation and 
behaviours such as treatment engagement. 
 Interestingly, the results show that clinicians 
did feel that MF changed their patient’s motivation 
as they reported lower introjected motivation and, 
when four or more MF sessions were performed, 
also lower external motivation. This suggests that 
clinicians noticed a reduction in relatively external 
motivation for engaging in treatment in their patients 
in response to MF, signifying that their perception 
of the patient’s motivation has changed in response 
to the intervention. We have previously found that 
especially introjected motivation for treatment was 
difficult for clinicians to estimate in the current 
patient sample 207 and, it is therefore reasonable 
to assume that the repeated conversations with 
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Figure 1. Flow diagram of MotivaTe-IT.
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patients regarding their motives has led to a change 
in the clinician’s perception of the motivation 
such that it became more closely aligned with the 
patient’s perspective. As such, the intervention may 
have enhanced the clinician’s ability to estimate the 
patient’s perspective on motivation. 
 The finding regarding the change in clinician’s 
ratings of the patient’s motivation raises the question 
of whether this is a beneficial outcome. If one 
takes a process-oriented perspective253, improving 
the ability of clinicians to estimate their patient’s 
motivation or - if one were to assume that clinicians 
actually perceived a reduction in external motives 
- improving the overall quality of motivation for 
engaging in treatment can be considered beneficial 
in itself. On the other hand, if one takes an outcome-
oriented perspective and observes that changes in 
motivation do not result in beneficial changes in 
treatment engagement or functional outcomes, the 
clinical relevance is ambiguous. 
 Furthermore, the interaction analyses of 
treatment with primary diagnosis suggest that 
clinicians felt the MF intervention had opposing 
effects depending on the primary diagnosis. It 
should be noted that, considering the theoretically 
possible changes on the TEQ scales (from -36 to 
36), the observed changes are small and the clinical 
relevance and implications are not straightforward. 
Nevertheless, impaired cognitive functioning in 
patients with psychotic disorders 175,254, including 
problems with synthetic metacognition255,256 (which 
involves integrating and bringing together several 
perceptions into complex ideas about the self and 
others256), may explain why the interaction analyses 
showed that MF was less effective for patients with 
psychotic disorders. Offering an intervention that 
requires patients to repeatedly reflect on internal 
motivational states while these patients may suffer 
such (meta)cognitive impairments may have been 
experienced as over-demanding or even frustrating, 
even more so for patients who had a relatively 
high level of motivation at the start of the study. 
Alternatively, the ‘additional’ personal attention that 
clinicians in MF give to their patients as reflected by 
an explicit interest in the nature of their motivation 
may be experienced as positive for those with 
primarily a personality disorder, whereas this may 
be experienced more neutral or even negative by 
patients with primarily a psychotic disorder. 
Motivation Feedback
N = 148
Treatment as Usual
N = 146
Age, mean (SD) 45.47 (10.4)* 42.50 (10.0)*
Male gender, n (%) 98 (66.2) 81 (55.5)
Dutch ethnicity A, n (%) 116 (78.4) ** 92 (63.0) **
Education level, n (%)
- No education/elementary
- Secondary school
- ≥Upper high school 
57 (38.5)
57 (38.5)
32 (21.6)
51 (34.9)
67 (45.9)
27 (18.5)
Living situation, n (%)
- Alone
- With partner and/or children 
- Mental health centre facility 
- Homeless
88 (59.5) **
49 (33.1) *
10 (6.8)
1 (0.7)
59 (40.4) **
70 (47.9)*
16 (11.0)
1 (0.7)
Primary diagnosis, n (%)
- Psychotic disorder
- Personality disorder
104 (70.2)
44 (29.7)
95 (65.1)
51 (34.9)
Comorbid substance use problemsB, n (% yes) 42 (28.4) 32 (21.9)
Prescribed medication, n (%)
- Classical antipsychotics
- Atypical antipsychotics
- Combination of typical and atypical
- Benzodiazepines
- Antidepressants
37 (25.0)
63 (42.6)
12 (8.1)
42 (28.4)
40 (27.0)
26 (17.8)
67 (45.9)
15 (10.3)
39 (26.7)
53 (36.3)
Age of first contact with mental health, mean (SD) 27.16 (10.34) 24.95 (10.24)
One or more previous hospitalizations, n (% yes) 113 (76.4) 114 (78.1)
Legal mandate, n (% yes) 11 (7.4) 13 (8.9)
Table 1. Baseline characteristics of participating patients.
A The definition of Dutch Ethnicity was based on the definition by the Dutch Bureau of Statistics234. 
B Substance abuse problem was defined as having a DSM-IV diagnosis of substance abuse and/or dependence  in the medical record. * 
P <0.05 ** P<0.01
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Comparison to other studies
Although the rationale of our study was plausible 
as demonstrated in several studies39,152,257, this was 
the first study to test a feedback intervention that 
was explicitly based on motivation for engaging in 
treatment and the first study to test it in a real-life 
heterogeneous SMI patient population. Our results 
are not consistent with results from other feedback 
studies148,152,257. For example, a study by Raes et 
al. 257 found that providing feedback to substance 
abuse patients about their personal resources 
and readiness to change (using a motivational 
questionnaire based on the Transtheoretical 
Model44,258) resulted in more patients attending 8 
sessions of treatment compared to a control group 
who did not receive such feedback. Other feedback 
studies, performed in non-SMI patient populations, 
have shown that the use of clinical support tools 
based on therapeutic alliance, social network 
support and motivation alongside outcome feedback 
systems are more effective at improving treatment 
retention and outcomes than outcome feedback 
alone148,259. It appears that successful outcome 
monitoring systems include additional support and 
services that are necessary alongside motivation 
feedback to cause changes in clinical outcomes, and 
that solely monitoring and discussing motivation is 
an insufficient cause for such changes. 
Generalizability
The estimated sample size was not reached which 
may have compromised the current results, although 
we feel that it is reasonable to assume that the 
statistical inferences would not have been different 
OutcomeA Treat-
ment 
group
T0 
(baseline)
Median (IQR)
T12
(post-test)
Median (IQR)
Mean difference 
between 
treatment 
groups1
(95% CI)
p-value1 Effect size Adjusted mean 
difference between 
treatment groups2 
(95% CI)
p-value2 Effect 
size
ICC
Treatment engagement
Clinician-reported engagement 
(SES; min = 0, max = 42)
MF
TAU
31 (25 to 37)
31 (24 to 36)
34 (30 to 37)
36 (30 to 38)
-0.0 (-2.2 to 2.2) 0.99 0.00 0.1 (-2.2 to 2.3) 0.96 0.00 0.05
Missed appointments 
(number of no-shows)
MF
TAU
0 (0 to 2)
0 (0 to 0)
0 (0 to 1)
0 (0 to 0)
-0.1 (-0.8 to 0.6) 0.83 0.01 0.1 (-0.7 to 0.8) 0.89 0.00 0.05
Patient-reported motivation
Identified motivation
(TEQ; min = 6, max = 42)
MF
TAU
36 (29 to 40)
36 (30 to 39)
33 (30 to 37)
36 (29 to 39)
-1.4 (-3.1 to 0.3) 0.10 -0.10 -0.8 (-2.7 to 1.0) 0.37 -0.03 0.00
Introjected motivation
(TEQ; min = 6, max = 42)
MF
TAU
21 (14 to 28)
24 (18 to 31)
20 (14 to 26)
22 (17 to 28)
0.1 (-1.8 to 2.1) 0.90 0.01 -0.8 (-2.9 to 1.4) 0.49 -0.03 0.00
External motivation
(TEQ; min = 6, max = 42)
MF
TAU
15 (11 to 21)
18 (12 to 24)
12 (8 to 18)
12 (9 to 20)
1.7 (-0.2 to 3.6) 0.07 -0.11 1.0 (-1.1 to 3.1) 0.34 0.04 0.00
Clinician-reported motivation 
Identified motivation 
(TEQ; min = 6, max = 42)
MF
TAU
30 (26 to 33)
32 (27 to 35)
29 (25 to 34)
32 (25 to 35)
-0.4 (-2.1 to 1.3) 0.66 -0.03 -0.6 (-2.6 to 1.3) 0.53 -0.03 0.01
Introjected motivation
(TEQ; min = 6, max = 42)
MF
TAU
20 (15 to 25)
22 (16 to 28)
17 (13 to 21)
21 (17 to 27)
-3.0 (-4.7 to -1.3) <0.01 -0.20 -4.5 (-6.4 to -2.6) <.001 -0.18 0.00
External motivation
(TEQ; min = 6, max = 42)
MF
TAU
20 (14 to 26)
21 (14 to 27)
17 (12 to 24)
21 (15 to 27)
-2.3 (-5.0 to 0.4) 0.09 -0.11 -2.0 (-4.9 to 0.9) 0.17 -0.07 0.09
Psychosocial functioning
(HoNOS; min = 0, max = 48)
MF
TAU
8 (6 to 13)
9 (6 to 14)
10 (6 to 14)
10 (7 to 15)
1.1 (-0.9 to 3.1) 0.27 0.07 0.6 (-1.5 to 2.6) 0.60 0.02 0.04
Quality of Life 
(MANSA; min = 1, max = 7)
MF
TAU
5 (4 to 5)
5 (4 to 5)
5 (4 to 5)
5 (4 to 5)
0.0 (-0.3 to 0.3) 0.91 0.00 0.0 (-0.3 to 0.3) 0.85 0.00 0.04
Table 2. Effects of Motivation Feedback on outcomes in the total patient sample (intention to treat analyses)
MF	=	Motivation	Feedback;	TAU	=	Treatment	as	Usual;	SES	=	Service	Engagement	Scale;	TEQ	=	Treatment	Entry	Questionnaire;	HoNOS	
=	Health	 of	 the	Nation	Outcome	 Scales;	MANSA	=	Manchester	 Short	 Assessment	 for	 quality	 of	 life;	 IQR	 =	 Interquartile	 range;	 ICC	 =	
Intracluster Correlation Coefficient at the level of treatment programs (teams). Effect size was calculated as the standardized mean 
difference between intervention groups.
A  The theoretically possible range of scores is reported next to the abbreviations of scale names, indicated by min (minimum score) and 
max (maximum score).
1 Results represent the effects of treatment allocation (MF relative to TAU), adjusted for clustering at team-level.
2  Results represent the effects of treatment allocation (MF relative to TAU), adjusted for clustering at team-level and a multivariate 
confounder score (which included patient sex, ethnicity, educational level, comorbid addiction problems, years of working experience 
of the clinician and the baseline value of the outcome).
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from a somewhat larger sample size. The current 
patient sample already showed relatively high levels 
of identified motivation, treatment engagement, 
and psychosocial functioning and low levels of 
no-shows to begin with (considering the range of 
scores). Further, the reasons that non-participants 
gave for declining participation in the trial, including 
feeling too ill or incapable, and the finding that non-
participants were more likely to be patients with a 
psychotic disorder, suggest that the most severely ill 
patients did not participate. This may reflect that the 
current study was not successful at recruiting SMI 
patients with substantial problems in their motivation 
for engaging in treatment, treatment engagement 
and psychosocial functioning. Such ceiling effects 
and selection bias may explain why MF was not able 
to improve outcomes, and suggest that the findings 
of the current study may not be generalizable to the 
Figure 2. Statistically significant moderation effects of primary diagnosis on treatment effects (intention to treat analyses). 
Note: Results are predicted change values based on a two-level multiple regression model that included treatment, primary diagnosis, 
treatment by primary diagnosis (interaction effect) and a multivariate confounder score which included patient sex, ethnicity, educational 
level, comorbid addiction problems, years of working experience of the clinician and the baseline value of the outcome. Treatment 
was coded as ‘0’ (treatment as usual) and ‘1’(motivation feedback); primary diagnosis was coded as ‘0’ (personality disorder) and ‘1’ 
(psychotic disorder). Values on the y-axis represent change scores on the TEQ (a and b) and MANSA (c), respectively.
A	Model:	intercept	(β=-2.72,df=11,p=0.07),	treatment	(β=1.90,df	=246,p=0.19),	primary	diagnosis	(β=2.03,df	=246,p=0.08)	,treatment	by	
primary	diagnosis	(β=-3.77,df	=246,p=0.03),	adjusted	for	the	multivariate	confounder	score	(β=2.00,df	=246,p=0.41).	
36
-36
6,0
-6,0
36
-36
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general SMI outpatient population but are limited to 
patients who are already relatively well engaged in 
treatment and function at a relatively high level. 
 
Strengths and limitations of the study
The study had several strengths including the 
implementation of this study in everyday practice of 
the community mental health teams, representative 
treatment as usual, independent raters, multiple 
methods for assessing motivation, intention-to-treat 
analysis, and the feasibility and low-costs of the 
intervention. Finally, the number of participating 
patients	(N=294)	and	the	follow-up	rate	for	patients	
(86%) was high considering the patient population. 
Despite its strengths, the current study may be 
viewed as a ‘negative trial’ and common causes for 
negative trials include failures of concept, design/
methodology and/or logistics. We will address each 
of these issues in the following.
Concept and rationale. Numerous studies suggest 
that evaluation of the patient’s motivation may help 
to understand how a patient may best be engaged 
in treatment 29,35-37,228 and other studies have found 
that clinicians have difficulties in estimating their 
patient’s motivation for treatment207, suggesting that 
the plausibility of the rationale for the current study 
was high. However, it should be noted that in the 
Netherlands, the accessibility and quality of mental 
health care for patients with SMI are currently at 
a relatively high level. 10. The treatment as usual 
was provided by multidisciplinary treatment teams 
that provided tailored care guided by the patient’s 
individual symptoms and needs for care and could 
include assertive outreach, medication, social 
and financial management, job counselling, crisis 
interventions and psychotherapy. Such care may 
have been sufficiently effective in engaging patients 
with SMI, especially highly motivated patients who 
were more likely to participate in this study, such 
that MF did not prove to be superior to TAU because 
the contrast between TAU and MF was (too) small.
Design and methodology. Although the current study 
was well designed197, in hindsight we may conclude 
that the expected effect size was too high and that 
the timing of our outcome evaluation might have 
been suboptimal . A meta-analysis on the effects of 
feedback in mental health care showed that outcome 
feedback had beneficial effects if outcomes were 
measured within 9 weeks after initial assessment 
(d=0.10,	95%CI	=	0.01	to	0.19),	but	these	effects	did	
not persist after 3 months39. Another meta-analyses 
on continuous feedback in outpatient psychotherapy 
found similar results147. As our study measured 
outcomes after 12 months, potential short-term 
beneficial changes of the MF intervention will have 
gone unnoticed and may have worn off by the end of 
follow-up. An additional assessment moment within 
the first three months of our study could have been 
informative in this respect, but due to practical and 
financial limitations this was not feasible. 
Another methodological issue is that clinicians and 
patients were not blind for treatment allocation 
which may have influenced the information that 
they gave on the outcome questionnaires (i.e. 
information bias). Although this is a common design 
in mental health research246 and blinding was not 
feasible, this might have biased the results towards 
no differences between the MF and TAU treatment 
groups or towards counterproductive effects of 
the MF intervention if clinicians generally did not 
expect the intervention to work or felt that the MF 
intervention was less/not appropriate for patients 
with psychoses.
Further, although we performed evaluation 
sessions with clinicians in MF alongside the trial, 
we have limited insight into what happened during 
MF sessions as these were neither recorded nor 
supervised. The exact communication processes 
within the sessions and whether or not they were 
autonomy supportive remain unclear, whereas such 
processes might explain why the MF intervention 
was not successful. Despite the training and 
evaluation sessions for clinicians in MF, we may 
have failed in providing the professionals with the 
necessary competencies and tools to be able to 
address different types of motivation for engaging 
in treatment and how to provide support for the 
needs of autonomy, competence, and relatedness 
in patients with SMI. More attention for the 
implementation process, including the influence of 
contextual factors as well as a minimum intensity of 
the feedback intervention, may be needed to reach 
favourable effects. Encouragement of both clinicians 
and patients into active involvement with MF is 
already difficult when facing patients with highly 
prevalent cognitive impairments, communication 
difficulties, and comorbidities, let alone in a health-
care context faced with reorganizations, and as such 
this requires a unique set of competencies from 
both researchers and clinicians to ensure sufficient 
implementation.
The heterogeneity of the current study sample is 
considered both a strength and a limitation. Our 
sample largely represents a broad population 
of outpatients with diagnoses of psychotic and 
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personality disorders with a variety of co-morbid 
psychiatric disorders, which strengthens the 
generalizability of the study and enhances the 
probability of adoption in clinical practice. However, 
MF may have different effects in different subgroups 
of patients which could only be addressed in an 
exploratory manner in the current study. 
Measuring treatment engagement and motivation 
for engaging in treatment is complex and gold 
standards are lacking20,37. A strength of the current 
study is that we had both patient and clinician 
reports of motivation and two methods to assess 
treatment engagement. Other objective measures for 
treatment engagement and medication compliance, 
such as pill counts, electronic methods, prescription 
monitoring, or urine assay tests were not available. 
Future studies may use such objective measures, 
although all have strengths and limitations20. To our 
knowledge, this was the first study to use the TEQ 
in a population of patients with SMI. The reliability 
and validity of the TEQ in the current sample were 
shown to be acceptable218 but should be improved 
upon and should be investigated more extensively 
to further determine the construct validity and 
sensitivity to change. 
Logistics. Logistical issues that have likely negatively 
impacted the current study, include the difficulties 
in recruiting the intended number of patients - 
especially the recruitment of patients with low 
levels of motivation and low levels of treatment 
engagement – and organisational changes in mental 
health care during the course of the study, including 
changes in the no-show policy and costs of mental 
health care for SMI patients. Further, there were 
large variations between teams and clinicians in the 
number and duration of SMFL assessments, reflecting 
the pragmatic nature of the trial. Our findings may 
reflect that too few MF sessions were actually 
utilised (i.e. 45% on average) or that the way MF 
was used in the sessions was not able to beneficially 
affect motivation and treatment engagement. Not 
seldom, clinicians admitted that they regularly 
forgot to do SMFL assessments despite efforts from 
the research team to help them remember, and 
some reported that they were burdening the patient 
with ‘yet another list to fill out’. Such comments 
seem reflective of a controlling health care context, 
where external demands and contingencies pressure 
people to behave in particular ways 225. If this was the 
case, this is likely to have been a counterproductive 
mechanism in the MF intervention64. 
Implications for theory and practice
Theoretically, MF was expected to lead to a higher 
level of autonomous motivation which would in turn 
lead to a higher level of treatment engagement. The 
question remains if this hypothesis can be retained, 
but the negative results should not be taken as 
evidence against SDT, as the MF intervention may not 
have been able to successfully affect SDT-constructs 
such as patient autonomy. The motivational 
constructs may still be able to predict treatment 
engagement in both conditions and this should be 
addressed in subsequent investigations. Future 
studies should address which contextual factors 
influence the implementation and interpretation 
of (motivation) feedback interventions, as these 
contextual factors can impact the motivational 
constructs that the intervention is trying to 
affect192,260. 
 Regarding implications for clinical practice, our 
study provided no evidence for the effectiveness of 
MF in outpatients with SMI and this discourages the 
implementation of the SDT-based MF intervention 
into community mental health care for such 
patients. Nevertheless, although this study didn’t 
show beneficial effects of MF in SMI outpatients, 
it contributes to the evidence base for optimal 
clinical decision making and is relevant to prevent 
an overestimation of the benefits of feedback 
interventions. The findings imply that monitoring 
and discussing the patient’s motivation is insufficient 
to improve motivation and treatment engagement 
in outpatients with SMI. It appears that successful 
outcome monitoring systems include additional 
support and services alongside motivation feedback 
which allows for beneficial changes in clinical 
outcomes. In the future, there may be a place for 
SDT-based MF as a communication tool for the 
clinician to explore the patient’s perspective, after 
which other tailored interventions and services may 
be applied to improve patient motivation, treatment 
engagement and most importantly, symptomatic 
and functional outcomes.
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Objective
It was investigated to which extent clinicians of 
patients with severe mental illness (SMI) were able 
to estimate their patient’s perspective on motivation 
for engaging in treatment, to which extent they 
agreed on the patient’s motivation, and which factors 
were associated with estimation and agreement on 
treatment motivation.
Methods
Motivation for engaging in treatment as rated 
by	 clinicians	 (N=57)	 and	 patients	 with	 severe	
mental	 illness	 (SMI,	 N=294)	 was	 assessed	 using	
measures based on three different motivation 
theories. Questionnaires were derived from Self-
Determination Theory, the Trans Theoretical Model 
and the Integral Model of treatment motivation.
Results
It was found that clinicians were poorly to 
moderately capable of estimating their patient’s 
type of motivation and readiness for change. Further, 
agreement on the level of motivation between 
patients and clinicians was moderate. These findings 
were consistent across diagnostic groups (psychotic 
disorders and personality disorders). A higher quality 
therapeutic relationship was generally associated 
with higher clinician-rated motivation. The patient’s 
ethnicity and socially desirable responding were 
factors that differentiated between scales of 
different motivation theories.
Conclusion
Patients with SMI and their clinicians have different 
perceptions on the patient’s motivation for engaging 
in psychiatric treatment, regardless of the theoretical 
framework that is used to measure motivation. The 
findings imply that a negotiated approach is needed 
where both perceptions of clinicians and patients on 
motivation for treatment are considered to ensure 
effective mental health interventions. 
Ch. 9
143
Introduction
The patient’s motivation for engaging in treatment 
is seen as a core determinant of treatment 
adherence and outcomes 29,37,65. In the treatment 
of patients with severe mental illness (SMI) such 
as those with psychotic disorders and personality 
disorders, impairment in and lack of motivation 
for engaging in treatment is known to negatively 
impact psychosocial outcomes 66,107,214. Assessing the 
patient’s motivation for engaging in treatment is the 
first step towards adequately addressing possible 
motivational problems, but such assessment is not 
straightforward. 
 Firstly, there is the issue of how and who should 
do the motivational assessment (e.g. patient, an 
independent observer or a clinician). The use of 
self-report measures on motivation in patients 
with schizophrenia spectrum disorders is gaining 
momentum 68,70,261, yet the measures currently 
being used in such studies have been validated 
with measures of other psychological constructs or 
other self-rated motivation measures rather than 
with clinician-rated or observer-rated measures 
of motivation. Previous studies have found that 
the self-report on domains of functioning that are 
less readily accessible such as negative symptoms, 
certain aspects of delusionality, and deficit symptoms 
are problematic for patients with schizophrenia 
spectrum disorders 262,263, which may also be the case 
for motivation. Further, it is unclear how for example, 
patient’s insight into illness 264 or socially desirable 
responding 265,266 influence self-reported motivation 
in patients with SMI. Observer-ratings may instead 
be used to avoid these issues, but clinician ratings for 
example can be time-consuming, costly, and prone 
to observer bias 267. In non-SMI patient populations, 
studies found low to moderate agreement between 
patients and clinicians on motivation for treatment 
93,160,268, but there is a lack of empirical research 
into the agreement between patients with SMI and 
clinicians on motivation for treatment. Although 
one recent study found no statistically significant 
associations between an interviewer-rated measure 
of motivation and self-reported motivation in 
patients with schizophrenia spectrum disorders 269, it 
was unclear whether this finding should be ascribed 
to differences between raters or differences between 
instruments. This suggests a need for more empirical 
research in patients with SMI to enable a better 
understanding of their motivation for engaging in 
treatment, including factors that may affect the way 
patients and clinicians view the patient’s motivation. 
To gain insight in whether the level of agreement on 
motivation for treatment is specific to schizophrenia 
spectrum disorders, it would be relevant to compare 
agreement between patients with different 
psychiatric disorders. For example, patients with 
personality disorders are also typically regarded as 
problematic regarding their motivation for engaging 
in treatment, yet have also been understudied in this 
respect 228.
 Secondly, the definition and measurement of 
motivation for engaging in treatment depends on 
the underlying theoretical framework. There is not 
one single widely accepted model but rather there 
are many models each explaining different aspects 
of the concept 37,86. Distinct - but not incompatible - 
definitions of motivation are provided by prominent 
theories such as Self-Determination Theory 48,82, 
the Transtheoretical Model 44,54, Expectancy-Value 
Theory 270 and derivatives of these models such as 
the Integral Model of treatment motivation 37. Some 
of these theories were developed specifically within 
treatment contexts, whereas others constitute more 
generalized motivation theories. Self-Determination 
Theory (SDT) 48,82 represents a broad framework for 
human motivation and considers different types of 
motivation along a continuum of self-determination 
from most self-determined (i.e. intrinsic motivation) 
to least self-determined (extrinsic motivation)64,82. 
Several studies have found support for SDT’s 
motivation continuum in the context of mental 
health care 65,128,210,215 yet to date very little studies 
have specifically been performed on motivation for 
treatment in SMI patients 218. The Transtheoretical 
Model (TTM) 44,83 asserts that individuals move 
through certain stages in the process of behavior 
change, and acknowledges that relapse is common in 
the change process. The TTM is typically regarded as 
a model for motivation for change, as the motivation 
or readiness to engage in behavior change increases 
with each progressive stage 37,86. The TTM has 
frequently been used as a basis for the development 
of health behavior interventions, especially in the 
field of addictions where it was originally developed 
38,44 and in patient populations with co-occurring 
psychiatric and substance abuse problems 57,102,271. 
The Integral Model of Treatment Motivation (IM) 37,118 
postulates six predictors of the patient’s motivation 
to engage in treatment (MET). This model resembles 
expectancy-value theory (EVT) 270 and the theory 
of planned behavior (TPB) 45 in its emphasis on the 
focus on individual beliefs, subjective norms and 
self-efficacy as essential predictors of motivation 
and behavior. IM was specifically developed for the 
assessment of motivation for engaging in treatment 
in forensic psychiatry. The patient’s perceived 
suitability of treatment and outcome expectancy 
were found to be important predictors of motivation 
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and treatment engagement in forensic outpatients 
116,117. Although all these theories may have utility 
in the psychiatric treatment of patients with severe 
mental illness 37,73,86,272, there appears to be a paucity 
of research regarding the differences between 
patient and clinician perspectives on motivation for 
engaging in treatment across different theoretical 
perspectives 86 . 
 
Aims of the study 
The current empirical study aimed to investigate the 
association between patient- and clinician-ratings 
on motivation for engaging in treatment, using 
measures of motivation based on SDT, TTM and IM. A 
distinction was made between the level of accuracy 
by which a clinician was able to estimate their 
patient’s report of motivation for treatment (which 
we labeled as ‘accuracy of estimation’) versus the 
level of agreement between patients and clinicians 
on the patient’s motivation (which we labeled as 
‘agreement’). This enabled to study to which extent 
clinicians were able to take the patient’s perspective 
(‘accuracy of estimation’) and to which extent the 
opinion of the clinician regarding the patient’s 
motivation was in line with the patient’s self-reported 
motivation (‘agreement’).
 Further, it was explored which patient- and 
clinician characteristics were related to differences in 
ratings between patients and clinicians on the patient’s 
motivation. Considering the exploratory nature of 
the current study, we decided to incorporate a large 
number of covariables. Some covariables such as age, 
gender, type of psychopathology, social functioning, 
impairments and behavioural problems were shown 
in other studies of self-other agreement to relate to 
differences between raters 273,274. Other covariables 
were chosen because they have previously been 
related to treatment motivation in patients with SMI 
and can thus be considered as ‘information sources’ 
that clinicians and patients may use differentially in 
their ratings of motivation68,107,218.
Methods
Participants and procedures
The data for the current cross-sectional study 
were obtained from the baseline assessments in a 
cluster randomized controlled trial 197. A total of 12 
outpatient treatment programs, including a forensic 
psychiatric outpatient clinic, specialized psychotic 
outpatient treatment programs and several function-
assertive community treatment teams (FACT-teams 
14) were approached for participation at two Dutch 
treatment centers: the Western North Brabant 
Mental Health Center and the Breburg Mental 
Health Center. As the name indicates, FACT-teams 
provide assertive, outreaching, community-based, 
and supportive psychiatric services to individuals 
with SMI 14. Since patients with psychotic disorders 
constitute the majority of patients treated in FACT-
teams in the Netherlands 14 and patients with severe 
personality disorders constitute another significant 
part of the caseload, it was decided to incorporate 
both patient groups into the study.
 Inclusion criteria for patients were: a primary 
diagnosis of psychotic or personality disorder, aged 
18 to 65 years, undergoing individual outpatient 
treatment and having a sufficient command of 
the Dutch language. A clinician was eligible for 
participation if he or she was the primary health 
care provider involved with the patient and saw 
the patient most frequently. Eligible patients on 
the clinicians’ caseload lists were approached and 
informed by researchers and asked for their signed 
consent. To enhance the likelihood of participation, 
patients were given an incentive of 15 euro for 
participating. This procedure was approved by a 
medical ethical committee (trial number NTR2968).
Measures
Motivation 
The motivation constructs described by SDT were 
assessed with the Treatment Entry Questionnaire 
(TEQ) 126, which measures three types of treatment 
motivation: identified, introjected and external 
motivation 126,198. Identified motivation is evident if 
a patient fully recognizes and accepts that treatment 
is useful for achieving personally relevant goals 
65. An example item is ‘I plan to go through with a 
treatment program because I have freely chosen to 
be here’. A less self-determined type of motivation 
is introjected motivation, which is evident when 
a patient is driven by feelings of guilt, shame or 
anxiety, and might feel ashamed or disappointed if 
he does not remain in treatment. An example item 
is ‘I plan to go through with treatment because I’ll 
be ashamed of myself if I don’t’. External motivation 
is evident when a patient feels pressured or even 
forced to engage in treatment, for example by the 
legal system 65. An example item is ‘I have agreed to 
follow a treatment program because I was pressured 
to come’. Items and response scales for the TEQ were 
identical for patients and clinicians, which included 
18 items rated on a scale from 1 (strongly disagree) to 
7 (strongly agree), and subscale scores are computed 
by averaging the item scores. Higher scores reflect 
greater motivation. Reliabilities were acceptable 
for	all	 scales	 in	both	versions	 (Cronbach’s	αs	 varied	
from 0.72 to 0.87). Validity of the Dutch TEQ was 
supported by significant associations with clinician-
rated	treatment	engagement	(r	=	0.25	to	0.58	(p<0.01)	
145
depending on the method of assessment) and with 
legally mandated treatment 218. Clinicians were asked 
to indicate how they thought patients responded to 
the items. As such, differences between patients and 
clinicians were interpreted as reflecting inaccurate 
estimates by the clinician of the patient’s motivation 
for engaging in treatment. 
 The stages of change described by the TTM were 
assessed using the Dutch version of the University 
of Rhode Island Change Assessment (URICA-D) 170, 
a self-report scale that asks a patient to rate the 
agreement with a particular statement reflecting 
one of four stages of change: precontemplation, 
contemplation, action and maintenance. Example 
items are ‘As far as I’m concerned, I don’t have any 
problems that need changing’[precontemplation], 
‘I have a problem and I really think I should work 
on it’[contemplation], ‘I am doing something about 
the problems that had been bothering me’ [action] 
and ‘It worries me that I might slip back on a 
problem I have already changed so I am here to seek 
help’[maintenance]. It consists of 24 items rated on 
a scale from 1 (totally disagree) to 5 (totally agree). 
A total readiness for change score was calculated 
by subtracting the precontemplation scale score 
from the sum of the other three scale scores. This 
readiness to change score was used in previous 
studies in patients with SMI where the alpha 
coefficient was estimated at 0.91 57,275. Higher scores 
reflect more readiness to change. In this study, items 
and response scales for the URICA-D were identical 
for	 patients	 (Cronbach’s	 α	 =	 0.76)	 and	 clinicians	
(Cronbach’s	α	=	0.80),	and	clinicians	were	asked	 to	
indicate how they thought patients responded to 
the items. As such, differences between patients and 
clinicians were interpreted as reflecting inaccurate 
estimates by the clinician of the patient’s motivation 
for engaging in behavior change. 
 To assess motivation according to the IM, patients 
were administered the subscale for motivation 
to engage in treatment (MET) from the Treatment 
Motivation Scale for forensic patients (TMS-f) 116,118. 
The items on the MET-subscale are considered 
sufficiently general for use outside a forensic setting 
218. There is a patient version and a therapist version, 
but number of items, wording of items and response 
scales for the TMS-f patient- and clinician versions 
were not identical. The patient version consists of 
16 items rated on a scale from 1 (strongly agree) 
to	 5	 (strongly	 disagree)	 (Cronbach’s	 α	 =	 0.83),	 the	
therapist version comprises 5 items rated on a scale 
from	1	(not)	to	5	(strongly)	(Cronbach’s	α	=	0.86)	and	
scale scores are derived by averaging the individual 
items. In both versions, higher scale scores reflect 
greater motivation. The MET-scale addresses the 
patient’s commitment to treatment, readiness 
for disclosure and readiness for efforts between 
sessions. Example items are ‘If I don’t see progress 
for several weeks, my engagement in treatment 
would probably decrease’ and ‘At home I wish to 
distance myself from treatment and not be engaged 
with it’. As clinicians are asked to rate their patient’s 
motivation, differences between patient reports 
and clinician reports will be interpreted as reflecting 
disagreement. 
Covariables 
Socio-demographic information was requested from 
the patient. Clinician characteristics were obtained 
from the clinicians. Treatment characteristics, 
including patient diagnoses as made by the 
psychiatrist of the team, were obtained from the 
medical record. 
 The patient’s current psychosocial functioning 
was assessed with the Health of the Nations Outcome 
Scales (HoNOS) 163,164, which was administered as 
a semi-structured interview with the patient, and 
scored by trained research assistants who were not 
involved with the patient’s treatment. It contains 
12 items that refer to behavioral problems (e.g. 
aggression and self-destructive behavior); symptoms 
(e.g. delusions, hallucinations, depression and 
anxiety); limitations (e.g. cognitive and physical 
impairments); and social functioning (e.g. frequency 
of social interactions, daily functioning and living 
conditions). All HoNOS items refer to the previous 
two weeks. Items are scored on a 5-point Likert scale 
from 0 (no problem) to 4 (severe problem), such that 
higher scores denote more problems. The total score 
is computed by summing the items. In the current 
study,	Cronbach’s	α	for	the	total	scale	was	0.73.	The	
HoNOS total score was found to be a valid, reliable 
summary measure of (changes in) functioning 
163,164,276. 
 The patient’s executive functioning was 
assessed using the Zoo Map test, a subtest of the 
Behavioural Assessment of Executive Functioning 
(BADS) 179,180. The Zoo Map test asks the patient to 
draw a route on a map of a zoo, and to visit specific 
sites while applying specific rules (e.g. ‘you can use 
the dotted pathways as often as you want, but the 
white pathways only once’). A total score ranging 
from 0 to 4 is derived, with higher scores denoting 
higher levels of executive functioning. The BADS 
has shown adequate validity in heterogeneous 
patient samples as evidenced by associations with 
other neuropsychological tests that assess planning 
functions 180,181,277. 
 Social desirable responses were assessed using 
the 15-item social desirability scale from the TMS-f 
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118, whose items reflect endorsement of behaviors 
that are culturally sanctioned and approved but 
also improbable, such as “I have never deliberately 
said anything that might have hurt another person’s 
feelings”. A higher score on this scale reflects a 
higher tendency to give socially desirable responses. 
The scale was found to have adequate reliability 
(Cronbach’s	 α	 =	 0.80)	 and	 construct	 validity	 was	
supported in a study with forensic psychiatric 
patients 160. 
 Treatment engagement behavior was rated 
by clinicians using the Service Engagement Scale 
(SES) 199. The SES covers four facets of service 
engagement: availability, collaboration, help-seeking 
and treatment engagement (including medication 
adherence). A total score was calculated, where 
higher values denote higher levels of treatment 
engagement. For patients who were not prescribed 
medications, the subscale for treatment engagement 
was computed by taking the mean of all other items 
as substitutes for the medication items. The SES 
total scale score was used in several studies with SMI 
patients 190,199,278, Cronbach’s alpha in the current 
study was 0.86. 
 The therapeutic relationship was measured with 
the Helping Alliance Questionnaire (HAQ), which was 
previously validated in a sample of Dutch substance-
dependent patients 182. Both a patient and a clinician 
version have been developed. The HAQ therapist 
version (22 items) was used since the patient version 
showed extremely skewed distributions signifying a 
ceiling effect. The therapist version consists of 2 parts, 
the first consisting of the clinician’s perception of 
the relationship, and the second asking the clinician 
how - according to him - the client perceives the 
relationship. The items are rated on a 5-point scale 
(completely disagree to completely agree). A higher 
score implies a better quality of the therapeutic 
relationship. In the current study, the total scale 
score of the 22 items was used as measure for the 
therapeutic	relationship	(Cronbach’s	α	=	0.94).
Statistical analyses 
Multilevel linear regression analyses were performed 
for the total sample and for diagnostic groups 
separately to estimate associations between patient-
rated and clinician-rated scale scores, adjusted for 
clustering of patients within clinicians. Interaction 
analyses were used (clinician-rating by diagnostic 
group) to assess whether the clinician’s agreement 
with the patient was different for the two diagnostic 
patient groups. Subsequently, we standardized all 
scales for both patients and clinicians in that they had 
a mean of 0 and SD of 1. This was done because for the 
MET-scale, the raw scores on the motivation scales 
were not directly comparable between patients and 
clinicians. A difference score (D) was then computed 
by subtracting the standardized clinician score from 
the standardized patient score (i.e. patient minus 
clinician). This approach was previously reported 
by Dorz et al. 279 to study differences between 
patients and clinicians on symptoms of depression. 
To identify patient-clinician pairs where clinicians 
were in agreement with the patient on the patient’s 
motivation for treatment (in case of the MET-scale) 
and pairs where clinicians were able to accurately 
estimate their patient’s motivation (in case of the 
URICA	 and	 TEQ),	 we	 considered	 D-scores	 ≥	 ±	 0.5	
SD from the mean as representing disagreement 
(in case of the MET) and inaccuracy (in case of the 
URICA and TEQ scales). All scores in between were 
considered as being in agreement (in case of the 
MET) and as accurate (in case of the URICA and 
TEQ). Thus, a positive difference score (D-score) 
indicates that clinicians regard the motivation to be 
low/underestimate relative to the patient report, 
whereas a negative D-score indicates that clinicians 
regard the motivation to be high/overestimate 
relative to the patient’s score.
 Multinomial multilevel regression models were 
used to explore which variables were significantly 
associated with the D-scores on all motivation scales. 
The outcome variables were the trichotomized 
D-scores; the reference category used in the analyses 
was	≥	0.5	SD	(underestimation	by	the	clinician).	Not 
all available levels (i.e. mental health institutions, 
teams, clinicians, patients) could simultaneously 
be included as random effects due to singularity 
problems. As patients were treated within teams 
where clinicians worked with shared caseloads, two 
levels were considered: patients (level one) and 
teams (level two). All models included clustering 
at team-level as a random effect. Missing data 
on predictor variables were not imputed; only all 
observed data was used . First, bivariate associations 
between predictor variables and D-scores were 
explored. Subsequently, any variable that was 
significantly associated with at least one D-score was 
retained in a final multiple multinomial regression 
where all predictors were entered simultaneously 
into the model. P-values (two-sided), odds ratios 
(ORs) and corresponding 95% confidence intervals 
(95%CIs) are reported. For the regression analyses, 
the glimmix procedure in SAS version 9.3 was used 
with the estimation method RSPL (corresponding to 
maximizing the residual log pseudo-likelihood with 
an expansion about the current solutions of the best 
linear unbiased predictors of the random effects280. 
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Results
A total of 57 clinicians agreed to participate: 49 
specialized psychiatric nurses (86%), 5 social workers 
(9%) and 3 psychologists (5%). They had a mean 
of	 16.5	 years	 of	 clinical	 experience	 (range	 =	 1	 to	 
40	 years).	 Their	mean	 age	was	 43.9	 years	 (range	 =	 
25 to 62 years); 63% of them were female. From 
their caseloads, 294 patients agreed to participate 
out of 470 approached eligible patients (63%). Table 
1 shows characteristics of the patient sample. Within 
the subsample of patients with psychotic disorders, 
the majority of patients were diagnosed with 
schizophrenia (48%), schizoaffective disorder (16%), 
or psychotic disorder not otherwise specified (24%). 
Within the subsample of personality disorders, 
40% had a borderline personality disorder, 13% 
had antisocial personality disorder, and 26% had a 
personality disorder not otherwise specified.
Differences between patients and 
clinicians on the patient’s motivation
Table 2 shows that three groups of about similar size 
were created that represented agreement/accuracy 
and over- and underestimation of treatment 
motivation, based on the D-scores. The accuracy by 
which clinicians were able to estimate patient ratings 
of motivation ranged from low for the introjected 
motivation	 scale	 (r	 =	 0.21,	 95%CI	 =	 0.06	 to	 0.37,	
p<0.05) to moderate for the other motivation scales 
(e.g.,	r	=	0.43,	95%CI	=	0.30	to	0.55,	p<0.01	for	the	
URICA-D) in the total patient sample (see Table 2). 
Agreement between patients and clinicians on 
the level of motivation on the MET was moderate 
(r=0.31,p<0.05)	 in	 the	 total	 sample.	 Interaction	
analyses showed no statistically significant effect 
of diagnostic group on the level of agreement on 
any of the questionnaires, such that there were no 
significant differences between diagnostic groups 
on agreement with the clinician on motivation for 
treatment. The weakest (and only non-significant) 
association between patient- and clinician-ratings 
was found for introjected motivation in the subgroup 
of patients with primarily personality disorders. 
Factors associated with agreement 
Bivariate analyses
Bivariate	 associations	 between	 predictor	 variables,	
including socio-demographics, medical record 
information	 (e.g.,	 primary	 psychiatric	 diagnosis,	
comorbid substance abuse problems and legally 
mandated treatment), clinical status (e.g., psycho-
social	functioning,	quality	of	the	therapeutic	relation-
ship and treatment engagement) and clinician 
characteristics	(e.g.	clinician	sex	and	years	of	clinical	
experience) and the D-scores were explored (see Table 
3). Regarding socio-demographics, the MET-scale 
(assessing	 agreement)	 differed	 from	 the	 URICA-D	
and TEQ scales (assessing accuracy of the clinician 
in	 estimating	 the	 patient’s	 motivation)in	 that	 MET	
showed	 a	 higher	 number	 of	 significant	 associations	
with socio-demographics. For example, clinicians 
were more likely to report higher motivation on 
the MET for female patients compared to males 
(OR=2.47,	95%CI=1.30	to	4.67,p<0.01)	and	for	those	
of higher educational level compared to those with 
lower	 educational	 levels	 (OR=2.35,	 95%CI=1.01	
to 5.53,p<0.05), whereas these variables were 
not associated with the accuracy of estimation 
on the URICA-D and TEQ scales. The therapeutic 
relationship was statistically significantly 
associated with all five motivation scales, such 
that for every higher level of the quality of the 
therapeutic relationship there was a 4% increase 
(OR=1.04,95%CI:	1.01	to	1.06,p<0.01	for	introjected	
motivation)	 to	 10%	 increase	 (OR=1.10,	 95%CI:1.07	
to 1.14,p<0.01 for readiness to change) in the odds 
of clinicians overestimating the patient’s motivation 
for treatment, except for external motivation 
where a decrease in clinicians overestimating 
the external motivation was found in response to 
higher	 quality	 relationships	 (OR=0.97,95%CI=0.95	
to 0.99,p<0.05). A similar pattern was found for the 
level of treatment engagement where higher levels 
of treatment engagement were associated with 
higher odds of agreement and higher clinician-rated 
motivation	(e.g.	OR=1.13,95%CI=1.08	to	1.19,p<0.01	
for MET). Conversely, clinicians were around 70% 
less likely to overestimate motivation for patients 
with a comorbid substance abuse, as can be seen for 
MET	(OR=0.26,95%CI=0.12	to	0.52,p<0.01),	URICA-D	
(OR=0.28,95%CI=0.12	 to	 0.66)	 and	 TEQ	 identified	
motivation	(OR=0.33,95%CI=0.15	to	0.7,p<0.01).	
	 In	 sum,	 thirteen	 variables	 were	 statistically	
significantly	 associated	 with	 at	 least	 one	 D-score;	
patient	 sex,	 education	 level,	 ethnicity,	 primary	
diagnosis, comorbid substance abuse, legally 
mandated	treatment,	duration	of	current	treatment,	
frequency	 of	 contacts,	 psychosocial	 functioning,	
therapeutic	relationship,	social	desirability,	treatment	
engagement and clinician sex. These variables were 
retained	for	subsequent	multiple	logistic	multinomial	
regression analyses (see Table 4).
Multivariate analyses 
Consistent with the bivariate associations, 
multivariate analyses showed that clinicians were 
over four times more likely to report higher scores 
than patients on the MET for patients of Dutch 
ethnicity	 (OR=4.82,	 95%CI=1.73	 to	 13.39,p<0.01)	
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compared to those of non-Dutch ethnicity, but the 
patient’s ethnicity was not associated with accuracy 
of estimation on the URICA-D or TEQ-scales. Further, 
it was found that clinicians were less likely to be 
in agreement or to report higher scores than their 
patients for patients who were more likely to 
respond	in	a	socially	desirable	way	(OR=0.93,95%CI	
=	0.88	to	0.98,p<0.01	and	OR=0.89,95%CI	=	0.84	to	
0.94, p<0.01, respectively). Social desirability was 
not associated with the D-scores on the URICA-D 
and TEQ. The therapeutic relationship remained 
significantly associated with agreement on several 
scales, such that for patients whom clinicians 
had a higher quality therapeutic relationship 
with, clinicians were more likely to agree but also 
to overestimate motivation, except for external 
motivation. 
Discussion
The	current	study	shows	that	clinicians	and	patients	
with	SMI	have	different	perceptions	on	the	patient’s	
motivation	for	engaging	in	psychiatric	treatment,	and	
that	the	level	of	agreement	is	not	different	between	
patients	 with	 a	 primary	 diagnosis	 of	 a	 psychotic	
disorder or a personality disorder. Clinicians appear 
to	 be	 moderately	 capable	 of	 taking	 the	 patient’s	
perspective	(i.e.	estimating	how	their	patients	would	
report)	 on	 readiness	 for	 change,	 identified	 and	
external	 motivation	 and	 poor	 ability	 in	 estimating	
introjected	 motivation	 for	 engaging	 in	 treatment.	
Further,	 in	 comparing	 opinions	 between	 patients	
and	clinicians	on	the	patient’s	motivation,	we	found	
moderate	 agreement	 on	 the	 level	 of	 motivation.	
These	findings	are	in	line	with	previous	studies	which	
found	 low	 to	 moderate	 agreement	 on	 motivation	
between	 patients	 and	 clinicians	 in	 other	 patient	
populations	93,116,268 and suggest that clinicians should 
be	 aware	 that	 patients	 with	 SMI	 generally	 have	 a	
different	 view	 on	 their	 motivation	 for	 engaging	 in	
treatment	 than	 the	 clinician	 can	 estimate	 or	 judge,	
regardless	of	the	theoretical	framework	that	is	used	
to	measure	motivation.	Thus,	regarding	the	question	
of	 who	 should	 do	 the	 motivational	 assessment,	
the	 results	 suggest	 that	 it	 is	not	sufficient	 to	assess	
either	the	patient	or	clinician	view	alone,	but	that	it	
is	necessary	to	take	both	perspectives	 into	account.	
It	 is	 likely	 that	 the	 perceptions	 are	 complementary	
and that a combined view meets the clinical reality. A 
motivational	assessment	that	explicitly	 incorporates	
both	perspectives	may	be	useful	in	clinical	practice	as	
it	 forces	 clinicians	 to	 evaluate	 potential	 differences	
between	 them	 and	 their	 patients.	 Such	 an	 explicit	
evaluation	 may	 help	 to	 increase	 the	 possibility	
that	 interventions	 are	 tailored	 to	 the	 patient’s	
motivational	perspective	which	in	turn	may	increase	
the likelihood of treatment success. It should be 
noted	 that	 we	 chose	 to	 take	 the	 patient	 report	 as	
‘reference’ in the current study to compare the 
clinician’s	 perspective	with,	 yet	 this	 does	 not	 imply	
that	the	patient	perspective	is	‘the	golden	standard’.	
In fact, currently there is no golden standard in 
the	 assessment	 of	 treatment	 motivation	 which	
underlines the importance of more empirical studies 
in this domain. For example, it would be relevant 
to	 study	 which	 perspective	 (patient	 or	 clinician)	 is	
most	predictive	of	treatment	outcomes	and	whether	
better	 clinician-patient	 agreement	 predicts	 more	
favourable treatment outcomes. 
Regarding the question whether the level of 
agreement between patients and clinicians depends 
on the theoretical framework that is chosen, 
the results suggest that the degree to which 
patients and clinicians differed on the motivation 
questionnaires did not differ substantially between 
the different motivational theories. If anything, 
clinicians had most difficulty with estimating their 
patient’s introjected motivation for treatment, 
which revolves around the patient’s experience of 
engaging in treatment “because of ‘shoulds’, guilt, or 
seeking social approval” (p. 187)65. Such motivation 
is presumably less observable and perhaps less 
often discussed between patients and clinicians 
which may result in more difficulties for clinicians 
in estimating it. SDT thus provides a potentially 
useful framework for exploring potentially unknown 
sources of motivation of a patient 48,67. On the 
other hand, depending on the specific purpose of 
the motivational assessment, a patient’s readiness 
to change or overall level of motivation may be 
clinically relevant to explore, which would make 
TTM or IM appropriate frameworks for assessment, 
respectively. All in all, it appears that the level 
of agreement between patients and clinicians 
is unsuited to use as a criterion for choosing a 
motivational assessment based on a certain theory, 
as neither of the three theories stood out from the 
other theories in this regard. Other criteria such as 
the type of information that can be derived from 
the different questionnaires may be used instead to 
guide assessment choices. 
 The different perspectives between patients 
and clinicians were associated with several factors. 
We found that the therapeutic relationship was 
associated with both agreement and accuracy 
across all motivation scales, such that the higher 
the clinician rated the quality of the relationship, 
the more likely that the clinician attributed higher 
scores to the patient’s motivation than patients 
themselves (except external motivation, where a 
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reverse relationship was found). Considering the 
quality of the therapeutic relationship as a reflection 
of the communication patterns between patients 
and clinicians, it is not surprising that a better 
relationship is associated with more agreement 
and higher motivation for engaging in treatment. 
Alternatively, these findings might be ascribed to the 
tendency of clinicians to provide consistent ratings 
based on a global positive (or negative) evaluation of 
the patient, instead of assessing distinct constructs 
separately, which is known as halo bias 160,281. That is, 
clinicians may rate patients higher in their motivation 
Total patient sample
N = 294
Psychotic disorder
N = 199
Personality disorder
N = 95
Age, mean (sd) 44.00 (10.3) 43.0 (10.2) 46.0 (10.2)
Male gender, n (%) 179 (60.9) 133 (66.2) 46 (50.0)
Dutch ethnicity, n (%) 208 (70.7) 140 (70.4) 68 (71.6)
Education level, n (%)
- No education/elementary
- Secondary school
- ≥Upper high school 
108 (36.7)
124 (42.2) 
59 (20.1)
76 (38.2)
75 (37.7)
47 (23.6)
32 (33.7)
49 (51.6)
12 (12.6)
Living situation, n (%)
- Alone
- With partner and/or kids 
- Mental health centre facility 
- Homeless
147 (50.0)
119 (40.5)
26 (8.8)
2 (0.7)
96 (48.2)
80 (40.2)
21 (10.6)
2 (1.0)
51 (53.7)
39 (41.1)
5 (5.3)
0 (0)
Comorbid substance use problems, n (% yes) 74 (25.2) 42 (21.2) 32 (33.7)
Prescribed medication, n (%)
- Classical antipsychotics
- Atypical antipsychotics
- Combination of typical and atypical
- Benzodiazepines
- AntidepressantsA
63 (21.4)
130 (44.2)
27 (9.2)
81 (27.6)
93 (31.6)
47 (23.6)
113 (56.8)
19 (9.5)
55 (27.6)
52 (26.1)
16 (16.8)
18 (18.9)
8 (8.4)
26 (27.4)
42 (44.2)
Age of first contact with mental health, mean (sd) 26.06 (10.3) 26.47 (9.8) 25.2 (11.4)
One or more previous hospitalizations, n (% yes) 227 (77.2) 162 (80.6) 65 (70.7)
Legal mandate, n (% yes) 24 (8.2) 13 (6.5) 11 (12.0)
Executive functioning, mean (sd) 2.1 (1.1) 2.0 (1.1) 2.1 (1.1)
Psychosocial functioning, median (IQR) 9.0 (6.0 to 13.0) 8.0 (5.0 to 12.0) 11.0 (8.0 to 15.0)
Table 1. Patient characteristics
Scale Sample Patient
Mean (sd)
Clinician
Mean (sd)
β 
(95% CI)
Agreementa
n (%)
Clinician underestimatesa
n (%)
Clinician overestimatesa
n (%)
Readiness to Change 
(URICA-D)
Total
Pers
Psych
8.84 (2.28)
9.58 (1.92)
8.48 (2.36)
7.91 (1.99)
8.30 (1.64)
7.74 (2.11)
0.43**  (0.30 to 0.55)
0.36** (0.12 to 0.59)
0.41** (0.26 to 0.57)
110 (37.4)
35 (37.2)
75 (37.5)
81 (27.6)
33 (35.1)
48 (24.0)
80 (27.2)
23 (24.5)
57 (28.5)
Identified motivation 
(TEQ)
Total
Pers
Psych
33.88 (7.31)
35.06 (6.10)
33.34 (7.77)
29.57 (6.83)
30.44 (5.67)
29.17 (7.30)
0.41**  (0.29 to 0.53)
0.30** (0.09 to 0.51)
0.44** (0.30 to 0.58)
110 (37.4)
38 (40.4)
72 (36.0)
85 (28.9)
29 (30.9)
56 (28.0)
82 (27.9)
23 (24.5)
59 (29.5)
Introjected motivation 
(TEQ)
Total
Pers
Psych
22.63 (9.37)
23.63 (9.17)
22.16 (9.45)
21.13 (7.11)
22.69 (7.41)
20.43 (6.88)
0.21*   (0.06 to 0.37)
0.10 (-0.16 to 0.37)
0.25* (0.05 to 0.44)
99 (33.7)
33 (35.1)
66 (33.0)
95 (32.3)
28 (29.8)
67 (33.5)
83 (28.2)
29 (30.9)
54 (27.0)
External motivation (TEQ) Total
Pers
Psych
17.24 (8.41)
14.70 (7.95)
18.42 (8.37)
20.24 (7.76)
18.67 (8.33)
21.04 (7.36)
0.32**  (0.20 to 0.45)
0.33** (0.14 to 0.53)
0.28** (0.12 to 0.43)
110 (37.4)
43 (45.7)
67 (33.5)
89 (30.3)
23 (24.5)
66 (33.0)
78 (26.5)
24 (25.5)
54 (27.0)
Motivation to Engage in 
Treatment (MET)
Total
Pers
Psych
2.95 (0.73)
2.94 (0.75)
2.95 (0.72)
3.70 (0.78)
3.67 (0.72)
3.71 (0.81)
0.31** (0.21 to 0.42)
0.34** (0.13 to 0.55)
0.29** (0.17 to 0.42)
104 (35.4)
34 (36.2)
70 (35.0)
78 (26.5)
28 (29.8)
50 (25.0)
93 (31.6)
29 (30.9)
64 (32.0)
Table 2. Associations between patient- and clinician ratings for the different motivation questionnaires
*p<0.05	**p<0.01	(two-tailed).	URICA-D	=	University	of	Rhode	Island	Change	Assessment-Dutch,	TEQ	=	Treatment	Entry	Questionnaire,	
MET	=	motivation	to	engage	in	treatment	scale,	Psych	=	psychotic	disorders,	Pers	=	personality	disorders.	
a	D-scores	were	computed	as	standardized	patient	score	minus	standardized	clinician	score.	D-scores	≥	0.5	SD	were	considered	as	the	
clinician	reporting	lower	scores	than	the	patient	(i.e.	underestimation),	D-scores	≤	0.5	SD	as	the	clinician	reporting	higher	scores	than	
the patient (i.e. overestimation) and all scores in between as being in agreement. Numbers may not sum to total sample size due to 
missing data. 
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because they feel the relationship is good, whereas 
these concepts are distinct and may go in different 
directions. For example, a patient may be motivated 
to engage in social contact with the clinician while at 
the same time may not be motivated for engaging in 
treatment-related behaviors.
 Further, the patient’s ethnicity and socially 
desirable responding were factors that differentiated 
between different motivation scales. When asked 
to give their own opinion about the patient’s 
motivation on the MET-scale, clinicians reported 
higher motivation for patients of Dutch ethnicity 
compared to those of non-Dutch ethnicity, and 
clinicians were less likely to overrate motivation in 
patients who responded in a more socially desirable 
way. At the same time, ethnicity and socially 
desirable responding were not associated with the 
difference scores on the URICA-D and TEQ, which 
may be related to the fact that clinicians were 
asked to estimate motivation from the patient’s 
perspective on these scales. These findings may 
reflect that clinicians were able to take the patients’ 
socially desirable responding and ethnicity into 
account when estimating their patient’s report 
on readiness to change (URICA-D) and types of 
motivation (TEQ), while at the same time, clinicians 
were also more likely to disagree with patients with 
such characteristics (MET). It is not surprising that 
patients who are more likely to respond in socially 
desirable ways rate themselves as having higher 
levels of motivation compared to their clinicians. 
The finding that clinicians more often disagree with 
patients of non-Dutch ethnicity (i.e. clinicians are 
less likely to overrate motivation for these patients), 
may be related to problems in communication or the 
therapeutic relationship which have been found to 
be more prevalent for ethnic minority patients 282,283. 
 Limiting the results of the current study, is 
that the patients in the research sample showed 
relatively high levels of motivation and psychosocial 
functioning, considering the range of scores. This 
may reflect that the current study was not successful 
at recruiting SMI patients with substantial problems 
in their motivation for engaging in treatment, 
suggesting ceiling effects and possibly a selection 
bias towards patients who were already relatively 
highly motivated for engaging in treatment and 
functioned at a relatively high level. Thus, the 
findings of the current study may not be generalizable 
to the total SMI outpatient population. Another 
limitation of the current study is that the MET asked 
a different question to clinicians (i.e. to give a rating 
of motivation) than the URICA-D and TEQ (i.e. to 
estimate motivation from the patient’s perspective). 
We did not assess both types of questions for all five 
instruments of motivation, as administering all five 
motivation scales twice to the clinicians (i.e. once for 
‘agreement’ and once for ‘accuracy’) was considered 
too burdensome and not feasible. Further, it should 
be noted that both the URICA-D and TEQ were 
developed as patient self-report questionnaires 
and their validity for clinicians might therefore 
be questionable, although previous work found 
preliminary support for the validity of the clinician-
rated TEQ in the form of statistically significant 
moderate to strong correlations with treatment 
engagement and therapeutic alliance218. Our choice 
of these questionnaires lay in the absence of validated 
questionnaires for clinician-rated motivation for 
treatment. Finally, as the current study used medical 
records to obtain patient diagnoses instead of with 
structured clinical interviews, this limited our ability 
to comprehensively examine differences between 
different diagnostic groups of patients.
 Research questions that remain include the 
identification of possible moderators of agreement 
between patients and clinicians, differences 
between diagnostic groups, and the determinants of 
agreement and accuracy over the course of treatment. 
In line with the broadly accepted use of the HoNOS 
total scale score in both research and practice 
276, the current study chose to use this summary 
measure of functioning as predictor of motivation 
reporting. However, future studies might also look 
at separate domains of psychosocial functioning 
(e.g. social or cognitive functioning), as these might 
be differentially related to (reporting of) motivation. 
Further, it could be insightful to investigate the use 
of more dynamic clinician characteristics, such as 
mood and symptoms of burn-out 284, and address 
the question of how clinician-patient acquaintance 
and clinician discipline are related to differences 
scores, as the current study was not able to address 
this appropriately. For example, different (kinds of) 
clinicians might be differentially “close” to patients 
in knowing their motivation and thus relatively 
better in rating the patient’s motivation. Although 
we assessed clinicians who had most frequent 
contact with the patient and could therefore be 
viewed as “most close” to the patient, future studies 
could address this by adding assessments of such 
variations in “closeness” or acquaintance. 
 Strengths of the current study include the 
inclusion of three theories of motivation, multiple 
methods of assessing motivation for engaging in 
treatment and the implementation of this study in 
everyday practice of the community mental health 
teams using a real-life heterogeneous patient 
population. The simultaneous exploration of three 
theories in the same patient population is fairly 
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Outcome:
Variables1:
Motivation 
to engage in 
treatment (MET)
Readiness to 
Change 
(URICA-D)
Identified 
motivation 
(TEQ)
Introjected 
motivation
(TEQ)
External motivation
(TEQ)
Under vs 
agreea
Under vs 
overb
Under vs 
agreea
Under vs 
overb
Under vs 
agreea
Under vs 
overb
Under vs 
agreea
Under vs 
overb
Under vs 
agreea
Under vs 
overb
Female sex
Patient age
Higher education
Dutch ethnicity
Living alone
1.24
1.00
1.89
1.59
1.08
2.47*
1.00
2.35*
3.30*
0.97
0.95
1.00
0.92
0.95
1.19
1.22
0.99
1.35
1.06
1.00
1.63
0.98
2.98
1.00
1.10
1.43
0.98
2.92
1.01
0.98
1.07
1.00
0.99
0.89
0.89
0.98
0.99
0.63
0.71
1.21
1.33
1.00
0.88
1.20
0.87
0.72
1.00
0.57
0.66
0.98
Psychotic disorder
Comorbid substance abuse 
Legally mandated treatment
Age of first contact with mental health services
Previous admissions
Missed appointments
Duration of current treatment
Frequency of contacts 
1.16
0.33*
0.66
1.00
1.30
0.72
1.00
1.32
1.10
0.26*
0.37
0.97
0.84
0.54*
1.00
1.20
1.47
1.02
0.80
1.00
1.46
0.71
1.00
0.97
1.58
0.28*
0.19*
1.01
0.62
0.64
1.01
1.24
0.98
0.76
0.29*
0.98
0.89
1.09
1.00
0.89
1.37
0.33*
0.40
1.00
0.71
0.73
1.01
1.39*
0.79
0.98
2.77
1.02
1.22
1.46
1.00
1.07
0.78
0.80
0.88
0.99
1.12
1.65
1.01
1.19
0.54*
1.87
1.88
0.97*
1.26
1.00
1.01*
0.75
0.78
2.03
2.77
1.00
1.44
0.93
1.00
0.76
Psychosocial functioning
Therapeutic relationship 
Social desirability
Treatment engagement
Executive functioning
0.91*
1.04*
0.96
1.07*
0.96
0.94*
1.08*
0.94*
1.13*
0.92
0.96
1.06*
1.00
1.10
1.08
0.89*
1.10*
1.03
1.13
1.07
1.00
1.05*
0.99
1.06*
1.12
0.97
1.07*
1.00
1.07*
1.06
0.96
1.02
1.02
1.01
1.10
0.95*
1.04*
1.05*
1.05*
1.38*
1.00
1.00
0.98
0.99
1.14
1.01
0.97*
1.01
0.96
1.21
Clinician female sex
Clinician years of clinical working experience
0.77
1.02
1.15
1.02
0.26*
1.00
0.24*
1.00
0.94
1.00
0.68
1.00
0.80
0.99
1.04
0.97
1.31
1.02
1.06
1.00
Table 3. Bivariate associations between variables and agreement for five different motivation scales
1 Numbers represent odds ratios, adjusted for clustering at team level. *p<0.05 (two-tailed). 
A Clinicians who rate lower than their patient’s treatment motivation are compared to clinicians in agreement with their patient’s report 
(the first being the reference category).
B Clinicians who rate lower than their patient’s treatment motivation are compared to clinicians who rate higher than their patient’s 
report (the first being the reference category).
Outcome:
Variables1:
Motivation 
to engage in 
treatment (MET)
Readiness to 
Change 
(URICA-D)
Identified 
motivation 
(TEQ)
Introjected 
motivation
(TEQ)
External motivation
(TEQ)
Under vs 
agreea
Under vs 
overb
Under vs 
agreea
Under vs 
overb
Under vs 
agreea
Under vs 
overb
Under vs 
agreea
Under vs 
overb
Under vs 
agreea
Under vs 
overb
Female sex
Higher education
Dutch ethnicity
1.07
1.32
1.41
1.83
1.70
4.82*
1.26
0.61
1.00
1.24
0.79
1.13
1.38
3.04*
0.88
1.42
2.58
0.78
1.06
0.86
0.87
0.74
0.54
0.52
1.47
0.80
1.12
0.90
0.55
0.61
Psychotic disorder
Comorbid substance abuse 
Legally mandated treatment
Duration of current treatment
Frequency of contacts 
1.27
0.43
0.77
0.99
1.14
1.77
0.37
1.08
0.98
1.26
1.77
1.96
0.77
1.00
0.98
2.52
0.70
0.17
1.01
1.22
1.00
0.82
0.21*
1.00
0.91
1.86
0.54
0.45
1.01
1.45
0.90
1.48
2.45
1.00
1.03
0.76
1.13
1.31
1.01
1.08
0.71
2.22
1.69
1.02*
0.71*
0.95
1.85
2.40
1.01
0.73
Psychosocial functioning
Therapeutic relationship 
Social desirability
Treatment engagement
Executive functioning
0.95
1.04*
0.93*
1.01
0.85
1.04*
1.09*
0.89*
1.09*
0.79
0.99
1.05*
0.98
1.05
1.11
0.96
1.10*
0.99
0.98
1.09
1.07*
1.07*
0.99
1.01
1.09
1.06
1.08*
0.98
0.96
1.07
0.95
1.04*
1.01
0.97
1.04
0.97
1.05*
1.04
1.00
1.49*
0.94
1.01
0.99
0.97
1.10
0.97
0.97
1.02
1.00
1.34
Clinician female sex 0.92 1.91 0.19* 0.15* 0.81 0.59 0.80 1.26 0.89 0.89
Table 4. Outcomes of the multivariate logistic regression models for agreement on five different motivation scales 
Numbers represent odds ratios, adjusted for clustering at clinician level and all other variables in the model. *p<0.05 (two-tailed). 
1 All variables were entered simultaneously into the multilevel regression model.
A Clinicians who rate lower than their patient’s treatment motivation are compared to clinicians in agreement with their patient’s report 
(the first being the reference category).
B Clinicians who rate lower than their patient’s treatment motivation are compared to clinicians who rate higher than their patient’s 
report (the first being the reference category).
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uncommon 75, while the comparisons between 
theories may help to advance what is currently 
known about interpersonal differences in treatment 
motivation and outcomes in severely mentally ill 
patients. 
 The current study underlines the importance 
of using multiple informants to assess motivation 
for psychiatric treatment in patients with SMI, 
and contributed to the knowledge base regarding 
assessment methods based on different motivation 
theories. Further research is needed to compare 
the motivational theories on other criteria, increase 
the knowledge concerning sources of disagreement 
and to investigate whether better clinician-patient 
agreement and more accurate assessment of 
the patient’s motivation predict more favorable 
treatment outcomes. 
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Aims and short summary of the 
findings
The main aim of the current thesis was to empirically 
test and compare three current theoretical models 
of motivation for treatment in the context of 
outpatient psychiatric care for patients with severe 
mental illness (SMI). In a literature review (Chapter 
2), we argued that Self-Determination Theory 
(SDT)64, the TransTheoretical Model (TTM)44 and 
the Integral Model of Treatment Motivation (IM)37 
provided unique yet complementary frameworks 
that could be useful as the basis for health care 
interventions in outpatients with SMI. A cluster 
randomised controlled trial was designed (Chapter 3) 
to test whether a Motivation Feedback intervention 
was effective at improving treatment engagement 
and outcomes, and data from the trial were used to 
empirically test the three motivation theories. 
 As the testing of theories is founded on the proper 
assessment of theoretical constructs, assessment 
methods were first investigated. Using structural 
equation modelling, assessment instruments from 
SDT were found to be valid and reliable (Chapter 4). 
Subsequently, support was found for the hypotheses 
from SDT and the model was found to be stable 
across time and different diagnostic patient groups, 
and was able to explain 18% to 36% of variance 
in clinical outcomes (i.e. treatment engagement, 
psychosocial functioning and quality of life) 
(Chapter 5). Similar empirical tests were performed 
to evaluate the applicability of the IM (Chapter 6) 
and the TTM (Chapter 7). Although the assessment 
of motivation was found to be reliable for the IM, 
the basic hypotheses from IM were not supported, 
nor was the model similar across time and patient 
groups. The IM constructs did explain between 22% 
and 86% of variance in clinical outcomes, depending 
on the timing of the assessment. Regarding the TTM, 
two different assessment methods for the stages 
of change were found to show low convergence 
and partially showed the expected associations 
with other TTM constructs and with treatment 
engagement. The TTM stages of change explained 
3% to 16% of variance in clinical outcomes.
 Regarding the trial, it was expected that 
Motivation Feedback (MF) based on SDT, which was 
provided additional to treatment as usual (TAU), 
would induce more awareness regarding motivation 
for treatment and aid the internalization of the 
patient’s motivation resulting in a higher level of 
treatment engagement, compared to TAU only. After 
one year of treatment, however, no differences 
between the intervention group and control 
group on treatment engagement, psychosocial 
functioning and quality of life were found (Chapter 
Ch. 10
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8). An evaluation of internal validity, including non-
response bias, information bias, implementation 
issues and differential effects between patients 
with psychotic disorders and personality disorders, 
largely explained why MF was not able to improve 
outcomes. Finally, it was found that the accuracy by 
which clinicians were able to estimate patient ratings 
of motivation ranged from low to moderate (Chapter 
9). It is concluded that a negotiated approach on 
motivation is needed, yet the use of Motivation 
Feedback is insufficient to improve motivation and 
treatment engagement in patients with SMI. 
Anna and Otto
Looking back, how does the research presented in 
this thesis regarding the three motivation theories 
relate to the cases of Anna and Otto as presented 
in the General Introduction? First of all, from the 
perspective of mental health care professionals, both 
cases presented with problems regarding motivation 
for engaging with treatment services and both cases 
raised questions regarding how the mental health 
care professionals (could have) approached these 
problems in order to help the patients achieve – 
at least partial - recovery from their mental health 
problems. 
 Regarding Anna, from the perspective of the 
Integral Model of Treatment Motivation it is plausible 
to assume that, although Anna was highly distressed 
and sought for help with Wilma, her motivation to 
engage with treatment may have been compromised 
by low perceived suitability of treatment and a 
low outcome expectancy due to several negative 
experiences with previous treatments. Although 
Wilma tried to address her distress and tried to 
build a relationship with Anna, Wilma gradually felt 
demotivated by the process. It is likely that Anna 
and Wilma had different perspectives on Anna’s 
motivation for treatment (see Chapter 5), which may 
have led to ineffective motivational interventions. 
For example, Wilma explained the necessary 
conditions for effective psychotherapy to Anna, yet 
this may have raised the perceived costs of treatment 
which – combined with already low outcome 
expectancies – may have further compromised 
Anna’s motivation. Perhaps, the approach taken 
by the assertive outreach team, differed from 
previous approaches in that it was perceived as 
more suitable and less costly by Anna, and was 
therefore more successful until now. Alternatively, 
taking a Transtheoretical Model perspective on 
this case, the timing of certain interventions is 
relevant. The previous attempts at engaging Anna 
in psychotherapy for her psychiatric problems, might 
be understood as failures to recognise the stage that 
Anna was in for each of her problems and to provide 
stage-matched	 interventions. For example, she 
might currently be in the maintenance stage for her 
alcohol abuse problems and in contemplation	stage 
for her drug abuse problems. Finally, taking a Self-
Determination Theory	perspective,	Anna	 is	 likely	 to	
have been deprived in her basic needs for autonomy, 
competence and relatedness which compromised 
her	 abilities	 to	 engage	 for	 a	 longer	 period	 of	 time	
with	the	offered	services.	For	example,	Anna	explains	
how	 it	 took	 her	 a	 long	time	 to	 build	 trust	with	 the	
team	 and	 confidence	 in	 herself,	 which	 may	 reflect	
a	 deprivation	 of	 the	 needs	 for	 relatedness	 and	
competence,	respectively.	Similarly,	Wilma	may	have	
experienced a lack of competence and relatedness 
in	 the	 therapeutic	 relationship	 with	 Anna	 over	
time,	while	also	finding	 it	difficult	to	stay	autonomy	
supportive	towards	Anna.	In	light	of	this,	the	assertive	
outreach team may have found an approach that was 
more	autonomy	supportive	and	more	 supportive	of	
her competence compared to previous approaches, 
for	 example	 by	 reaching	 out	 continuously	 and	 by	
providing individual placement and support.
 Regarding Otto, the Integral Model of 
Treatment Motivation would argue that Otto does 
not recognize his psychiatric illness, as is frequently 
observed in patients with psychoses176, which is one 
of the reasons why Otto feels that medication is not 
a suitable treatment for his problems. Also, Otto 
has experienced external pressure to engage with 
treatment as he has been hospitalized involuntarily, 
but this was so distressing that it has compromised 
his motivation for subsequent psychiatric treatment. 
It appears that Remco and his colleagues have thus 
addressed other determinants of motivation than 
the above, such that Otto accepted their help. From 
the perspective of Self-Determination Theory, it 
can be argued that the need for relatedness may 
have been helpful in establishing a relationship with 
Otto, while also providing support for autonomy 
in respecting his choice for not taking medication 
and by addressing issues that were important 
to Otto. Otto’s motivation was likely external in 
nature from the start (i.e. by pressures from the 
housing association), yet seems to have internalized 
somewhat to a more introjected motivation towards 
Remco (i.e. a feeling of indebtedness). From the 
perspective of the Transtheoretical Model, Otto is 
in the precontemplation stage regarding the use of 
antipsychotic medication and Remco has provided 
a stage-matched intervention by only providing 
information about medication instead of offering (or 
pressuring) him the medication. 
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For both cases, it is relevant for clinicians to 
know which motivation theory provides the most 
plausible explanation of treatment engagement, and 
importantly, which interventions have the highest 
potential to be effective at improving the patients’ 
(psychosocial) functioning and quality of life. The 
research as described in this thesis, provided some 
answers to these questions. 
Reflecting on the three theories of 
motivation and their future
 
The use of any theory is founded on the reliability 
and validity of its theoretical constructs and the 
relationships between these constructs, as well 
as the ability of the framework to explain the 
phenomena it intends to describe75,285,286. More 
specifically, it has been argued that, when theories 
have the purpose to inform the design of effective 
interventions, they are perceived as ‘good’ theories 
when they: “…include constructs that are clearly 
defined and used consistently, are not clearly 
falsified by existing observations, explain the major 
observations in a parsimonious, coherent, and 
comprehensible narrative, and make predictions that 
can be tested through observation.” (p. 582)285. In line 
with this, the three motivation theories that were 
empirically tested in the current research project in 
the context of outpatient psychiatric treatment for 
patients with SMI, were evaluated according to the 
internal consistency and validity of their constructs, 
the plausibility of their proposed framework, the 
robustness of their proposed framework over time 
and different patient diagnostic groups and their 
ability to predict treatment engagement and clinical 
outcomes. 
Self-Determination Theory
Construct validity
Firstly, we found that perceived autonomy support 
by the primary health care professional and the 
different types of motivation as postulated by SDT, 
could be assessed in reliable and valid ways in 
Dutch outpatients with SMI using the Health Care 
Climate Questionnaire (HCCQ) and the Treatment 
Entry Questionnaire (TEQ) (Chapter 4). Specifically, 
the factor structure tested for the TEQ was best 
represented by a model with three interrelated 
factors, namely identified, introjected and external 
motivation. These findings provided the basis for 
further investigations of SDT in the context of 
psychiatric outpatient treatment. 
 Additionally, the short and simple version of 
the TEQ called the Short Motivation Feedback List 
(SMFL) was developed, but this measure did not 
show acceptable reliability and construct validity 
(Chapter 4). The items of the SFML may be understood 
by consideration of both Self Determination Theory 
and approach-avoidance theories of motivation208. 
Although primarily based on SDT, several items can 
be interpreted as representing approach motives 
(‘I will feel proud of myself if I do so’) or avoidance 
motives (‘I may not disappoint myself’ and ‘I may 
not disappoint others’). Considering the brevity of 
the questionnaire (i.e. 8 items), very high reliabilities 
were not desirable as this could indicate that items 
were redundant. It was concluded that the SMFL was 
useful as a communication tool, such that it could 
be the starting point for a discussion between the 
patient and clinician regarding the patient’s current 
motivation for treatment, where these external/
internal and approach/avoidance motives could be 
explored further. 
Plausibility, robustness and explanatory 
power of the theory
The relations between perceived autonomy support, 
perceived competence, types of motivation for 
engaging in treatment and clinical outcomes, which 
represented the basic process model of SDT, were 
investigated using structural equation modelling 
(Chapter 5). In the full sample of 294 patients, the 
results supported all the hypothesized relationships 
in the model, yet it was also found that direct 
additional associations were required between 
perceived competence and clinical outcomes which 
were not a-priori hypothesized (see Figure 1). The 
necessity of such direct effects from competence to 
all outcomes suggested that the patient’s perception 
of being able to do what the treatment required 
was one of the most important factors in relation to 
the patient’s treatment engagement, psychosocial 
outcomes and quality of life. Alternative models in 
which, for example, autonomy support was directly 
related to clinical outcomes were not supported 
by the data. Further, we found that this model was 
robust, in the sense that it was stable across time 
(i.e. baseline assessment and follow-up assessment 
after 12 months) and across different diagnostic 
groups of SMI patients (i.e. psychotic disorders and 
personality disorders). The most plausible clinical-
empirical model suggested that that gaining a sense 
of competence was facilitated by autonomy. In other 
words, once patients experience a high degree of 
choice, respect and relevance of treatment, they are 
then most likely to also experience competence to 
learn and do what the treatment requires.
 These findings are consistent with previous 
studies on SDT in other health-related contexts, 
which have also found support for the indirect 
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link between perceived autonomy support and 
health outcomes via perceived competence 217. 
Finally, it was found that the SDT process model 
explained around 18% to 24% of the variance 
of treatment engagement, around 26% of the 
variance of psychosocial functioning and around 
31% to 36% of the variance of quality of life. These 
findings compare favourably to most other studies 
investigating models that include attitude-behaviour 
relationships 224, and therefore provide support for 
the explanatory power of SDT in the outpatient 
treatment of patients with SMI. 
Conclusions and implications regarding SDT in 
outpatients with SMI
In sum, the findings support the application of 
SDT in the mental health care for patients who 
are in outpatient treatment for a severe mental 
illness, as SDT was found to be sufficiently valid, 
plausible and robust to provide a useful basis for 
(future) interventions in this context. SDT has 
shown explanatory power, yet most variance in 
clinical outcomes remained unexplained which 
suggests that there is (clearly) room for additional 
constructs to be considered as potential targets for 
interventions to improve clinical outcomes. Other 
SDT constructs that were not part of the current 
study, such as perceived relatedness, other types of 
motivation and/or causality orientations48, may need 
to be incorporated into future modelling efforts and 
subsequent interventions such that explanatory 
power and effectiveness of interventions may be 
improved. 
 Before clinical practice will be able to optimally 
profit from SDT-based interventions, further research 
is needed. Further longitudinal monitoring of SDT 
constructs in outpatient treatment is needed to 
allow for more elaborate (i.e. “complete”) models to 
be constructed to examine the crucial mechanisms 
of change. In doing so, the most essential and 
powerful (explanatory) constructs can be identified, 
which may then be specifically targeted in health 
care interventions. Future studies could benefit from 
a so-called conjoint analytic approach which can, 
for example, include the combined effects of high 
and low autonomy and competence or motivational 
profiles of patients who show high ratings on all 
types of motivation compared to patients who show 
low ratings on several or all types of motivation, 
such that we could further clarify the potential 
additive, synergistic or antagonistic effects between 
these constructs. Eventually, experimental research 
is needed to confirm the causality of the relations 
between the SDT constructs and their ability to 
influence treatment outcomes. 
The Integral Model of Treatment 
Motivation
Construct validity
The IM is theoretically affiliated with Ajzen and 
Fishbein’s theory of planned behaviour45, with a 
strong focus on attitudes toward the behaviour, 
subjective norms, and perceived behavioural 
control. The theory of planned behaviour 
however, does not account for other factors that 
can influence motivation, such as distress, past 
experience or environmental factors, which are 
relevant in the context of motivation for engaging 
in treatment (-related behaviours)37. The IM does 
take into account these factors more explicitly and 
may therefore be useful in the context of mental 
health care for patients with SMI. The concept of 
motivation for engaging with treatment by the IM 
was found to show statistically significant positive 
association with autonomy support, identified 
motivation, readiness to change, the quality of the 
therapeutic relationship and treatment engagement, 
whereas it was negatively associated with external 
motivation (Chapter 4). This provided preliminary 
support for the construct validity of the motivation 
concept from IM. The Treatment Motivation Scales 
for Forensic patients (TMS-f) as developed by the 
originators of IM116,118, was investigated such that 
all IM constructs could be studied in relation to 
clinical outcomes in outpatients with SMI (Chapter 
6). The original TMS-f comprises of one subscale 
for motivation for engaging with treatment, six 
subscales for the so-called internal determinants (i.e. 
problem recognition, distress, perceived costs of the 
treatment, perceived suitability of the treatment, 
outcome expectancy, perceived legal pressure) and 
a scale for social desirability. As the research in the 
current thesis aimed to explore whether the IM was 
also applicable outside a forensic psychiatric setting, 
we decided to adapt the construct of perceived 
legal pressure into a more broad perceived external 
pressure by others. This adjustment was justified by 
considering that only a subgroup of outpatients with 
SMI would be referred to or pressured into psychiatric 
treatment via the legal system, while (most) others 
would likely experience other pressures that drive 
their motivation for engaging with treatment (i.e. 
family, friends, partner, assertive outreaching 
clinicians). In our patient sample, the congeneric 
estimates of reliability for the internal determinants 
and motivation as assessed with the TMS-f ranged 
from moderate to excellent. This provided the basis 
for further investigations of the IM.
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Plausibility, robustness and explanatory 
power of the theory
Using structural equation modelling, it was 
investigated whether the relations between the 
internal determinants, motivation, treatment 
engagement, psychosocial functioning and quality 
of life were in line with original hypotheses from IM 
(Chapter 6). It was found that the final empirically 
obtained model in the current sample was not in 
line with original hypothesized theory nor similar 
to the obtained empirical model which was 
previously found by Drieschner and Boomsma116. 
The hypothesized mediational effect of motivation 
between internal determinants and treatment 
engagement was only partially supported. It was 
found that motivation fully mediated the effects of 
problem recognition, suitability of treatment, costs 
of treatment and outcome expectancy on treatment 
engagement (see Figure 2). Further, the model 
was not acceptable in our patient sample unless 
additional direct associations between distress 
and all clinical outcomes were incorporated. Also, 
perceived external pressure was found to be of direct 
influence on the patient’s treatment engagement, 
independent of a mediational effect by motivation. 
Taken together, these findings thus did not support 
the plausibility of the total IM in outpatients with 
SMI, but some support was found for the utility 
of IM constructs in relation to clinical outcomes. 
Specifically, the patient’s perceived suitability 
of treatment, perceived costs of treatment and 
outcome expectancy were most strongly associated 
with motivation and treatment engagement. Further, 
the empirically derived most plausible model was 
not stable across time nor across different patient 
groups, indicating that the IM in its current form 
does not constitute a robust framework for patterns 
through which patients become motivated to engage 
in treatment.
	 Interestingly,	 the	 level	 of	 distress	 is	 generally	
regarded an important determinant of treatment 
motivation,	 such	 that	 more	 (symptomatic)	 suffering	
makes	 patients	 more	 motivated	 to	 engage	 in	
treatment227. Indeed, studies have found that 
treatment-seeking	patients	with	personality	disorders	
or	substance-use	disorders	reported	higher	subjective	
distress than those who did not seek treatment228,229. 
However, in a previous study (not a part of the current 
thesis)	we	found	that	patients	with	SMI	who	showed	
more symptoms and more psychosocial problems 
were	 less	 motivated	 for	 engaging	 in	 treatment230. 
Consistent with this, for the IM we found that distress 
showed	 a	 negative	 association	 with	 treatment	
engagement	 and	 was	 unrelated	 to	 motivation	 for	
engaging in treatment (controlling for the other 
internal determinants). This implies that, higher 
distress	 may	 withhold	 outpatients	 with	 SMI	 from	
in engaging with treatment, which may be related 
to	 the	finding	 that	higher	distress	 is	 also	 associated	
with lower outcome expectancy and lower perceived 
suitability of treatment (for reference, see Table 2 in 
Chapter 6).
 It is likely that the interrelations of internal 
determinants are different from what the current 
theory suggests. For example, it was rather 
remarkable that the correlation between perceived 
suitability of treatment and motivation was positive 
at both time points, yet when corrected for the 
influence of the other internal determinants in the 
final model resulted in a negative association at 
baseline, and again a positive association at follow-
up. Such findings indicate that the interrelations 
of the internal determinants are likely to be more 
complex than the current theory suggests, and 
this should therefore be subject of subsequent 
investigations of the IM. 
The obtained plausible model explained between 
22% to 86% of treatment engagement, between 38% 
to 43% of psychosocial functioning and between 31% 
to 42% of quality of life, depending on the timing of 
the assessment. This is considerable and clinically 
relevant, suggesting that the concepts contained 
within the IM hold good potential to predict 
treatment outcomes. The discrepancy between 
explained variances at baseline and at follow-up 
may be explained by the relative contributions of 
perceived suitability of treatment and motivation, 
which were more pronounced at the follow-up 
assessment. All in all, these findings warrant further 
empirical investigations into the IM.
Conclusions and implications regarding the IM 
in outpatients with SMI
In sum, the findings in the current thesis indicate 
that currently, the IM does not constitute a plausible 
nor robust framework for patterns through which 
patients become motivated to engage in treatment, 
but the theory does include valid constructs that can 
explain substantial amounts of variance in clinical 
outcomes. Clinical implications of the findings in 
the current thesis include that perceived suitability 
of treatment, perceived costs of treatment and 
outcome expectancy currently seem the most 
interesting targets for interventions aimed at 
improving motivation and treatment engagement. 
However, similar to SDT, before clinical practice 
will be able to optimally profit from IM-based 
interventions, further research is needed. 
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Future studies should aim to test the IM in other 
clinical populations, to further specify the relations 
between constructs in the model and to re-specify 
(or reject) the initially hypothesized principles. 
Depending on the context of these future studies, 
researchers may choose to use the original TMS-f, 
or to use the version that was used in the current 
thesis in which the legal pressure subscale was 
adapted to represent external pressure. Also 
similar to SDT, future studies could benefit from 
studying the combined effects of specific scores on 
the internal determinants to provide motivational 
“profiles” of patients. The IM might be improved 
by re-specifying the interrelations of the internal 
determinants and/or by including intermediary 
factors such as action planning between the level 
of MET and the actual treatment engagement86,115. 
Including such intermediary factors might create 
opportunities to beneficially influence the pathway 
to treatment engagement, besides the targeting of 
the most relevant and crucial internal determinants 
that may improve motivation. In further (clinical-) 
empirical testing of the theory, it will become more 
accurate and thus more useful for application in 
clinical practice. 
The Transtheoretical Model
Construct validity
TTM researchers have evaluated two distinct but 
related aspects of motivation: motivation for change 
and motivation for engaging in treatment53. Although 
related, these two concepts are not equivalent, as 
patients may want to change their health behaviour 
problem without professional help, or vice versa, 
patients can come into treatment and be motivated 
to engage in treatment activities but still be reluctant 
to change their health behaviour problems. At the 
start of the current research project, it appeared 
that the TTM had been understudied regarding 
motivation for changing psychiatric problems 
in outpatient treatment for patients with SMI63, 
despite its potential in this domain86. Therefore, 
the convergent validity and criterion validity of the 
staging algorithm and the University of Rhode Island 
Change Assessment (URICA-D) were studied for such 
application. Using these two measures, as well as 
measures for other TTM constructs, validity was 
investigated using structural equation modelling in 
the sample of 294 SMI outpatients (see Figure 3). 
 It was found that the two measures showed 
low convergence at both time points (i.e. baseline 
and follow-up) and thus seemed to assess different 
aspects of motivation to engage with psychiatric 
treatment (Chapter 7). As such, no support was 
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Figure 1. Empirically supported process model for SDT in Dutch outpatients with SMI
Note: Variables reflect patient-rated constructs unless indicated otherwise. Arrows indicate the direction of the relationships, dotted 
lines represent intercorrelations of variables. Boldface indicates that associations were empirically supported. 
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found for convergent validity. Also, both measures 
only partially showed the theoretically expected 
associations with criterion measures such as other 
TTM constructs, including the processes of change, 
decisional balance and self-efficacy. Findings were 
also mixed regarding the associations between stages 
and clinical outcomes for both assessment methods, 
such that the majority of the theoretically expected 
associations were not confirmed. For example, the 
stages generally did not show the theoretically 
expected differentiation between stages and the 
mean level of treatment engagement. Thus, these 
findings revealed important problems regarding the 
construct validity of stages for changing psychiatric 
problems in outpatient treatment for patients with 
SMI.
 Despite the limited range of scores on the URICA-D 
and the frequency distributions on the staging 
algorithm, it was expected that, in a population 
of patients who receive assertive outreaching 
psychiatric care, a distinction between patients in 
contemplation and those in maintenance should be 
possible (if these stages are indeed present and are 
a ‘real’ entity). However, the results suggested that 
– at least in so far as these stages are assessed with 
the algorithm or the URICA – the stages are difficult 
to distinguish from each other and therefore may 
not constitute clinically identifiable separate stages 
regarding readiness to engage with treatment. 
Minimally, this casts doubt on the potential utility 
of the stage construct from TTM as a framework for 
motivation for engaging with treatment considering 
that the processes, markers and outcomes that 
are supposed to be capable of distinguishing the 
stages do not do so. Acknowledging that the cross-
sectional approach to studying the stage construct is 
limited in its ability to identify stages from pseudo-
stages or a (nonlinear) continuum model77, the 
findings of the current study do not seem to support 
a stage theory. It has previously been argued that 
the use of the stage construct in clinical practice for 
patients with SMI is problematic even aside from 
the lack of validated measures, as patients typically 
present with multiple problems whereas the stage 
construct seems to require “that central, one and 
only, specifically identified problem” (p. 54) 113. The 
findings in the current thesis seem to affirm these 
problems. 
 It should be noted that, there were reliability 
issues for the URICA-D which, by definition, 
undermine validity. Only the action scale of the 
URICA-D showed an acceptable level of internal 
consistency, whereas the other scales showed 
poor to questionable internal consistencies. Inter-
item correlations were generally in the low range 
overall, implying that the items within each subscale 
did not reflect the same underlying construct. It 
is plausible that the generic problem statement 
‘willingness to change psychiatric problems during 
outpatient treatment’ was too broad, such that 
patients with different types of psychiatric problems 
and different treatments (e.g. with or without 
medication, additional supportive employment, 
volunteer work opportunities etc.) may have had 
different response tendencies, resulting in problems 
with internal consistency. Studies using the URICA 
in other populations have shown higher internal 
consistencies, such as in patients in methadone 
maintenance treatment232 and dually diagnosed 
patients57, which may imply that the use of the 
URICA is more suited for treatment settings which 
specifically focus on addiction problems in psychiatric 
outpatients rather than the psychiatric problems 
itself. However, the URICA was found to have 
questionable external validity in those patient groups 
as well101,232. Alternatively, when a total “readiness 
for change score” was calculated by subtracting 
the precontemplation scale score from the sum of 
the other three scale scores (consistent with other 
studies using the URICA-D57), this resulted in good 
internal consistency, namely a congeneric estimate 
of 0.90. This readiness to change score was found 
to show statistically significant positive association 
with identified and introjected motivation, 
motivation for engaging with treatment, perceived 
autonomy support and the quality of the therapeutic 
relationship (Chapter 4). The readiness to change 
score also showed statistically significant negative 
association with external motivation, yet it was 
not significantly related to treatment engagement. 
Taken together, the findings are contradictive of the 
hypothesized stage construct of the TTM, but rather 
seem supportive of an underlying continuum of 
readiness to change. 
 To summarize, when using existing popularly 
applied measures to assess the TTM constructs, it 
seems that we still lack empirical support for the 
validity of the stage construct of the TTM model 
as a way of evaluating the patient’s motivation for 
engaging with the treatment services. The findings 
in the current thesis thus underscore the need for 
the further (development and) evaluation of such 
measures.
Plausibility, robustness and explanatory 
power of the theory
The problems with the validity of the stage construct 
as described above, cast serious doubt on the 
plausibility of the stage construct for engaging with 
psychiatric treatment services. Although it was 
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found that the associations between stages and 
treatment engagement were consistent across time 
and different patient diagnostic groups (Chapter 7), 
showing support for robustness, the stages showed 
limited ability to explain treatment engagement 
behaviour and clinical outcomes. Only 6% to 16% of 
treatment engagement was explained by the stage 
construct, and between 8% to 17% of psychosocial 
functioning and between 5% to 15% of quality of 
life, depending on the timing of the assessment. 
The relevance of these findings is ambiguous, 
considering the previously mentioned problems 
with the validity of the stage construct. The stage 
construct is only one part of the TTM, as TTM also 
includes other constructs and hypotheses, yet 
the stage construct is considered the central and 
distinctive construct in the theory. It seems that, 15 
years after Stephen Sutton urged researchers to go 
“back to the drawing board” with the TTM88, little 
advancement has been made regarding changes in 
the definition and operationalization of the stage 
construct, resulting in applications of unreliable and 
invalid measures in clinical practice. This currently 
prevents advancements in the further development 
and research on the TTM. 
Conclusions and implications regarding the 
TTM in outpatients with SMI
In sum, the findings in the current thesis indicate 
that currently, the TTM does not constitute a 
plausible framework for patterns through which 
patients are motivated to change their psychiatric 
problems in outpatient treatment. There are serious 
problems with existing popular methods used to 
assess the central stage construct, casting doubt on 
the reality of ‘stages’ and questioning whether the 
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Figure 2. Empirically supported process model for IM in Dutch outpatients with SMI
Note: Variables reflect patient-rated constructs unless indicated otherwise. Arrows indicate the direction of the relationships, dotted 
lines represent intercorrelations of variables. Boldface indicates that associations were empirically supported.
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TTM provides a valid description and explanation of 
the process of change during psychiatric treatment. 
These problems have previously been identified in 
other populations, mainly in the context of smoking 
cessation and addiction treatment80,88,90, while the 
findings in the current thesis indicate that these 
problems also exist in the context of outpatient 
psychiatric treatment for patients with SMI. 
 These findings are problematic, as the potentially 
unique and useful contribution that the TTM can 
bring to the psychiatric treatment of patients with 
SMI, can only be adequately studied if we can 
reliably and validly assess its main constructs. The 
main focus of future studies should therefore be to 
(develop and) test other staging instruments, such 
that these can be a foundation for further research 
into the utility of the TTM in psychiatric treatment 
services. Until such reliable and valid assessments 
for the patient’s stage of change for engaging with 
psychiatric services are available, essential questions 
regarding the potential utility of the TTM in this 
context cannot be adequately addressed. 
 It seems that there is a rather large discrepancy 
between the evidence base for the application 
of the TTM in clinical practice, and the still 
enormously popular use of the TTM in actual clinical 
practice43,61,257. The popularity of the TTM in clinical 
practice has mainly been ascribed to its considerable 
heuristic value, as the model portrays change as 
“more than a simple, one-step process and may 
promote a less pejorative view of people who are not 
ready for change and those who relapse” (p. 224)79. 
It seems that the TTM is primarily used to encourage 
greater patience and persistence in change efforts 
(both in patients and clinicians) and to evaluate the 
timing of certain interventions. The questions that 
TTM raises remain important for clinical practice, 
including whether there are critical periods during 
which specific intervention strategies should be 
applied to facilitate treatment engagement and 
improve clinical outcomes for patients with SMI. 
However, the research presented in the current 
thesis, combined with previous critical reviews on 
the TTM in other health behaviour contexts79,80,88,99, 
suggest that the TTM cannot have much practical 
utility if its basic constructs are not accurately 
defined and operationalized, or if the basic 
constructs (i.e. the stages) do not reflect actual real-
life qualitatively different states. Several randomised 
clinical trials to date which have investigated 
stage-matched versus mismatched interventions 
have found little support for the superiority 
of matched over mismatched interventions 235-237,287, 
suggesting that the studies showing beneficial 
effects for TTM-based interventions compared 
to	other	types	of	interventions	may	be	a	consequence	
of	 other	 mechanisms	 and	 characteristics	 of	 
the	 TTM-interventions,	 but	 not	 a	 consequence	 of	
stage-matching.
 Although the TTM raises important questions 
and appears to have provided useful ways of thinking 
in clinical practice about how people engage in 
health behaviour changes, we agree with Littell79 
and Sutton88 that it is time to consider alternative 
conceptualizations of motivation and behaviour 
change. Specifically, the heuristic value of TTM may 
be maintained, including the importance of the 
timing of interventions, while the notion of ‘stages’ 
may be replaced by a more parsimonious continuous 
model of motivation and behaviour change79. Such 
a model may still include TTM constructs such as 
self-efficacy, decisional balance and processes of 
change, and may be more easily integrated with 
potent and useful constructs from SDT, the IM and 
other theories. In the following, an attempt is made 
for such an integration. 
An integrated approach to motivation 
in outpatient treatment
Based on the findings of the three motivation 
theories, we suggest that the model as depicted in 
Figure 4 may be used as the basis for an integrated 
approach to motivation in the context of outpatient 
psychiatric care for patients with severe mental 
illness. Figure 4 visualises our empirical findings, 
as well as (further) testable hypotheses regarding 
the relationships within and between the theories. 
Central to this integrated model is the use of SDT 
as the connecting theory between the other two 
theories (shown in grey), which was chosen for 
several reasons.
 Firstly, motivation as defined by SDT applies to 
motivation for engaging with treatment (as in IM) 
as well as motivation for engaging in behaviour 
changes that may occur inside or outside of 
treatment (as in TTM). Secondly, the use of SDT 
in outpatient treatment for patients with SMI was 
empirically supported by the research in this thesis, 
as this model compared favourably to the other two 
theories in terms of reliability, validity, plausibility 
and robustness. Regarding explanatory power in 
terms of how much variance was explained by each 
theory in the clinical outcomes, the three theories 
are not easily compared as they include different 
(and unequal numbers of) constructs. Obviously, 
theories that include more predictors have a higher 
likelihood of explaining more variance (assuming 
that these predictors are meaningful). In line with 
this, it was found that the IM was most powerful 
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while the TTM stages of change were least powerful. 
As noted previously, all three theories deserve 
further empirical research to ensure further theory 
development, albeit that each theory has different 
“empirical needs” in terms of reliability, validity, 
plausibility, robustness and explanatory power. 
 The third reason that SDT was chosen as the 
connecting theory, is that preliminary empirical 
support was found for the associations between 
the qualitatively different types of motivation from 
SDT and the quantification of motivation by the 
IM and TTM (Chapter 4). That is, higher levels of 
identified motivation were associated with higher 
levels of motivation for treatment and readiness to 
change, while higher levels of external motivation 
were associated with lower levels of motivation for 
treatment and readiness to change. These findings 
were consistent with other studies in different 
contexts97,127,140,141, and deserve further empirical 
testing in outpatients with SMI. Nevertheless, 
several important questions for both research and 
practice are raised by this integrated theoretical 
model. These include whether high distress and 
high perceived external pressure are consistently 
associated with low motivation, low treatment 
engagement and low readiness to change, whether 
more internalized motives are associated with 
more long-term behaviour change and whether 
higher need satisfaction is consistently associated 
with better quality and more enduring motivation 
for engaging with treatment services as well as 
behaviour changes. 
 Figure 4 also assumes that certain internal 
determinants are differentially associated with the 
quality of a patient’s motivation (as depicted), as 
for example high distress and perceived external 
pressure are hypothesized to be associated with 
low patient need satisfaction and thus with more 
extrinsic motivation or even amotivation, while 
also being associated with low readiness to 
Figure 3. Empirically supported process model for TTM stages of change in Dutch outpatients with SMI 
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change and if change occurs, it would be short-
term only. Conversely, high outcome expectancy 
is hypothesized to be associated with higher 
motivation for treatment but also with higher patient 
need satisfaction and more long-term behaviour 
changes (if they occur). Further, it can be seen 
that three internal determinants, namely problem 
recognition, perceived costs of treatment and 
perceived suitability of treatment are hypothesized 
as specific predictors for motivation for treatment, 
whereas distress, perceived external pressure and 
outcome expectancy may be related to motivation 
for engaging with activities outside of treatment. 
Figure 4 also assumes that, intrinsic motivation does 
not apply to motivation for engaging in treatment 
whereas it may apply to behaviour changes. 
 Regarding the TTM, we argue for a more 
parsimonious continuous approach to readiness 
for change and we show in Figure 4 that we have 
abandoned the idea of distinct stages in this respect. 
Rather, we agree with the originators of TTM that 
there may be a certain threshold to readiness for 
change, after which a change attempt is made, 
which may or may not be persistent over time. 
Similar to the original TTM, it is still acknowledged 
that relapse is common and that change is a cyclical 
process, rather than linear. We believe that our 
alteration to the TTM still fosters the heuristic 
value of the model and acknowledges the relevance 
of the timing of certain interventions, while also 
acknowledging the empirical research base that has 
shown serious and systematic problems with the 
validity of the stage construct. Other TTM constructs 
have not been investigated in the models of the 
current thesis, yet previous research shows that the 
constructs of decisional balance and self-efficacy 
are associated with readiness to change and change 
attempts in outpatients with SMI 60,275,288-290, and 
may thus be relevant for future studies to include in 
more extensive empirical-statistical modelling. The 
TTM processes of change, which in the proposed 
revised theoretical model are no longer associated 
with specific stages but rather with either the level 
of readiness to change or with the duration of actual 
behaviour change, may also be subject to future 
investigations. 
 Finally, regarding the clinical outcomes of 
patients with SMI, Figure 4 suggests that the level 
of psychosocial functioning and the patient’s 
quality of life are products of both treatment 
engagement, the fulfilment of basic psychological 
needs and behaviour changes. In other words, it 
is acknowledged that psychiatric treatment is only 
one of many pathways through which a patient may 
achieve a healthy, meaningful and satisfactory life. 
Importantly, we also assume a feedback process over 
time, in which a patient’s psychosocial functioning 
and quality of life can influence the experienced 
distress, outcome expectancy (of treatment) 
and self-efficacy (in or outside of treatment) and 
decisional balance for change. This feedback process 
implies that factors may influence each other in a 
beneficial way over time, for example when engaging 
in behaviour change leads to a higher quality of life 
and better psychosocial functioning and hence, less 
distress and higher perceived self-efficacy. Vice 
versa, factors may also influence each other in a 
detrimental way, such that substantial problems in 
psychosocial functioning may lead to more distress 
such that patients do not engage in treatment nor 
in long-term behaviour changes, leaving them in a 
potentially downward spiral. All these assumptions 
may be empirically tested in future research to 
further clarify the interrelations of the theories and 
to identify the most useful targets for mental health 
care interventions. 
 Future studies should consider a conjoint 
analytical approach to motivational models, to 
investigate the combined effects of different types 
of motivation, such that we can further clarify 
the potential additive, synergistic, or antagonistic 
effects between these constructs. Although this 
does not directly follow from Figure 4, as the 
figure depicts the different types of motivation as 
a continuum from least to most self-determined, 
it is theoretically possible for patients to endorse 
all types of motives simultaneously. Supported 
employment may be an example of such conjoint 
endorsement, as this combines the intrinsically 
motivating psychological benefits of work (e.g. 
sense of competence and having a valued social 
role, sense of autonomy) with the externally 
rewarding benefits of earning money196. If such 
dynamics are found to also apply to engaging 
with treatment services, this could argue for 
an approach that simultaneously fosters both 
extrinsic and identified motivation for engaging in 
treatment. For example, extrinsic rewards such as 
praise by a mental health worker or receiving help 
for financial problems, may help to achieve short-
term desired goals and provide a sense of self-
competency and relatedness, while the support 
for autonomy could ensure that patients do not 
become dependent on such external rewards 
and still feel self-determined in their choices and 
behaviour 196,214. Also, for patients where distress is 
high while other motivational determinants are low, 
this may provide an argument for the paternalistic 
practices as performed by the assertive outreach 
teams, trying to engage patients who are in need of 
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help but do not seek or accept it36. These patients 
might be engaged by first increasing the external 
(legal) pressure, which could provide a starting 
point for short-term behaviour changes and initial 
treatment engagement after which – preferably 
as soon as possible or even parallel to it, if the 
proposed model is plausible and has explanatory 
power – more autonomy supportive interventions 
are applied in order to foster the basic needs and 
facilitate the internalization process. 
Limitations to the proposed revised 
theoretical model
It should be noted that the three motivation theories 
considered in the current thesis are psychosocial 
models of motivation tailored to individuals, as 
opposed to for example, community and societal 
models that focus more on how individuals interact 
with their environments, social networks and 
organisations, or biopsychosocial models that 
also explicitly include biological factors such as 
genetics and developmental, immunological and 
neurological factors that may influence or interact 
with motivation. Researchers, program developers 
and clinicians should not ignore the wide array of 
unconscious, biological and higher-level influences 
that affect motivation and behaviour. As such, 
neither of the three theories alone nor our proposed 
revised theoretical model (Figure 4) should be 
viewed as holistic or complete. Further, other 
theories of motivation and health behaviour, such as 
protection motivation theory291, approach-avoidance 
models208, distinctions between implicit and 
explicit motives292,293, implementation intentions294, 
expectancy-value theory270, social cognitive theory46 
and/or the health belief model47, may prove to have 
incremental value or provide substitutes for the 
theoretical	constructs	and	interrelationships	depicted	
Figure 4. Revised visualisation of the three motivation theories and their interrelations in outpatients with severe mental illness
Note:	 IM	 =	 Integral	 Model,	 SDT	 =	 Self	 Determination	 Theory,	 TTM	 =	 Transtheoretical	 Model.	 Dotted	 lines	 represent	 proposed	 and	
preliminary empirically supported relationships between the three theories. Arrows represent the direction of proposed and empirically 
supported relationships within a theory.
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in Figure 4. We encourage researchers to design 
and conduct studies to test two or more theories 
simultaneously and compare them, to further 
advance	theory	and	practice	for	outpatients	with	SMI.	
Reflecting on the results of the 
randomised controlled trial
The overarching design for all the research 
presented in the current thesis was the cluster-
randomised controlled trial. Our trial should be 
viewed as exploratory and pragmatic of character, 
as opposed to confirmatory and explanatory295. 
That is: “A pragmatic randomised trial is undertaken 
in the “real world” and with usual care and is 
intended to help support a decision on whether to 
deliver an intervention. An explanatory randomised 
trial is undertaken in an idealised setting, to give 
the initiative under evaluation its best chance to 
demonstrate a beneficial effect”(p. 1) 295. The rationale 
for the Motivation Feedback (MF) intervention 
tested in our trial, was based on numerous studies 
that suggested that evaluation of the patient’s 
motivation could help to understand how a patient 
may best be engaged in treatment 29,35-37,228 and on 
meta-analyses that had shown beneficial effects of 
employing feedback to clinicians on their patients’ 
mental health outcomes 39,49,242. This supported the 
assumption that MF could be a valuable addition 
to treatment as usual for outpatients with SMI. The 
main hypothesis of the trial was that MF would induce 
more awareness regarding motivational issues that 
were at play during treatment, and subsequently 
to more suitable (motivational) interventions that 
would help to improve the patient’s motivation, 
leading to better outcomes (i.e. treatment 
engagement and psychosocial functioning). MF was 
provided additional to treatment as usual (TAU), 
which consisted of assertive outreaching care by 
multidisciplinary community mental health teams. 
 After one year of treatment, there were no 
differences between MF and TAU regarding clinician-
rated treatment engagement and the number of no-
shows, and no differences regarding the patient’s 
psychosocial functioning and quality of life (Chapter 
8). The results of the trial further showed that SMI 
patients felt that talking about their motivation 
with their clinician did not change their motivation, 
while interestingly, clinicians reported lower 
introjected motivation and, when four or more 
MF sessions were performed, also lower external 
motivation. This suggested that clinicians noticed 
a reduction in relatively external motivation for 
engaging in treatment in their patients in response 
to MF, signifying that their perception of the 
patient’s motivation had changed in response to the 
intervention. Combined with findings that especially 
introjected motivation for treatment was difficult 
for clinicians to estimate at baseline (Chapter 
9), this suggested that MF led to a change in the 
clinician’s perception of the motivation such that 
it became more closely aligned with the patient’s 
perspective. As such, the intervention may have 
enhanced the clinician’s ability to estimate the 
patient’s perspective on motivation, supporting the 
first premise of our main hypothesis of the trial. 
This suggests that SDT-based MF can be a useful 
communication tool for the clinician to explore the 
patient’s perspective, resulting in more accurate 
assessments by the clinician regarding the patient’s 
motives for engaging with services. 
 However, considering the lack of effectiveness 
of MF on the other outcomes, we concluded that 
the addition of MF did not result in more effective 
health care interventions as compared to TAU only. 
An evaluation of our trial’s internal validity, or in 
other words, an evaluation of biases, may explain 
why MF was not found to be more effective than 
TAU only. Three main sources of bias296 will be 
reviewed here: selection bias, information bias, 
and confounding. Regarding selection bias, we 
feel that a bias is likely to have occurred during 
the implementation of the study, rather than in 
the design stage. In our design, we introduced an 
incentive to all patients who participated in the 
trial, such that the likelihood would improve that 
patients with low levels of motivation, treatment 
engagement and psychosocial functioning would 
participate in the trial. Nevertheless, we found 
evidence for a non-response bias in our study sample 
such that SMI patients with substantial problems 
in their motivation for engaging in treatment, 
treatment engagement and psychosocial functioning 
were less likely to participate. The current patient 
sample already showed relatively high levels of 
identified motivation, treatment engagement, and 
psychosocial functioning and low levels of no-shows 
to begin with (considering the range of scores). 
Further, the reasons that non-participants gave 
for declining participation in the trial, including 
feeling too ill or incapable, and the finding that non-
participants were more likely to be patients with a 
psychotic disorder, suggest that the most severely ill 
patients did not participate. Such ceiling effects and 
selection bias may explain why MF was not able to 
improve outcomes, and suggest that the findings of 
the current study may not be generalizable to the 
general SMI outpatient population but are limited to 
patients who are already relatively well engaged in 
treatment and function at a relatively high level.
169
Further, a limitation in the trial was that clinicians 
and patients were not blind for treatment allocation 
which may have influenced the information that 
they gave on the outcome questionnaires (i.e. 
information bias). Observer bias in clinicians, and 
potentially (under)reporting bias in patients, may 
have obscured the results. Although it is common 
in mental health research246 that blinding is not 
feasible, the lack of blinding might have biased the 
results towards the null or even counterproductive 
effects of the MF intervention if clinicians generally 
did not expect the intervention to work. Finally, 
assuming that the randomisation procedure was 
successful, we believe that confounding was unlikely 
to explain the negative results of the intervention 
trial. 
 A further evaluation of the design of our 
pragmatic trial, using the PRECIS-tool295 for 
applicability, learns that we made adequate 
efforts to optimize eligibility, recruitment, setting, 
organisational factors and statistical analyses while 
we may have failed to adequately address issues of 
1) adherence to the intervention, 2) the follow-up of 
patients, and 3) to choose a primary outcome that 
was relevant to participants.
 Regarding the first issue, there were large 
variations between teams and clinicians in the 
number and duration of SMFL assessments, 
reflecting that there were implementation 
difficulties. Although such variation is common 
in pragmatic trials, the findings may reflect that 
too few MF sessions were actually utilised (i.e. 
45% on average) or that the way MF was used in 
the sessions was not able to beneficially affect 
motivation and treatment engagement. Not seldom, 
clinicians admitted that they regularly forgot to 
do SMFL assessments despite efforts from the 
research team to help them remember, and some 
reported that they were burdening the patient with 
‘yet another list to fill out’. Such comments seem 
reflective of a health care context where external 
demands and contingencies pressure people to 
behave in particular ways 225. If this was the case, 
this is likely to have been a counterproductive 
mechanism in the MF intervention64. Although we 
performed evaluation sessions with clinicians in MF 
alongside the trial, we have limited insight into what 
happened during MF sessions as these were neither 
recorded nor supervised. The exact communication 
processes within the sessions and whether or not 
they were autonomy supportive remain unclear, 
whereas such processes might explain why the MF 
intervention was not successful. Despite the training 
and evaluation sessions for clinicians in MF, we may 
have failed in providing the professionals with the 
necessary competencies and tools to be able to 
address different types of motivation for engaging in 
treatment in patients with SMI and how to provide 
support for the needs of autonomy, competence, and 
relatedness. More attention for the implementation 
process, including a minimum intensity of the 
feedback intervention, may be needed to reach 
favourable effects. Encouragement of both clinicians 
and patients into active involvement with MF is 
already difficult when facing patients with highly 
prevalent cognitive impairments, communication 
difficulties, and comorbidities, let alone in a health-
care context faced with reorganizations, and as such 
this requires a unique set of competencies from 
both researchers and clinicians to ensure sufficient 
implementation.
  Regarding the second issue, the timing of our 
outcome evaluation might have been suboptimal. 
Meta-analyses have shown that outcome feedback 
had beneficial effects if outcomes were measured 
within 9 weeks after initial assessment39,147. As 
our study measured outcomes after 12 months, 
potential short-term beneficial changes of the MF 
intervention will have gone unnoticed and may 
have worn off by the end of follow-up. An additional 
assessment moment within the first three months 
of our study could have been informative in this 
respect, but due to practical and financial limitations 
this was not feasible. Future trials may choose to 
shorten the period to follow-up assessment or to 
include more frequent intermediate assessments of 
important process variables and outcomes. 
 Regarding the third issue, our choice for 
treatment engagement as the primary outcome 
may not have been of obvious importance from 
the patient’s perspective and can be considered 
as somewhat distant from the key focus of the 
intervention295, namely a discussion about the 
patient’s motivation and the support of basic needs 
by the clinician. Other (primary) outcomes that we 
could have considered are, for example, perceived 
autonomy support, the quality of the therapeutic 
relationship and/or the patient’s outcome 
expectancy of the treatment. Future pragmatic trials 
should therefore consider whether their primary 
outcome is relevant (enough) to participants. 
Conclusions and implications regarding the 
use of Motivation Feedback based on SDT
In hindsight, we may have had a too optimistic view of 
the potential effectiveness of MF additional to TAU. 
In the Netherlands, the accessibility and quality of 
mental health care for patients with SMI are currently 
at a relatively high level 10. TAU was provided by 
multidisciplinary treatment teams that provided care 
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tailored to the patient’s individual symptoms and 
needs for care and could include assertive outreach, 
medication, social and financial management, job 
counselling, crisis interventions and psychotherapy. 
Such care may have been sufficiently effective for 
the patients participating in our trial, such that MF 
did not prove to be of additional value in our patient 
sample. Acknowledging the limitations of our trial 
(as mentioned previously), we believe that several 
conclusions regarding the use of MF are justified. 
 MF may have resulted in a better assessment 
of the patient’s motivation by clinicians, but was 
otherwise ineffective at improving outcomes. These 
findings were not attributed to problems in the 
underlying theory, but rather to an inability of the 
intervention to beneficially affect crucially important 
mediators of change: the patient’s perceived 
competence and identified motivation. Remaining 
questions include which specific techniques 
clinicians need to be trained in and which other 
contextual factors need to be influenced in order for 
patients to experience an improvement in their basic 
needs (over and above the effects of the treatments 
that are currently provided), and whether the use of 
SDT-based interventions are differentially effective 
for patients at the start of treatment as compared 
to patients who have been in treatment for many 
years already (the latter being the case for most 
patients in the current trial). Regardless, the results 
of the trial currently discourage the implementation 
of the SDT-based MF intervention into community 
mental health care for SMI patients. It appears that 
successful outcome monitoring systems include 
additional support and services alongside motivation 
feedback which allows for beneficial changes in 
clinical outcomes. In the future, there may be a place 
for SDT-based MF as a communication tool for the 
clinician to explore the patient’s perspective, after 
which other tailored interventions and services may 
be applied to improve patient motivation, treatment 
engagement and most importantly, symptomatic 
and functional outcomes. 
 We have concluded that the findings of the 
trial were not attributable to problems with the 
underlying theory, namely SDT, whereas one could 
still question whether the SDT process model was 
stable and comparable across the two treatment 
groups. Additional analyses were therefore 
performed for this General Discussion (not reported 
in Chapter 8), to potentially explain the findings of 
the trial more thoroughly. We argue that, if the SDT 
process model is found to be stable across the two 
patient groups, this would further support the idea 
that the SDT process model was applicable in both 
treatment groups in similar ways. If not, the findings 
could help to understand more thoroughly which 
mechanisms may have been responsible for the lack 
of effectiveness (i.e. no superiority) of MF compared 
to TAU. To this end, we compared the obtained most 
plausible SDT model across the two treatment groups 
using structural equation modelling, in line with the 
analyses from Chapters 5, 6 and 7. Both at baseline 
and at follow-up, it was found that the model was 
different across the two treatment groups (baseline 
model:	 Δχ2=38.49,	 Δdf=21,p=0.01,	 follow-up	
model:	Δχ2=38.66,	Δdf=21,p=0.01).	After	inspecting	
the regression estimates, it was found that both 
treatment groups generally showed the theoretically 
expected associations between SDT constructs, yet 
a noticeable difference was found in the association 
between autonomy support and introjected 
motivation, regarding both the strength and 
direction of the regression coefficients. For patients 
in MF, the association between autonomy support 
and introjected motivation was positive at baseline 
(β=	0.17,	S.E.	=	0.05,	p<0.01)	while	it	was	negative	at	
follow-up	(β=	-0.27,	S.E.	=	0.13,	p=0.04).	For	patients	
in TAU, the association between autonomy support 
and introjected motivation remained positive across 
the two time points and was stronger compared to 
the associations found for the MF group (baseline 
β=	0.55,	S.E.	=	0.10,	p<0.01	and	 follow-up	β=	0.39,	
S.E.	=	0.14,	p<0.01).	No	such	differences	were	found	
for the other types of motivation, where both groups 
showed positive associations between autonomy 
support and identified motivation at the two time 
points, as well as comparable negative associations 
between external motivation and autonomy support. 
Thus, although the averages of patient-reported 
introjected motivation were not statistically 
significantly different between the two treatment 
groups (Chapter 8), it appears that the relationship 
between autonomy support and introjected 
motivation differed between the treatments. 
Although speculative, these findings suggest that 
MF may impact on the therapeutic relationship and 
on introjected motivation, such that an autonomy 
supportive health care climate combined with the 
use of MF may reduce introjected motives. In other 
words, there may have been an interaction effect 
between the use of MF and the nature of the health 
care climate in which it was introduced. 
 The implications of these findings are not 
straightforward, certainly when also considering 
other findings regarding potentially differential 
effects of SDT principles in patients with psychotic 
disorders as compared to those with personality 
disorders (Chapter 5 and Chapter 8). It was found 
that the SDT model at follow-up was slightly 
different for the two patient groups (Chapter 5). 
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Although both patients groups generally showed the 
theoretically expected associations between SDT 
constructs, differences were found in the strengths 
of the associations between SDT constructs. For 
example, autonomy support was found to show a 
stronger and more stable positive relationship to 
identified motivation in patients with psychotic 
disorders compared to personality disorders, which 
may indicate that patients with psychotic disorders 
show more stable continuous benefit from autonomy 
support in terms of their motivation whereas this 
may be more fluctuant in patients with primarily 
personality disorders. Further, the findings suggested 
that MF had opposing effects depending on the 
primary diagnosis, such that patients with primarily 
psychotic disorders showed less favourable changes 
in quality of life and clinician-rated motivation in 
response to MF compared to patients with primarily 
personality disorders (Chapter 8). Although the 
observed changes were small, it is plausible that the 
intervention may have had differential effects. For 
example, commonly found impairments in (social) 
cognitive functioning in patients with psychotic 
disorders 175,254 may explain why an intervention that 
requires patients to repeatedly reflect on internal 
motivational states may have been experienced as 
over-demanding or even frustrating. 
 All in all, it seems that the SDT process model 
and SDT-based interventions may be moderated 
by certain characteristics of the target population, 
which warrants further investigation. Potential 
moderators of the processes described by SDT in 
clinical populations may, for example, be treatment 
duration, duration of illness, cognitive functioning, 
patient age, diagnosis and type of treatment and the 
health care climate.
Strengths and limitations to the 
current research
The research presented in this thesis had several 
strengths including the conduct of studies in 
everyday practice of the community mental health 
teams, the real-life heterogeneity of the research 
sample and importantly, the inclusion of three 
theories of motivation. Other strengths included 
a	 relatively	 large	 sample	 size	 (N=294)	 and	 follow-
up rate (86%) considering the often difficult to 
engage patient population, multiple methods for 
assessing motivation and the use of independent 
research assistants to assess the patient’s 
psychosocial functioning, and the use of advanced 
multilevel statistical analyses in which corrections 
for unreliability of measurements were made 
(i.e. latent variables were modelled) and in which 
rivalling models were tested. Besides these general 
strengths, several other strengths and limitations to 
the research in this thesis deserve consideration. 
Design and methodology
The strengths and limitations to the randomised 
controlled trial have been discussed previously. 
A major strength of the design and conduct of 
the current research project was the inclusion of 
three theories of motivation. Structural equation 
modelling (SEM) was chosen as the main analytical 
technique to address criteria of validity, plausibility, 
robustness and explanatory power of each of the 
theories. SEM offers several primary advantages 
over more conventional analytical approaches. First, 
SEM enables the testing of the plausibility (i.e. the 
overall goodness of fit) of a full theoretical model, 
which conventional multiple regression analyses are 
unable to do. Given the three motivation theories, 
with multiple hypothesized mediating variables and 
multiple outcomes, conventional multiple regression 
analyses could not evaluate the multiple mediators 
and multivariate outcomes simultaneously. Second, 
conventional regression analyses assume that 
scales perfectly measure the theoretical constructs, 
whereas measurement error is to be expected. 
Using SEM, latent variables can be identified which 
are considered free of random measurement error, 
thus making the test more powerful200. Third, SEM 
enables comparisons of alternative models (for 
example whether certain parameters can be fixed 
at a certain value or can be restricted to 0.00), 
modelling of growth trajectories in case of repeated 
measurements and possibilities for estimating direct 
and indirect effects. 
 Nonetheless, several limitations to our approach 
on model testing should be acknowledged. For all 
models tested (Chapters 7, 8, and 9), there is the 
possibility of misspecification of the identified most 
plausible model. For example, misspecification 
of the model may have occurred if (some of) the 
relations in the models are in fact bidirectional. 
These alternatives were not tested if they were 
not in line with original theoretical hypotheses, 
but such relations are likely for ongoing, repeated 
behaviours77 as is the case in our study sample, where 
patients were not new to treatment; most had been 
in treatment for many years. For example, a patient 
who shows better psychosocial functioning would 
likely experience more competence in doing what 
the treatment requires 217 (which may be assumed 
in the process model of SDT), and it is plausible that 
the patient’s outcome expectancy may depend on 
(previous) motivation for engaging in treatment and 
previous treatment engagement behaviours (which 
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may be assumed in the process model of the IM). 
A strength of the studies presented in this thesis is 
that for each statistical model, efforts were made 
to compare different structural models in order to 
identify the most plausible model according to both 
theory and data. 
 Another limitation is the possibility of omitted 
variables, or in other words, the absence of certain 
theoretical constructs that are of substantial 
relevance. Omission of relevant constructs may 
threaten the identified most plausible model. In case 
of SDT for example, constructs such as perceived 
relatedness, other types of motivation such as 
intrinsic, integrated and amotivation and/or causality 
orientations which are also part of the larger holistic 
theoretical framework of SDT 48, were not available 
for modelling. Although we feel confident that the 
constructs that have been recognized as the core 
constructs of SDT were included, namely autonomy 
support and perceived competence 65,123,217 and 
different types of motivation, future studies may 
include additional theoretical constructs.
 Further, the associations between theoretical 
constructs may be moderated by certain 
characteristics of the target population, which 
warrants further investigation. For example, it was 
found that treatment engagement in patients with 
psychotic disorders was most strongly associated 
with perceived competence (independent of the type 
of motivation), whereas for patients with personality 
disorders, treatment engagement was most strongly 
related to identified motivation (Chapter 7). These 
findings may reflect different courses of motivational 
changes in these groups over time and, in case these 
findings are replicated by future studies, could 
argue for a differential approach to motivational 
(feedback) interventions in different diagnostic 
patient groups. Future studies should investigate 
potential moderators of the processes described by 
the theories. The association between theoretical 
constructs and various outcomes may vary in 
strength as a function of, for example, treatment 
duration, duration of illness, patient age, and type 
of treatment. These analyses were beyond the scope 
of the current thesis, but the detection of such 
moderators may have implications for the design 
of future theory-based studies and interventions. 
Furthermore, it might be indicated to perform latent 
class analyses to detect homogeneous subgroups. 
 Finally, the tests in the current study represent 
cross-sectional associations which were largely 
based on correlations that cannot be used to infer 
causality. Future efforts in modelling of theories may 
consider longitudinal approaches and cross-lagged 
analyses such that changes over time in theoretical 
constructs can be modelled, preferably by making 
use of multiple repeated measurements over 
clinically relevant periods of time, such that relevant 
changes are observed and can be understood in light 
of the theory under study. The utility of the three 
theories for SMI patients should be proven in clinical 
practice, preferably by randomized clinical trials 
that aim to effectively influence core theoretical 
constructs. 
 Acknowledging the limitations mentioned 
above, we believe that the approach to the testing 
of multiple motivation theories that was taken 
in the current thesis holds much promise for 
the identification of mechanisms through which 
changes in clinical outcomes occur which may be 
useful for clinical practice. Today, it is still rather 
unique and scarce to test multiple theories in 
the same population simultaneously, especially 
in daily clinical practice for patients with SMI. We 
encourage researchers to design and conduct future 
studies to test two or more theories simultaneously 
and evaluate them, to further advance theory and 
practice for outpatients with SMI. 
Assessment issues
Measuring motivation for engaging in treatment 
and treatment engagement is complex and gold 
standards are lacking20,37. A strength of the current 
research is that we had both patient and clinician 
reports of motivation, two methods for assessing 
treatment engagement (although the registration 
of no-shows was compromised by policy changes 
during the study, namely the introduction of a fine), 
and the use of structured interviews for assessing 
psychosocial functioning by independent research 
assistants. Another strength is that we investigated 
relevant theoretical constructs on their reliability 
and validity (Chapters 4, 5, 7, 8, 9), before using 
them in subsequent analyses.
 The research in the current thesis has produced 
several Dutch assessment instruments based on SDT, 
and it was shown that the Dutch HCCQ and TEQ can 
be used reliably and validly for assessment purposes 
at the level of groups and for research purposes. An 
advantage of the Dutch TEQ is that it only comprises 
18 items, which allows for a rather quick assessment 
of the quality of the patient’s motivation in terms 
of identified, introjected and external motives. The 
research in the current thesis did not provide a norm-
referenced	 or	 criterion-referenced	 interpretation	 of	
the	HCCQ	nor	the	TEQ,	such	that	these	questionnaires	
are	 not	 yet	 suited	 for	 assessment	 applications	 at	
the individual level. Future studies may aim to 
produce such normative data, such that these 
SDT questionnaires may prove their utility at this 
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level as well. Further, the research in the current 
thesis provided support for the use of the TMS-f in 
outpatients with SMI. An advantage of the TMS-f 
is that it was norm-referenced by the developers 
of the scale160 in a forensic psychiatric population 
(albeit not in other populations yet), such that it may 
be applied at the level of individuals. A disadvantage 
of the TMS-f is that it comprises 85 items, which is 
relatively long and time-consuming for patients with 
SMI, especially for those with cognitive impairments. 
Compared to the TEQ, which comprises 18 items 
and provides information regarding the quality of a 
patient’s motivation, this could be a reason to prefer 
the TEQ over the TMS-f. Depending on the specific 
purpose of the motivational assessment however, the 
internal determinants or overall level of motivation 
may be clinically relevant to explore, which would 
make the IM a more appropriate framework for 
assessment. As noted previously, the use of the 
URICA-D or staging algorithm for the assessment 
of stages for changing psychiatric problems during 
outpatient treatment was problematic. The use of 
these instruments for such purpose is therefore 
discouraged based on the findings in this thesis. 
 In the future, the development and evaluation 
of assessment instruments may focus on the 
shortening of questionnaires, without substantial 
loss of information (validity and reliability) such 
that they may easily be applied in clinical practice 
for outpatients with SMI, where sufficient attention 
must be paid to who is doing the assessment and to 
consider multiple assessors and methods to measure 
one construct. To this end, the use of a multitrait-
multimethod (MTMM) approach using structural 
equation modelling can be applied, which allows 
for an evaluation of discrepancies between two 
assessors or between two methods of assessments. 
Examples include evaluation of differences between 
patients and clinicians, or between questionnaires 
and ratings based on video recordings. 
Logistics and organisational issues
Logistical issues that have likely negatively impacted 
the current study, include the difficulties in recruiting 
patients with low levels of motivation and low 
levels of treatment engagement and organisational 
changes in mental health care during the course of 
the study, including changes in the no-show policy 
and costs of mental health care for SMI patients. 
Generalizability
Our study sample largely represented a heterogeneous 
population	of	outpatients	with	diagnoses	of	psychotic	
and personality disorders with a variety of co-
morbid psychiatric disorders, which strengthens the 
generalizability of the study. Nevertheless, patients 
included in the study sample were already engaged 
with services for some time, whereas patients who 
have just entered or who are in need for help but not 
yet in contact with services, are likely to present with 
a different motivational profile and more variety in 
levels of functioning and quality of life. Therefore, 
the results of this thesis may be limited to patients 
who are already engaged with services and thus 
may not be generalizable to the entire population 
of outpatients with SMI, in particular those patients 
who are not in contact with services.
Summary of implications and 
recommendations
Assessment of motivation in 
outpatients with SMI
Choosing a measure for the assessment of a patient’s 
motivation may be guided by several considerations. 
It appears that the level of agreement between 
patients and clinicians is unsuited to use as a criterion 
for choosing a motivational assessment based on 
a certain theory, as neither of the three theories 
stood out from the other theories in this regard 
(Chapter 9). Other criteria such as the duration of 
the assessment, the type of information that can 
be derived from the different questionnaires, the 
availability of norms, and whether the assessment 
will be used for research or practice may thus be 
used instead to guide assessment choices. In sum, 
the Dutch TEQ and HCCQ may be used to assess 
the quality of a patient’s motivation and perceived 
autonomy support for research purposes and 
have the advantage that assessment is short (and 
therefore quick), 2) the Dutch TMS-f (or the version 
that was used in the current thesis, if applicable) 
may be used to assess internal determinants and 
the level of motivation in research and clinical 
practice, yet this takes relatively long and patients 
may need to be assisted during the assessment, and 
3) the assessment of stages for changing psychiatric 
problems during outpatient treatment using the 
Dutch URICA-D or staging algorithm is problematic, 
and is therefore not recommended. The URICA-D 
may be used for research purposes in outpatients 
with SMI, preferably by using the total score for 
readiness to change (instead of subscales scores) to 
ensure adequate reliability. 
 In choosing a method of assessment, such as 
observer-rated, clinician-rated, patient self-report 
or even other methods such as video-recordings, 
several points deserve attention. Clinicians should 
be aware that patients with SMI generally have a 
different view on their motivation for engaging in 
treatment than the clinician can estimate or judge 
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(Chapter 9). When the therapeutic relationship is 
regarded as ‘good’, clinicians should be especially 
aware of the potential for halo bias160,281. That is, 
clinicians may rate patients higher in their motivation 
because they feel the relationship is good, whereas 
these concepts are distinct and may go in different 
directions. For example, a patient may be motivated 
to engage in social contact with the clinician while 
at the same time may not be motivated for engaging 
in treatment-related behaviours. This argues for 
a multi-method approach to the assessment of 
motivation, such that all perspectives are taken into 
account to ensure effective planning and conducting 
of mental health interventions. 
Interventions that may optimise 
motivation for engaging with 
treatment and motivation for 
behaviour change
The research in this thesis supports the application 
of SDT in the mental health care for patients who are 
in outpatient treatment for a severe mental illness, 
as SDT was found to be sufficiently valid, plausible 
and robust to provide a useful basis for (future) 
interventions in this context. The results of the trial 
currently discourage the implementation of the SDT-
based MF intervention into community mental health 
care for outpatients with SMI. If future research has 
further determined the essential mechanisms and 
moderators of motivation and behaviour change 
in outpatients with SMI, then there may be a place 
for SDT-based MF as a communication tool for the 
clinician to explore the patient’s perspective, after 
which other tailored interventions and services may 
be applied to improve outcomes. Potentially fruitful 
future interventions might include more extensive 
and thorough training and monitoring of clinicians in 
the	application	of	SDT,	techniques	from	motivational	
interviewing that align with SDT 191,225,	accounting	for	
potential	 problems	 in	 (social)	 cognitive	 functioning	
and	 taking	 into	 account	 differences	 between	
diagnostic	 groups	 of	 patients,	 as	 well	 as	 feedback	
components. Specific techniques that clinicians may 
use to support the needs for autonomy, competence 
and relatedness have been described elsewhere 
65,123,212 and may be adjusted for applications in 
outpatient psychiatric treatment for SMI patients.
 The other two theories, were found to need 
more extensive research into reliability and validity 
of constructs (TTM) and plausibility and robustness 
(IM and TTM) before application in future clinical 
trials and interventions for outpatients with SMI are 
considered. Specifically, the IM does not constitute a 
plausible nor robust framework for patterns through 
which patients become motivated to engage 
in treatment, but the theory does include valid 
constructs that can explain substantial variation in 
clinical outcomes, thus showing potential for this 
model to – eventually - inform clinical practice. 
Regarding the TTM, the research presented in the 
current thesis combined with previous critical 
reviews on the TTM in other health behaviour 
contexts79,80,88,99, suggest that the TTM cannot have 
much practical utility if its basic theoretical constructs 
are not accurately defined and operationalized, or if 
the basic constructs (i.e. the stages) do not reflect 
actual real-life qualitatively different states. Future 
studies on TTM in outpatients with SMI should aim 
to test other staging instruments and perhaps, as 
shown in Figure 4, consider an alternative framework 
for the research on TTM that takes into account both 
the cyclical process of behaviour change as well as 
the problems with the stage construct, both in 
research and practice. 
 The model as depicted in Figure 4 may be 
used as the basis for an integrated approach to 
motivation in outpatient psychiatric care for patients 
with SMI. This model may first serve to guide future 
research, after which it can potentially also inform 
the development and use of clinical interventions. 
Future research on motivation in 
outpatients with SMI
We hope that the research presented in this thesis 
will inspire other researchers to design and conduct 
studies	 to	 test	 multiple	 (motivation)	 theories	
simultaneously and compare them, to further advance 
theory	 and	 practice	 for	 outpatients	 with	 SMI.	 As	
noted, Figure 4 may be used to clinically-empirically 
test	 hypotheses	 regarding	 the	 associations	 between	
the	 three	 motivation	 theories,	 while	 researchers	
may	 also	 decide	 to	 empirically	 investigate	 other	
theories	of	motivation	and	health	behaviour	 such	as	
models that include biological factors or those that 
focus	on	motivation	from	a	societal	or	organisational	
perspective.
 The development and evaluation of assessment 
instruments deserves specific attention in future 
research, as the reliable and valid assessment of 
theoretical constructs is the basis for building and 
testing theories. Such studies may focus on the 
optimal shortening of questionnaires such that they 
may be applied in clinical practice for outpatients 
with SMI, and to consider multiple information 
sources and methods. To this end, the use of a 
multitrait-multimethod (MTMM) approach using 
structural equation modelling could be helpful.
 Research within theories, should be dedicated 
to further examine models in outpatients with 
SMI, preferably with longitudinal monitoring (and 
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cross-lagged analyses) of theoretical constructs in 
outpatient treatment to allow for more elaborate 
models to be constructed to get a solid understanding 
of change. In doing so, the essential and powerful 
explanatory constructs may be identified, which may 
then be targeted in (clinical trials on) health care 
interventions. An analytical approach that includes 
the combined effects of high and low autonomy and 
competence, or motivational profiles of patients 
who show different ratings on internal determinants, 
could be informative such that we could further clarify 
the potential additive, synergistic or antagonistic 
effects between the theoretical constructs. The 
detection of moderators and synergistic effects 
may have important implications for optimising the 
design and conduct of future theory-based studies 
and interventions. Eventually, experimental research 
is needed to confirm (or to falsify) the causality of 
the relations between theoretical constructs and 
their ability to influence treatment outcomes.
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Doelen en belangrijkste 
bevindingen
Bij aanvang van het onderzoek in dit proefschrift 
was duidelijk dat motivatie voor behandeling wordt 
gezien als belangrijke voorspeller voor de uitkomsten 
van de psychiatrische behandeling van patiënten 
met een ernstige psychiatrische aandoening (EPA), 
zoals patiënten met een psychotische stoornis 
en/of ernstige persoonlijkheidsproblematiek. 
Echter, het was onduidelijk op welke (empirische) 
gronden de ene motivatietheorie boven de andere 
verkozen zou moeten worden om als basis te dienen 
voor motiverende interventies in de klinische 
praktijk. Het belangrijkste doel van het empirische 
onderzoek in dit proefschrift was daarom om drie 
motivatietheorieën te toetsen en vergelijken. Naar 
aanleiding van literatuuronderzoek (Hoofdstuk 2) 
werd beargumenteerd dat Zelf-Determinatie Theorie 
(ZDT)48, het Transtheoretisch Model (TTM)44 en het 
Integraal Model van Behandelmotivatie (IM)37 allen 
een uniek maar complementair raamwerk boden 
op motivatie. In ZDT wordt onderscheid gemaakt 
tussen verschillende kwaliteiten van motivatie, 
variërend van minst geïnternaliseerd (externe 
motivatie) tot meest geïnternaliseerd (intrinsieke 
motivatie). Het TTM biedt een raamwerk over de 
tijd door onderscheid te maken tussen vijf fasen 
van verandering, waarbij elke fase volgens de 
theorie gepaard gaat met specifieke eigenschappen 
en benodigde interventies om naar een volgende 
fase over te gaan. Het IM maakt onderscheid 
tussen de voorspellende factoren voor motivatie 
voor behandeling en de effecten van motivatie op 
therapietrouw en behandeluitkomsten. Er werd 
een model samengesteld waarin enkele aannames 
werden gedaan over de relaties tussen de theorieën, 
waaruit specifieke onderzoeksvragen naar voren 
kwamen (Hoofdstuk 2). Deze vragen werden gebruikt 
als richtlijn voor de empirische onderzoeken in dit 
proefschrift. Als overkoepelend design werd gekozen 
voor een cluster-gerandomiseerde trial (Hoofdstuk 
3). De trial had als hoofddoel om te toetsen of 
een Motivatie Feedback interventie effectief zou 
zijn in het verbeteren van de therapietrouw en 
klinische uitkomsten, en als nevendoel om de 
drie motivatietheorieën empirisch te toetsen op 
hun betrouwbaarheid, validiteit, plausibiliteit, 
robuustheid en voorspellende waarde.
 Het toetsen van theorieën is gebaseerd op 
valide metingen van theoretische constructen en 
daarom werd eerst van elke theorie vastgesteld 
wat de psychometrische kwaliteiten waren van de 
theorie-specifieke vragenlijsten. Middels gebruik 
van structural equation modelling (SEM) werd 
vastgesteld dat de Nederlandse vertalingen van 
vragenlijsten voor ZDT voldoende betrouwbaar 
en valide waren voor gebruik in de populatie EPA 
(Hoofdstuk 4). Vervolgens werd ondersteuning 
gevonden voor hypothesen van ZDT, namelijk dat 
ondersteuning van autonomie en de ervaren zelf-
effectiviteit in de behandeling voorspellend waren 
voor motivatie voor behandeling en klinische 
uitkomsten (therapietrouw, het psychosociaal 
functioneren en de kwaliteit van leven), waardoor 
deze theorie plausibel werd bevonden (Hoofdstuk 
5). Daarnaast vonden we ondersteuning voor de 
robuustheid van de theorie, toen bleek dat ZDT 
stabiel was over de tijd en stabiel over verschillende 
diagnostische groepen van patiënten. Tot slot bleek 
ZDT circa 18-36% van de variantie in klinische 
uitkomsten te verklaren, waarmee de voorspellende 
waarde werd aangetoond. 
 Vergelijkbare toetsen werden uitgevoerd voor 
de toepasbaarheid van het IM (Hoofdstuk 6) en 
het TTM (Hoofdstuk 7) in de ambulante zorg van 
patiënten met EPA. Hoewel we vonden dat de – 
deels aangepaste – Nederlandse vragenlijst voor het 
meten van constructen van IM ook betrouwbaar en 
valide was, werden de hypothesen van de samenhang 
van deze constructen niet bevestigd, noch was het 
model robuust over tijd en diagnostische groepen. 
Hierdoor zijn er twijfels over de plausibiliteit en 
robuustheid van het IM in de doelgroep EPA. 
Desalniettemin waren de constructen van IM in staat 
om 22-88% van de variatie in klinische uitkomsten 
te verklaren, waardoor de voorspellende waarde 
aanzienlijk is. Betreft het TTM, werden twee 
verschillende methoden voor het meten van de 
fasen van verandering gebruikt om te bepalen welke 
methode het meest geschikt was voor gebruik in 
de klinische praktijk. Deze twee methoden bleken 
niet goed met elkaar overeen te komen, waardoor 
aannemelijk is dat zij niet hetzelfde construct ‘fasen 
van verandering’ meten. Daarnaast bleken de 
twee methoden slechts gedeeltelijk de verwachte 
verbanden te vertonen met andere constructen van 
het TTM en met therapietrouw. Hieruit volgt dat, 
als het construct van fasen niet goed gemeten kan 
worden, de validiteit ervan onder druk komt te staan. 
Hoewel beide meetinstrumenten wel robuust over 
de tijd en over diagnostische groepen bleken te zijn 
in hun samenhang met therapietrouw, verklaarden 
de TTM fasen van verandering slechts 3-16% van de 
variatie in klinische uitkomsten. 
 In de cluster-gerandomiseerde trial werd de 
effectiviteit onderzocht van Motivatie Feedback 
(MF); een interventie waarbij behandelaren en 
patiënten maandelijkse systematische metingen 
en gesprekken (uit)voerden over de motivatie voor 
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behandeling van de patiënt, gebaseerd op ZDT. 
MF werd aanvullend op de reguliere ambulante 
behandeling aangeboden, welke bestond uit 
psychiatrische zorg door multidisciplinaire teams 
genaamd Flexible Assertive Community Treatment 
teams. De hoofdhypothese van de trial was dat 
MF zou leiden tot meer bewustzijn van motivatie-
processen in de behandeling, meer internalisatie 
van de motivatie van de patiënt, en zodoende 
tot betere therapietrouw in vergelijking met de 
reguliere behandeling alleen. Echter, na een jaar 
behandeling bleek er geen verschil te zijn tussen 
de twee groepen op therapietrouw, psychosociaal 
functioneren en kwaliteit van leven (Hoofdstuk 
8). Een evaluatie van de interne validiteit van de 
trial, inclusief non-respons bias, informatie bias, 
problemen in de implementatie en de verschillende 
effecten op patiënten met een primair psychotische 
stoornis vergeleken met patiënten met primair 
persoonlijkheidsproblematiek, bood verklaringen 
waarom MF niet voldoende was om de uitkomsten 
te verbeteren. Opvallend was de bevinding dat 
behandelaren van mening waren dat de motivatie 
van hun patiënten minder extrinsiek was geworden 
door MF, terwijl patiënten dat zelf niet vonden. Dit 
geeft mogelijk aan dat MF er wel voor heeft gezorgd 
dat behandelaren meer inzicht hebben gekregen 
in de aard van de motivatie voor behandeling van 
hun patiënten, maar vervolgens niet in staat waren 
om dit (nog verder) te verbeteren zodat ook de 
therapietrouw en andere behandeluitkomsten 
gunstiger werden beïnvloed dan in de reguliere 
behandeling. Tot slot werd bevonden dat, op de 
baseline-meting, de mate waarin behandelaren in 
staat waren om de motivatie van hun patiënten in 
te schatten laag tot gemiddeld was (Hoofdstuk 9). 
We concluderen dat MF onvoldoende werkzaam is 
om motivatie en therapietrouw van patiënten met 
EPA te verbeteren, maar dat het wel zinvol is (MF te 
gebruiken) om een shared-decision making proces 
rondom de motivatie voor behandeling te hanteren 
zodat zowel de perspectieven van de behandelaar 
alsook van de patiënt expliciet worden overwogen 
bij het uitzetten van behandelbeleid. 
Implicaties en aanbevelingen 
Het meten van motivatie in de 
ambulante zorg van patiënten met EPA
Het kiezen van een meetinstrument voor de 
behandelmotivatie van een patiënt kan gebaseerd 
worden op een aantal overwegingen. Uit het 
onderzoek in dit proefschrift blijkt dat de mate van 
overeenstemming tussen patiënten en behandelaren 
niet geschikt is als criterium voor het kiezen van 
een instrument, gezien geen enkele theorie hierin 
duidelijk superieur was aan een andere theorie 
(Hoofdstuk 9). Andere criteria kunnen daarom 
leidend zijn bij de keuze, waaronder de duur van de 
meting, het type informatie dat uit de meting naar 
voren komt, de beschikbaarheid van normeringen en 
de overweging of de meting voor wetenschappelijk 
onderzoek bedoeld is of voor de beoordeling van 
een individu. Onze Nederlandse vertalingen van de 
Treatment Entry Questionnaire (TEQ, 18 items) en 
Health Care Climate Questionnaire (HCCQ, 15 items) 
kunnen gebruikt worden voor onderzoeksdoeleinden 
rondom ZDT, bijvoorbeeld om de kwaliteit van 
de motivatie te meten en de mate waarin de 
behandelaar als ondersteunend in de autonomie 
van de patiënt wordt ervaren. Het voordeel van 
deze instrumenten is dat zij relatief kort zijn t.o.v. de 
instrumenten van de andere theorieën. De Treatment 
Motivation Scales for Forensic patients (TMS-f), 
welke de constructen van het IM valide kan meten, 
werd deels aangepast voor de doeleinden van het 
huidige onderzoeksproject zodat het instrument ook 
buiten een forensisch psychiatrische setting gebruikt 
kan worden. De TMS-f heeft 85 items en heeft als 
voordeel dat er normen beschikbaar zijn vanuit een 
forensisch psychiatrische steekproef160, maar als 
nadeel dat de afname vrij lang duurt en dat patiënten 
mogelijk geholpen moeten worden bij het invullen 
van de vragenlijst. Het meten van de vijf fasen van 
verandering van het TTM voor het veranderen van 
psychiatrische problemen gedurende de ambulante 
behandeling, bleek problematisch te zijn wanneer 
gebruik wordt gemaakt van de University of Rhode 
Island Change Assessment – Dutch version (URICA-D) 
of van een algoritme. Het gebruik van deze – klinisch 
populaire instrumenten – voor dergelijke doeleinden 
wordt daarom afgeraden. De URICA-D zou gebruikt 
kunnen worden in wetenschappelijk onderzoek bij 
patiënten met EPA, indien gebruik gemaakt wordt 
van de totaalscore van veranderingsbereidheid 
gezien deze als voldoende betrouwbaar en valide 
werd bevonden in het huidige onderzoek (i.t.t. de 
sub-schalen). 
 Verder zijn er nog enkele aandachtspunten 
betreft het kiezen van een methode voor het 
meten van motivatie, zoals beoordelingen door 
onafhankelijke observatoren, door behandelaren, 
door patiënten zelf of eventueel middels video-
opnamen die achteraf gescoord kunnen worden 
door meerdere beoordelaars. Uit het huidige 
onderzoek blijkt dat behandelaren en patiënten een 
verschillende visie op motivatie van de patiënt hebben 
(m.a.w. zij vertonen geringe overeenstemming met 
elkaar), en dat de behandelaar niet altijd een goede 
inschatting kan maken van de visie van de patiënt 
op diens motivatie (Hoofdstuk 9). Vooral wanneer 
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de therapeutische relatie als ‘goed’ wordt gezien 
door de behandelaar, dan is de kans groter dat 
de behandelaar de motivatie van de patiënt ook 
hoog beoordeeld, iets wat ‘halo-bias’ 160,281 wordt 
genoemd. Echter, de motivatie van de patiënt voor 
de behandeling moet gezien worden als iets wat ook 
los kan staan van de therapeutische relatie, waarbij 
het mogelijk is dat een patiënt bijvoorbeeld wel erg 
gemotiveerd is om een steunend sociaal contact aan 
te gaan met de behandelaar maar weinig motivatie 
heeft om zijn/haar gedrag te veranderen. Deze 
bevindingen tonen het belang aan van een multi-
methodische aanpak voor het meten van motivatie, 
waarbij alle perspectieven worden overwogen. 
Interventies voor het optimaliseren 
van motivatie voor behandeling en 
gedragsverandering
Gezien ZDT als voldoende valide, plausibel, robuust 
en verklarend werd bevonden, ondersteunt dit 
het gebruik van ZDT als basis voor interventies in 
de ambulante zorg voor patiënten met EPA. De 
resultaten van de trial ontmoedigen het gebruik 
van de door ons ontwikkelde Motivatie Feedback 
in de ambulante zorg voor patiënten met EPA. Als 
toekomstig onderzoek verder inzicht oplevert in 
de essentiële mechanismen en moderatoren van 
motivatie en gedragsverandering in patiënten 
met EPA, dan kan er mogelijk ruimte zijn voor het 
gebruik van MF als een communicatie tool voor de 
behandelaar om het perspectief van de patiënt mee 
te verkennen en vervolgens hiermee rekening te 
houden bij het uitzetten van zorgbeleid. Potentieel 
effectieve interventies zouden kunnen bestaan uit 
een meer uitgebreide training en monitoring van 
behandelaren in het gebruik van ZDT, technieken 
van motiverende gespreksvoering die aansluiten 
op ZDT 191,225, rekening houden met problemen in 
(sociaal) cognitief functioneren van patiënten en 
verschillen tussen diagnostische groepen, als ook 
het gebruik van feedback componenten. Specifieke 
technieken die behandelaren kunnen inzetten 
voor het ondersteunen van de basisbehoeften aan 
autonomie, competentie en verbondenheid van 
patiënten zijn elders beschreven 65,123,212 en moeten 
mogelijk aangepast worden voor toepassing in de 
doelgroep EPA. 
 De andere twee motivatietheorieën bleken 
uitgebreider wetenschappelijk onderzoek te 
behoeven naar de betrouwbaarheid en validiteit van 
theoretische constructen (TTM) en de plausibiliteit 
en robuustheid (TTM en IM) van hun raamwerk, 
alvorens toepassingen in klinisch trials en de praktijk 
kunnen worden overwogen. Betreft het IM werd 
bevonden dat het geen plausibel noch robuust 
raamwerk is voor patronen waardoor patiënten 
gemotiveerd worden/zijn voor behandeling, 
maar dat de theoretische constructen wel valide 
zijn en in substantiële mate verklarend zijn voor 
therapietrouw en klinische uitkomsten. Dit laatste 
toont aan dat het IM op termijn wel relevant en 
zinvol kan zijn in de klinische praktijk. Betreft 
het TTM werd in dit proefschrift, alsmede ook in 
eerdere kritische reviews over het TTM in andere 
gezondheidssettingen79,80,88,99, bevonden dat het 
model weinig praktische waarde kan hebben als 
diens theoretische constructen niet accuraat 
gedefinieerd zijn en onvoldoende betrouwbaar 
en valide gemeten kunnen worden. Hierdoor zijn 
er sterke twijfels of de vijf fasen van verandering 
wel reële entiteiten zijn. Toekomstige studies naar 
het TTM in patiënten met EPA zouden andere 
instrumenten voor de fasen kunnen (ontwikkelen 
en) testen, ofwel een alternatief raamwerk voor het 
TTM kunnen overwegen (zoals getoond in Figuur 4 
van Hoofdstuk 10). Wij stellen in ons alternatieve 
raamwerk voor TTM voor dat de heuristische waarde 
van het model, die zo gewaardeerd wordt in de 
klinische praktijk, behouden blijft door rekening te 
houden met het cyclische proces van verandering 
terwijl er anderzijds erkend wordt dat er substantiële 
problemen zijn met het construct van de fasen, 
zowel in wetenschappelijk onderzoek als de klinische 
praktijk. 
 Het door ons voorgestelde model van de 
samenhang tussen de drie motivatietheorieën 
(Figuur 4, Hoofdstuk 10) kan gebruikt worden als 
basis voor een geïntegreerde aanpak van motivatie 
in de ambulante zorg voor patiënten met EPA. 
Dit model kan eerst als leidraad dienen voor 
vervolgonderzoek, waarna het mogelijk ingezet 
kan worden om de ontwikkeling en het gebruik van 
klinische interventies vorm te geven. 
 
Toekomstig onderzoek naar motivatie 
in ambulante patiënten met EPA
Onze hoop is dat het empirische onderzoek in dit 
proefschrift andere onderzoekers zal inspireren om 
studies te ontwerpen en uit te voeren naar het testen 
van meerdere (motivatie)theorieën tegelijkertijd. 
Zodoende kunnen deze theorieën geëvalueerd en 
vergeleken worden, en hierdoor de theorie en praktijk 
voor patiënten met EPA dichter bij elkaar brengen. 
Zoals eerder gemeld, kan het door ons voorgestelde 
geïntegreerde model (Figuur 4, Hoofdstuk 10) 
gebruikt worden om hypothesen over de samenhang 
tussen de drie motivatietheorieën op een klinisch-
empirische wijze te toetsen. Onderzoekers kunnen 
echter ook besluiten om andere motivatietheorieën 
of theorieën over gezondheidsgedrag te vergelijken, 
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waarin bijvoorbeeld explicieter biologische factoren 
worden overwogen of een (breder) perspectief 
vanuit de organisatie of maatschappelijke context 
van de gezondheidszorg. 
	 De	 ontwikkeling	 en	 evaluatie	 van	 meetinstru-
menten	verdient	aandacht	 in	toekomstig	onderzoek,	
omdat het op een betrouwbare en valide wijze kunnen 
meten van theoretische constructen de basis is voor 
het bouwen en toetsen van theorieën. Dergelijke 
studies kunnen zich richten op het optimaal verkorten 
van vragenlijsten zodat ze toegepast kunnen worden 
in de klinische praktijk voor patiënten met EPA, en 
hierbij meerdere informatiebronnen en methoden 
overwegen voor dergelijke metingen. Hierbij zou een 
multitrait-multimethod aanpak middels structural 
equation modelling behulpzaam kunnen zijn. 
 Onderzoek binnen theorieën zou zich moeten 
richten op het verder onderzoeken van modellen 
in ambulante patiënten met EPA, bij voorkeur door 
gebruik te maken van longitudinale monitoring (en 
cross-lagged analyses) van theoretische constructen. 
Hierdoor wordt het mogelijk om meer uitgebreide 
modellen te maken die meer inzicht kunnen bieden 
in veranderingsprocessen in deze doelgroep. De 
meest essentiële en krachtige constructen kunnen zo 
geïdentificeerd worden, die vervolgens doelgericht 
in interventies aangepakt kunnen worden (en 
onderzocht middels klinische gerandomiseerde 
trials). Een analytische aanpak waarbij ook gekeken 
wordt naar de gecombineerde effecten van 
theoretische constructen, bijv. combinaties van hoge 
en lage autonomie en competenties of hoge scores 
op alle typen motivatie vergeleken met andere 
“motivatieprofielen”, zou informatief kunnen zijn. 
Hierdoor kan onderzocht worden of er bepaalde 
additieve, synergistische, antagonistische of andere 
effecten zijn tussen de theoretische constructen in 
een theorie. Het detecteren van moderatoren en 
synergistische effecten kan belangrijke implicaties 
hebben voor het optimaliseren van het design en de 
uitvoering van toekomstige interventies. Uiteindelijk 
zal experimenteel onderzoek nodig zijn om de 
causaliteit van de relaties tussen de constructen, en 
hun vermogen om klinische uitkomsten gunstig te 
beïnvloeden, vast te stellen (danwel te falsifiëren). 
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Dutch Treatment Entry Questionnaire (TEQ)
Geeft u alstublieft aan in hoeverre u het eens of oneens bent met de stelling, door een getal te omcirkelen 
dat het beste past bij uw mening. Het gaat over uw mening op dit moment. Er zijn geen “goede” of “slechte” 
antwoorden, en uw antwoorden worden vertrouwelijk behandeld. 
Omcirkel een cijfer van 1 (helemaal niet mee eens) tot 7 (helemaal mee eens) achter elke stelling.
 
               Helemaal                   Helemaal
               niet mee           mee
                 eens           eens
1. Als ik in behandeling blijf, is dat waarschijnlijk omdat ik het gevoel 
heb dat dit de beste manier is om mezelf te helpen. 
1 2 3 4 5 6 7
2. Ik ben van plan om de behandeling te doorlopen omdat ik mezelf zal 
haten als ik mijn klachten niet onder controle krijg.
1 2 3 4 5 6 7
3. Ik besloot om in behandeling te gaan omdat ik mezelf niet zal mogen 
als ik mijn klachten niet onder controle krijg.
1 2 3 4 5 6 7
4. Ik had geen keuze over het wel of niet in behandeling gaan. 1 2 3 4 5 6 7
5. Ik ben van plan om de behandeling te doorlopen, omdat het hebben 
van klachten het moeilijk voor me maakt om dingen te doen zoals 
ik wil. 
1 2 3 4 5 6 7
6. Mijn familie heeft ervoor gezorgd dat ik in behandeling ging. 1 2 3 4 5 6 7
7. Ik besloot om in behandeling te gaan omdat ik echt enkele dingen 
wil veranderen in mijn leven.
1 2 3 4 5 6 7
8. Ik heb ermee ingestemd om een behandeling te volgen, omdat ik wil 
dat anderen zien dat ik echt probeer mijn klachten aan te pakken.
1 2 3 4 5 6 7
9. Ik ben van plan om de behandeling te doorlopen omdat ik me zal 
schamen als ik het niet doe.
1 2 3 4 5 6 7
10. De reden dat ik in behandeling ben, is omdat andere mensen mij 
onder druk hebben gezet om hier te komen.
1 2 3 4 5 6 7
11. Als ik in behandeling blijf is dat waarschijnlijk omdat ik me anders 
een mislukkeling voel. 
1 2 3 4 5 6 7
12. Ik ben van plan om de behandeling te doorlopen omdat ik zelf heb 
kunnen kiezen.
1 2 3 4 5 6 7
13. Ik ben van plan om de behandeling te doorlopen, omdat vrij zijn van 
klachten een keuze is die ik echt wil maken. 
1 2 3 4 5 6 7
14. Mijn vrienden hebben mij sterk onder druk gezet om in behandeling 
te gaan.
1 2 3 4 5 6 7
15. Als ik in behandeling blijf, is dat waarschijnlijk omdat ik een erg 
slecht gevoel over mezelf zal krijgen als ik het niet doe.
1 2 3 4 5 6 7
16. Ik besloot om in behandeling te gaan omdat het voor mij persoonlijk 
belangrijk voelt om mijn klachten aan te pakken. 
1 2 3 4 5 6 7
17. Ik heb ermee ingestemd om een behandeling te volgen omdat ik 
onder druk werd gezet om te komen. 
1 2 3 4 5 6 7
18. Ik werd in feite gedwongen om een behandeling te volgen. 1 2 3 4 5 6 7
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Dutch Health Care Climate Questionnaire (HCCQ)
Deze vragenlijst bestaat uit stellingen die gaan over uw behandelaar. Verschillende behandelaars hebben 
verschillende stijlen in hoe ze omgaan met cliënten, en we willen graag weten hoe uw ervaringen zijn met uw 
behandelaar. 
Uw antwoorden zijn vertrouwelijk en zullen niet besproken worden met uw behandelaar. Antwoordt u 
alstublieft eerlijk.
Omcirkel een cijfer van 1 (helemaal niet mee eens) tot 7 (helemaal mee eens) achter elke stelling. 
               Helemaal                   Helemaal
               niet mee           mee
                 eens           eens
1. Ik heb het gevoel dat mijn behandelaar mij keuzes biedt. 1 2 3 4 5 6 7
2. Ik voel me begrepen door mijn behandelaar. 1 2 3 4 5 6 7
3. Ik kan open zijn naar mijn behandelaar tijdens onze afspraken. 1 2 3 4 5 6 7
4. Mijn behandelaar geeft aan dat hij vertrouwen heeft in mijn vermogen 
om te veranderen.
1 2 3 4 5 6 7
5. Ik heb het gevoel dat mijn behandelaar mij accepteert. 1 2 3 4 5 6 7
6. Mijn behandelaar heeft ervoor gezorgd dat ik mijn aandoening echt 
begrijp en wat ik kan doen.
1 2 3 4 5 6 7
7. Mijn behandelaar moedigt mij aan om vragen te stellen. 1 2 3 4 5 6 7
8. Ik heb veel vertrouwen in mijn behandelaar. 1 2 3 4 5 6 7
9. Mijn behandelaar beantwoordt mijn vragen volledig en zorgvuldig. 1 2 3 4 5 6 7
10. Mijn behandelaar luistert naar hoe ik graag dingen doe. 1 2 3 4 5 6 7
11. Mijn behandelaar kan erg goed omgaan met emoties van mensen. 1 2 3 4 5 6 7
12. Ik heb het gevoel dat mijn behandelaar om mij geeft als persoon. 1 2 3 4 5 6 7
13. Ik voel me niet goed bij de manier waarop mijn behandelaar tegen me 
praat.
1 2 3 4 5 6 7
14. Mijn behandelaar probeert te begrijpen hoe ik de dingen zie, voordat hij/
zij een nieuwe manier voorstelt om dingen te doen. 
1 2 3 4 5 6 7
15. Ik voel me in staat om mijn gevoelens te delen met mijn behandelaar. 1 2 3 4 5 6 7
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Short Motivation Feedback List (SMFL)
VERSIE VOOR BEHANDELAAR  
Hieronder volgen uitspraken over het deelnemen aan de behandeling. Met deelnemen aan de behandeling 
bedoelen we niet alleen dat de cliënt aanwezig is op afspraken, maar ook bijvoorbeeld het opvolgen van 
adviezen van de behandelaar en het innemen van eventuele medicatie. Omcirkel het cijfer waarvan u denkt 
dat het de mening van de cliënt op dit moment het beste weergeeft.
        Helemaal              Helemaal
                      niet mee            mee  
           eens                         eens
1. De cliënt blijft op dit moment in behandeling omdat…
 …hij/zij zo problemen op kan lossen.
0 1 2 3 4 5 6 7 8 9 10
2. De cliënt blijft op dit moment in behandeling omdat…
…hij/zij zo een beter leven kan leiden.
0 1 2 3 4 5 6 7 8 9 10
3. De cliënt blijft op dit moment in behandeling omdat…
…hij/zij anderen niet teleur mag stellen.
0 1 2 3 4 5 6 7 8 9 10
4. De cliënt blijft op dit moment in behandeling omdat…
…hij/zij het interessant vindt.
0 1 2 3 4 5 6 7 8 9 10
5. De cliënt blijft op dit moment in behandeling omdat…
…hij/zij zichzelf niet teleur mag stellen. 
0 1 2 3 4 5 6 7 8 9 10
6. De cliënt blijft op dit moment in behandeling omdat…
…anderen vinden dat hij/zij dat moet. 
0 1 2 3 4 5 6 7 8 9 10
7. De cliënt blijft op dit moment in behandeling omdat…
…hij/zij zich trots zal voelen als hij/zij dat doet. 
0 1 2 3 4 5 6 7 8 9 10
8. De cliënt blijft op dit moment in behandeling omdat…
…hij/zij door anderen gewaardeerd word als hij/zij dat doet.
0 1 2 3 4 5 6 7 8 9 10
Naam behandelaar:
Naam cliënt: 
199
SMFL - VERSIE VOOR CLIËNT 
Hieronder volgen uitspraken over het deelnemen aan de behandeling. Met deelnemen aan de behandeling 
bedoelen we niet alleen dat u als cliënt aanwezig bent op afspraken, maar ook bijvoorbeeld het opvolgen van 
adviezen van de behandelaar en het innemen van eventuele medicatie. 
Omcirkel het cijfer dat uw mening op dit moment het beste weergeeft.
        Helemaal              Helemaal
                      niet mee            mee  
           eens                         eens
1. Ik ben op dit moment in behandeling omdat…
…ik zo problemen op kan lossen.
0 1 2 3 4 5 6 7 8 9 10
2. Ik ben op dit moment in behandeling omdat…
…ik zo een beter leven kan leiden.
0 1 2 3 4 5 6 7 8 9 10
3. Ik ben op dit moment in behandeling omdat…
…ik anderen niet teleur mag stellen.
0 1 2 3 4 5 6 7 8 9 10
4. Ik ben op dit moment in behandeling omdat…
…ik het interessant vind. 
0 1 2 3 4 5 6 7 8 9 10
5. Ik ben op dit moment in behandeling omdat…
…ik mezelf niet teleur mag stellen. 
0 1 2 3 4 5 6 7 8 9 10
6. Ik ben op dit moment in behandeling omdat…
…anderen vinden dat ik dat moet. 
0 1 2 3 4 5 6 7 8 9 10
7. Ik ben op dit moment in behandeling omdat…
…ik me trots zal voelen als ik dat doe. 
0 1 2 3 4 5 6 7 8 9 10
8. Ik ben op dit moment in behandeling omdat…
…ik door anderen gewaardeerd word als ik dat doe.
0 1 2 3 4 5 6 7 8 9 10
Naam client:
Datum: 
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Supplementary material for Chapter 6
Changes to the perceived legal pressure scale such that it represents perceived 
external pressure
In the original TMS-f 118, perceived legal pressure is the patient’s perception of the external pressure through 
the legal system. As the current study aimed to explore whether the IM is also applicable outside a forensic 
psychiatric setting, the current study decided to adapt the construct of perceived legal pressure into a more 
broad perceived external pressure. This adjustment can be justified by considering that only a subgroup of 
outpatients with SMI will be referred to or pressured into psychiatric treatment via the legal system, while 
(most) others will likely experience other pressures that drive their motivation for engaging with treatment 
(i.e. family, friends, partner, assertive outreaching clinicians).
Table S1 (see next page) shows the 9 items of the original Dutch TMS-f and how these were adapted to represent 
9 Dutch items for perceived external pressure. The last two columns of Table S1 show their translations in 
English, which were made for the purpose of this supplement only, such that non-Dutch readers can also see 
the precise formulation and understand their content. 
Table S1. Items of the original perceived legal pressure scale compared to the items on the perceived external pressure scale 
Item 
number
Original TMS-f
(items in Dutch)
Current study 
(items in Dutch)
Original TMS-f
(loosely translated to English for 
the purpose of this supplement 
only)
Current study 
(loosely translated to English for 
the purpose of this supplement 
only)
5 Als therapeuten vinden dat ik 
mij onvoldoende inzet, zou dat 
vervelende justitiële gevolgen voor 
mij kunnen hebben 
Als therapeuten vinden dat ik 
mij onvoldoende inzet, zou dat 
vervelende gevolgen voor mij 
kunnen hebben.
If therapists feel that I do not show 
enough effort for the treatment, 
this could have negative legal 
consequences for me
If therapists feel that I do not 
show enough effort for the 
treatment, this could have negative 
consequences for me
13 Wanneer ik door de kliniek 
weggestuurd zou worden, zou ik 
met zekerheid problemen krijgen 
met justitie 
Wanneer ik door de kliniek 
weggestuurd zou worden, zou ik 
met zekerheid problemen krijgen. 
If the clinic would send me away, 
this would certainly result into 
problems with the legal authorities 
for me. 
If the clinic would send me away, 
this would certainly result into 
problems for me.
25 De justitiële stok achter de deur 
stelt bij mij weinig voor 
De stok achter de deur van anderen 
stelt bij mij weinig voor
The big stick of the justice 
department does not impress me 
much
The big stick of other people does 
not impress me much
34 Het is best wel mogelijk dat justitie 
een oogje zou dichtknijpen, als ik 
de behandeling zou afbreken 
Het is best wel mogelijk dat 
anderen een oogje zouden 
dichtknijpen, als ik de behandeling 
zou afbreken.
It is possible that the justice 
department would turn a blind 
eye, if I were to terminate the 
treatment
It is possible that other people 
would turn a blind eye, if I were to 
terminate the treatment
43 De druk van justitie voel ik sterk De druk van anderen voel ik sterk. I feel a strong pressure from the 
justice department
I feel a strong pressure from others
57 De justitiële gevolgen wanneer ik 
de behandeling nu zou afbreken 
zouden wel meevallen 
Wanneer ik de behandeling nu zou 
afbreken, zouden de gevolgen wel 
meevallen.
If I were to drop out of treatment 
right now, the legal consequences 
would not be so bad
If I were to drop out of treatment 
right now, the consequences would 
not be so bad
66 Als de kliniek mij voortijdig zou 
wegsturen, zou justitie mijn straf 
zeker ten uitvoer leggen 
Als de kliniek mij voortijdig zou 
wegsturen, zou ik zeker problemen 
met anderen krijgen.
If the clinic were to dismiss me 
prematurely, the legal department 
would certainly follow through 
with my punishment 
If the clinic were to dismiss me 
prematurely, I would certainly get 
into problems with others
76 Als ik niet in behandeling was 
gegaan, dan had dat justitiële 
gevolgen gehad waar ik nogal 
tegenop zie 
Als ik niet in behandeling was 
gegaan, dan had dat gevolgen 
gehad waar ik nogal tegenop zie.
If I had not entered into 
treatment, it would have had legal 
consequences that I find dreadful
If I had not entered into treatment, 
it would have had consequences 
that I find dreadful
85 Door mijn justitiële situatie heb 
ik geen echte keus, ik moet de 
behandeling wel afmaken
Door mijn situatie heb ik geen 
echte keus, ik moet de behandeling 
wel afmaken
Because of my legal situation, I 
don’t really have a choice. I have to 
finish the treatment.
Because of my situation, I don’t 
really have a choice. I have to finish 
the treatment.
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Sub-scale Item Standar-dized 
factor loading
Residuals 
(standard 
errors)
PR 2 0,465 0,784
  19 0,604 0,635
  78 0,628 0,606
  11 0,384 0,853
  26 0,763 0,418
  36 0,451 0,797
  49 0,610 0,628
  58 0,533 0,716
  70 0,568 0,677
DS 44 0,462 0,787
  71 0,586 0,657
  9 0,696 0,516
  18 0,760 0,422
  30 0,684 0,532
  40 0,747 0,442
  54 0,784 0,385
  63 0,716 0,487
  83 0,838 0,298
EP 25 0,181 0,967
  34 0,208 0,957
  57 0,555 0,692
  5 0,282 0,920
  13 0,586 0,657
  43 0,161 0,974
  66 0,468 0,781
  76 0,537 0,712
  85 0,391 0,847
CT 1 0,570 0,675
  14 0,264 0,930
  51 0,516 0,734
  24 0,489 0,761
  41 0,601 0,639
  61 0,609 0,629
  67 0,609 0,629
  80 0,577 0,667
  27 0,470 0,779
Sub-scale Item Standardized 
factor loading 
Residuals 
(standard 
errors)
ST 15 0,665 0,558
  52 0,634 0,598
  69 0,590 0,652
  3 0,753 0,433
  21 0,737 0,457
  33 0,682 0,535
  47 0,623 0,612
  62 0,513 0,737
  79 0,552 0,695
OE 6 0,545 0,703
  12 0,758 0,425
  35 0,739 0,454
  39 0,758 0,425
  53 0,618 0,618
  64 0,533 0,716
  77 0,675 0,544
  84 0,668 0,554
  46 0,398 0,842
MET 17 0,502 0,748
  28 0,441 0,806
  37 0,541 0,707
  42 0,546 0,702
  48 0,520 0,730
  55 0,531 0,718
  68 0,518 0,732
  82 0,449 0,798
  10 0,407 0,834
  23 0,424 0,820
  31 0,550 0,698
  73 0,480 0,770
  7 0,447 0,800
  20 0,273 0,925
  60 0,547 0,701
  74 0,415 0,828
In Table S2, the standardized factor loadings are shown that resulted from testing single-factor models on 
each of the subscales of the TMS-f, using confirmatory factor analyses (CFAs) with the robust maximum 
likelihood (MLR) estimation method. 
Table S2. Standardized factor loadings and residuals (standard errors) of items for each TMS-f subscale
Note:	PR	=	problem	recognition,	DS	=	distress,	EP	=	external	pressure,	CT	=	perceived	costs	of	treatment,	ST	=	perceived	suitability	of	
treatment,	OE	=	outcome	expectancy,	MET	=	motivation	to	engage	in	treatment.
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Table S3 shows the item properties of the 9 items 
represented in the perceived external pressure scale. 
It was decided to retain all items for subsequent use 
in order to maximize the comparability with the 
original TMS-f perceived legal pressure scale. 
 Results for the single factor CFAs for each TMS-f 
scale are shown in Table S4. For all CFAs, the MLR 
estimation method was used. Using the criteria 
as outlined in the main manuscript (see Statistical 
Analyses), it appears that the scales showed 
borderline to acceptable model fit. The best fit 
was found for the EP-subscale, although this scale 
showed the lowest congeneric estimate of reliability 
(0.61). 
 In the next step, a CFA was performed including 
all six internal determinants as predictors for 
motivation to engage in treatment and including 
correlations between the internal determinants as 
specified by Drieschner and Boomsma 116. In line 
with Drieschner and Boomsma 116, “we followed 
the recommendation of Beauducel and Wittmann 
297 to give priority to the combination of the SRMR 
and RMSEA. This recommendation was based on the 
finding that in models with low or moderate factor 
loadings, incremental fit indices such as the TLI and 
the CFI penalize unspecified small secondary factor 
loadings (i.e., loadings on unintended factors) to a 
degree that such models “would only have a chance 
to be accepted when incremental fit indexes and the 
GFI are not used for model evaluation” (p. 70). In 
multidimensional questionnaires, secondary factor 
loadings are hardly avoidable, if only because of 
formal or linguistic features shared by items of 
different scales”(p. 10). 
 The CFA including all six IDs as predictors for 
MET, showed an acceptable combination of RMSEA 
<0.06 and SRMR <.10, while CFI and TLI were low 
(χ2/df=1.71,	 RMSEA=0.05,	 CFI=0.74,	 TLI=0.73,	
SRMR=0.09).	These fit indices of RMSEA and SRMR 
were comparable to those found by Drieschner and 
Boomsma116 , while the CFI and TLI were found to be 
somewhat lower in the current study. In line with the 
choices made by Drieschner and Boomsma 116, it was 
decided that the current results of the CFAs justified 
using this model for the TMS-f for subsequent 
analyses. 
 In Table S5, the Pearson correlations between 
the observed sum scores on the subscales of the 
TMS-f as found in the current study are shown below 
the diagonal (i.e. lower triangle). For comparison, 
the correlations found in the study by Drieschner 
and Boomsma 116 are shown above the diagonal 
(i.e. upper triangle). Correlations in our study that 
appeared to stand out (regarding strength and 
direction) from those found by Drieschner and 
Boomsma were those between Problem Recognition 
and	 External	 Pressure	 (r=0.54	 versus	 r=-0.12)	 and	
between	 Distress	 and	 External	 Pressure	 (r=0.28	
versus	 r=-0.15),	 respectively.	 These	 substantial	
differences may be explained by changes in the 
External Pressure -scale, such that external pressure 
is more closely affiliated with problem recognition 
than legal pressure. For example, a patient who is 
convinced that leaving the treatment prematurely 
will lead to certain negative consequences (e.g. 
problems with partners, family, friends or in 
general) may be more likely to also recognize that 
there are problems for which psychiatric treatment 
is indicated, maybe more so than a patient who is 
merely pressured into treatment by the legal system. 
A similar line of reasoning may apply to the higher 
correlation that was found in the current study 
between Distress and External Pressure, compared 
to Drieschner and Boomsma, as it can be argued 
that patients who expect that they will experience 
negative consequences in multiple life-domains (e.g. 
problems with relatives and friends) if they were to 
leave the treatment prematurely, may be more likely 
to also experience higher levels of distress, compared 
to a patient who expects negative consequences in 
the legal domain only. 
 Similar to the findings of Drieschner and 
Boomsma, motivation was strongly correlated 
with the subscales costs of treatment, sutability of 
treatment and outcome expectancy. It should be 
noted that the apparently different directions of 
associations between the costs of treatment-scale 
in our study compared to Drieschner and Boomsma, 
have to be attributed to differences in coding (i.e. 
we coded this subscale such that a higher score 
represents higher perceived costs of treatment). As 
such, in the interpretation of the associations with 
the costs of treatment -scale, these differences in 
direction between the studies should be ignored. 
Descriptive statistics of the subscales of the TMS-f 
are shown in Table S6. Again for comparison, both 
the distribution of the sum scores on the TMS-f 
scales of our sample and the total sample used by 
Drieschner and Boomsma are shown. 
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Table S3. Item properties of the perceived external pressure scale and factor loadings
Item number Mean Variance Skewness (standard error) Kurtosis (standard error) Observed range Factor Loading
5 3.18 2.08 -0.17 (0.14) -1.29 (0.29) 1 to 5 0.282
13 2.63 2.28 0.32 (0.14) -1.35 (0.29) 1 to 5 0.586
25 3.53 1.74 -0.50 (0.14) -0.80 (0.29) 1 to 5 0.181
34 3.60 1.69 -0.46 (0.14) -0.86 (0.29) 1 to 5 0.208
43 2.74 2.07 0.28 (0.14) -1.24 (0.29) 1 to 5 0.161
57 3.64 1.74 -0.55 (0.14) -0.86 (0.29) 1 to 5 0.555
66 3.28 2.12 -0.33 (0.14) -1.21 (0.29) 1 to 5 0.468
76 1.94 1.35 1.14 (0.14) 0.48 (0.29) 1 to 5 0.537
85 2.53 2.15 0.45 (0.14) -1.16 (0.29) 1 to 5 0.391
Table S4. Results of single factor CFAs for each TMS-f scale
Scale (number of items) χ2 df χ2/df p-value CFI TLI RMSEA SRMR Reliability estimate (congeneric)
PR (9) 77.77 27 2.88 <0.001 0.887 0.850 0.08 0.06 0.804
DS (9) 77.00 27 2.85 <0.001 0.941 0.921 0.08 0.04 0.897
EP (9) 30.86 27 1.14 0.2768 0.973 0.964 0.02 0.04 0.612
CT (9) 51.06 27 1.89 0.0034 0.927 0.902 0.06 0.05 0.775
ST (9) 57.01 27 2.11 <0.001 0.943 0.923 0.06 0.04 0.862
OE (9) 79.96 27 2.96 <0.001 0.912 0.883 0.08 0.05 0.860
MET (16) 216.05 104 2.08 <0.001 0.832 0.806 0.06 0.06 0.824
Table S5. Pearson correlations between observed sum scores on subscales of the TMS-f
PR DS CT ST OE LP MET
PR 0.60 0.08 0.32 -0.04 -0.12 0.18
DS 0.54 -0.19 -0.04 -0.45 -0.15 -0.16
CT 0.02 0.35 0.44 0.43 -0.13 0.36
ST 0.12 -0.34 -0.59 0.65 0.06 0.50
OE -0.11 -0.55 -0.61 0.68 0.12 0.61
EP 0.54 0.28 0.01 0.24 0.08 0.06
MET 0.10 -0.18 -0.50 0.38 0.51 0.07
Below diagonal: correlations found in the current study. Above diagonal: correlations found in the study by Drieschner and Boomsma 116. 
PR	=	problem	recognition;	DS	=	distress;	CT	=	perceived	Costs	of	the	Treatment;	ST	=	perceived	Suitability	of	the	Treatment;	OE	=	outcome	
expectancy;	LP	=	perceived	Legal	Pressure;	EP	=	perceived	external	pressure,	MET	=	Motivation	to	Engage	in	the	Treatment.	Boldface	
indicates that correlation is significant at the 0.05 level (two-tailed). 
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Table S6. Descriptive statistics of the observed sum scores on the subscales of the TMS-f
Scale Statistic Our sample
N = 294
Drieschner and Boomsma
N = 376
PR Mean 
S.D.
Skewness (standard error)
Kurtosis (standard error)
30.25 
7.75
-0.23 (0.14)
 -0.51 (0.28)
32.50 
7.76
-0.68 
0.07
DS Mean 
S.D.
Skewness (standard error)
Kurtosis (standard error)
25.70
9.61
0.09 (0.14)
 -1.01 (0.28)
27.11 
8.83
-0.06
-0.84
CT Mean 
S.D.
Skewness (standard error)
Kurtosis (standard error)
34.06 
6.88
-0.52 (0.14)
-0.14 (0.28)
32.85
6.91
-0.38
-0.33
ST Mean 
S.D.
Skewness (standard error)
Kurtosis (standard error)
34.96
7.17
-0.36 (0.14)
-0.49 (0.28)
35.67
6.72
-0.92
 1.01
EP / LP Mean 
S.D.
Skewness (standard error)
Kurtosis (standard error)
30.41
 5.96
-0.06 (0.14)
-0.18 (0.28)
24.00
 9.36
0.15
 -1.00
MET Mean 
S.D.
Skewness (standard error)
Kurtosis (standard error)
47.23
11.74
0.08 (0.14)
0.08 (0.28)
51.65
12.39
-0.19
 -0.26
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Supplementary material for Chapter 7
Psychometric properties of the Dutch Processes of Change scale 
The processes of change were measured by asking patients to indicate how often they made use of the 
strategies described in 20 statements, where each process of change was represented by two statements 197. 
The statements were rated on a five point Likert scale, ranging from 1 (never) to 5 (repeatedly), consistent 
with other short measures of the processes of change 57,96,171,172.
 The item properties of the 20 Dutch statements are shown in Table S1 as well as the congeneric estimates 
of reliability of the experiential and behavioural processes of change. 
Table S1. Item properties of the Dutch processes of change scale 
English Dutch Mean/ 
variance
Skewness/
kurtosis
Observed 
range
Loading Congeneric 
estimate
Items addressing experiential processes of change
5 Warnings about health risks related to my 
unhealthy behaviours upset me
Waarschuwingen over de gevaren van 
mijn ongezonde gewoontes raken mij 
emotioneel
3.21 / 1.56 -0.19 / -0.86 1 to 5 0.484 0.705
6 I get upset when I hear or read about 
illnesses caused by my problems
Ik raak van streek als ik denk aan 
onderzoeken die gaan over aandoeningen 
veroorzaakt door mijn klachten
2.53 / 1.57 0.43 / -0.74 1 to 5 0.409
7 I consider the view that my behaviour is 
harmful to my environment
Ik denk erover na dat mijn gedrag 
schadelijk is voor mijn omgeving
2.39 / 1.59 0.43 / -0.96 1 to 5 0.467
8 I am aware that my unhealthy behaviours 
are harmful to my environment
Ik ben me ervan bewust dat mijn 
ongezonde gewoonten schadelijk zijn 
voor mijn omgeving
2.65 / 1.68 0.25 / -1.02 1 to 5 0.507
15 I received signals from my environment that 
reminded me of addressing my problems
Ik vang signalen op uit mijn omgeving die 
me herinneren aan het aanpakken van mijn 
klachten
3,13 / 1.48 -0.16 / -0.89 1 to 5 0.443
16 I find that society changes such that life 
is easier for people without problems 
Ik merk dat de samenleving verandert 
waardoor het leven makkelijker is voor 
mensen die geen klachten hebben
3,31 / 1.52 -0.38 / -0.74 1 to 5 0.266
17 I am disappointed in myself because of 
my problems
Door mijn klachten voel ik me 
teleurgesteld in mezelf
3.00 / 1.65 -0.10 / 0.07 1 to 5 0.615
18 I get upset when I think about my problems Ik raak van streek als ik aan mijn klachten 
denk
2.92 / 1.62 -0.97 / 0.18 1 to 5 0.627
Items addressing behavioural processes of change
1 I remember information about how to 
address my problems
Ik herinner mij informatie die ging over 
het aanpakken van mijn klachten
3.47 / 1.18 -0.51 / -0.22 1 to 5 0.465 0.766
2 I think about information that is 
concerned with how to address my 
problems
Ik denk na over informatie die gaat over 
hoe je mijn klachten kunt aanpakken
3.81 / 0.95 -0.73 / 0.43 1 to 5 0.579
3 I told myself that I had a choice in 
addressing my problems
Ik zeg tegen mezelf dat ik kan kiezen of 
ik mijn klachten aanpak
3.34 / 1.44 -0.37 / 0.67 1 to 5 0.536
4 I made a commitment to myself to 
address my problems
Ik spreek met mezelf af om mijn 
klachten aan te pakken
3.82 / 1.10 -0.87 / 0.42 1 to 5 0.690
9 I have someone who listens when I need 
to talk about my problems
Ik heb iemand die naar mij luistert als ik 
over mijn klachten wil praten
4.04 / 0.93 -1.11 / 1.17 1 to 5 0.373
10 I have someone I can count on when I’m 
having problems
Ik heb iemand waarop ik kan rekenen 
als ik klachten heb
4.12 / 0.97 -1.16 / 1.01 1 to 5 0.421
13 When I am tempted to give in to my 
problems, I think about something else
Wanneer ik in de verleiding kom om toe 
te geven aan ongezonde gewoonten, 
denk ik aan iets anders
2.97 / 1.50 -0.09 / -0.89 1 to 5 0.496
14 Instead of giving in to unwanted 
behaviours, I do something else when I 
want to relax
In plaats van toegeven aan de 
ongezonde gewoonte, doe ik iets anders 
wanneer ik me wil ontspannen
3.33 / 1.42 -0.30 / -0.72 1 to 5 0.502
206
Chapter 13 } Appendices
19 I will be rewarded by others when 
I don’t relapse to my unhealthy 
behaviours
Ik zal beloond worden door anderen 
als ik niet terugval op mijn ongezonde 
gewoonten
2.70 / 1.66 0.18 / -1.02 1 to 5 0.388
20 I reward myself when I don’t relapse to 
my unhealthy behaviours
Ik beloon mezelf als ik niet terugval op 
mijn ongezonde gewoonten
3.25 / 1.73 -0.31 / -0.92 1 to 5 0.500
 *Items 11 and 12 showed substantial cross-loadings and were therefore removed.
Analysis strategy for model testing using Structural Equation Modeling (SEM)
Latent variables were identified for the stages of change as assessed with the URICA-D, the experiential and 
behavioural processes of change and all outcome variables. Using classical reliability theory reformulated 
in terms of confirmatory factor analysis, the observed variables were corrected for unreliability. Congeneric 
reliability estimates 203,219 were obtained as both the common factors loadings and the residuals turned out 
to differ. Subsequently, a factor analysis model for each observed variable was defined , in which the factor 
loading was fixed at 1.0 and the residual variance of that factor (i.e. 1- reliability) was multiplied by the 
variance of the variable at issue. 
 Next, the plausibility and stability of the model was investigated for both assessment methods. The 
model as depicted in Figure 1 was fitted to the data for the full sample using the baseline and follow-up 
measurements separately. It was tested whether the baseline model showed good overall fit. If not, it was 
evaluated how it could be adapted such that the fit would improve or alternatively, whether the model could 
be simplified while not violating the overall model fit. The most plausible model was obtained by evaluating 
the model fit criteria and standardized residuals. The following measures were used to test for adequacy of 
the	model	 fit:	χ2	 for	model	 fit	 (low	and	non-significant	values	of	 the	χ2	were	desired;	P-value	>	0.05);	χ2/
df ratio (a value <2.0 was considered to be acceptable); information criteria including Akaike (AIC), Bayesian 
(BIC), sample-size adjusted BIC (SS-BIC) (the smaller the better); Comparative Fit Index (CFI), and Tucker-
Lewis Index (TLI) (high values are desired (> 0.95), values > 1.0 point to over identification 201,220,221; Root Mean 
Square Error of Approximation (RMSEA: a value < 0.05 indicates a close fit 222; and Standardized Root Mean 
Squares of Residuals (SRMR: a value of < 0.05 indicates a reliable fit)201.	The	MLR	χ2	difference	test	was	used	
to	compare	different	models	which	were	nested.	The	χ2	difference	was	based	on	log-likelihood	values	and	
scaling	correction	factors	obtained	with	the	MLR	estimator,	using	the	formula	Δχ2=	-2*(L0	-	L1)/cd	where	L0	
is the log likelihood of the restricted (nested) model, L1 is the log likelihood of the unrestricted model and cd 
is the difference test scaling correction (which is based on scaling correction factors (c0 and c1) and number 
of parameters (p0 and p1) for the restricted and unrestricted models, respectively). 
 To address the stability of the most plausible structural model (objective 2) across time and patient 
groups, additional analyses were performed. The invariance of the most plausible path model across time was 
evaluated by testing the invariance of the regression estimates of the latent variables, by comparing those 
assessed	at	baseline	with	those	assessed	at	follow-up	using	the	MLR	χ2	difference	test.	Fitting	both	latent	path	
models (baseline and follow-up) jointly was used to test whether the regression estimates of both time points 
could	be	considered	invariant.	Specifically,	a	non-significant	MLR	χ2	difference	test	between	the	model	with	
all regression estimates constrained to be equal for the corresponding measurements versus all regression 
estimates unconstrained was considered statistical evidence for the latent path model being invariant across 
time. Individual estimates were regarded statistically significant if the two-sided P-values were < 0.05. The 
correlations of the latent variables between the corresponding measurements were allowed to be free as 
the measurements were repeated. The next step was to test whether this model was also invariant across 
different	patient	groups	(personality	disorders	versus	psychotic	disorders).	The	MLR	χ2	difference	test	was	
used to test equality constraints between nested models. Finally, to test to what extent the obtained IM- 
model has utility for clinical practice, explained variances (R2) on the dependent variables in the model, 
including treatment engagement, psychosocial functioning and quality of life, were reported. 
Results of SEM
Associations between stages of change, treatment engagement and clinical 
outcomes: fit of the structural model
The hypothesized model as depicted in Figure 2 was fitted to the data at baseline and at follow-up, for both 
the staging algorithm and the URICA-D. Results are shown in Table S3. Starting with the staging algorithm, 
the model in Figure 2 provided good fit to the data at baseline:	χ2/df=0.68,	RMSEA=0.00,	CFI=1.00,	TLI=1.04,	
207
Table S2. Spearman intercorrelations of URICA-D stages of change, processes of change and outcomes for the total study sample
Baseline assessment Follow-up assessment
P C A M TE PF QL EXP BEH P C A M TE PF QL
P
C -.26
A -.29 .44
M -.19 .64 .33
TE -.05 -.02 .15 -.08
PF .06 -.29 -.01 -.34 .35
QL .06 -.26 .10 -.25 .39 .57
Follow-up assessment
EXP -.08 .31 .12 .33 -.02 .12 -.17
BEH -.07 .21 .35 .17 .23 -.12 .21 .25
P .40 -.17 -.18 -.18 -.06 .07 .13 -.23 -.12
C -.20 .43 .29 .35 .00 -.15 -.13 .44 .22 -.33
A -.24 .24 .51 .23 .26 .12 .16 .14 .48 -.29 .44
M -.14 .39 .31 .49 .06 -.09 -.06 .44 .23 -.32 .62 .45
TE -.07 .06 .14 .08 .62 .21 .25 -.08 .14 -.14 .06 .31 .16
PF .04 -.18 -.00 -.27 .30 .52 .40 .29 -.10 .12 -.27 .04 -.29 .23
QL .15 -.22 .07 -.21 .25 .33 .58 .28 .28 .20 -.24 .17 -.27 .20 .61
Boldface	indicates	p	<	0.05	(two-tailed).	URICA-D	=	University	of	Rhode	Island	Change	Assessment	–	Dutch	version,	
P	=	precontemplation,	C=	contemplation,	A	=	action,	M	=	maintenance,	TE	=	Treatment	engagement,	PF	=	Psychosocial	functioning,	QL	
=	Quality	of	life.	
Figure S1. Means for outcome variables across the stages of change, as assessed with the staging algorithm
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SRMR=0.02)	 and	 bad	 fit	 at	 follow-up:	 χ2/df=4.86,	
RMSEA=0.12,	 CFI=0.79,	 TLI=0.62,	 SRMR=0.08.	 The	
model fit improved slightly at follow-up when stages 
were	regressed	onto	the	previous	stage	(χ2/df=4.86,	
RMSEA=0.12,	CFI=0.91,	TLI=0.77,	SRMR=0.08),	while	
model fit for the baseline assessment remained 
exactly the same. When Figure 2 was fitted for 
the URICA-D, the model showed borderline fit 
at	 baseline	 (χ2/df=3.53,	 RMSEA=0.09,	 CFI=0.94,	
TLI=0.84,	 SRMR=0.09)	 and	 bad	 fit	 at	 follow-up	
(χ2/df=7.05,	 RMSEA=0.15,	 CFI=0.87,	 TLI=0.66,	
SRMR=0.12).	Model	fit	did	not	change	when	stages	
were regressed onto the previous stage, nor when 
stages were regressed on all previous stages (please 
see Table S3). Despite the potential for further 
improvements of model fit, it was decided not to 
include additional paths between stages and clinical 
outcomes of psychosocial functioning and quality of 
life, as this was not in line with theory. It was therefore 
decided to retain model b for further analyses. 
Testing the stability of the theoretical 
model across time and diagnostic 
groups
The most plausible structural models for the 
staging algorithm and URICA-D were tested for 
stability across time, by testing the invariance of 
the paths in the model across the two measurement 
occasions. To this end, a model was created in 
which both baseline and follow-up path models 
were included simultaneously. Two versions of this 
model were created and compared: one model in 
which the regression weights were allowed to be 
free (unconstrained) for the baseline and follow-
up measurements and one model in which the 
regression weights for the corresponding paths 
at baseline and follow-up were constrained to be 
similar. The test for invariance across time was 
represented	by	the	MLR	χ2	difference	test	between	
these	 two	models,	 where	 a	 non-significant	 χ2-test	
was considered statistical evidence for the path 
model being invariant across time. As can be seen 
in	Table	S4,	the	χ2-test	for	the	staging	algorithm	did	
not reach statistical significance for the comparison 
across	 time	 (Δχ2=11.13,	 Δdf=9,	 p=0.27),	 implying	
that the path model was invariant across time. That 
is, the regression coefficients between variables 
in the model could be considered similar for the 
baseline and follow-up assessments. This process 
was repeated for comparisons of patient diagnostic 
groups, for both time points separately. Both at 
baseline and at follow-up assessment, the model 
was found to be invariant for patients with psychotic 
disorders and personality disorders as shown by the 
non-significant	 MLR	 χ2	 difference	 tests	 (Δχ2=7.62,	
Δdf=9,	 p=0.85	 and	 Δχ2=14.44,	 Δdf=9,	 p=0.11,	
respectively). 
 Similarly, tests were performed to evaluate the 
invariance across time and diagnostic groups for the 
URICA-D. As can be seen in Table S4, the URICA-D 
also	 showed	 invariance	 across	 time	 (Δχ2=9.77,	
Δdf=9,	 p=0.37),	 and	 across	 diagnostic	 groups	 for	
both	 time	 points	 (Δχ2=8.55,	 Δdf=9,	 p=0.48	 and	
Δχ2=7.92,	Δdf=9,	p=0.54,	respectively).
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Models for the staging algorithm
C or U χ2 df χ2/df p-value RMSEA 90% C.I. for 
RMSEA
CFI TLI SRMR AIC BIC SS-BIC
1a. Baseline (figure 2) - 5.42 8 0.68 0.71 0.00 0.00 to 0.05 1.00 1.04 0.02 199.79 299.25 213.63
1b. Stages regressed on previous adjacent 
stage, and including correlations between 
non-adjacent stages
- 5.42 8 0.68 0.71 0.00 0.00 to 0.05 1.00 1.02 0.02 199.79 299.25 213.63
1c. Stages regressed on all previous stages - 5.42 8 0.68 0.71 0.00 0.00 to 0.05 1.00 1.02 0.02 199.79 299.25 213.63
2a. Follow-up (figure 2) - 38.90 8 4.86 <0.01 0.12 0.08 to 0.15 0.79 0.62 0.08 403.01 502.47 416.85
2b. Stages regressed on previous adjacent 
stage, and including correlations between 
non-adjacent stages
38.90 8 4.86 <0.01 0.12 0.08 to 0.15 0.91 0.77 0.08 403.01 502.47 416.85
2c. Stages regressed on all previous stages - 38.90 8 4.86 <0.01 0.12 0.08 to 0.15 0.91 0.77 0.08 541.88 633.96 554.69
Models for the URICA-D
C or U χ2 df χ2/df p-value RMSEA 90% C.I. for 
RMSEA
CFI TLI SRMR AIC BIC SS-BIC
1a. Baseline (figure 2) - 28.25 8 3.53 <0.01 0.09 0.06 to 0.13 0.94 0.84 0.09 3108.55 3208.00 3122.38
1b. Stages regressed on previous adjacent 
stage, and including correlations between 
non-adjacent stages
- 28.25 8 3.53 <0.01 0.09 0.06 to 0.13 0.94 0.84 0.09 3108.55 3208.00 3122.38
1c. Stages regressed on all previous stages - 28.25 8 3.53 <0.01 0.09 0.06 to 0.13 0.94 0.84 0.09 3108.55 3208.00 3122.38
2a. Follow-up (figure 2) - 56.39 8 7.05 <0.01 0.15 0.11 to 0.18 0.87 0.66 0.12 2581.34 2679.96 2594.34
2b. Stages regressed on previous adjacent 
stage, and including correlations between 
non-adjacent stages
- 56.39 8 7.05 <0.01 0.15 0.11 to 0.18 0.87 0.66 0.12 2581.34 2679.96 2594.34
2c. Stages regressed on all previous stages - 56.39 8 7.05 <0.01 0.15 0.11 to 0.18 0.87 0.66 0.12 2581.34 2679.96 2594.34
Note:	 C	 or	 U	 =	Model	 with	 either	 constrained	 (C)	 or	 unconstrained	 (U)	 regression	 coefficients	 for	 corresponding	measurements	 at	
baseline	 and	 follow-up.	 χ2 =	 chi-square	 statistic;	 df	 =	 degrees	of	 freedom;	RMSEA	=	 root	mean	 square	 error	 of	 approximation;	 CFI	 =	
Comparative	Fit	Index,	TLI	=	Tucker-Lewis	Index,	SRMR	=	standardized	root	mean	square	residual;	AIC	=	Akaike	Information	Criterion,	BIC	
=	Bayesian	Information	Criterion,	SS-BIC	=	Sample	size	adjusted	BIC.
Table S3. Model fit information for the staging algorithm and URICA-D
Table S4. Model comparisons: Testing stability across time and patient groups, for the staging algorithm and the URICA-D
Note:	C	or	U	=	Model	with	either	constrained	(C)	or	unconstrained	(U)	regression	coefficients	for	corresponding	measurements	at	baseline	
and follow-up. The constrained (nested) model is the more restrictive model with more degrees of freedom than the comparison model. 
The	grey	and	white	shading	indicates	models	that	are	rivalling	(nested)	models	(similar	shading	indicates	rivaling	models).	χ2	=	chi-square	
statistic;	df	=	degrees	of	freedom;	Δ	χ2	=	chi-square	value	of	the	MLR	difference	test,	Δ	df	=	difference	in	degrees	of	freedom	between	
the models being compared.
Models for the staging algorithm C or U χ2 df χ2/df Δ Χ2 Δ df Δ Χ2 / Δ df p-value Interpretation based on statistical inference
3a. Baseline and follow-up jointly (as model 2b) U 119.53 56 2.13
11.13 9 1.23 0.2669
The model is invariant across time
3b. Baseline and follow-up jointly (as model 2b)) C 133.18 65 2.05
4a. Baseline model (as model 2b) for psychotic 
versus personality disorders U 30.77 16 1.92
7.62 9 0.85 0.5728
The model is invariant across patient groups at 
baseline4b. Baseline model (as model 2b) for psychotic 
versus personality disorders C 39.22 25 1.56
5a Follow-up model (as model 2b) for psychotic 
versus personality disorders U 45.42 16 2.84
14.44 9 1.60 0.1075
The model is invariant across patient groups at 
follow-up5b Follow-up model (as model 2b) for psychotic 
versus personality disorders C 61.56 25 2.46
Models for the URICA-D C or U χ2 df χ2/df Δ Χ2 Δ df Δ Χ2 /  
Δ df
p-value Interpretation based on statistical inference
3a. Baseline and follow-up jointly (as model 2b) U 185.88 56 3.32
9.77 9 1.09 0.3694
The model is invariant across time
3b. Baseline and follow-up jointly (as model 2b) C 197.85 65 3.04
4a. Baseline model (as model 2b) for psychotic 
versus personality disorders U 31.80 16 1.99
8.55 9 0.95 0.4798
The model is invariant across patient groups at 
baseline4b. Baseline model (as model 2b) for psychotic 
versus personality disorders C 42.25 25 1.69
5a Follow-up model (as model 2b) for psychotic 
versus personality disorders U 67.46 16 4.22
7.92 9 0.88 0.5422
The model is invariant across patient groups at 
follow-up5b Follow-up model (as model 2b) for psychotic 
versus personality disorders C 70.94 25 2.84
210
Ch.
211
14
About the author
212
Chapter 14 } About the Author
Curriculum Vitae
Eline Jochems was born in 1987 in Eindhoven, the 
Netherlands. After she graduated from the bilingual 
program (“Tweetalig VWO”) at the Stedelijk College 
Eindhoven in 2005, she started studying Biological 
Psychology at Maastricht University. During her 
time as a bachelor student in Maastricht, she was 
chairman of the board of the student association, 
worked as a student tutor and freelance student 
counselor, graduated from the honours programme. 
She obtained her bachelor degree ‘cum laude’ in 
2008. Subsequently, she moved to Tilburg to study 
Medical Psychology at Tilburg University. During the 
second year of this master education, she combined 
a clinical internship with a research internship at the 
department of Medical Psychology and Psychiatry 
of the St. Anna hospital. In 2010 she obtained 
her master degree (‘met genoegen’) and started 
her research project - as described in this thesis - 
at the Department of Psychiatry of the Erasmus 
MC University Medical Center Rotterdam. During 
this time, she also obtained her master degree in 
Clinical Epidemiology at the Netherlands Institute 
for Health and Sciences. Starting from November 
2013, she started working on her dissertation 
part-time, while also working as a psychologist at 
GGz Breburg; a specialty mental health institution 
located in the province North Brabant, the 
Netherlands. From November 2013 to September 
2015, she worked within this institution in Tilburg 
at the Topclinical Center for Body, Mind and Health 
(‘Topklinisch Centrum voor Lichaam, Geest en 
Gezondheid’) and since then at the Center for 
Anxiety and Mood Disorders (Centrum voor Angst- 
en Stemmingsstoornissen’). In September 2016 she 
will start with the post-doctoral training in health 
psychology (“gz-psycholoog”).
213
PhD portfolio
Name PhD student: E.C. Jochems  Promotors:  Prof. dr. C.L. Mulder
Erasmus MC Department: Psychiatry   Prof. dr. C.M. van der Feltz-Cornelis
PhD period: Aug 2010 – Feb 2016  Copromotors:  Dr. A. van Dam
        Dr. H.J. Duivenvoorden
PhD training Year Hours ECTS
General courses 
BROK (‘Basiscursus Regelgeving Klinisch Onderzoek’)
Training in the Health of the Nations Outcome Scales (HoNOS)
Preconference training for Health Care professionals – Self-Determination Theory applications to practice
Workshop Endnote
Workshop Systematic literature retrieval in PubMed
Workshop Systematic literature retrieval in other databases
Research Integrity
2010
2010
2013
2013
2013
2013
2014
32
12
8
3
5
4
0.3
NIHES Master of Science in Clinical Epidemiology
Clinical Epidemiology 
Courses for the Quantitative Researcher
Erasmus Summer Programme 2011 
Psychiatric Epidemiology
Health Services: Research and Practice
Repeated Measurements in Clinical Studies
Missing Values in Clinical Research
Erasmus Summer Programme 2012 
Study Design
Methodological Topics in Epidemiologic Research
Modern Statistical Methods
Research proposal and oral research presentation
2010
2010
2011
2011
2011
2012
2012
2012
2012
2012
2012
2012
70
Presentations and (inter)national conferences
-  Various presentations at the Department of Psychiatry of the Erasmus MC and in the mental health institutions GGZ 
WNB, GGz Breburg and Bavo Europoort
-  Symposium Therapietrouw en ziekte-inzicht bij patiënten met psychotische stoornissen, Rotterdam, the Netherlands 
(attendance)
- First European Congress on Assertive Outreach - “Crossing Borders”, Rotterdam, the Netherlands (attendance)
- 6th Annual Meeting of the Society for the Study of Motivation, Washington DC, U.S.A. (poster presentation)
- 5th International Conference on Self-Determination Theory, Rochester NY, U.S.A. (poster presentation)
-  Voorjaarscongres Nederlandse Vereniging voor Psychiatrie “Motivatie”, Maastricht, the Netherlands  
(organisation of two symposia, two oral presentations at each of these symposia)
- Third European Congress on Assertive Outreach – “reaching out together”, Oslo, Norway (oral presentation)
- Fifth European Conference on Schizophrenia Research,  Berlin, Germany (oral presentation)
2010-2015
2010
2011
2013
2013
2014
2015
2015
2
1
1
1
1
2
1
1
Teaching Year Hours ECTS
Tutoring
- Tutoraat
- Cursus ‘Omgaan met Groepen’ 
- Second year “keuzeonderwijs” for medical students
2011
2011
2011
2012
2013
80
4
40
40
40
Supervising Master’s theses of five students 2011 -2013 5
214
Chapter 14 } About the Author
Publications
Jochems, E. C., Mulder, C. L., van Dam, A., & 
Duivenvoorden, H. J. (2011). A critical analysis of the 
utility and compatibility of motivation theories in 
psychiatric treatment. Current Psychiatry Reviews, 
7(4), 298-312. doi:10.2174/157340011797928204
Jochems, E. C., Mulder, C. L., van Dam, A., 
Duivenvoorden, H. J., Scheffer, S. C., van der Spek, W., 
& van der Feltz-Cornelis, C. M. (2012). Motivation 
and treatment engagement intervention trial 
(MotivaTe-IT): the effects of motivation feedback 
to clinicians on treatment engagement in patients 
with severe mental illness. BMC Psychiatry, 12, 209. 
doi:10.1186/1471-244X-12-209
Kortrijk,	H.	E.,	Mulder,	C.	L.,	van	Vliet,	D.,	van	Leeuwen,	
C., Jochems, E., & Staring, A. B. (2013). Changes 
in Motivation for Treatment in Precontemplating 
Dually Diagnosed Patients Receiving Assertive 
Community Treatment. Community Mental Health 
Journal. doi:10.1007/s10597-012-9582-2
Mulder,	 C.	 L.,	 Jochems,	 E.,	&	 Kortrijk,	 H.	 E.	 (2014).	
The motivation paradox: higher psychosocial 
problem levels in severely mentally ill patients 
are associated with less motivation for treatment. 
Social Psychiatry and Psychiatric Epidemiology, 
49(4), 541-548. doi:10.1007/s00127-013-0779-7
Jochems, E. C., Mulder, C. L., Duivenvoorden, H. 
J., van der Feltz-Cornelis, C. M., & van Dam, A. 
(2014). Measures of Motivation for Psychiatric 
Treatment Based on Self-Determination Theory: 
Psychometric Properties in Dutch Psychiatric 
Outpatients. Assessment, 21(4), 494-510. 
doi:10.1177/1073191113517928
Jochems, E. C., Van Dam, A., Duivenvoorden, H. J., 
Scheffer, S., Van der Feltz-Cornelis, C. M., & Mulder, 
C. L. (2015). Different Perspectives of Clinicians 
and Patients with Severe Mental Illness on 
Motivation for Treatment. Clinical Psychology and 
Psychotherapy. doi:10.1002/cpp.1971
Jochems, E. C., Van der Feltz-Cornelis, C. M., Van 
Dam, A., Duivenvoorden, H. J., & Mulder, C. L. (2015). 
The effects of motivation feedback in patients 
with severe mental illness: a cluster randomized 
controlled trial. Neuropsychiatric Disease and 
Treatment, 11, 3049-3064. doi:http://dx.doi.
org/10.2147/NDT.S95190
Jochems, E. C., Duivenvoorden, H. J., van Dam, 
A., Van der Feltz-Cornelis, C. M., & Mulder, C. L. 
(2016). Motivation, treatment engagement and 
psychosocial outcomes in outpatients with severe 
mental illness: A test of Self-Determination Theory. 
(Revised and resubmitted).
Jochems, E. C., Duivenvoorden, H. J., Van Dam, A., 
Mulder, C. L., & Van der Feltz-Cornelis, C. M. (2016). 
Testing the Integral Model of Treatment Motivation 
in outpatients with severe mental illness. (Revised 
and resubmitted).
Jochems, E. C., Duivenvoorden, H. J., Van Dam, A., 
Van der Feltz-Cornelis, C. M., & Mulder, C. L. (2016). 
The TransTheoretical Model Stages of Change for 
Motivation to Engage with Psychiatric Treatment in 
Outpatients with Severe Mental Illness. (Submitted).
Measures and tools
Jochems, E. C., Mulder, C. L., Duivenvoorden, H. J., 
van der Feltz-Cornelis, C. M., & van Dam, A. (2014). 
Dutch version of the Treatment Entry Questionnaire 
(TEQ).
Jochems, E. C., Mulder, C. L., Duivenvoorden, H. 
J., van der Feltz-Cornelis, C. M., & van Dam, A. 
(2014). Dutch version of the Health Care Climate 
Questionnaire (HCCQ).
Jochems, E. C., Mulder, C. L., Duivenvoorden, H. J., 
van der Feltz-Cornelis, C. M., & van Dam, A. (2014). 
The Dutch Short Motivation Feedback List (SMFL).
Jochems, E. C., Duivenvoorden, H. J., Van Dam, A., 
Mulder, C. L., & Van der Feltz-Cornelis, C. M. (2016). 
Adaptation of the ‘perceived legal pressure scale’ 
from the Treatment Motivation Scales for Forensic 
outpatient treatment 116,118 to ‘perceived external 
pressure’. 
Jochems, E. C., Duivenvoorden, H. J., Van Dam, A., 
Van der Feltz-Cornelis, C. M., & Mulder, C. L. (2016). 
The Dutch Short Processes of Change scale (SPoC-
Dutch). 
215
216
Ch.
217
15
Dankwoord
218
Chapter 15 } Dankwoord
Dankwoord
Motivatie. Een woord met veel betekenissen, 
inmiddels ook met veel persoonlijke betekenis voor 
mij. Zonder de samenwerking en steun van veel 
inspirerende en motiverende mensen had dit project 
en dit proefschrift niet gerealiseerd kunnen worden. 
De afgelopen jaren heb ik me o.a. kunnen verheugen 
op het vooruitzicht om ooit dit stukje tekst te 
kunnen schrijven waarin ik mijn ‘motivators’ zou 
mogen bedanken voor hun bijdrage aan dit werk. Ik 
realiseer me dat ik met dit schrijven nooit iedereen 
voldoende recht kan doen en ik hoop daarom dat 
jullie weten dat mijn dankbaarheid verder gaat dan 
de woorden in deze tekst. 
∞
Beste Niels, als promotor en als persoon heb 
ik je ervaren als een inspirator, toegankelijk en 
betrokken. Ik heb vanaf het begin veel vertrouwen 
gevoeld om dit project mijn eigen invulling te geven 
en daardoor lukte het mij om het ‘eigen’ te maken 
en te houden. Bedankt voor dat vertrouwen. Ook 
de steunende, motiverende gesprekken tussendoor 
waren voor mij belangrijk. Zowel de inhoudelijke 
gesprekken en discussies over de wetenschap, maar 
ook de persoonlijke aandacht voor andere dingen in 
het leven en je begrip voor de emotionele achtbaan 
die een promotietraject ook is, heb ik gewaardeerd. 
Ondanks je drukke agenda, voelde ik bij jou de 
ruimte om zowel mijn zakelijke als persoonlijke 
verhaal te kunnen doen. Ik heb onze samenwerking 
als erg prettig ervaren en hoop die in de toekomst 
nog te kunnen voortzetten.
 Beste Christina, als tweede promotor en als 
persoon heb je zowel in dit project als in mijn 
persoonlijke ontwikkeling een belangrijke rol 
gespeeld. Het project had zonder jou niet op 
dergelijke schaal kunnen worden uitgevoerd en 
de artikelen zijn door jouw feedback scherper 
geformuleerd en strakker gestructureerd. Jij zag 
in mij al gauw een scientist-practitioner en jij hebt 
mij de kans geboden om parttime als psycholoog 
te kunnen werken in “jouw” Topklinisch Centrum 
voor Lichaam, Geest en Gezondheid. Ik heb in dit 
onderzoeksproject, maar vooral ook de afgelopen 
twee jaar tijdens het combineren van praktijk en 
onderzoek, erg veel over mezelf geleerd. Ik ben 
erachter gekomen dat ik in de toekomst ook graag 
de combinatie wil blijven maken van onderzoek en 
praktijk. Bedankt daarvoor. 
 Beste Arno, als co-promotor en als persoon 
wil ik je bedanken voor jouw inspirerende en 
optimistische aanwezigheid in dit project. Ik heb 
je leren kennen als iemand die denkt in kansen en 
oplossingen, iemand die beschouwend en rustig 
naar complexe zaken kan kijken en dat was in mijn 
ogen voor dit project en voor mijzelf zeer waardevol. 
Onze gesprekken over de motivatietheorieën en 
hoe deze in de praktijk vertaald konden worden, 
hebben mij steeds uitgedaagd om de zaken weer in 
een ander perspectief te zien. Ook de momenten 
tussendoor, bijvoorbeeld in de auto van Rotterdam 
naar Dordrecht, waarin we iets uitgebreider konden 
spreken over de andere - meer moeizame - processen 
waar elke promovendus mee te maken krijgt, hebben 
mij gerustgesteld en geholpen. Daarnaast hebben 
we ook gelachen, wat altijd een fijn medicijn is tegen 
teleurstellingen en tegenslagen! 
 Beste Hugo, als tweede co-promotor en als 
mens heb ik jou leren kennen als zeer intelligente, 
gepassioneerde professional en daarnaast, 
belangrijker nog, als een warm, geduldig en sociaal 
persoon. Ik wil je bedanken voor je nimmer aflatende 
enthousiasme voor (complexe) methodologie en 
statistiek en je geduldige en inspirerende begeleiding 
op zowel de inhoud als het proces. Hoewel ik tijdens 
mijn traject een master klinische epidemiologie heb 
afgerond, ben ik van mening dat jouw persoonlijke 
coaching en kennis in de wetenschap mijn grootste 
leerschool is geweest. Gewapend met koffie en 
chocolade hebben wij flink wat uren samen achter 
de computer gezeten om strategieën te bedenken, 
eindeloze analyses te draaien in Mplus, SAS en/
of SPSS en dan werd ik altijd positief verrast door 
jouw onstuitbare enthousiasme, nieuwsgierigheid 
en uitgebreide kennis. Tussendoor waren er ook 
momenten waarop we even achterover leunden, 
afstand namen en dan konden we ook goed in 
gesprek zijn over het leven buiten de wetenschap. 
Ik hoop dat ik, net als jij, altijd gepassioneerd en 
enthousiast zal blijven over mijn vak en dat kan 
uitdragen naar andere mensen, zodat ik ook een 
inspiratie kan worden voor anderen zoals jij dat 
bent voor mij. Hugo, datgene wat ik van jou heb 
geleerd heeft grote waarde voor mijn ontwikkeling 
en carrière. Bedankt! 
∞
De leden van de kleine en grote commissie wil ik 
bedanken voor het lezen van mijn proefschrift en 
voor uw aanwezigheid tijdens de verdediging. 
∞
Ik voel me zeer dankbaar naar alle cliënten en 
behandelaren die wilden meewerken met dit 
onderzoek. Aan de cliënten: de openheid en de 
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zeer persoonlijke inkijk die jullie mij gaven in jullie 
beleving van het contact met de hulpverlening heb ik 
bijzonder gewaardeerd. Ik heb gezien en geleerd van 
jullie dat kwetsbaarheid en kracht altijd samengaan 
en ik probeer dat nu uit te dragen in mijn werk als 
psycholoog. Bedankt voor alles!
 Aan de behandelaren: zonder jullie inzet was 
dit onderzoek onmogelijk geweest. Ondanks al jullie 
ROM(p)slomp en jullie drukke dagelijkse bezigheden 
hebben jullie toch de tijd gevonden om voor mij 
vragenlijsten in te vullen en extra aandacht te hebben 
voor motivatie in jullie contacten met de cliënten. 
Deels opgejaagd door mijn lunch-presentaties, 
mails, boekenleggers, evaluaties, smeekbedes en 
peptalks, maar vooral dankzij jullie eigen motivatie 
en professionaliteit hebben jullie dit onderzoek tot 
een succes gemaakt. Ik ben daarom veel teams en 
mensen dankbaar. 
 In het bijzonder, van de teams van GGZ Westelijk 
Noord	Brabant	(geclusterd	zoals	de	teams	destijds	in	
het onderzoek en verder in willekeurige volgorde): 
Karel	 de	 Bruijn,	 Annet	 Elst,	 Willem	 Hoogstraten,	
Dorthy	 Knoop-Floresse,	 Cissy	 Klaassen,	 Ilona	 Kreuk,	
Lisette	de	Wit,	Carla	Masseurs	en	Kris	Goethals;	Peter	
Huijsmans,	Artin	Khayri,	Marije	Jongeneelen,	Hanneke	
Coumans-van	de	Velde,	Marian	Schijvenaars,	Jantien	
van	 der	 Made-Booij,	 Sandra	 Konings-Koks,	 Sabine	
Verheijen-Vervoort, Annelies Postema, Anthony van 
Es,	Sven	van	Harn,	Wilfred	Timmers,	Karin	Wilbrink,	
Hans-Jan Bonsma, Anja van Heemst, Peter Janssen, 
Monique Gijzen, Remco Bijl en Sara Aben; en Arian 
Kommers,	 Robert	 van	den	Bosch,	 Lilian	 Fens,	 Jouke	
van Zundert en Carolien Franken. 
 Van de teams van GGz Breburg: Tom van Mierlo, 
Rob	 Fitters,	 Ben	 Haagh,	 Daan	 van	 Baar,	 Hanjo	 van	
Berkel,	 Truus	 ter	 Braak,	 Jackelien	 Klerks,	 Marieta	
Verhoeven, Barbara Breugelmans, Petra Rops, Cees 
Santbergen, Marieke Arnoldus, Mandy van der 
Pluijm,	Yerko	Raams,	Roland	Hoven,	Netty	Nix,	 Tom	
Verrijp, Nico Appel, Ad de Leeuw, Marcel Verdonk, 
Willem van Hezewijk, Anton Mols, Lianne van 
Broekhoven,	 Jobke	Debats,	Suanne	Bitter,	Marianne	
Damen, Cecile van Glabbeek, Susan Reijrink, Jitske de 
Graaf, Els van Abeelen, Ron Maidman, Ton op ’t Hoog, 
Petra Dalmaijer, Ad van der Made, Frank Baarends, 
Karin	Kleinjan,	Miriam	van	Woenzel	en	John	Vije.	Ook	
mensen wiens naam hier niet genoemd staan, maar 
die	destijds	in	de	teams	werkzaam	waren	om	voor	mij	
de deur open te doen, een vraag te beantwoorden, 
een mailtje door te sturen of andere behulpzame 
acties	tussendoor	te	doen;	bedankt!	
∞
Sylvia	Scheffer	en	Willem	van	der	Spek	wil	ik	bedanken	
voor	 hun	 enthousiasme	 en	 doorzettingsvermogen	
om bij dit project aan te haken. Sylvia, we hebben 
samen de training opgezet voor de behandelaren 
en	 hard	 gelachen	 bij	 het	 maken	 van	 de	 filmpjes!	
Onderzoek doen kan – zoals je ook hebt ervaren 
–	 stressvol	 en	 weerbarstig	 zijn,	 zeker	 als	 je	 het	
combineert	 met	 de	 praktijk,	 maar	 de	 aanhouder	
wint en ik ben blij met ons resultaat. Jouw hulp bij 
de training en je persoonlijke interesse in mij, ook na 
onze samenwerking, waardeer ik zeer. Willem, ook bij 
jou	was	het	onderzoek	in	combinatie	met	je	opleiding	
tot	psychiater	 een	pittige	pil.	 Ik	weet	dat	 jij	 ook	op	
meerdere manieren geïntrigeerd en geïnspireerd 
bent	 geraakt	 door	 het	 onderwerp	 motivatie.	 We	
hebben daarover leuke gesprekken gevoerd en je 
past	het	nu	toe	in	de	dagelijkse	praktijk	bij	de	FACT-
teams. Bedankt daarvoor. 
∞
Mijn dank gaat ook uit naar Saskia Asselbergs en 
de	studenten	Briëtte	Hitzert,	Marjolein	van	Leijden,	
Inga	 Mockute,	 Koen	 de	 Vlam,	 Zeynep	 Bagiran	 en	
Özlem Ergec, die deelonderzoeken hebben gedaan 
binnen dit project. Bedankt voor jullie hulp met de 
dataverzameling, met het invoeren in SPSS en met 
het nadenken over de materie vanuit jullie eigen 
onderzoeken. Door jullie enthousiasme en inzet werd 
mijn werk lichter, leuker en gezelliger!
∞
Al mijn collega’s op de afdeling Psychiatrie van 
het Erasmus MC wil ik bedanken voor leerzame 
gesprekken, bijeenkomsten en feedback, maar ook 
voor	 de	 gezelligheid	 tijdens	 lunches,	 koffiepraatjes	
en congressen. In het bijzonder wil ik hier de 
namen	 noemen	 van	 Leontien,	 Karin,	 Astrid,	 Jurate,	
Vandhana,	Ernst,	Janneke	en	Stefanie.	Het	is	fijn	om	
mensen te hebben waar je de ups en downs van 
promotieonderzoek	 mee	 kunt	 delen	 en	 ervaringen	
uit kunt wisselen, symposia op congressen mee 
kunt presenteren en bezoeken, maar ook mee kunt 
borrelen	en	op	stap	gaan	(in	Rotterdam,	Maastricht,	
Oslo en Berlijn en wie weet waar in de toekomst nog 
meer J)!
∞
Mijn collega’s bij GGz Breburg wil ik bedanken voor de 
steun die ik vanuit jullie ervaar in mijn ontwikkeling 
als	psycholoog,	voor	de	fijne	samenwerking	en	voor	
de gezelligheid. 
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∞	
Mijn lieve vriendinnen en vrienden wil ik bedanken 
voor hun steun, motiverende woorden, interesse 
en vooral ook de afleiding die ik nodig had 
tijdens mijn proces. Ik wil een paar mensen in het 
bijzonder noemen. Allereerst Nikkie en Vivian, mijn 
paranimfen, jullie zijn goud waard! Jullie stonden 
altijd dichtbij om de succesjes met me te vieren 
en de teleurstellingen op te vangen, die gepaard 
gaan met de ups en downs van een promotie. Het 
waren behoorlijk pittige jaren, dus laten we het de 
komende tijd iets rustiger houden en genieten van 
onze vrije tijd waarin we samen kunnen reizen, 
lekker eten en borrelen, praten en natuurlijk dansen 
J! Mijn andere vriendinnen uit Eindhoven en mijn 
jaarclub, wil ik ook ontzettend bedanken voor de 
goede gesprekken, gekkigheid en gezelligheid: 
Pauline, Dionne, Channou, Taiger, Femke, Merel, 
Juliette, Stephanie, Evy, Iona, Oenone en Marlon. Ik 
kijk uit naar onze volgende gezellige get-togethers!
Mijn vriendinnen (en ook de mannen!) van 
Eindhoven Atletiek wil ik bedanken voor de nodige 
hardloop-momenten, die me hebben geholpen 
om fit en gezond te blijven en daarnaast ook 
(daarbuiten) erg gezellig zijn! Sanne, Larissa en Liza; 
ook al zie ik jullie wat minder vaak, ik kan altijd snel 
de ‘rode draad’ weer met jullie oppakken en ik wil 
jullie bedanken voor jullie steun en gezelligheid. 
Koen,	 we	 zijn	 al	 lang	 bevriend	 en	 ik	 vind	 het	 leuk	
dat we dat de laatste jaren weer meer invulling 
geven, bedankt voor jouw steun en inspiratie! Mijn 
vrienden uit het “oude Maastrichtse” (you know 
who you are!) wil ik bedanken voor de weekendjes 
weg met fijne wandelingen, outdoor-activiteiten, de 
goede gesprekken en jullie humor! 
Lieve Bart, jouw geduld werd regelmatig en 
behoorlijk op de proef gesteld door mijn werk en 
het proefschrift waar ik de afgelopen jaren dagelijks 
mee bezig was, maar je steunde me en je verzorgde 
belangrijke randvoorwaarden: het eten stond klaar 
als ik laat thuis kwam, de boodschappen waren 
gedaan, een kopje thee na het eten werd gezet en je 
moedigde me aan om me te ontspannen. We hebben 
veel mooie bijzondere jaren gedeeld samen en daar 
ben ik je voor altijd dankbaar voor. 
∞
Ik ben ontzettend dankbaar voor mijn plekje tussen 
de mooie mensen die ik mijn ooms, tantes, neven, 
nichten, broer en ouders mag noemen. Lieve familie, 
bedankt voor al jullie interesse en steun!
∞	
Lieve Rogier, je bent altijd geïnteresseerd in hoe 
het met me gaat op alle levensgebieden en je staat 
altijd voor me klaar. We kunnen samen lachen 
(gieren zelfs!), speciaalbiertjes drinken en urenlang 
reflecteren op onszelf en de mensen om ons heen, 
en ik ben blij dat wij het zo goed met elkaar kunnen 
vinden. We hebben een bijzondere band als broer 
en zus, en dat waardeer ik enorm. Bedankt dat je er 
voor me bent!
Lieve pap en mam, dit proefschrift draag ik op aan 
jullie. De combinatie van het analytische, kritische 
en oplossingsgerichte denken met de sociale, 
empathische en levens-beschouwende insteek die ik 
als rode draad door mijn leven zie, dank ik aan jullie. 
Woorden schieten tekort voor de dankbaarheid 
die ik naar jullie ervaar, in mijn leven als geheel. 
Onvoorwaardelijke liefde is het en dat voel ik elke 
dag. Bedankt voor alles.
∞
221

